Document:

<![CDATA[Collaborative Development & License Agreement]]>

 Exhibit 10.1 
 EXECUTION VERSION 
 Enanta has requested that portions of this document
be accorded confidential treatment 
 pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as
amended. 
 COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT 

by and between 
 ENANTA PHARMACEUTICALS, INC. 
 and 

ABBOTT LABORATORIES 
 November 27, 2006 
 Confidential materials omitted and filed separately
with the Securities and Exchange Commission. 
 Asterisks denote such omission. 

									
			
	1.	  	DEFINITIONS	  	 	1	  
			
	2.	  	ADMINISTRATION OF THE RESEARCH PROGRAM, DEVELOPMENT PROGRAM AND COMMERCIALIZATION	  	 	17	  
				
		  	2.1	  	Joint Steering Committee	  	 	17	  
				
		  	2.2	  	Affiance Managers	  	 	20	  
				
		  	2.3	  	Joint Co-Development and Commercialization Committee	  	 	20	  
			
	3.	  	RESEARCH PROGRAM	  	 	22	  
				
		  	3.1	  	Objectives of the Research Program	  	 	22	  
				
		  	3.2	  	Research Plan	  	 	22	  
				
		  	3.3	  	Conduct of Research Program	  	 	23	  
				
		  	3.4	  	Records	  	 	23	  
				
		  	3.5	  	Reports	  	 	24	  
				
		  	3.6	  	Selection of Candidates	  	 	24	  
				
		  	3.7	  	Supply of Proprietary Materials	  	 	24	  
				
		  	3.8	  	Research Program Term	  	 	25	  
			
	4.     	  	DEVELOPMENT AND COMMERCIALIZATION	  	 	25	  
				
		  	4.1    	  	Development of Candidates	  	 	25	  
				
		  	4.2	  	Commercialization of Products	  	 	26	  
				
		  	4.3	  	Development and Commercialization Diligence	  	 	26	  
				
		  	4.4	  	Compliance	  	 	27	  
				
		  	4.5	  	Reports; Information; Updates	  	 	27	  
				
		  	4.6	  	Product Recalls	  	 	29	  
				
		  	4.7	  	Product Labeling	  	 	29	  
			
	5.	  	CO-DEVELOPMENT AND PROFIT SHARE OPTION	  	 	29	  
				
		  	5.1	  	Exercise of Co-Development and Profit Share Option	  	 	29	  
				
		  	5.2	  	Effect of Exercise	  	 	29	  
				
		  	5.3	  	Reconciliation and Auditing of Development Costs	  	 	30	  
				
		  	5.4	  	Allocation of Shared Clinical Trial Costs	  	 	31	  
				
		  	5.5	  	Roll-Over Payments	  	 	31	  
				
		  	5.6	  	[*****]	  	 	31	  
				
		  	5.7	  	Co-Promotion	  	 	31	  
			
	6.	  	CONSIDERATION AND FUNDING	  	 	32	  
				
		  	6.1	  	Upfront Fee	  	 	32	  

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

							
				
		  	6.2	  	Purchase of Equity; Participation Right	  	32
				
		  	6.3	  	R&D Funding	  	33
				
		  	6.4	  	Milestone Payments	  	34
				
		  	6.5	  	Payment of Royalties; Operating Income Payments; Sublicense Income Payments; Accounting and Records	  	36
				
		  	6.6	  	No Other Compensation	  	40
				
		  	6.7	  	Enanta Payments	  	40
			
	7.     	  	TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY; NON-SOLICITATION	  	40
				
		  	7.1	  	Confidentiality	  	40
				
		  	7.2    	  	Publicity	  	41
				
		  	7.3	  	Publications and Presentations	  	41
				
		  	7.4	  	Prohibition on Solicitation	  	42
			
	8.	  	LICENSE GRANTS; EXCLUSIVITY	  	42
				
		  	8.1	  	Research Licenses	  	42
				
		  	8.2	  	Development and Commercialization Licenses	  	42
				
		  	8.3	  	Right to Sublicense	  	43
				
		  	8.4	  	No Other Rights	  	44
				
		  	8.5	  	Exclusivity	  	44
			
	9.	  	INTELLECTUAL PROPERTY RIGHTS	  	45
				
		  	9.1	  	Disclosure of Program Inventions	  	45
				
		  	9.2	  	Enanta Intellectual Property Rights	  	45
				
		  	9.3	  	Abbott Intellectual Property Rights	  	45
				
		  	9.4	  	Joint Technology Rights	  	45
				
		  	9.5	  	Patent Coordinators	  	46
				
		  	9.6	  	Inventorship	  	46
			
	10.	  	FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS	  	46
				
		  	10.1	  	Patent Filing, Prosecution and Maintenance	  	46
				
		  	10.2	  	Legal Actions	  	47
				
		  	10.3	  	Trademark Prosecution	  	50
			
	11.	  	TERM AND TERMINATION	  	50
				
		  	11.1    	  	Term	  	50
				
		  	11.2	  	Termination	  	50

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

							
				
	 	  	11.3    	  	Consequences of Termination of Agreement	  	51
				
		  	11.4	  	Surviving Provisions	  	55
			
	12.  	  	REPRESENTATIONS AND WARRANTIES	  	56
				
		  	12.1	  	Mutual Representations and Warranties	  	56
				
		  	12.2  	  	Additional Representations of Enanta	  	56
			
	13.	  	INDEMNIFICATION	  	57
				
		  	13.1	  	Indemnification of Abbott by Enanta	  	57
				
		  	13.2	  	Indemnification of Enanta by Abbott	  	57
				
		  	13.3	  	Conditions to Indemnification	  	57
				
		  	13.4	  	Warranty Disclaimer	  	58
				
		  	13.5	  	No Warranty of Success	  	58
				
		  	13.6	  	Limited Liability	  	58
				
		  	13.7	  	Insurance	  	58
			
	14.	  	MISCELLANEOUS	  	58
				
		  	14.1	  	Arbitration	  	58
				
		  	14.2    	  	Change of Control	  	59
				
		  	14.3	  	Notices	  	59
				
		  	14.4	  	Governing Law	  	60
				
		  	14.5	  	Binding Effect	  	60
				
		  	14.6	  	Headings	  	60
				
		  	14.7	  	Counterparts	  	60
				
		  	14.8	  	Amendment; Waiver	  	60
				
		  	14.9	  	No Third Party Beneficiaries	  	60
				
		  	14.10	  	Purposes and Scope	  	60
				
		  	14.11	  	Assignment and Successors	  	60
				
		  	14.12	  	Force Majeure	  	61
				
		  	14.13	  	Interpretation	  	61
				
		  	14.14	  	Integration; Severability	  	61
				
		  	14.15	  	Further Assurances	  	61
				
		  	14.16	  	HSR Filing	  	61
				
		  	14.17	  	Board Approvals	  	62

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 List of Exhibits and Schedules 

 

			
	 Exhibit A
	  	Research Plan
	 Exhibit B
	  	Form of Stock Purchase Agreement
	 Exhibit C
	  	Form of Press Release
	 Exhibit D
	  	ADR Procedure
		
	 Schedule 1
	  	[*****]
	 Schedule 2
	  	Abbott Patent Rights
	 Schedule 3
	  	[*****]
	 Schedule 4
	  	Licensed Patent Rights
	 Schedule 5
	  	Material Terms to Be Included in Co-Promotion Agreement
	 Schedule 6
	  	Calculation of Operating Income

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT 

This COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into as of November 27th,
2006, by and between Enanta Pharmaceuticals, Inc., with principal offices at 500 Arsenal Street, Watertown, Massachusetts 02472 (“Enanta”) and Abbott Laboratories, having a place of business at 100 Abbott Park Road, Abbott
Park, Illinois 60064 (“Abbott”). Each of Abbott and Enanta is sometimes referred to individually herein as a “Party” and collectively as the “Parties.” 

WHEREAS, Enanta Controls certain Technology and/or Proprietary Materials related to or otherwise useful in the discovery and development
of HCV NS3 or NS3/4A protease inhibitors (as those terms are defined below); 
 WHEREAS, Abbott has expertise in
discovering, developing, testing, obtaining regulatory approvals with respect to, manufacturing and marketing human therapeutic products; and 
 WHEREAS, Enanta and Abbott desire to enter into a collaboration for the purpose of identifying, developing and commercializing Enanta’s proprietary HCV NS3 or NS3/4A protease inhibitors and/or
certain of Abbott’s proprietary protease inhibitors as more fully described herein, 
 NOW, THEREFORE, in consideration of
the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as follows: 
  

	1.	DEFINITIONS 

Whenever used in this Agreement with an initial capital letter, the terms defined in this Section 1 shall have the meanings
specified. 
 1.1 “Abandoned Compounds” means all Products designated as Abandoned Compounds by Enanta
pursuant to Section 11.3.6. 
 1.2 “Abbott Background Technology” means any Technology related to
the Field used by Abbott, or provided by Abbott for use, in the Research Program or the Development Program that is (a) Controlled by Abbott as of the Effective Date or (b) developed or conceived by employees of, or consultants to, Abbott
after the Effective Date in the conduct of activities outside the Research Program or Development Program. 
 1.3
“Abbott Compounds” means the HCV protease inhibitors Controlled by Abbott and listed on Schedule 1 attached hereto, and any direct analogs thereof created during the Research Program. 

1.4 “Abbott Decision” means any decision that is not an Enanta Decision and relates solely to the Development of
a Candidate or Commercialization of a Product. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 1.5 “Abbott Improvement” means any Abbott Program Technology or
Abbott’s interest in any Joint Technology that contains one or more claims that covers the composition or use of any HCV protease inhibitor. The Parties understand that the term Abbott Improvement (a) shall not include any Abbott Program
Technology or Abbott’s interest in any Joint Technology that relates to the [*****] discovered by Abbott and (b) shall include any Abbott Patent Rights that contain one or more claims that cover Abbott Program Technology and/or
Abbott’s interest in any Joint Technology whether such Abbott Patent Rights are filed during, or, subject to Section 10.1, following the expiration of the Research Program Term. 

1.6 “Abbott Materials” means any Proprietary Materials that are Controlled by Abbott and used by Abbott, or
provided by Abbott for use, in the Research Program or the Development Program. 
 1.7 “Abbott Patent
Rights” means any Patent Rights containing one or more claims that cover Abbott Technology. All Abbott Patent Rights existing as of the Effective Date are described on Schedule 2 attached hereto. For clarification, the
Abbott Compounds listed in Schedule 1 will be covered under Abbott Patent Rights. 
 1.8 “Abbott Program
Technology” means any Program Invention conceived or first reduced to practice by employees of, or consultants to, Abbott, alone or jointly with any Third Party. 
 1.9 “Abbott Research Activities” means any research activities specified to be conducted by Abbott in any Research Plan. 

1.10 “Abbott Technology” means, collectively, Abbott Background Technology and Abbott Program Technology.

 1.11 “Adverse Event” means any untoward medical occurrence in a human clinical trial subject or in a
patient who is administered a Product, whether or not considered related to the Product including, without limitation, any undesirable sign (including abnormal laboratory findings of clinical concern), symptom or disease associated with the use of
such Product. 
 1.12 “Affiliate” means, with respect to any Party, any Person that, directly or through
one or more Affiliates, controls, or is controlled by, or is under common control with, such Party. For purposes of this definition, “control” means (a) ownership of more than fifty percent (50%) of the shares of stock entitled
to vote for the election of directors, in the case of a corporation, or more than fifty percent (50%) of the equity interests in the case of any other type of legal entity, (b) status as a general partner in any partnership, or
(c) any other arrangement whereby a Person controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity. 
 1.13 “Annual Net Sales” means the aggregate Net Sales during a particular Calendar Year. 
 1.14 “Applicable Laws” means all Federal, state, local, national and supra-national laws, statutes, rules and regulations, including any rules, regulations, guidelines or
requirements 

  
 - 2 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
of Regulatory Authorities, national securities exchanges or securities listing organizations that may be in effect from time to time during the Term and applicable to a particular activity
hereunder. 
 1.15 “Approval Date” means the date when both (a) the waiting period (or any
extension thereof) applicable to this Agreement under the HSR Act (as defined in Section 14.16) has been terminated or has expired, and (b) the Abbott Board, Abbott’s Chief Executive Officer and the Enanta Board have provided
approvals described in Section 14.17. 
 1.16 “Calendar Quarter” means the period beginning on the
Effective Date and ending on the last day of the calendar quarter in which the Effective Date falls, and thereafter each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30 or
December 31. For purposes of this definition, the Calendar Quarter for all activities outside the United States by Abbott shall be the three (3) consecutive calendar months ending February 28, May 31, August 31 or
November 30. 
 1.17 “Calendar Year” means each successive period of twelve (12) months
commencing on January 1 and ending on December 31; provided, that, the initial Calendar Year shall commence on the Effective Date and end on December 31, 2007. For purposes of this definition, the Calendar Year for all activities
conducted outside the United States by Abbott pursuant to this Agreement, shall be the twelve (12) month period commencing on December 1 and ending on November 30. 

1.18 “Candidate” means any Compound and/or any Abbott Compound designated by the JSC pursuant to
Sections 2.1.4(h) and 3.6 to proceed into GLP toxicity studies and enter the Development Program. 
 1.19
“Change of Control” means, with respect to a Party (a) a merger, consolidation, share exchange or other similar transaction involving such Party and any Third Party which results in the holders of the outstanding voting
securities of such Party immediately prior thereto ceasing to hold more than fifty percent (50%) of the combined voting power of the surviving, purchasing or continuing entity immediately after such merger, consolidation, share exchange or
other similar transaction, (b) any transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the
outstanding securities of such Party, other than in connection with a bona fide financing transaction provided by financial and/or venture capital investors to such Party, or (c) the sale or other transfer to a Third Party of all or
substantially all of such Party’s assets which relate to this Agreement. 
 1.20 “CTA” means a
notification submitted to EU Regulatory Authorities prior to the initiation of clinical trials in the EU. 
 1.21
“CTN” means the notification submitted to the Japanese Ministry of Health, Labor and Welfare prior to the Initiation of a Clinical Trial in Japan. 

  
 - 3 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 1.22 “Co-Developed Product” means any Product with respect to which
Enanta has exercised a Co-Development and Profit Share Option as described in Section 5.1. 
 1.23
“Co-Development and Profit Share Option Exercise Date” means, with respect to each Co-Developed Product, the date of exercise by Enanta of the Co-Development and Profit Share Option applicable to such Co-Developed Product.

 1.24 “Co-Development and Profit Share Option Exercise Period” means, with respect to each Compound or
Candidate, as the case may be, the period commencing on the Approval Date and continuing until [*****] after Enanta receives a study summary, including all primary statistical analyses, with respect to the first Phase Ib/2a Clinical Trial for such
Candidate. All raw data, both positive and negative, which would be reasonable to be considered in formulating such summary will be made available to Enanta promptly upon Enanta’s request. 

1.25 “Co-Development Territory” means the United States of America and its territories and possessions.

 1.26 “Collaboration” means the alliance of Enanta and Abbott established pursuant to this Agreement
for the purpose of identifying Compounds, Developing Candidates and Commercializing Products in the Field in the Territory. 

1.27 “Combination Product” means any commercialized HCV therapeutic that contains or comprises a Product and one
or more other ingredients that are therapeutically or biologically active and are not themselves Products. 
 1.28
“Commercialization” or “Commercialize” means any and all activities directed to the commercialization of a Product, including pre-launch and post-launch marketing, manufacturing for commercial sale,
promoting, Detailing (as defined in Schedule 5 hereof), distributing, offering to sell and selling a Product, importing a Product for sale, conducting additional human clinical studies other than those that are required due to
post-approval regulatory commitments (but not pre-clinical studies) and interacting with Regulatory Authorities regarding the foregoing. When used as a verb, “Commercializing” means to engage in Commercialization and
“Commercialized” has a corresponding meaning. 
 1.29 “Commercially Reasonable Efforts” means
(a) with respect to activities of either Party in the Research Program, the efforts and resources typically used by companies that are similar in size to such Party in the performance of research programs of comparable research compounds and
(b) with respect to the Development by Abbott of a particular Candidate or the Commercialization by Abbott of a particular Product, the efforts and resources typically used by Abbott in the development of product candidates or the
commercialization of products of comparable market potential, taking into account all relevant factors including, as applicable and without limitation, stage of development, mechanism of action, efficacy and safety relative to competitive products
in the marketplace, actual or anticipated Regulatory Authority approved labeling, the nature and extent of market exclusivity (including patent coverage and regulatory exclusivity), cost and likelihood of obtaining Commercialization Regulatory
Approval actual or projected profitability and availability of capacity to manufacture and supply for commercial sale. 

  
 - 4 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 1.30 “Commercialization Regulatory Approval” means, with respect to
any Product, the Regulatory Approval required by Applicable Laws in any country or region in the Territory in order to sell such Product for use in the Field in such country or region. “Commercialization Regulatory Approval” in the United
States shall mean final approval of an NDA or sNDA permitting marketing of the applicable Product in interstate commerce in the United States, “Commercialization Regulatory Approval” in the European Union shall mean marketing authorization
for the applicable Product, including price reimbursement approval, pursuant to Council Directive 2001/83/EC, as amended, or Council Regulation 2309/93/EEC, as amended and “Commercialization Regulatory Approval” in Japan shall mean final
approval of an application submitted to the Ministry of Health, Labor and Welfare and the publication of a New Drug Approval Information Package permitting marketing of the applicable Product, including price reimbursement approval, in Japan, as any
of the foregoing may be amended from time to time. 
 1.31 “Compound” means any HCV NS3 or
HCV NS3/4A protease inhibitor Controlled by Enanta, other than the Excluded Compounds. 
 1.32
“Co-Promote” or “Co-Promotion” means, with respect to any Co-Developed Product, the joint promotion and Detailing of such Co-Developed Product in the Co-Developed Territory using a coordinated sales
force consisting of representatives of both Parties. 
 1.33 “Confidential Information” means:
(a) with respect to Enanta, all tangible embodiments of Enanta Technology; (b) with respect to Abbott, all tangible embodiments of Abbott Technology; and (c) with respect to each Party, (i) all tangible embodiments of Joint
Technology and (ii) all information, Technology and Proprietary Materials disclosed or provided by of on behalf of such Party (the “Disclosing Party”) pursuant to this Agreement or the Existing Agreements to the other
Party (the “Receiving Party”) or to any of the Receiving Party’s employees, consultants, Affiliates or sublicensees; provided that none of the foregoing shall be Confidential Information if: (A) as of the date of
disclosure, it is known to the Receiving Party or its Affiliates, as demonstrated by credible written documentation, other than by virtue of a prior confidential disclosure to such Receiving Party or its Affiliates; (B) as of the date of
disclosure it is in the public domain, or it subsequently enters the public domain through no fault of the Receiving Party or its Affiliates; (C) it is obtained by the Receiving Party from a Third Party having a lawful right to make such
disclosure free from any obligation of confidentiality to the Disclosing Party; or (D) it is independently developed by or for the Receiving Party without reference to or use of any Confidential Information of the Disclosing Party as
demonstrated by credible written documentation. Further, (y) any scientific, technical or financial information of a Disclosing Party disclosed at any meeting of any of the committees or teams established pursuant to this Agreement or disclosed
through an audit report prepared pursuant to this Agreement shall constitute Confidential Information of the Disclosing Party and (z) the terms of this Agreement shall constitute Confidential Information of each Party. 

  
 - 5 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 1.34 “Control” or “Controlled” means
(a) with respect to Technology (other than Proprietary Materials) or Patent Rights, the possession by a Party of the right to grant a license or sublicense to such Technology or Patent Rights without violating the terms of any agreement or
arrangement with, any Third Party and (b) with respect to Proprietary Materials, the possession by a Party of the right to supply such Proprietary Materials to the other Party without violating the terms of any agreement or arrangement with,
any Third Party. 
 1.35 “Designated Senior Officer” means, with respect to a Party, the senior officer
designated by such Party to have final decision-making authority over Disputed Matters, which shall be (a) the Chief Executive Officer of Enanta and (b) the Executive Vice President of the Pharmaceutical Products Group for Abbott.

 1.36 “Development” or “Develop” means, with respect to each Candidate, all
non-clinical and clinical activities required to obtain Regulatory Approval of such Candidate in accordance with this Agreement on and after the Approval Date and up to and following the obtaining of Commercialization Regulatory Approval of such
Candidate. These activities include, without limitation, test method development and stability testing, regulatory toxicology, animal studies, formulation, process development, manufacturing, manufacturing scale-up, development-stage manufacturing,
quality assurance/quality control development, statistical analysis and report writing, and clinical trial design and operations. When used as a verb, “Developing” means to engage in Development and “Developed” has a
corresponding meaning. 
 1.37 “Development Costs” [*****]. 

1.38 “Development Plan” means, with respect to each Candidate and Calendar Year, the written plan for the
Development activities for such Candidate for such Calendar Year, as such written plan may be amended, modified or updated. Each Development Plan shall include: (a) the specific Development objectives, projected milestones, resource allocation
requirements and activities to be performed over such period; (b) the Party responsible for such activities; (c) a timeline for such activities; (d) an estimate of the expected Development costs to be incurred over such period;
(e) the expected Regulatory Filings to be required and prepared, and the expected timetable for making such Regulatory Filings; and (f) the manufacturing strategy, budget and proposed timelines for manufacturing scale-up, formulation,
filling and/or shipping. The initial Development Plan shall be prepared within ninety (90) days of the Approval Date and in any event, on or prior to the initiation of Development activities with respect to the initial Candidate. Each
Development Plan, amendment and update to the Development Plan shall be set forth in a written document prepared by Abbott and reviewed and/or approved by the JSC, shall specifically state that it is an amendment, modification or update to the
Development Plan and shall be attached to the minutes of the meeting of the JSC at which such amendment, modification or updated is approved by the JSC. The Development Plan shall be updated at least once prior to the end of each Calendar Year to
describe the Development activities to be carried out by each Party during the next Calendar Year pursuant to this Agreement. 

1.39 “Development Program” means the set of activities outlined in the Development Plan aimed at achieving
regulatory approval for a Candidate. 

  
 - 6 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 1.40 “Drug Approval Application” means, with respect to a Candidate
in a particular country or region, an application for Commercialization Regulatory Approval for such Candidate in such country or region, including without limitation: (a) an NDA or sNDA; (b) a counterpart of an NDA or sNDA (including,
without limitation, a CTN) in any country or region in the Territory; and (c) all supplements and amendments to any of the foregoing. 
 1.41 “Effective Date” means the date first set forth above. 
 1.42 “EMEA” means the European Medicines Evaluation Agency, or any successor thereto, which coordinates the scientific review of human pharmaceutical products under the centralized
licensing procedures of the European Union. 
 1.43 “Enanta Background Technology” means any Technology
used by Enanta, or provided by Enanta for use, in the Research Program or the Development Program that is (a) Controlled by Enanta as of the Effective Date or (b) developed or conceived by employees of, or consultants to, Enanta after the
Effective Date in the conduct of activities outside the Research Program or the Development Program. 
 1.44 “Enanta
Co-Development Percentage” means forty percent (40%). 
 1.45 “Enanta Decision” means any
decision with respect to the application by Enanta of FTEs to the research of Compounds under the Research Program. 
 1.46
“Enanta Materials” means any Proprietary Materials that are Controlled by Enanta and used by Enanta, or provided by Enanta for use, in the Research Program or the Development Program. For purposes of clarity, (a) Enanta
Materials shall include all Compounds provided by Enanta for use in the Research Program or Candidates used in the Development Program and (b) all other Enanta Materials shall be listed in the Research Plan or the Development Plan. 

1.47 “Enanta Patent Rights” means any Patent Rights that contain one or more claims that cover Enanta Technology.

 1.48 “Enanta Program Technology” means any Program Invention conceived or first reduced to practice
by employees of, or consultants to, Enanta, alone or jointly with any Third Party. 
 1.49 “Enanta Research
Activities” means any research activities specified to be conducted by Enanta in any Research Plan. 
 1.50
“Enanta Technology” means, collectively, Enanta Background Technology and Enanta Program Technology. 

1.51 “European Union” or “EU” means the member states (whether on the Effective Date or
later admitted) of the European Union. 

  
 - 7 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 1.52 “Excluded Compounds” means (a) the
compounds listed on Schedule 3 attached hereto and incorporated herein by reference, and (b) the compounds licensed from Chiron under the License and Option Agreement between Chiron Corporation and Enanta, dated May 4th, 2005. 

1.53 “Existing Agreements” means the [*****]. 

1.54 “FDA” means the United States Food and Drug Administration or any successor agency or authority thereto.

 1.55 “FDCA” means the United States Federal Food, Drug, and Cosmetic Act, as amended. 

1.56 “Field” means the prevention and treatment of viral infections in humans. 

1.57 “First Commercial Sale” means, with respect to a Product in any country after Regulatory Approval in the
Territory, the first sale, transfer or disposition of such Product for value in such country. 
 1.58 “Force
Majeure” means any occurrence beyond the reasonable control of a Party that (a) prevents or substantially interferes with the performance by such Party of any of its obligations hereunder and (b) occurs by reason of any act of
God, flood, fire, explosion, earthquake, strike, lockout, labor dispute, casualty or accident, or war, revolution, civil commotion, act of terrorism, blockage or embargo, or any injunction, law, order, proclamation, regulation, ordinance, demand or
requirement of any government or of any subdivision, authority or representative of any such government. 
 1.59
“FTE” means one (1) or more qualified employees of a Party who collectively spend time and effort conducting Enanta Research Activities or Abbott Research Activities, as the case may be, pursuant to the Research Plan or
any Development Plan equivalent to the time and effort of one (1) full-time employee for one (1) Calendar Year based on at least [*****] hours of work/[*****] weeks per Calendar Year/forty (40) hours per week of work (less public
holidays). 
 1.60 “FTE Cost” means, for any Calendar Quarter during the Research Program Term, the FTE
Rate divided by 4, multiplied by the applicable number of FTEs applied during such Calendar Quarter. 
 1.61 “FTE
Rate” means during the Research Program Term, [*****] per Calendar Year, or any prorated portion thereof. Notwithstanding the foregoing, if the Parties agree to any extension of the Research Program pursuant to Section 3.8, then,
as of the date of such extension and on each anniversary thereafter, the FTE Rate shall be increased by multiplying the FTE Rate applicable on December 31 of the immediately preceding Calendar Year by 1 + ((CPIx -CPIy) / CPIy), where CPIx is
the Consumer Price Index for All Urban Consumers in the Boston Metropolitan Area published by the Bureau of Labor Statistics of the United States Department of Labor for December in the immediately preceding Calendar Year and CPIy is the Consumer
Price Index for All Urban Consumers in the Boston Metropolitan Area published by the Bureau 

  
 - 8 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
of Labor Statistics of the United States Department of Labor for the December in the immediately preceding Calendar Year less one. Any such increase shall be rounded to the nearest one hundred US
Dollars ($100). 
 1.62 “GAAP” means generally accepted accounting principles as in effect in the United
States from time to time. 
 1.63 “GLP” means the then current Good Laboratory Practice Standards
promulgated or endorsed by the FDA or in the case of foreign jurisdictions, comparable regulatory standards promulgated or endorsed by the applicable Regulatory Authority, including those procedures expressed or implied in the Regulatory Filings.

 1.64 “GMP” means the then current Good Manufacturing Practices in accordance with the GMP standards
of the European Union and the FDA, as amended from time to time. 
 1.65 “Hatch-Waxman Act” means the
Drug Price Competition and Patent Term Restoration Act of 1984, as amended. 
 1.66 [*****] 

1.67 “IND” means: (a) an Investigational New Drug Application, as defined in the FDCA and the regulations
promulgated thereunder, or any successor application or procedure required to initiate clinical testing of a Compound, Candidate or Product in humans in the United States; (b) a counterpart of an Investigational New Drug Application that is
required in any other country or region in the Territory before beginning clinical testing of a Compound, Candidate or Product in humans in such country or region; and (c) all supplements and amendments to any of the foregoing. 

1.68 “Initiation” means, with respect to a human clinical trial, the first date that a subject is dosed in such
clinical trial. 
 1.69 “Joint Co-Development and Commercialization Committee” or
“JDCC” means the committee of Enanta and Abbott representatives established pursuant to Section 2.3 to coordinate the Development and Commercialization activities of Co-Developed Products within the Co-Development
Territory. 
 1.70 “Joint Patent Rights” means Patent Rights that contain one or more claims that cover
Joint Technology. For clarification, patents filed before or during the Research Program that cover the Abbott Compounds will be Joint Patent Rights, but excluding the Abbott Compounds listed in Schedule 1. 

1.71 “Joint Steering Committee” or “JSC” means the committee of Enanta and Abbott
representatives established pursuant to Section 2.1 to oversee the conduct and progress of the Research Program, the Development Program and the Commercialization of Products. 

1.72 “Joint Technology” means any Program Invention (a) conceived or first reduced to practice jointly by
employees of, or consultants to, Abbott and employees of, or consultants to, 

  
 - 9 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
Enanta or (b) conceived or first reduced to practice solely by employees of, or consultants to, one Party with the use in any material respect of any Technology, Patent Rights or Proprietary
Materials of the other Party. For purposes of clarity, Joint Technology shall include any and all Technology conceived or reduced to practice by Abbott in its conduct of any chemistry activities with respect to Compounds or Abbott Compounds (other
than the Abbott Compounds listed in Schedule 1) as part of the Research Program. 
 1.73 “Knowledge”
means the [*****] of the chief executive officer or any vice president of Enanta. 
 1.74 “Licensed Patent
Rights” means any Enanta Patent Rights and any of Enanta’s interest in Joint Patent Rights that contain one or more claims that cover any Compound, Candidate or Product. All Licensed Patent Rights existing as of the Effective Date
are described on Schedule 4 attached hereto. 
 1.75 “MAA” means an application filed with
the EMEA, or through the mutual recognition procedures in the European Union, for Regulatory Approval to Commercialize a Product as a drug in the European Union, or in any country or territory therein, including decentralized procedures or mutual
recognition procedures. 
 1.76 “Major Market Country” [*****]. 

1.77 “Marketing and Sales Plan” means, with respect to each Co-Developed Product, the written plan for the
Commercialization of such Co-Developed Product in the Co-Development Territory prepared in accordance with Section 4.2.1, which shall include, without limitation, (a) a regulatory and Commercialization strategy with proposed timelines and
sales forecasts, that are, in each case, applicable to such Co-Developed Product and (b) the written plan for the manufacture of such Co-Developed Product in the Co-Development Territory, including, without limitation, expected manufacturing
scale-up, formulating, and filing activities to be conducted for such Co-Developed Product as well as a budget and proposed timelines for such activities, as such plan may be amended or updated from time to time. 

1.78 “Materially Used” means, with respect to Shared Clinical Trial Data, the inclusion of such Shared Clinical
Trial Data in the core efficacy registration package of an NDA or equivalent registration package used outside of the Co-Development Territory (as defined as Phase II Clinical Trials and Phase DI Clinical Trials required by a Regulatory
Authority to substantiate evidence of both safety and efficacy). 
 1.79 “NDA” means a New Drug
Application, as defined in the FDCA and applicable regulations promulgated thereunder, or any successor application or procedure required to sell a Product in the United States. 

1.80 “Net Sales” means the total amount billed or invoiced on sales of the Product by Abbott or its Affiliates or
Sublicensees (including invoiced royalties and any other compensation of any other kind whatsoever) to independent, unrelated Third Parties, including wholesalers, in bona fide arm’s length transactions, less the following deductions, in each
case related 

  
 - 10 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
specifically to the Product and incurred in the ordinary course of business and actually allowed or taken by such Third Parties and not otherwise recovered by or reimbursed to Abbott or its
Affiliates: 
 (i) trade, cash and quantity discounts, allowances, adjustments, and rejections, rebates, recalls and returns;

 (ii) price reductions or rebates, retroactive or otherwise, imposed by governmental authorities; 

(iii) sales, excise, turnover, inventory, value-added, and similar taxes assessed on sales of the Product, but not including any income
tax paid by or assessed against Abbott or its Affiliates; 
 (iv) transportation, importation, shipping, insurance and other
handling expenses directly chargeable to the sale of the Product, including any fees for services provided by wholesalers and warehousing chains related to the distribution of the Product; 

(v) chargebacks granted to Third Party distributors based on sales to their customers; and 

(vi) the portion of any management fees or administration fees paid during the relevant time period to group purchasing organizations,
pharmaceutical benefit managers and/or Medicare prescription drug plans relating specifically to the Product. 
 [*****].

 1.81 “Patent Rights” means the rights and interests in and to issued patents and pending patent
applications in the HCV protease inhibition area (which, for purposes of this Agreement, include certificates of invention, applications for certificates of invention and priority rights) in any country or region, including all provisional
applications, substitutions, continuations, continuations-in-part, divisions, renewals, all letters patent granted thereon, and all reissues, reexaminations and extensions thereof including Hatch-Waxman patent term extensions, Supplemental
Protection Certificates, and all foreign counterparts of any of the foregoing. 
 1.82 “Person” means an
individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or
organization, including a government or political subdivision, department or agency of a government. 

  
 - 11 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 1.83 “Phase I Clinical Trial” means a clinical trial conducted in
any country or countries that generally provides for the first introduction into humans of an investigational drug with the purpose of assessing its safety, tolerability, toxicity, metabolism, absorption, elimination or other pharmacological action
as more fully defined in 21 C.F.R. 312.21(a). 
 1.84 “Phase Ib/IIa Clinical Trial” means the
initial clinical trial conducted with a Candidate in HCV infected patients designed to assess virologic potency, pharmacokinetics and tolerability and to support the decision to advance development to Phase IIb. 

1.85 “Phase II Clinical Trial” means a clinical trial conducted in any country or countries in patients with a
particular disease or condition with the purpose of further assessing the safety and tolerability of an investigational drug and initially exploring its efficacy for such disease or condition, as more fully defined in 21 C.F.R. 312.21(b).

 1.86 Phase IIb Clinical Trial” means, as to a particular Product and indication, the portion of a Phase II
Clinical Trial which contains a sufficient number of subjects to generate sufficient data (if successful) to commence a Phase III Clinical Trial of such Product for such indication. 

1.87 “Phase III Clinical Trial” means a clinical trial conducted in any country or countries in patients with a
particular disease or condition with the purpose of establishing the safety and tolerability of an investigational drug and confirming or establishing its efficacy for such disease or condition, as more fully defined in 21 C.F.R. 312.21(c).

 1.88 “Product” means any pharmaceutical dosage form that is comprised of a Candidate that has
obtained Commercialization Regulatory Approval (whether or not such Candidate is the sole active ingredient). The term Product shall include Co-Developed Products and Royalty-Bearing Products. 

1.89 “Product Trademark” means (a) any trademark or trade name, whether or not registered, or any trademark
application, renewal, extension or modification thereto, in the Territory, or any trade dress and packaging, that is applied to or used with Products by Abbott and (b) all goodwill associated therewith, and any promotional materials relating
thereto. 
 1.90 “Program Invention” means any Technology (including, without limitation, any process,
method of manufacture or composition of matter) that is conceived or first reduced to practice in the conduct of the Research Program or the Development Program. 
 1.91 “Program Patent Rights” means any Patent Rights that contain one or more claims that cover Program Inventions. 

1.92 “Proprietary Materials” means tangible chemical, biological or physical materials that are furnished by or
on behalf of one Party to the other Party in connection with this Agreement, whether or not specifically designated as proprietary by the transferring Party. 

  
 - 12 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 1.93 “Regulatory Approval” means, with respect to any country or
region in the Territory, any approval (including, without limitation, any pricing approval), product and establishment license, registration or authorization of any Regulatory Authority required for the manufacture, use, storage, importation,
export, transport or sale of a Product in such country or region. 
 1.94 “Regulatory Authority” means
the FDA, or any counterpart of the FDA outside the United States, or any other national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity with authority over the
distribution, importation, exportation, manufacture, production, use, storage, transport, clinical testing or sale of a Candidate or Product. 
 1.95 “Regulatory Filings” means, collectively: (a) all INDs, NDAs, establishment license applications, drug master files, applications for designation of a Product as an
“Orphan Product(s)” under the Orphan Drug Act, for “Fast Track” status under Section 506 of the FDCA (21 U.S.C. § 356) or for a Special Protocol Assessment under Section 505(b)(4)(B) and (C) of the
FDCA (21 U.S.C. § 355(b)(4)(B)) or all other similar filings (including, without limitation, any counterparts of any of the foregoing in any country region in the Territory) as may be required by any Regulatory Authority for the
Development of a Candidate or Commercialization of a Product; (b) all supplements and amendments to any of the foregoing; and (c) all data contained in, and correspondence relating to, any of the foregoing. 

1.96 “Relative Market Size” [*****]. 
 1.97 “Research Plan” means the written plan describing the research activities to be carried out by each Party during each Calendar Year during the Research Program Term in
conducting the Research Program pursuant to this Agreement, as such written plan may be amended, modified or updated. The initial Research Plan is attached hereto as Exhibit A, which describes the research activities, and the specific
research objectives, milestones and resource allocation requirements, to be carried out by each Party during the first full or partial Calendar Year following the Approval Date. Each amendment, modification and update to the Research Plan shall be
set forth in a written document prepared by, or at the direction of, the JSC and approved by the JSC, shall specifically state that it is an amendment, modification or update to the Research Plan and shall be attached to the minutes of the meeting
of the JSC at which such amendment, modification or updated was approved by the JSC. Without limiting the nature or frequency of any other amendments, modifications or updates of the Research Plan that may be approved by the JSC, the Research Plan
shall be updated at least once prior to the end of each Calendar Year to describe the research activities to be carried out by each Party, and the specific research objectives, milestones and resource allocation requirements, during the next
Calendar Year during the Research Program Term in conducting the Research Program pursuant to this Agreement. 
 1.98
“Research Program” means the collaborative research program commencing on the Approval Date and conducted by the Parties pursuant to Section 3.1 and the Research Plan for the purpose of identifying and researching
Candidates. 

  
 - 13 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 1.99 “Research Program Term” means the period beginning on the
Approval Date and, subject to Section 3.7, ending on the third anniversary of the Approval Date. 
 1.100
“Royalty-Bearing Product” means (a) any Product that is not a Co-Developed Product and (b) any Co-Developed Product to the extent sold outside of the Co-Development Territory. 

1.101 “Royalty-Bearing Territory” means (a) with respect to Co-Developed Products, all countries outside of
the Co-Development Territory and (b) with respect to Products, all countries within the Territory. 
 1.102
“Royalty Term” means, with respect to each Royalty-Bearing Product in each country in the Royalty-Bearing Territory, the period beginning on the date of First Commercial Sale of such Royalty-Bearing Product in such country
and continuing until the later of (a) the last date on which the manufacture, use or sale of such Royalty-Bearing Product in such country would infringe a Valid Claim included in the Licensed Patent Rights but for the license granted hereunder,
(b) ten (10) years from the date of the First Commercial Sale of such Royalty-Bearing Product in such country. 

1.103 “Shared Clinical Trial” means any clinical trial conducted by or on behalf of a Party the results of which
are Materially Used in the Regulatory Filings for a Co-Developed Product that is Commercialized both in the Co-Development Territory and outside of the Co-Development Territory. 

1.104 “Shared Clinical Trial Costs” means the reasonable out-of-pocket costs and internal costs incurred by a
Party (or for its account by an Affiliate or a Third Party) that are specifically attributable to the conduct of a Shared Clinical Trial. 
 1.105 [*****]. 
 1.106 “Shared Clinical Trial Data” means
all data, results and information produced in the conduct of a Shared Clinical Trial. 
 1.107 “sNDA”
means a Supplemental New Drug Application, as defined in the FDCA and applicable regulations promulgated thereunder. 

1.108 “Sublicensee” means any Third Party to which Abbott grants a sublicense in accordance with
Section 8.3. 
 1.109 “Sublicense Agreement” means any agreement by and between Abbott or its
Affiliates and a Sublicensee with respect to a Product. 
 1.110 “Sublicense Income” means all payments
(including all upfront payments, milestone payments, other consideration and the reasonable monetary value of all non-monetary consideration) received by Abbott from any Sublicensee under a Sublicense Agreement less that portion of the Development
Costs incurred by Abbott that is attributable to the conduct of Development activities with respect to the Product in the country or countries covered by the 

  
 - 14 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
Sublicense Agreement through the date of the grant of the applicable sublicense, and excluding: (a) royalty payments paid by such Sublicensee to Abbott; (b) payments made by a
Sublicensee to Abbott in consideration of the issuance of equity or debt securities of Abbott to the extent that the price paid for such equity does not exceed the then fair market value of such equity; and (c) payments made by a Sublicensee to
support or fund research and development activities to be undertaken by Abbott pursuant to a budget for sponsored research which has been agreed to with the Sublicensee and based on full-time equivalent or other cost-accounting methodologies that
are consistent with then current industry practices. 
 1.111 “Successful Completion of Phase Ib/IIa Clinical
Study” [*****]. 
 1.112 “Technology” means, collectively, inventions, discoveries,
improvements, trade secrets and proprietary methods, whether or not patentable, including without limitation: (a) methods of production or use of, and structural and functional information pertaining to, chemical compounds; and
(b) compositions of matter, data, formulations, processes, techniques, know-how and results (including any negative results). 
 1.113 “Territory” means all countries of the world. 

1.114 “Third Party” means any Person other than Abbott and Enanta and their respective Affiliates. 

1.115 “Valid Claim” means any claim of an issued unexpired patent that (a) has not been finally cancelled,
withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (b) has not been permanently revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other body of
competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable through disclaimer or otherwise, and (d) is not lost through an interference proceeding. 

Additional Definitions. In addition, each of the following definitions shall have the respective meanings set forth in the
section of this Agreement indicated below: 
  

			
	 Definition
	  	 Section

	Abbott Board	  	14.17
	Abbott Indemnitees	  	13.1
	Acquired Party	  	14.2(a)
	Acquiring Party	  	14.2(a)
	Additional Co-Developed Product	  	6.4.1(d)
	[*****]	  	[*****]
	Additional Product	  	6.4.1(b)
	ADR	  	Exhibit D
	Alliance Manager	  	2.2
	Annual Operating Income	  	Schedule 6
	Annual Research Payment	  	6.3.1
	Applicable Percentage	  	6.5.3

  
 - 15 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

			
	 Definition
	  	 Section

	 Arbitration Matter
	  	14.1
	 Candidate Designation
	  	3.6
	 Change of Control Notice
	  	14.2(a)
	 Claims
	  	13.1
	 Co-Development and Profit Share Option
	  	5.1
	 Co-Development Term
	  	6.5.2
	 Co-Promotion Agreement
	  	5.7.1
	 CPR
	  	Exhibit D
	 Disputed Matter
	  	2.1.6
	 Enanta Board
	  	14.17
	 Enanta Indemnitees
	  	13.2
	 Generic Product
	  	6.5.1(d)
	 HSR Act
	  	14.16
	 Indemnified Party
	  	13.3
	 Indemnifying Party
	  	13.3
	 Infringement
	  	10.2.1(a)(i)
	 Infringement Notice
	  	10.2.1(a)(i)
	 Initial Co-Developed Product
	  	6.4.1(c)
	 Initial Press Release
	  	7.2
	 Initial Product
	  	6.4.1(a)
	 Losses
	  	13.1
	 Novartis
	  	3.3.2
	 Operating Income Payments
	  	6.5.2
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]
	 Patent Coordinator
	  	9.5
	 Quarterly Research Payment
	  	6.3.1
	 Recipient Party
	  	3.7
	 Roll-Over Payment
	  	5.4
	 Royalty Payments
	  	6.5.1(a)
	 Shared Clinical Trial Notice
	  	5.4.1
	 Shares
	  	6.2
	 Stock Purchase Agreement
	  	6.2
	 Sublicense Income Payments
	  	6.5.3
	 Term
	  	11.1
	 Third Party Payments
	  	6.5.1(b)
	 Transferring Party
	  	3.7

  
 - 16 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

	2.	ADMINISTRATION OF THE RESEARCH PROGRAM, DEVELOPMENT PROGRAM AND COMMERCIALIZATION 

2.1 Joint Steering Committee. 
 2.1.1 Establishment. Enanta and Abbott hereby establish the Joint Steering Committee. The JSC shall have and perform the responsibilities set forth in Section 2.1.4. 

2.1.2 Membership. Each of Enanta and Abbott shall designate an equal (not less than two (2)) number of representatives
to the JSC who shall be members of senior management with decision-making authority. Unless otherwise agreed by the Parties, one (1) representative of each Party shall be designated as Co-Chairs of the JSC. Each Party shall have the right at
any time to substitute individuals, on a permanent or temporary basis, for any of its previously designated representatives to the JSC by giving written notice to the other Party; provided such substitute has similar decision-making authority within
that Party’s organization as the individual being replaced. 
 2.1.3 Meetings. 

(a) Schedule of Meetings; Agenda. The JSC shall establish a schedule of times for regular meetings, taking into account the
planning needs of the Research Program and Development Program and the responsibilities of the JSC. Special meetings of the JSC may be convened by any member upon not less than [*****] (or, if such meeting is proposed to be conducted by
teleconference, upon not less than [*****] written notice to the other members; provided that (i) notice of any such special meeting may be waived in writing at any time, either before or after such meeting and (ii) attendance of any
member at a special meeting shall constitute a valid waiver of notice from such member, unless such member attends the meeting for the express purpose of objecting to its conduct for failure to provide valid notice. In no event shall the JSC meet
less frequently than [*****]. Regular and special meetings of the JSC may be held in person or by teleconference or videoconference; provided that (i) meetings held in person shall alternate between the respective offices of the Parties in
Watertown, Massachusetts and Abbott Park, Illinois, or such other locations mutually agreeable to the JSC members and (ii) not less than one (1) meeting per Calendar Year shall be held in person. The Co-Chairs shall
alternate responsibility for preparing and circulating to each JSC member an agenda for each JSC meeting not later than [*****] prior to such meeting. 
 (b) Quorum; Voting; Decisions. At each JSC meeting, (i) the presence in person of at least one (1) member designated by each Party shall constitute a quorum and (ii) each member who
is present shall have one (1) vote on all matters before the JSC at such meeting. All decisions of the JSC shall be made by majority vote; provided, that, any member designated by a Party shall have the right to cast the votes of any of such
Party’s members on the JSC who are absent from the meeting. Alternatively, the JSC may act by written consent signed by at least one (1) member designated by each Party. Whenever any action by the JSC is called for hereunder during a time
period in which the JSC is not scheduled to meet, either Co-Chair shall cause the JSC to take the action in the requested time period by calling a special meeting or by circulating a written consent. Representatives of each Party or of its
Affiliates who are not members of the JSC may attend JSC meetings as non-voting observers with the consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. 

  
 - 17 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (c) Minutes. The JSC shall keep minutes of its meetings that record all decisions
and all actions recommended or taken in reasonable detail. Drafts of the minutes shall be prepared and circulated to the members of the JSC within a reasonable time after the meeting, not to exceed [*****], and the Chairs shall alternate
responsibility for the preparation and circulation of draft minutes. Each member of the JSC shall have the opportunity to provide comments on the draft minutes. The minutes shall be approved, disapproved and revised as necessary at the next JSC
meeting or within [*****] of the meeting, whichever occurs first. Upon approval, the Chair with responsibility for preparing minutes shall circulate the final minutes of each meeting to the members of the JSC. 

(d) Expenses. Enanta and Abbott shall each bear all expenses of their respective JSC representatives related to their
participation on the JSC and attendance at JSC meetings. 
 2.1.4 Responsibilities. The JSC shall be responsible
for overseeing the conduct and progress of the Research Program, the Development Program and the Commercialization of Products. Without limiting the generality of the foregoing, the JSC shall have the following responsibilities: 

(a) Reviewing each Research Plan, Development Plan and Marketing and Sales Plan (including all budgets applicable thereto); 

(b) with respect to (i) any Research Plan, (ii) any Development Plan that covers a Co-Developed Product, or (iii) any
Marketing and Sales Plan that covers a Co-Developed Product, approving such Research Plan, Development Plan and Marketing and Sales Plan; 
 (c) directing the preparation of and reviewing any amendment to any Research Plan, Development Plan and/or Marketing and Sales Plan and/or budget applicable thereto; 

(d) with respect to any amendment to (i) any Research Plan, (ii) any Development Plan that covers a Co-Developed Product, or
(iii) any Marketing and Sales Plan that covers a Co-Developed Product, approving such amendment; 
 (e) monitoring the
progress of each Research Plan, Development Plan and Marketing and Sales Plan, and of each Party’s activities thereunder; 

(f) providing a forum for consensual decision-making with respect to the (i) Research Program, (ii) Development Program for
Co-Developed Products and (iii) Commercialization of Co-Developed Products; 
 (g) reviewing data, reports or other
information submitted by either Party with respect to work conducted in the Research Program and the Development Program; 

  
 - 18 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (h) designating Compounds and Abbott Compounds to be Candidates eligible to enter the
Development Program in accordance with Section 3.6, and reviewing prioritization of the Development activities in the event multiple Candidates are selected to enter the Development Program; 

(i) monitoring the progress of the Commercialization of each Product in accordance with the applicable Marketing and Sales Plan,
including, without limitation, reviewing and, to the extent it covers a Co-Developed Product, approving, each annual update to each Marketing and Sales Plan and reviewing all sales forecasts and the results of all efforts in the Co-Development
Territory provided by the JDCC; 
 (j) resolving any dispute as to whether a milestone event for a Product under this Agreement
has occurred; 
 (k) implementing a mutually acceptable mechanism for reporting Adverse Events between the Parties for each
Candidate and Product; 
 (l) developing and discussing strategies for the promotion and marketing of all Co-Developed
Products; 
 (m) implementing the Marketing and Sales Plan that covers any Co-Developed Product; 

(n) resolving all issues referred to the JSC by the Alliance Managers and the JDCC; and 

(o) making any other decisions as may be delegated to the JSC pursuant to this Agreement or by mutual written agreement of the Parties
after the Approval Date and performing such activities as may be delegated to the JSC pursuant to this Agreement, or by mutual written agreement of the Parties after the Approval Date. 

2.1.5 Interests of the Parties. Notwithstanding any other provisions of this Agreement, all decisions made and all actions
taken by the JSC shall be made or taken in the best interest of the Collaboration. 
 2.1.6 Dispute Resolution.
The JSC members shall use reasonable efforts to reach agreement on any and all matters for which the JSC is responsible pursuant to Section 2.1.4. In the event that, despite such reasonable efforts, agreement on a particular matter cannot
be reached by the JSC within [*****] after the JSC first meets to consider such matter (each such matter, a “Disputed Matter”), then: (a) if the Disputed Matter involves an Enanta Decision, one of the Enanta members of
the JSC shall have the right to make the final decision on such Disputed Matter, but shall only exercise such right in good faith after full consideration of the positions of both Parties; and (b) if the Disputed Matter involves an Abbott
Decision or any other matter that is not an Enanta Decision, the Disputed Matter shall be referred to the Designated Senior Officer of each Party, who shall promptly initiate discussions in good faith to resolve the Disputed Matter. If the Disputed
Matter is not resolved by such Designated Senior Officers within the first to occur of [*****] after the date the Designated Senior Officers first 

  
 - 19 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
met to consider such Disputed Matter or [*****] after the date the JSC first met to consider such Disputed Matter, the Disputed Matter shall be referred for resolution to the Executive Vice
President of Abbott’s Pharmaceutical Products Group, who shall have the right to make the final decision on such Disputed Matter, but shall only exercise such right in good faith after full consideration of the positions of both Parties and
shall base any such decision, in part, on the principle of maximizing the commercial potential of each Product, but shall not base such decision on providing economic advantage to one Party over the other Party. 

2.2 Affiance Managers. Each Party shall appoint a person with experience in and abilities with respect to project
management and coordination and communication among various divisions and disciplines who shall oversee contact between the Parties for all matters related to the Collaboration between meetings of the JSC (each, an “Alliance
Manager”). The Alliance Managers shall have such responsibilities as the Parties may mutually agree in writing. Each Party may replace its Alliance Manager at any time by notice in writing to the other Party. 

2.3 Joint Co-Development and Commercialization Committee. 

2.3.1 Establishment. As soon as practicable following the exercise by Enanta of a Co-Development and Profit-Share Option
with respect to a Compound or Candidate, as the case may be, in accordance with Section 5.1, Enanta and Abbott shall establish the Joint Co-Development and Commercialization Committee which shall have and perform the responsibilities set forth
in Section 2.3.4. 
 2.3.2 Membership. Each of Enanta and Abbott shall designate an equal (not less than two
(2)) number of representatives to the JDCC. Unless otherwise agreed by the Parties, Abbott shall designate one (1) of its designees as the Chairman. Each Party shall have the right at any time to substitute individuals, on a permanent or
temporary basis, for any of its previously designated representatives to the JDCC by giving written notice to the other Party. 

2.3.3 Meetings. 
 (a) Schedule of Meetings; Agenda. The JDCC shall establish a schedule of times for regular meetings, taking into account, without limitation, its responsibilities hereunder and the planning needs
for the Co-Developed Products. Special meetings may be convened by any member of the JDCC upon [*****] (or, if such meeting is proposed to be conducted by teleconference, upon [*****]) written notice to the other members; provided that
(1) notice of any such special meeting may be waived in writing at any time, either before or after such meeting, and (ii) attendance of any member at a special meeting shall constitute a valid waiver of notice from such member, unless
such member attends the meeting for the express purpose of objecting to its conduct for failure to provide valid notice. If formed, in no event shall the JDCC meet less frequently than [*****]. Regular and special meetings of the JDCC may be held in
person or by teleconference or videoconference; provided, that, meetings held in person shall alternate between the respective offices of the Parties in Watertown, Massachusetts and Abbott Park, Illinois. The Chairman shall prepare and circulate to
each JDCC member an agenda for each JDCC meeting not later than one (1) week prior to such meeting. 

  
 - 20 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (b) Quorum; Voting; Decisions. At each JDCC meeting, (i) the presence in person
of at least one (1) member designated by each Party shall constitute a quorum and (ii) each member who is present shall have one (1) vote on all matters before the JDCC at such meeting. All decisions of the JDCC shall be made by
majority vote; provided, that, any member designated by a Party shall have the right to cast the votes of any of such Party’s members on the JDCC who are absent from the meeting. Alternatively, the JDCC may act by written consent signed by at
least one (1) member designated by each Party. Whenever any action by the JDCC is called for hereunder during a time period in which the JDCC is not scheduled to meet, the Chairman shall cause the JDCC to take the action in the requested time
period by calling a special meeting or by circulating a written consent. Representatives of each Party or of its Affiliates who are not members of the JDCC may attend JDCC meetings as non-voting observers with the consent of the other Party, which
consent shall not be unreasonably withheld, conditioned or delayed. 
 2.3.4 Responsibilities. The JDCC shall be
responsible for overseeing the Development and Commercialization of Co-Developed Products in the Co-Development Territory. Without limiting the generality of the foregoing, the JDCC shall have the following responsibilities: 

(a) the development and discussion of strategies for the Development and Commercialization of each Co-Developed Product in the
Co-Development Territory, including allocation of responsibilities for such Development and Commercialization activities; 

(b) reviewing and discussing a Marketing and Sales Plan for each Co-Developed Product in the Co-Development Territory; 

(c) coordinating the Development and Commercialization efforts of both Parties in the Co-Development Territory with respect to
Co-Developed Products. For purposes of clarity, the JDCC shall not be responsible for coordinating communications with Regulatory Authorities, which is the sole responsibility of Abbott, however, Abbott will work directly with a regulatory liaison
to be designated by Enanta on coordinating key regulatory FDA communications on Co-Developed Products and will keep Enanta’s liaison informed as to other regulatory proceedings on Co-Developed Products that will materially affect approvals or
product labeling in the Co-Developed Territory. For clarity, this would not apply to routine regulatory submissions or communications necessary to ensure regulatory compliance with FDA guidelines. Abbott will keep the JDCC informed of key regulatory
communications involving key regulatory filings and milestone meetings as specified in Section 4.5.5. 
 (d) reviewing and
providing input in the preparation of a Marketing and Sales Plan containing a Co-Promotion Plan for each Co-Developed Product in the Co-Development Territory; 

  
 - 21 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (e) reviewing and providing input on the short-term and long-term sales forecasts for
Co-Developed Products in the Co-Developed Territory; 
 (f) presenting sales forecasts and the results of all efforts in the
Co-Development Territory to the JSC as needed, but no less often than two (2) times per Calendar Year; 
 (g) coordinating
the Detailing efforts of both Parties in the Co-Development Territory with respect to Co-Developed Products; 
 (h) overseeing
all recalls, market withdrawals and any other corrective actions related to Co-Developed Products in the Co-Development Territory; 
 (i) receiving and providing to the Parties sales reports pertaining to Co-Developed Products in the Co-Developed Territory; 
 (j) approving all Third Parties to be engaged by either Party to provide Representatives to Co-Promote Co-Developed Products in the Co-Developed Territory; 

(k) reviewing and approving any ingredients that are therapeutically or biologically active that are proposed by either Party for
inclusion with a Co-Developed Product to create a Combination Product; and 
 (l) performing such activities as may be
delegated to the JDCC pursuant to this Agreement, or by mutual written agreement of the Parties after the Approval Date. 

2.3.5 Dispute Resolution. The JDCC members shall use reasonable efforts to reach agreement on any and all matters for which
the JDCC is responsible pursuant to Section 2.3.4. In the event that, despite such reasonable efforts, agreement on a particular matter cannot be reached by the JDCC within [*****] after the JDCC first meets to consider such matter, then the
Chairman of the JDCC shall bring such matter to the JSC for a final decision in accordance with Section 2.1.6. 
  

	3.	RESEARCH PROGRAM 

3.1 Objectives of the Research Program. The objectives of the Research Program shall be the identification of one
(1) or more Compounds or Abbott Compounds suitable for further Development as Candidates and for Commercialization as Products. 
 3.2 Research Plan. The initial Research Plan is attached hereto as Exhibit A. For each Calendar Year during the Research Program Term commencing with the second full Calendar
Year, the Research Plan shall be amended and updated by the Parties, which amendments and updates shall be submitted to and approved by the JSC in accordance with Section 2.1.4. Each such amendment shall: (a) set forth (i) the
research objectives and activities to be performed for the Calendar Year covered by the update with reasonable specificity; (ii) the Party that shall be responsible for performing such activities; (iii) a timeline and budget for such

  
 - 22 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
activities; and (iv) with respect to Enanta Research Activities, the number of FTEs estimated to be required to perform such Enanta Research Activities; and (b) shall be consistent with
the terms of this Agreement. 
  

	 	3.3	Conduct of Research Program. 

 3.3.1 Abbott Responsibilities. During the Research Program Term, Abbott will (a) use Commercially Reasonable Efforts to conduct the Abbott Research Activities assigned to it in each
Research Plan and (b) commit such other resources as are reasonably necessary to conduct such Abbott Research Activities and achieve the goals of the Research Program. 
 3.3.2 Enanta Responsibilities. During the Research Program Term, Enanta will (a) use Commercially Reasonable Efforts to conduct the Enanta Research Activities assigned to it in each
Research Plan and (b) commit to the Research Program at least [*****] FTEs for each of the first [*****] years of the Research Program Term and such other resources for the remainder of the Research Term as are reasonably necessary to conduct
such Enanta Research Activities and achieve the goals of the Research Program; provided, that, Enanta shall not be required to commit FTEs to the Research Program prior to the Approval Date. 

3.3.3 Compliance. Each Party shall perform its obligations under each Research Plan in good scientific manner and in
compliance in all material respects with all Applicable Laws. With respect to each activity performed under the Research Plan that will or could reasonably be expected to be submitted to a Regulatory Authority in support of a Regulatory Filing or
Drug Application Approval, the Party performing such activity shall comply in all material respects with the regulations and guidance of the FDA that constitute Good Laboratory Practice or Good Manufacturing Practice or, if and as appropriate under
the circumstances, International Conference on Harmonization (ICH) guidance or other comparable regulation and guidance of any Regulatory Authority in any country or region in the Territory. Each Party shall be solely responsible for paying the
salaries and benefits of its employees and consultants conducting its activities under the Research Plan. 
 3.3.4
Cooperation. Scientists at Enanta and Abbott shall cooperate in the performance of the Research Program and, subject to the terms of this Agreement and any confidentiality obligations to Third Parties, shall exchange such data,
information and materials as is reasonably necessary for the other Party to perform its obligations under the Research Plan. 

3.4 Records. 
 3.4.1 Record Keeping. 
 (a) Research Program Records. Each
Party shall maintain records of its activities under the Research Program in sufficient detail, in good scientific manner and otherwise in a manner that reflects all work done and results achieved in the performance of the Research Program. Subject
to Article 7, each Party shall provide the other Party with access during normal business hours and upon reasonable advance notice to inspect and copy such records to the extent reasonably required for the performance of the requesting Party’s
obligations and exercise of its rights under this Agreement. 

  
 - 23 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (b) Record Keeping Policies. Without limiting the generality of
Section 3.4.1(a), each Party agrees to maintain a policy that requires its employees and consultants to record and maintain data and information developed during the Research Program in standard laboratory notebooks that are dated and
corroborated by non-inventors on a regular, contemporaneous basis and otherwise in a manner designed to establish the earliest date of invention or reduction to practice. 
 3.5 Reports. The Parties shall keep the JSC regularly informed of the progress of the Research Program and shall present to the JSC all data and results generated from such efforts. Without
limiting the generality of the foregoing, each Party shall, at least once each Calendar Quarter during the Research Program Term, provide: (a) reports to the JSC in reasonable detail regarding the status of its activities under such Research
Program; (b) advise the JSC of its identification of any Compound or Abbott Compound it reasonably determines should be Developed as a Candidate and provide the JSC with any supporting data applicable to such Compound or Abbott Compound so as
to enable the JSC to determine whether such Compound or Abbott Compound should be approved by the JSC as a Candidate; and (c) provide such additional information that it has in its possession as may be reasonably requested from time to time by
the JSC. 
 3.6 Selection of Candidates. Within [*****] after its receipt of each report from a Party pursuant to
Section 3.5(b) identifying a Compound or Abbott Compound which such Party determines be Developed as a Candidate, the JSC shall (i) review such supporting data and information using standards and criteria to be developed by the JSC, and
(ii) if it determines that a Candidate has been identified, notify the Parties in writing of such determination (each, a “Candidate Designation”). Upon the issuance by the JSC of a Candidate Designation for a Compound or
Abbott Compound, (a) such Compound or Abbott Compound shall be deemed to be a Candidate for purposes of this Agreement and (b) the Parties shall, as promptly as possible, prepare and submit to the JSC for its review and, if such Candidate
is a Co-Developed Product for its approval, a Development Plan with respect to the Development activities to be conducted with respect to such Candidate. For purposes of clarity, the Parties hereby acknowledge and agree that no Compound or Abbott
Compound may be Developed under the Development Program unless and until it is designated as a Candidate by the JSC. 
 3.7
Supply of Proprietary Materials. From time to time during the Research Program Term, either Party (a “Transferring Party”) may supply the other Party (a “Recipient Party”) with
Proprietary Materials of the Transferring Party for use in the Research Program. In connection therewith, each Recipient Party hereby agrees that: (a) it shall not use such Proprietary Materials for any purpose other than exercising its rights
or performing its obligations hereunder; (b) it shall use such Proprietary Materials only in compliance with all Applicable Laws; (c) it shall not transfer any such Proprietary Materials to any Third Party without the prior written consent
of the Transferring Party, except as expressly permitted hereby; (d) it shall not acquire any right, title or interest in or to such Proprietary Materials as a result of such supply by the Transferring Party; and (e) upon the expiration or
termination of the Research Program Term, it shall, if and as instructed by the Transferring Party, either destroy or return any such Proprietary Materials that are not the subject of the grant of a continuing license hereunder. 

  
 - 24 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 3.8 Research Program Term. Subject to Section 11.2.1, the Research
Program may be extended (a) for an additional period of one (1) year by Abbott by providing not less than six (6) months’ prior written notice to Enanta and (b) for one (1) or more periods of one (1) year each
thereafter by either Party providing not less than six (6) months’ prior written notice to the other Party, subject to the Parties reaching mutual agreement on all of the terms and conditions applicable to any such extension. In the event
this Agreement is terminated prior to the end of the Research Program Term, the effective date of termination of the Research Program Term shall be the same date as the termination of this Agreement. 

 

	4.	DEVELOPMENT AND COMMERCIALIZATION 

 4.1 Development of Candidates. 
 4.1.1 Development
Plans. A Development Plan and budget for each Candidate for the balance of the Calendar Year during which the Compound or Abbott Compound is designated by the JSC as a Candidate shall be prepared by Abbott and submitted to the JSC promptly
after the designation of such Compound or Abbott Compound as provided in Sections 2.1.4(h) and 3.6. Thereafter, for each Calendar Year during the Development Program, an updated Development Plan and budget for each Candidate shall be prepared by
Abbott and submitted to the JSC as provided in Section 2.1.4(a) or (b), as applicable. To the extent JSC approval is required, the Parties shall manage the preparation of each Development Plan and budget in a manner designed to obtain such JSC
approval no later than [*****] prior to the end of the then-current Calendar Year. Each Development Plan and amendment thereto shall: (a) set forth (i) the Development objectives, activities, priorities, timelines, budget and resources for
the Calendar Year covered by the Development Plan with reasonable specificity, (ii) the Development objectives and activities to be performed for each Calendar Year period covered by the Development Plan with reasonable specificity, broken down
by Calendar Quarters, (iii) the Party that shall be responsible for performing such activities, (iv) a timeline for such activities and (v) the expected Development Costs over such Calendar Year; and (b) be consistent with the
other terms of this Agreement. 
 4.1.2 Responsibility for the Development of Candidates. Unless otherwise set
forth in any Development Plan; Abbott shall have the sole right and responsibility for all aspects of the Development of Candidates in accordance with the applicable Development Plan in the Territory, including, without limitation, (a) the
conduct of: (i) all IND-enabling non-clinical studies for Candidates; and (ii) all activities related to the conduct of human clinical trials (including, without limitation, Phase I Clinical Trials, Phase II Clinical Trials and Phase III
Clinical Trials), including the manufacture of all clinical trial materials, (b) making all Regulatory Filings for Candidates and filing all Drug Approval Applications and otherwise seeking all Regulatory Approvals for Candidates, as well as
all correspondence and communications with Regulatory Authorities regarding such matters, subject in each case to Section 4.5.5, and (c) reporting all Adverse Events to Regulatory Authorities, if and to the extent required by Applicable
Laws. Abbott shall own all Regulatory Filings and Drug Approval Applications for Candidates, subject to Section 11.3. 

  
 - 25 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 4.2 Commercialization of Products. 

4.2.1 Marketing and Sales Plans. Within [*****] of the Initiation of a Phase III Clinical Trial with respect to each
Candidate, Abbott shall prepare and provide to the JSC for its review a Marketing and Sales Plan for each Candidate, and approval, if such Marketing and Sales Plan pertains to a Co-Developed Product. Thereafter, for each Calendar Year during the
Term, the Marketing and Sales Plan for each Candidate or Product, as the case may be, shall be updated by Abbott and submitted to the JSC for its approval in accordance with Section 2.1.4(a) or (b), as applicable. Each update to the Marketing
and Sales Plan shall set forth: (a) the Commercialization objectives and activities to be performed for the Calendar Year covered by the Marketing and Sales Plan with reasonable specificity; (b) the manufacturing scale-up, formulating and
filing requirements for each Candidate or Product, as the case may be, to be performed for the Calendar Year with reasonable specificity: and (c) a timeline for such activities. 

4.2.2 Responsibility for Commercialization of Products. Subject to the exercise by Enanta of a Co-Development and Profit
Share Option and unless otherwise set forth in any Marketing and Sales Plan, Abbott shall have the sole right and responsibility for all aspects of the Commercialization of Products, in accordance with the applicable Marketing and Sales Plan in the
Field. Without limiting the foregoing, Abbott shall have the sole right and responsibility for (a) the conduct of: (i) all activities relating to the manufacture and supply of Products (including all required process development and scale
up work with respect thereto); and (ii) all pre-marketing, marketing, promotion, FDA DDMAC interactions, sales, distribution, import and export activities (including securing reimbursement, sales and marketing and conducting any post-marketing
trials or post-marketing safety surveillance or maintaining databases), subject to the oversight of the JSC and (b) for: (i) subject to Section 4.5.5, making all Regulatory Filings for Candidates and filing all Drug Approval
Applications and otherwise seeking all Regulatory Approvals for Products, as well as all correspondence and communications with Regulatory Authorities regarding such matters; (ii) reporting all Adverse Events to Regulatory Authorities if and to
the extent required by Applicable Laws; and (iii) subject to making the Co-Development Payments to Enanta for Co-Developed Products contemplated by Section 6.4.1(b). Abbott shall own all Regulatory Approvals for Products, subject to
Section 11.3. 
 4.2.3 Manufacture and Supply of Products. Abbott shall be responsible for manufacturing or
having manufactured through Third Party contract manufacturers, any materials (including, without limitation, all Candidates) as may be required for all pre-clinical and clinical studies necessary to obtain Regulatory Approval of Products and any
materials and quantities of each Candidate as may required for all pre-clinical and clinical studies applicable to such Candidates. 
 4.3 Development and Commercialization Diligence. Abbott shall use Commercially Reasonable Efforts during the Term to Develop Candidates and Commercialize

  
 - 26 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
Products in the Field and in the Territory. Without limiting the foregoing, Abbott shall seek Regulatory Approvals for, and Commercialize, each Product in all of the Major Market Countries and in
every other country in the Territory identified in the Marketing and Sales Plan. If Enanta at any time believes that Abbott is not meeting its diligence obligations pursuant to this Section 4.3, Enanta may give written notice to Abbott
requesting written justification, in the form of detailed reasons, that would support the proposition that Abbott is meeting such diligence obligations. In such event, Abbott shall provide such written justification to Enanta within [*****] after
such notice is given. In the event that Enanta does not receive such justification within such [*****] period or does not agree with such justification, then Enanta shall have the right, in its sole discretion, to pursue a declaration of breach and
seek available remedies under Section 11.3.6 or any or all other rights or remedies that it may have under this Agreement, at law or in equity. 
 4.4 Compliance. Each Party shall perform its obligations under each Development Plan in good scientific manner and under each Marketing and Sales Plan using Commercially Reasonable Efforts,
and both in compliance in all material respects with all Applicable Laws; provided that with respect to each activity performed under a Development Plan and under a Marketing and Sales Plan that will or would reasonably be expected to be submitted
to a Regulatory Authority in support of a Regulatory Filing or Drug Approval Application, such Party shall comply in all material respects with, if and as applicable, the regulations and guidance of the FDA that constitute Good Laboratory Practice,
Good Manufacturing Practice or Good Clinical Practice (or, if and as appropriate under the circumstances, International Conference on Harmonization (ICH) guidance or other comparable regulation and guidance of any Regulatory Authority in any country
or region in the Territory). 
 4.5 Reports; Information; Updates. 

4.5.1 Development Reports. Abbott shall keep the JSC regularly informed of the progress of its efforts to Develop Compounds
in the Field and in the Territory. Without limiting the generality of the foregoing, Abbott shall, at least once per Calendar Quarter, provide the JSC with reports in reasonable detail regarding the status of all pre-clinical IND-enabling studies
and activities (including toxicology and pharmacokinetic studies), clinical trials and other activities conducted under each Development Plan, together with summary data and results and raw data made available if requested for each such pre-clinical
IND-enabling study or activity, clinical trial and such additional information that it has in its possession as may be reasonably requested from time to time by the JSC. 
 4.5.2 Commercialization Reports. Abbott shall keep the JSC regularly informed of the progress of its efforts to Commercialize Products in the Field and in the Territory. Without limiting the
generality of the foregoing, Abbott shall provide Enanta with semi-annual written updates to each Marketing and Sales Plan, which shall (a) summarize Abbott’s efforts to Commercialize Products, (b) identify the Regulatory Filings and
Drug Approval Applications with respect to Candidates that Abbott or any of its Affiliates or Sublicensees have filed in the prior twelve (12) month period or reasonably expect to make in the following twelve (12) month period,
(c) identify the Regulatory Approvals with respect to Products that Abbott or any of its Affiliates or Sublicensees have obtained in the prior twelve 

  
 - 27 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
(12) month period or reasonably expect to obtain in the following twelve (12) month period, and (d) summarize all clinical and other data generated by Abbott with respect to Products.
In addition, Abbott shall provide such additional information that it has in its possession as may be reasonably requested from time to time by the JSC regarding the Commercialization of any Product. 

4.5.3 Supply of Products for Development and Commercialization. Abbott shall be solely responsible, at its sole cost for
manufacturing or having manufactured through Third Party contract manufacturers, any and all Products for Commercialization. For purposes of clarification, manufacturing costs for Co-Developed Products are referenced in Sec. 1.37 “Development
Costs” and Schedule 6 “Cost of Goods”. 
 4.5.4 Adverse Event Reports. Within ninety (90) days
after the date of this Agreement, the Parties shall enter into an agreement to initiate a process for the exchange of adverse event safety data in a mutually agreed format, including, but not limited to, post-marketing spontaneous reports received
by the Party or its Affiliates in order to monitor the safety of the Product and to meet reporting requirements with any applicable Regulatory Authority. 
 4.5.5 Preparation and Review of Regulatory Filings and Correspondence. 
 (a) Preparation of Drug Approval Applications. Abbott shall consult with Enanta in good faith in the preparation of all Drug Approval Applications for Candidates. Abbott shall consider all comments
of Enanta in good faith, taking into account the best interests of the Collaboration and of the Development of the applicable Candidate and Commercialization of the corresponding Product on a global basis. 

(b) Regulatory Meetings; Review of Regulatory Filings and Correspondence. Abbott shall use Commercially Reasonable Efforts to
provide Enanta with at least [*****] advance notice of any key meetings with the FDA or other Regulatory Authority regarding a Drug Approval Application relating to, or Regulatory Approval for, any Candidate or Product, as the case may be, and
provide Enanta with material related to such meeting. Enanta may elect to send one (1) individual reasonably acceptable to Abbott to participate as an observer (at Enanta’s sole cost and expense) in meetings with the FDA. In addition,
Abbott shall provide Enanta with initial IND filings or Drug Approval Applications sufficiently in advance of submission so that Enanta may review and comment on the substance of such Regulatory Filing or other document or correspondence. In
addition, Abbott shall promptly provide Enanta with copies of any FDA milestone meetings or NDA labeling discussions pertaining to any Candidate or Product. If Enanta has not commented on such Regulatory Filing or other document or correspondence
within [*****] after it is provided to Enanta, then Enanta shall be deemed to have no comments on such Regulatory Filing or other documents or correspondence. Abbott shall consider all comments of Enanta in good faith, taking into account the best
interests of the Collaboration and of the Development of the applicable Candidate or Commercialization of the corresponding Product on a global basis. 

  
 - 28 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 For a Co-Developed Product, Abbott shall notify Enanta of any material communication with any Regulatory
Authority regarding drug approval, drug labeling, or safety matters and shall promptly provide copies of any material document or other material correspondence received from any Regulatory Authority. 

4.6 Product Recalls. In the event that any Regulatory Authority issues or requests a recall or takes similar action in
connection with a Co-Developed Product, or in the event a Party reasonably believes that an event, incident or circumstance has occurred that may result in the need for a recall, market withdrawal or other corrective action regarding a Co-Developed
Product, such Party shall promptly advise the other Party thereof by telephone or facsimile. Following such notification, Abbott shall decide and have control of whether to conduct a recall or market withdrawal (except in the event of a recall or
market withdrawal mandated by a Regulatory Authority, in which case it shall be required) or to take other corrective action in any country and the manner in which any such recall, market withdrawal or corrective action shall be conducted; provided
that Abbott shall keep Enanta regularly informed regarding any such recall, market withdrawal or corrective action. Abbott shall bear all expenses of any such recall, market withdrawal or corrective action (including, without limitation, expenses
for notification, destruction and return of the affected Co-Developed Product and any refund to customers); provided, that, any such expenses shall be allocable as Co-Developed Costs or Commercialization Expenses and shared by the Parties in
accordance with Section 5.3. 
 4.7 Product Labeling. All product labels for Products shall include the names
and logos of both Abbott and Enanta, to the extent consistent with the Applicable Laws of any country in which Products are sold. 
  

	5.	CO-DEVELOPMENT AND PROFIT SHARE OPTION 

 5.1 Exercise of Co-Development and Profit Share Option. Enanta shall have the option (the “Co-Development and Profit Share Option”), but not the obligation, to
co-develop and share in the profits of any Product in the Co-Development Territory by providing written notice to Abbott at any time during the Co-Development and Profit Share Option Period, which notice shall identify the Compound or Candidate, as
the case may be. 
 5.2 Effect of Exercise. If Enanta exercises the Co-Development and Profit Share Option with
respect to a Compound or Candidate, as the case may be, as described in Section 5.1 then: (a) that Compound or Candidate, as the case may be, will thereafter be deemed to be a Co-Developed Product for purposes of this Agreement;
(b) the Parties shall prepare and provide to the JSC for its review and approval a Marketing and Sales Plan for such Co-Developed Product within the Co-Development Territory which shall be updated and submitted by the Parties to the JSC not
less than annually; (c) Abbott shall provide Enanta, as promptly as possible thereafter, with Abbott’s revised non-binding, good faith estimate of Development Costs it expects to incur with respect to that Co-Developed Product within the
Co-Development Territory for each Calendar Quarter for the next five (5) Calendar Years; (d) except with respect to the allocation of Shared Clinical Trial Costs in accordance with Section 5.4, Enanta shall be responsible for the
Enanta Co-Development Percentage of all Development Costs applicable to that Co-Developed Product incurred on and after the Co-Development and Profit Share Option Exercise Date within 

  
 - 29 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
the Co-Development Territory; (e) Enanta shall have the right to employ a number of Enanta Representatives to Co-Promote such Co-Developed Product in the Co-Development Territory equal to
the Enanta Co-Development Percentage; (f) the Parties shall negotiate a Co-Promotion Agreement for such Co-Developed Product in accordance with Section 5.7; and (g) Enanta shall receive the Enanta Co-Development Percentage of all
Operating Income derived from that Co-Developed Product in accordance with Section 6.5.2. The Parties hereby acknowledge and agree that either Party shall have the right to propose the addition of other therapeutically or biologically active
ingredients for inclusion with a Co-Developed Product to create a Combination Product. Enanta and Abbott will negotiate in good faith on the terms for the development and commercialization of a Combination Product created from a Co-Developed Product
that have not been contemplated in this Agreement. 
 5.3 Reconciliation and Auditing of Development Costs.

 5.3.1 Reconciliation of Development Costs. Within [*****] following the end of each Calendar Quarter following
the exercise of the Co-Development and Profit Share Option applicable to a given Co-Developed Product, Abbott shall submit to JSC a written report setting forth in reasonable detail all Development Costs incurred by Abbott over such Calendar
Quarter. Within [*****] following the JSC’s receipt of such written reports, the JSC shall prepare and submit to Enanta a written report setting forth in reasonable detail the calculation of the net amount owed by Enanta to Abbott in order to
ensure the appropriate sharing of the Development Costs in accordance with the Enanta Co-Development Percentage and the Abbott Co-Development Percentage, respectively. Enanta shall pay the net amount to Abbott within [*****] after the distribution
by the JSC of such written report. 
 5.3.2 Records; Audit Rights. Abbott shall keep and maintain for [*****]
complete and accurate records of Development Costs incurred with respect to Co-Developed Products in sufficient detail to allow confirmation of same by Enanta. Enanta shall have the right for a period of [*****] after such Development Cost is
reconciled in accordance with Section 5.2 to inspect or audit, or to appoint, at its expense, an independent certified public accountant reasonably acceptable to Abbott to inspect or audit, the relevant records of Abbott and its Affiliates to
verify that the amount of such Development Costs was correctly determined. Abbott and its Affiliates shall each make its records available for inspection or audit by such independent certified public accountant during regular business hours at such
place or places where such records are customarily kept, upon reasonable notice from Enanta, solely to verify that Development Costs hereunder were correctly determined; provided that Enanta shall not have the right to inspect or audit any Calendar
Year [*****]. All records made available for inspection or audit shall be deemed to be Confidential Information of Abbott. The results of each inspection or audit, if any, shall be binding on both Parties. In the event there was an error in the
amount of Development Costs reported by Abbott hereunder, (a) if the amount of Development Costs was over-reported, Abbott shall promptly (but in any event no later than [*****] after Abbott’s receipt of the independent accountant’s
report so concluding) make payment to Enanta of the over-reported amount and (b) if the amount of Development Costs was underreported, Enanta shall promptly (but in any event no later than [*****] after Enanta’s receipt of the independent
accountant’s report so concluding) make payment to Abbott of the underreported amount. Enanta shall bear the full cost of such audit unless such audit discloses 

  
 - 30 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
an over-reporting by Abbott of more than [*****] of the aggregate amount of Development Costs reportable in any Calendar Year, in which case Abbott shall reimburse Enanta for all costs incurred
by Enanta in connection with such inspection or audit. 
 5.4 Allocation of Shared Clinical Trial Costs.

 5.4.1 Use of Shared Clinical Trial Data. On and after the date of exercise by Enanta of its
Co-Development and Profit Share Option for a Co-Developed Product and continuing for the Term of this Agreement [*****], whichever date is earlier, each Party shall provide written notice to the other Party to the extent it Materially Used any
Shared Clinical Trial Data (the “Shared Clinical Trial Notice”). 
 5.4.2 True- Up of Clinical
Trial Costs. Within [*****] of the end of each Calendar Year following the date of the Shared Clinical Trial Notice, each Party shall submit to JSC a written report setting forth in reasonable detail all Shared Clinical Trial Costs incurred
by such Party over such Calendar Year. Within [*****] following the JSC’s receipt of such written reports, the JSC shall prepare and submit to each Party a written report setting forth in reasonable detail the calculation of the net amount owed
by a Party to the other Party in order to ensure the appropriate sharing of the Shared Clinical Trial Costs [*****]. The net amount payable shall be due within [*****] after receipt of any such accounting. 

5.4.3 Data Audit. Promptly following the submission of each Regulatory Filing, and any amendments or supplements thereto,
the Party making such submission shall provide a full and complete copy of such filing to the other Party for purposes of determining whether the submitting Party has Materially Used the other Party’s Shared Clinical Trial Data without having
paid its applicable Shared Clinical Trial Cost Sharing Percentage associated with such Shared Clinical Trial Data. In the event that a Party Materially Used the other Party’s Shared Clinical Trial Data in such submission, the submitting Party
shall immediately pay its applicable Shared Clinical Trial Cost Sharing Percentage to the other Party upon written request by the other Party. 
 5.5 Roll-Over Payments. If, in any Calendar Quarter, the actual Development Costs incurred by Enanta with respect to a Co-Developed Product for that Calendar Quarter exceeds by greater than
[*****] Abbott’s good faith estimate of Development Costs for that Co-Developed Product for that Calendar Quarter, Enanta may, upon written notice to Abbott, delay payment of its share of any such excess until the subsequent Calendar Year (the
“Roll-Over Payment”). Enanta shall make the Roll-Over Payment in two (2) equal amounts over the first two (2) consecutive Calendar Quarters of the subsequent Calendar Year. 

5.6 [*****]. 

5.7 Co-Promotion. 
 5.7.1 Preparation and Execution of Co-Promotion Agreement. As soon as practicable but no later than the date of completion of a Phase III Clinical Trial with respect to a Co-Developed
Product, the Parties shall complete and execute a Co-Promotion Agreement (the 

  
 - 31 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
“Co-Promotion Agreement”) which shall provide for the terms applicable to such Co-Promotion and shall conform in all material respects with the terms and conditions set
forth in Schedule 5 attached hereto and such additional provisions as are usual and customary for inclusion in a co-promotion agreement between companies in the pharmaceutical industry of comparable sizes to the respective Parties. Such
additional terms shall supplement and shall not materially expand, limit or change the terms set forth on Schedule 5. The Parties shall negotiate the Co-Promotion Agreement in good faith and with sufficient diligence as is required to
execute and deliver the Co-Promotion Agreement within [*****] of commencing negotiations. 
 5.7.2 Dispute
Resolution. In the event the Parties fail to execute and deliver the Co-Promotion Agreement within the [*****] period described in Section 5.6.1, the Parties shall (a) use reasonable efforts to complete such negotiations and to
execute and deliver the Co-Promotion Agreement as soon as possible after such [*****] period and (b) without limiting the generality of the foregoing, after the expiration of such [*****] period, each produce a list of issues on which they have
failed to reach agreement and submit its list to the JSC to be resolve in accordance with Section 2.1.6. Notwithstanding the foregoing, the Parties shall, upon the request by either Party during the negotiation period, discuss in good faith
whether to enter into an agreement with a Third Party to Co-Promote the Co-Developed Product, in which case, Enanta shall share in the consideration received from such Third Party in accordance with the Enanta Co-Development Percentage. 

5.7.3 Co-Promotion Plan. The JDCC shall prepare a Co-Promotion Plan for each Co-Developed Product for the Co-Development
Territory which shall include, but not be limited to, (a) demographics and market dynamics, market strategies, and estimated launch date of such Co-Developed Product in the Co-Development Territory, (b) a sales and expense forecast
(including at least five (5) years of estimated sales and expenses), manufacturing plans and targeted label claims for such Co-Developed Product in the Co-Development Territory, (c) a marketing plan (including five (5) year
advertising and Detailing forecasts and pricing strategies) for such Co-Developed Product in the Co-Development Territory, and (d) a five (5) year budget for such Co-Developed Product for the Co-Development Territory. The Co-Promotion Plan
and annual written updates thereto shall be submitted to the JDCC for review by a date to be established by the JDCC, taking into account Abbott’s and Enanta’s annual budget planning calendars, but no later than December 31 of each
Calendar Year. 
  

	6.	CONSIDERATION AND FUNDING 

 6.1 Upfront Fee. On the Approval Date, Abbott shall be obligated to pay Enanta a non-refundable, non-creditable fee in the amount of Forty-Four Million Seven Hundred Thousand Dollars (US
$44,700,000). [*****] of this fee is payable by wire transfer of immediately available funds on the first business day following the Approval Date. [*****] of this fee is payable by wire transfer on the first anniversary of the first business day
following the Approval Date. 
 6.2 Purchase of Equity; Participation Right. In partial consideration of the
rights granted by Enanta to Abbott hereunder, Abbott agrees to purchase from Enanta, and Enanta hereby agrees to issue and sell to Abbott, shares of Series G Preferred Stock, $.001 par value per

  
 - 32 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
share (the “Shares”), of Enanta for an aggregate purchase price of Twelve Million Five Hundred Thousand Dollars (US $12,500,000). Abbott shall be obligated to make such
payment to Enanta on the Approval Date. Such payment is payable by wire transfer of immediately available funds on the first business day following the Approval Date and pursuant to the terms and subject to the conditions set forth in the Stock
Purchase Agreement attached hereto as Exhibit B (the “Stock Purchase Agreement”). 
 6.3
R&D Funding. 
 6.3.1 FTE Costs. Beginning on the first day of the third year of the
Research Program Term and on the first day of each subsequent Calendar Quarter during the Research Program Term, Abbott shall make a payment equal to [*****] (“Quarterly Research Payment”, which is equal to [*****] per
Calendar Year (the “Annual Research Payment”)). For the third year of the Research Program Term (and any subsequent years of the Research Program Term, if extended as per Section 3.8), Enanta shall provide Abbott with an
annual reconciliation statement that specifies the actual number of FTEs for that third (and subsequent, if applicable) year of the Research Program Tenn. If, with respect to that third (and subsequent, if applicable) year of the Research Program
Term, the FTE Cost attributable to the number of FTEs specified in the annual reconciliation statement for such third (and subsequent, if applicable) year of the Research Program Term is less than the Annual Research Payment for such third (and
subsequent, if applicable) year of the Research Program Term, Abbott shall have the right to apply the excess paid by it towards the FTE Cost due to Enanta in subsequent years of the Research Program Teini, if any, until such balance is zero. If the
Research Program Term ends before such balance is zero, Enanta will pay such excess payment to Abbott within thirty (30) days after the end of the Research Program Term. If, with respect to that third (and subsequent, if applicable) year of the
Research Program Term, the FTE Cost attributable to the number of FTEs specified in the annual reconciliation statement for such third (and subsequent, if applicable) year of the Research Program Term is more than the Annual Research Payment for
such third (and subsequent, if applicable) year of the Research Program Term, Enanta shall be solely responsible for such excess FTE Cost. 
 6.3.2 Research Funding Audit Rights. Enanta shall keep complete and accurate books and financial records pertaining to its costs and expenses of conducting the Research Program, which books
and financial records shall be kept in accordance with GAAP and shall be retained by Enanta until [*****] after the end of the Calendar Year to which they pertain. Abbott shall have the right to appoint, at its expense, an independent certified
public accountant reasonably acceptable to Enanta to inspect or audit, the books and financial records of Enanta relating to its costs and expenses of conducting the Research Program during any Calendar Year; provided that Abbott shall not have the
right to inspect or audit any Calendar Year more than [*****]. All books and financial records made available for inspection or audit shall be deemed to be Confidential Information of Enanta. The results of each inspection or audit, if any, shall be
binding on both Parties. In the event there was an error in the amount of FTE Costs reported by Enanta hereunder, (a) if the amount of FTE Costs was over-reported, Enanta shall promptly (but in any event no later than [*****] after
Enanta’s receipt of the independent accountant’s report so concluding) make payment to Abbott of the over-reported amount and (b) if the amount of FTE Costs was underreported, Abbott shall promptly (but in any

  
 - 33 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
event no later than [*****] after Abbott’s receipt of the independent accountant’s report so concluding) adjust its records to reduce the balance of any excess payment by the amount of
the under-reported amount. Abbott shall bear the full cost of such audit unless such audit discloses an over-reporting by Enanta of more than [*****] of the aggregate amount of FTE Costs reportable in any Calendar Year, in which case Enanta shall
reimburse Abbott for all costs incurred by Abbott in connection with such inspection or audit. 
 6.4 Milestone
Payments. 
 6.4.1 Milestones. 

(a) First Product. Abbott shall make each of the following non-refundable, non-creditable payments to Enanta within thirty
(30) days after the occurrence of each of the following milestone events for the first Candidate or Product, as the case may be, that is not a Co-Developed Product (the “Initial Product”): 

 

			
	 Milestone Event
	  	 Milestone Payment

	 Successful Completion of Phase Ib/IIa Clinical Study
	  	$40 million
		
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]

 (b) Additional Products. To the extent that one (1) or more additional Candidates or
Products, as the case may be, are Developed and Commercialized following receipt of Commercialization Regulatory Approval of the first Product, Abbott shall make each of the following non-refundable, non-creditable payments to Enanta within thirty
(30) days after the occurrence of each of the following milestone events for each additional Product that is not a Co-Developed Product (each, an “Additional Product”): 

 

			
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]

 (c) First Co-Developed Product. In lieu of the payments to be made by Abbott pursuant to
Section 6.4.1(a), Abbott shall make each of the following non-refundable, non-creditable payments to Enanta within thirty (30) days after the occurrence of each of the following milestone events in the event the first Candidate or Product,
as the case may be, is a Co-Developed Product (the “Initial Co-Developed Product”): 
  

			
	 Milestone Event
	  	 Milestone Payment

	 [*****]
	  	[*****]
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]

  
 - 34 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Notwithstanding the foregoing, in the event that Enanta exercises a Co-Development and
Profit-Share Option with respect to a Candidate or Product, as the case may be, the milestone payments applicable under this Section 6.4.1(c) shall be reduced in the aggregate by [*****] for the first to occur of (i) filing of the first
Regulatory Filing for such Co-Developed Product in the European Union, (ii) the first Commercialization Regulatory Approval in Japan received for such Co-Developed Product and (iii) the first Commercialization Regulatory Approval in the
European Union received for such Co-Developed Product. The forgoing reduction shall only apply to the Initial Co-Developed Product. 
 (d) Additional Co-Developed Products. In lieu of the payments to be made by Abbott pursuant to Section 6.4.1(b), to the extent that one (1) or more Co-Developed Products are
Developed and Commercialized following receipt of Commercialization Regulatory Approval of the first Product, regardless of whether the first Product is an Initial Product or an Initial Co-Developed Product, Abbott shall make each of the following
non-refundable, non-creditable payments to Enanta within thirty (30) days after the occurrence of each of the following milestone events for each additional Co-Developed Product (each, an “Additional Co-Developed
Product”): 
  

			
	 [*****]
	  	[*****]
	 [*****]
	  	[*****]

 6.4.2 Milestone Payments and Notices. Abbott shall provide Enanta with prompt written
notice upon each achievement of a milestone event set forth in Section 6.4.1, which notice shall include a description of the applicable milestone event. In the event that, notwithstanding the fact that Abbott has not given such a notice,
Enanta believes any such milestone event has occurred, it shall so notify Abbott in writing and shall provide to Abbott data, documentation or other information that supports its belief. Any dispute under this Section 6.4.2 that relates to
whether a milestone event has been achieved shall be referred to the JSC to be resolved in accordance with Section 2.1.6. In the event Abbott proceeds to the next stage of Development for a Candidate, any milestone payments that were not paid
for any prior stages of Development that are otherwise applicable to such Candidate, shall also be due and payable. For example, if a Phase IIb Clinical Trial is initiated without payment of the Successful Completion of Phase Clinical Study, then
the Successful Completion of Phase Ib/IIa Clinical Study will be deemed to have occurred and will be paid in full upon payment of the milestone payable upon the submission of the first NDA filing. 

  
 - 35 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

	 	6.5	Payment of Royalties; Operating Income Payments; Sublicense Income Payments; Accounting and Records. 

6.5.1 Payment of Royalties. 
 (a) Payment of Royalties. Abbott shall pay Enanta a royalty based on Annual Net Sales of each Royalty-Bearing Product commencing with the Calendar Year (or partial Calendar Year) in which the First
Commercial Sale of such Royalty-Bearing Product occurs and ending upon the expiration of the Royalty Term for such Royalty-Bearing Product, at the following rates (such royalty payments, the “Royalty Payments”): 

 

			
	 Annual Net Sales
	  	 Royalty Rate

	 Up to (but not including) [*****]
	  	[*****]
		
	 Equal to or greater than [*****] and up to (but not including) [*****]
	  	[*****]
		
	 Equal to or greater than [*****] and up to (but not including) [*****]
	  	[*****]
		
	 Equal to or greater than [*****] and up to (but not including) [*****]
	  	[*****]
		
	 Equal to or greater than [*****]
	  	[*****]

 For example, if Annual Net sales of a Royalty-Bearing Product were [*****], the royalty payment would be [*****].

 (b) Offsets for Third Party Payments. In the event Abbott, in order to practice the license granted to it under
Section 8.2.1 of this Agreement in any country in the applicable portion of the Territory in which royalties are payable as provided in Section 6.5.1, is required to and actually makes royalty payments to any Third Party (“Third
Party Payments”) in order to obtain a license to an issued patent or patents in the absence of which the Compound portion of the Royalty Bearing Product could not legally be researched, Developed, manufactured, imported, sold, exported,
or otherwise exploited in such country (as evidenced, to the extent reasonably requested by Enanta, by an opinion of patent counsel), then the royalties payable to Enanta for such Royalty-Bearing Product under this Agreement with respect to such
country may be reduced by [*****] of the amount of such Third Party Payments. Notwithstanding the foregoing, (i) [*****], and (ii) such reductions shall in no event reduce the royalty that would otherwise be payable for such
Royalty-Bearing Product under Section 6.5.1 with respect to such country by more than [*****] of the amount otherwise payable with respect to Net Sales of such Royalty-Bearing Product in such country. 

(c) No Patent Coverage. Notwithstanding Section 6.5.1(a), if any Royalty-Bearing Product is sold in a country and is not
covered by a Valid Claim of the Licensed Patent Rights, Abbott Patent Rights or Joint Patent Rights in such country, the royalty rate in such country shall be reduced by [*****] of the rates set forth above, continuing until the last

  
 - 36 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
day of the Royalty Term with respect to such Royalty-Bearing Product; provided, that, in the event the royalty rate on a Royalty-Bearing Product is reduced in a country under this
Section 6.5.1(c) and is subsequently covered by a Valid Claim under the Licensed Patent Rights, Abbott Patent Rights or Joint Patent Rights in such country, (i) the full royalty rates otherwise applicable under Section 6.5.1(a) shall
be reinstated for the remainder of the Royalty Term, and (ii) for any period of time that the royalty rate on a Royalty-Bearing Product is reduced but a pending patent application exists which subsequently results in such Valid Claim, Abbott
shall make a one-time payment to Enanta in an amount equal to the difference between (A) the amounts that would have been payable under full royalty rates applicable under Section 6.5.1(a) during such time, and (B) amounts that were
paid under the royalty rates applicable under this Section 6.5.1(c) during such time. 
 (d) Generic Products. In
the event one or more Third Parties sell a Generic Product (as defined below) in a country in which a Royalty-Bearing Product is then being sold, then, during the period in which sales of the Generic Product by such Third Parties in the aggregate
are equal to at least [*****] of Abbott’s volume-based or revenue-based market share of the Royalty-Bearing Product in such country (as measured by prescriptions or other similar information available in such country), all applicable royalties
in effect with respect to such Royalty-Bearing Product in such country as specified in Section 6.4.1 shall be reduced by [*****]. Notwithstanding the foregoing, Abbott’s obligation to pay royalties at the full royalty rates shall be
reinstated on the first day of the Calendar Quarter immediately following the Calendar Quarter in which sales of such Generic Product account for less than [*****] of Abbott’s volume-based or revenue-based market share in such country. For
purposes of this Section 6.5.1(d), a “Generic Product” means a pharmaceutical product that (i) is not covered by a Valid Claim under the Licensed Patent Rights, Abbott Patent Rights or Joint Patent Rights in the
relevant country, (ii) contains the same active ingredient as a Royalty-Bearing Product and (iii) is bioequivalent to such Royalty-Bearing Product. 
 (e) Combination Products. For each Royalty-Bearing Product that is a Combination Product, the Parties shall, on a country-by-country basis, agree to an appropriate adjustment to Net Sales to
reflect a good faith determination of the relative value of each pharmaceutically active ingredient, based on the estimated fair market value of each such therapeutically or biologically active ingredient, as follows: [*****]. In the case where the
Parties are unable to agree on [*****], the Parties shall agree upon an internationally recognized independent certified public accountant who shall make such determination and whose determination shall be final and binding on the Parties.

 (f) Know-How Payments. The Parties hereby acknowledge and agree that any royalties that are payable for a
Royalty-Bearing Product under 6.5.1 (c) for which no Patent Rights exist shall be in consideration of: (i) Enanta’s expertise and know-how concerning the identification of Compounds in the Field, and its other Compound-related
development activities conducted prior to the Effective Date; (ii) the performance by Enanta of the Research Program; (iii) the disclosure by Enanta to Abbott of results obtained in the Research Program; (iv) the licenses granted to
Abbott hereunder with respect to Licensed Technology and Joint Technology that are not within the claims of any Patent Rights Controlled by Enanta; (v) the restrictions on Enanta in Section 8.5; and (vi) the “head start”
afforded to Abbott by each of the foregoing. 

  
 - 37 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (g) Payment Dates and Reports. Abbott shall make Royalty Payments within [*****].
All payments shall be made by wire transfer to the credit of such bank account as shall be designated in writing from time to time by Enanta. Abbott shall also provide, at the same time each such payment is made, a report showing: (i) the Net
Sales of each Royalty-Bearing Product by country in the Territory; (ii) the basis for any deductions from gross amounts billed or invoiced to determine Net Sales; (iii) the applicable royalty rates for such Royalty-Bearing Product;
(iv) the exchange rates used in calculating any of the foregoing; and (v) a calculation of the amount of royalty due to Enanta. 
 6.5.2 Operating Income Payments. Enanta shall receive from Abbott, in lieu of receiving any Royalty Payments with respect to each Co-Developed Product in the Co-Development Territory, the
Enanta Co-Development Percentage of all Annual Operating Income derived from sales of that Co-Developed Product in the Co-Development Territory (such payments, the “Operating Income Payments”) for as long as there are sales
by Abbott, its Affiliates and Sublicensees of such Co-Developed Product (the “Co-Development Term”). Within thirty (30) days following the end of each Calendar Quarter commencing on and after the date of First Commercial
Sale of each Co-Developed Product, (a) Enanta shall submit to the JSC a statement identifying all Commercialization Expenses and License Fees incurred by it with respect to such Co-Developed Product in the Co-Development Territory and
(b) Abbott shall submit to the JSC a statement identifying the Net Sales, Cost of Goods, freight, Third Party Payments, R&D and all Commercialization Expenses incurred by it with respect to such Co-Developed Product. Within forty-five
(45) days following the end of the Calendar Quarter, the JSC shall submit to the Parties a written report setting forth in reasonable detail (c) the calculation of Operating Income, determined in accordance with Schedule 6
attached hereto and (d) the calculation of the amount of Operating Income payable to Enanta in accordance with the Enanta Co-Development Percentage for that Co-Developed Product taking into account Enanta’s expenditures for the period.
Abbott shall make the Operating Income Payments to Enanta within thirty (30) days following the issuance of such written report. 
 6.5.3 Sublicense Income Payments. Abbott shall pay Enanta the Applicable Percentage of all Sublicense Income received by Abbott under Sublicense Agreements with respect to Products
(“Sublicense Income Payments”). As used herein, the term “Applicable Percentage” shall mean [*****]. Abbott shall make all Sublicense Income Payments within thirty (30) days of the end of the
Calendar Quarter commencing with the first Calendar Quarter in which any Sublicense Income is received. 
 6.5.4 Records;
Audit Rights. Abbott and its Affiliates and Sublicensees shall keep and maintain for [*****] from the date of each Royalty Payment, Operating Income Payment and Sublicense Income Payment complete and accurate records of gross sales and Net
Sales by Abbott and its Affiliates and Sublicensees of each Product, in sufficient detail to allow Royalty Payments, Operating Income Payments and Sublicense Income Payments to be determined accurately. Enanta shall have the right for a period of
[*****] after receiving any such payment to inspect or audit, or to appoint at its expense an independent certified public 

  
 - 38 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
accountant reasonably acceptable to Abbott to inspect or audit the relevant records of Abbott and its Affiliates and Sublicensees to verify that the amount of such payment was correctly
determined. Abbott and its Affiliates and Sublicensees shall each make its records available for inspection or audit by such independent certified public accountant during regular business hours at such place or places where such records are
customarily kept, upon reasonable notice from Enanta, solely to verify that Royalty Payments and Sublicense Income Payments were correctly accounted for or determined. Enanta shall not exercise such inspection or audit right [*****]. All records
made available for inspection or audit shall be deemed to be Confidential Information of Abbott. The results of each inspection or audit, if any, shall be binding on both Parties. In the event there was an underpayment by Abbott, Abbott shall
promptly (but in any event no later than [*****] after Abbott’s receipt of the independent accountant’s report so concluding) make payment to Enanta of any shortfall, together with the interest payment as provided in Section 6.5.5. In
the event that there was an overpayment by Abbott, Enanta shall promptly (but in any event no later than [*****] after Enanta’s receipt of the independent accountant’s report so concluding) refund to Abbott the excess amount. Enanta shall
bear the full cost of such audit unless such audit discloses an underreporting by Abbott of more than [*****] of the aggregate amount of Royalty Payment or Sublicense Income Payments payable in any Calendar Year, in which case Abbott shall reimburse
Enanta for all costs incurred by Enanta in connection with such inspection or audit. 
 6.5.5 Overdue Royalties, Operating
Income Payments and Milestones. All Royalty Payments, Operating Income Payments and Sublicense Income Payments not made within the time period set forth in Section 6.5.1, 6.5.2 and 6.5.3, and all milestone payments not made within the
time period specified in Section 6.4.1, shall bear interest at a rate of [*****] percent ([*****]%) per month from the due date until paid in full or, if less, the maximum interest rate permitted by Applicable Laws. Any such overdue Royalty
Payment, Sublicense Income Payment, Operating Income Payment or milestone payment shall, when made, be accompanied by, and credited first to, all interest so accrued. 
 6.5.6 Withholding Taxes. All payments made by Abbott hereunder shall be free and clear of any taxes, duties, levies, fees or charges except for applicable withholding taxes, if any. Abbott
shall make any applicable withholding payments due from Enanta on its behalf and shall promptly thereafter provide Enanta with written documentation of any such payment sufficient to enable Enanta to satisfy the requirements of the United States
Internal Revenue Service with regard to an application for a foreign tax credit for such payment. 
 6.5.7 Foreign
Currency Exchange. All Royalty Payments, Operating Income Payments and Sublicense Income Payments shall be payable in full in United States Dollars, regardless of the countries in which sales are made. For the purpose of computing Net Sales
for Products sold in any currency other than United States Dollars, the quarterly Royalty Payment will be calculated as follows: 

(A/B) × C= United States Dollars Royalty Payment on Net Sales sold in any currency other than United States Dollars during a
Calendar Quarter, where 

  
 - 39 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 A= foreign “Net Sales” (as defined above) in such Calendar Quarter expressed in
such foreign currency; 
 B= foreign exchange conversion rate, expressed in local currency of the foreign country per United
States Dollar (using, as the applicable foreign exchange rate, the average of the monthly average rates for that Calendar Quarter as published by Bloomberg, and if Bloomberg is not available then another similar third party source); and 

C= the royalty rate(s) applicable to such Net Sales under this Agreement. 

6.6 No Other Compensation. The Parties hereby agree that the terms of this Agreement and the Stock Purchase Agreement fully
define all consideration, compensation and benefits, monetary or otherwise, to be paid, granted or delivered by each Party to the other Party in connection with the transactions contemplated herein. Neither Party has previously paid or entered into
any other commitment to pay, whether orally or in writing, any employee of the other Party, directly or indirectly, any consideration, compensation or benefits, monetary or otherwise, in connection with the transactions contemplated herein.

 6.7 [*****]. 
  

	7.	TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY; NON-SOLICITATION 

 7.1 Confidentiality. 
 7.1.1 Confidentiality Obligations.
Enanta and Abbott each recognizes that the other Party’s Confidential Information constitutes highly valuable assets of such other Party. Enanta and Abbott each agrees that, subject to Section 7.1.2, during the Term and for an
additional five (5) years thereafter, it will not disclose or use, and will cause its Affiliates and sublicensees not to disclose or use, any Confidential Information of the other Party, except as expressly permitted hereunder. In fulfilling
its obligations of confidentiality under this Article 7, each Party shall take such action, and shall cause its Affiliates and sublicensees to take such action, to preserve the confidentiality of the other Party’s Confidential Information as
such Party would customarily take to preserve the confidentiality of its own Confidential Information. 
 7.1.2 Limited
Disclosure. Enanta and Abbott each agrees (a) that disclosure of its Confidential Information or any transfer of its Proprietary Materials may be made by the other Party to any employee, consultant, director or Affiliate of such other
Party to enable such other Party to exercise its rights or to carry out its responsibilities under this Agreement; provided that any such disclosure or transfer shall only be made to Persons who are bound by written obligations as described in
Section 7.1.3, and (b) disclosure of its Confidential Information may be made by the other Party (1) on a need-to-know basis to such other Party’s legal and financial advisors, or (ii) as reasonably necessary in connection
with an actual or potential (A) permitted sublicense of such other Party’s rights hereunder, (B) debt or equity financing of such other Party or (C) Change of Control involving such other Party, provided, in any case, the Person
receiving such Confidential Information of the other Party agrees in writing to maintain the confidentiality 

  
 - 40 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
of such Confidential Information of the other Party with terms at least as restrictive as those contained in Section 7.1.1. In addition, each Party agrees that the other Party may disclose
such Party’s Confidential Information (a) as reasonably necessary to file, prosecute or maintain Patent Rights, or to file, prosecute or defend litigation related to Patent Rights, in accordance with this Agreement or (b) as required
by Applicable Laws; provided that, in the case of any disclosure under this clause (b), the Disclosing Party shall (i) provide the other Party with written notice not less than five (5) business days prior to such disclosure and provide
the other Party with an opportunity to comment on any such required disclosure, (ii) if requested by such other Party, seek, or cooperate in all reasonable respects with such other Party’s efforts to obtain, confidential treatment or a
protective order with respect to any such disclosure to the extent available at such other Party’s expense, and (iii) use good faith efforts to incorporate the comments of such other Party in any such disclosure or request for confidential
treatment or protective order. 
 7.1.3 Employees and Consultants. Enanta and Abbott each represents that
all of its employees and consultants, and all of the employees and consultants of its Affiliates or sublicensees, who participate in the activities of the Collaboration or have access to Confidential Information of the other Party are or will, prior
to their participation or access, be bound by written obligations to maintain such Confidential Information in confidence and not to use such information except as expressly permitted hereunder. Each Party agrees to use, and to cause its Affiliates
and sublicensees to use, reasonable efforts to enforce such obligations. 
 7.2 Publicity. The Parties
acknowledge that the terms of this Agreement constitute Confidential Information of each Party and may not be disclosed except as permitted by Section 7.1.2. Notwithstanding anything to the contrary in Section 7.1, the Parties, after
approval of this Agreement by the Abbott Board, Abbott’s Chief Executive Officer and the Enanta Board and agreement by both Parties, shall file the press release attached hereto as Exhibit C (the “Initial Press
Release”) and, once the Initial Press Release is disclosed by either Party, then either Party may make subsequent public disclosure of the specific contents of such press release without further approval of the other Party. Thereafter,
except as may be required by Applicable Laws, neither Party shall publish, present or otherwise disclose publicly any material related to the Research Program, the Development of a Candidate or the Commercialization of a Product without the prior
written consent of the other Party; provided, that notwithstanding the foregoing, (a) either Party shall be permitted to publish such material in scientific journals or present such material at scientific conferences in accordance with
Section 7.3, (b) Abbott shall control interactions with the FDA DDMAC regarding publicity of marketed products, as provided in Section 4.2.2, and (c) Abbott and Enanta agree that it shall not unreasonably withhold, condition or
delay its consent to any request by the other Party to publish, present or otherwise announce publicly developments in the Research Program, the Development of Candidates or the Commercialization of Products. 

7.3 Publications and Presentations. The Parties acknowledge that scientific publications must be strictly monitored
to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Except as required by Applicable Laws, each Party agrees that it shall not publish or present, or permit to be published or presented,
the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of

  
 - 41 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each Party shall provide to the JSC the opportunity to review any of the submitting
Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) which relate to the Research Program, the Development of a Candidate or the Commercialization of a Product at least [*****] prior to its
intended presentation or submission for publication, and such submitting Party agrees, upon written request from the TSC within such [*****] period, not to submit such abstract or manuscript for publication or to make such presentation until the
other Party is given up to [*****] from the date of such written request to seek appropriate patent protection for any material in such publication or presentation which the JSC reasonably believes is patentable. Once such abstracts, manuscripts or
presentations have been reviewed by the JSC, the same abstracts, manuscripts or presentations do not have to be provided again to the JSC for review for a later submission for publication. Each Party also shall have the right to require that its
Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be
duly recognized, and co-authorship shall be determined in accordance with customary industry standards. 
 7.4 Prohibition
on Solicitation. Without the written consent of the other Party, neither Party nor its Affiliates shall, for a period of [*****] from the Approval Date, solicit (directly or indirectly) any employee of the other Party or its
Affiliates who participated in the Research Program at any time. This provision shall not restrict either Party or its Affiliates from advertising employment opportunities in any manner that does not directly target the other Party or its
Affiliates. 
  

	8.	LICENSE GRANTS; EXCLUSIVITY 

 8.1 Research Licenses. 
 8.1.1 Enanta Grant.
Enanta hereby grants to Abbott and its Affiliates during the Research Term a non-exclusive, royalty-free, worldwide license, with the limited right to grant sublicenses as provided in Section 8.3.1(a), under Enanta Technology, Enanta Patent
Rights, Licensed Patent Rights and Enanta’s interest in Joint Technology and Joint Patent Rights for the sole purpose of conducting Abbott Research Activities under the Research Program in accordance with the Research Plan. 

8.1.2 Abbott Grant. Abbott hereby grants to Enanta and its Affiliates during the Research Term, a non-exclusive,
royalty-free, worldwide license, with the limited right to grant sublicenses as provided in Section 8.3.1(b), under Abbott Technology, Abbott Patent Rights and Abbott’s interest in Joint Technology and Joint Patent Rights for the sole
purpose of conducting Enanta Research Activities under the Research Program in accordance with the Research Plan. 
 8.2
Development and Commercialization Licenses. 
 8.2.1 Enanta Grant. Enanta hereby grants to
Abbott during the Term an exclusive, royalty-bearing license, including the right to grant sublicenses as provided in Section 8.3, 

  
 - 42 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
under Enanta Technology, Enanta Patent Rights, Licensed Patent Rights and Enanta’s interest in Joint Technology and Joint Patent Rights, for the sole purpose of Developing Candidates and
Commercializing Products in the Field in the Territory; provided, that, Enanta shall retain such rights as may be necessary to Develop and Commercialize Co-Developed Products in the Field and in the Co-Development Territory. 

8.2.2 Abbott Grants. 
 (a) Commercialization License. Abbott hereby grants to Enanta during the Term a co-exclusive (together with Abbott), royalty-free, fully paid license, without the right to grant sublicenses, under
Abbott Technology, Abbott Patent Rights and Abbott’s interest in Joint Technology and Joint Patent Rights for the sole purpose of Developing and Commercializing Co-Developed Products in the Field in the Co-Development Territory. 

(b) Abbott Improvements. Subject to Section 8.5, Abbott hereby grants to Enanta a co-exclusive (together with Abbott), fully
paid, royalty-free license, including the right to grant sublicenses, under Abbott’s interest in Abbott Improvements to develop, make, have made, use, sell, have sold, offer for sale, import, have imported, export and have exported, and
otherwise exploit for all uses in the Field, any product that is not a Compound, Candidate or Product. 
 8.3 Right to
Sublicense. 
 8.3.1 Research Licenses. 

(a) Abbott Right to Sublicense. Abbott shall have the right to grant sublicenses under the license granted to it under
Section 8.1.1 solely to Third Party subcontractors engaged by Abbott to perform designated support functions related to the conduct of Abbott Research Activities under the Research Program and the Development of Candidates under the Development
Program; provided however, that (i) Abbott shall obtain the prior approval of the JSC to each sublicense grant; (ii) Abbott shall remain responsible for the satisfactory accomplishment of such work in accordance with the teuus and
conditions of this Agreement; and (iii) each such subcontractor shall enter into a written agreement binding such subcontractor to the obligations Abbott has to Enanta under this Agreement (and containing such other provisions as are normal and
customary for similar types of agreements). 
 (b) Enanta Rights to Sublicense. Enanta shall have the right to grant
sublicenses under the license granted to it under Section 8.1.2 solely to Third Party subcontractors engaged by Enanta to perform designated support functions related to the conduct of Enanta Research Activities under the Research Program;
provided however, that (i) Enanta shall obtain the prior approval of the JSC to each sublicense grant; (ii) Enanta shall remain responsible for the satisfactory accomplishment of such work in accordance with the terms and conditions of
this Agreement; and (iii) each such subcontractor shall enter into a written agreement binding such subcontractor to the obligations Enanta has to Abbott under this Agreement (and containing such other provisions as are normal and customary for
similar types of agreements). 

  
 - 43 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 8.3.2 Commercialization License. Abbott shall have the right to grant sublicenses
under the license granted to it under Section 8.2.1 to any Affiliate of Abbott and to any Third Party with respect to any Product, other than any Co-Developed Product in the Co-Development Territory after which time Enanta has exercised its
Co-Development and Profit Share Option with respect to such Co-Developed Product; provided, that: (a) it shall be a condition of any such sublicense that such Sublicensee agrees to be bound by all terms of this Agreement applicable to the
Development of Candidates and the Commercialization of Products in the Field in the Territory (including, without limitation, Article 7); (b) Abbott shall provide written notice to Enanta of any such proposed sublicense at least thirty
(30) days prior to such execution; and (c) Abbott shall not be relieved of any of its obligations pursuant to this Agreement as a result of such sublicense. 
 8.4 No Other Rights. Abbott shall have no rights to use or otherwise exploit Enanta Technology, Enanta Patent Rights or Enanta Materials, and Enanta shall have no rights to use or
otherwise exploit Abbott Technology, Abbott Patent Rights or Abbott Materials, in each case, except as expressly set forth herein. 
 8.5 Exclusivity. 
 8.5.1 Enanta. 

(a) Exclusivity. During the Research Term, and thereafter during the remainder of the Term for so long as a Candidate or Product
is being actively Developed or Commercialized, respectively, for use in the Field, Enanta shall not, and shall cause each of its Affiliates to not: (a) conduct any activity, either on its own, or with, for the benefit of, or sponsored by any
Third Party, that is designed to research, Develop or Commercialize any Compound or any Candidate or Product derived therefrom for use in the Field; (b) grant any license or other rights to any Third Party to utilize any Technology or Patent
Rights Controlled by Enanta or any of its Affiliates for the express purpose of researching, Developing or Commercializing any Compound or Candidate or Product derived therefrom for use in the Field; or (c) in-license from any Third Party any
Technology or Patent Rights Controlled by such Third Party, for the express purpose of researching, Developing or Commercializing any Compound or any Candidate or Product derived therefrom for use in the Field, except in any case as is necessary to
advance the Research Program, the Development Program or the Commercialization of Products as set forth herein. Without limiting the generality of the foregoing, there shall be no restriction on Enanta hereunder with regard to (y) the use of
Abandoned Compounds outside the Field during the Term or (b) the use of Abandoned Compounds, whether within or outside of the Field, after the expiration of the Term. 
 (b) Exclusivity Exception. Notwithstanding anything to the contrary in this Agreement, Section 8.5.1(a) shall not be deemed to restrict or prevent Enanta from conducting any activity under
that certain License and Option Agreement dated as of May 4, 2005 by and between Enanta and Chiron Corporation. 

  
 - 44 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 8.5.2 Abbott. 

(a) Exclusivity. During the Research Term, and thereafter during the remainder of the Term for so long as a Candidate or Product
is being actively Developed or Commercialized, respectively, for use in the Field, Abbott shall not, and shall cause each of its Affiliates to not: (a) conduct any activity, either on its own, or with, for the benefit of, or sponsored by any
Third Party, that is designed to research, Develop or Commercialize any Compound or any Candidate or Product derived therefrom for use in the Field; (b) grant any license or other rights to any Third Party to utilize any Technology or Patent
Rights Controlled by Abbott or any of their respective Affiliates for the express purpose of researching, Developing or Commercializing any Compound or any Candidate or Product derived therefrom for use in the Field; or (c) in-license from any
Third Party any Technology or Patent Rights Controlled by such Third Party, for the express purpose of researching, Developing or Commercializing any Compound or any Candidate or Product derived therefrom for use in the Field, except in any case as
is necessary to advance the Research Program, the Development Program or the Commercialization of Products as set forth herein and as described in Section 8.5.2(b). 
 (b) Exclusivity Exception. Notwithstanding anything to the contrary in this Agreement, Section 8.5.2(a) shall not be deemed to restrict or prevent Abbott from entering into non-exclusive
license agreements with Third Parties with respect to the use of [*****], Abbott shall (i) provide Enanta with written notice of such license grant and (ii) pay Enanta a royalty equal to [*****] of all royalty payments received by Abbott
under such license agreement for a co-formulation of an Additional Compound in each country in the Territory in which a Product is then being Commercialized, commencing with the Calendar Year (or partial Calendar Year) in which the First Commercial
Sale of such Additional Compound occurs and ending upon the date on which the Product or the Additional Product is no longer being Commercialized in such country. 
  

	9.	INTELLECTUAL PROPERTY RIGHTS 

 9.1 Disclosure of Program Inventions. Each of Enanta and Abbott shall promptly provide the other Party, through the Patent Coordinators (as defined in Section 9.5), with written notice
concerning all Program Inventions that are conceived or reduced to practice by employees or consultants of such Party or its Affiliates, alone or jointly with employees or consultants of the other Party or its Affiliates or any Third Party.

 9.2 Enanta Intellectual Property Rights. Enanta shall have sole and exclusive ownership of all right, title and
interest on a worldwide basis in and to any and all Enanta Technology and Enanta Patent Rights. 
 9.3 Abbott Intellectual
Property Rights. Abbott shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to any and all Abbott Technology and Abbott Patent Rights, 

9.4 Joint Technology Rights. Abbott and Enanta shall jointly own all Joint Technology and Joint Patent Rights, subject to
the rights of, and the licenses granted to, each Party hereunder. 

  
 - 45 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 9.5 Patent Coordinators. Enanta and Abbott shall each appoint a patent
coordinator reasonably acceptable to the other Party (each, a “Patent Coordinator”), who shall serve as such Party’s primary liaison with the other Party on matters relating to patent filing, prosecution, maintenance and
enforcement. Each Party may replace its Patent Coordinator at any time by notice in writing to the other Party. 
 9.6
Inventorship. In case of a dispute between Enanta and Abbott over inventorship, such dispute shall be resolved by application of United States patent law by patent counsel selected by the JSC who (and whose firm) is not at the time of
the dispute, and was not at any time during the five (5) years prior to such dispute, performing services for either of the Parties. The Parties shall share equally the expenses of such patent counsel. 

 

	10.	FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS 

 10.1 Patent Filing, Prosecution and Maintenance. Subject to the foregoing, the responsibility for filing, prosecuting and maintaining Patent Rights shall be as follows: 

10.1.1 Licensed Patent Rights. Subject to Section 10.1.3, Enanta, acting through patent counsel or agents of its
choice, shall be solely responsible, at its sole cost and expense, for the preparation, filing, prosecution and maintenance of the Licensed Patent Rights. In accordance with Section 10.1.5, Enanta will collaborate with Abbott on the
preparation, filing and prosecution of the Licensed Patent Rights worldwide by providing Abbott with copies of any substantive office actions and setting up meetings with respective Patent Coordinators to discuss strategies and responses.

 10.1.2 Enanta Patent Rights. Enanta, acting through patent counsel of its choice, shall be responsible, at its
sole cost and expense, for the preparation, filing, prosecution and maintenance of all Enanta Patent Rights. 
 10.1.3
Abbott Patent Rights. Abbott, acting through patent counsel of its choice, shall be responsible, at its sole cost and expense, for the preparation, filing, prosecution and maintenance (a) of all Abbott Patent Rights and
(b) commencing on the date of receipt of Commercialization Regulatory Approval with respect to a Product and continuing for the remainder of the applicable Royalty Term, of any Licensed Patent Rights that contain one or more claims that cover
such Product. 
 10.1.4 Joint Patent Rights. The JSC shall determine the jurisdictions within the Territory in
which patent applications will be filed with respect to Joint Patent Rights and the Party that shall be responsible for the preparation, filing, prosecution and maintenance of Joint Patent Rights. The Parties will share equally all expenses incurred
by the filing Party for the preparation, filing, prosecution and maintenance of such Joint Patent Rights. 
 10.1.5
Information and Cooperation. Each filing Party shall (a) regularly provide the other Party with copies of all patent applications filed hereunder and other material submissions and correspondence with the patent offices, in
sufficient time to allow for review and comment by the other Party and (b) provide the other Party and its patent counsel with an 

  
 - 46 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
opportunity to consult with the filing Party and its patent counsel regarding the filing and contents of any such application, amendment, submission or response. The filing Party hereby agrees
that the advice and suggestions of the other Party and its patent counsel shall be taken into reasonable consideration by the filing Party and its patent counsel in connection with each filing. Each Party shall, upon request from the filing Party
and at the filing Party’s sole cost, reasonably cooperate with the filing Party in connection with such patent filing activities. 
 10.1.6 Abandonment. If either Party decides to expressly abandon or to allow to purposely lapse any of the Patent Rights covering any Program Inventions in any country or region in the
Territory that specifically cover any Compound, Candidate or Product or specifically cover the manufacture or formulation or the delivery or use of a Compound, Candidate or Product in the Field, such Party shall inform the other Party of such
decision promptly and, in any event, so as to provide the other Party a reasonable amount of time to meet any applicable deadline to establish or preserve such Patent Rights in such country or region. The other Party shall have the right to assume
responsibility for continuing the prosecution of such Patent Rights in such country or region and paying any required fees to maintain such Patent Rights in such country or region or defending such Patent Rights, in the latter case only at the other
Party’s sole expense, through patent counsel or agents of its choice. The Party taking over the responsibility will not become an assignee of any such Patent Rights as a result of such Party’s assumption of any such responsibility. Upon
transfer of a Party’s responsibility for prosecuting, maintaining and defending any of the Patent Rights to the other Party under this Section 10.1.6, the transferring Party shall promptly deliver to the other Party copies of all necessary
files related to the Patent Rights with respect to which responsibility has been transferred and shall take all actions and execute all documents reasonably necessary for the other Party to assume such prosecution, maintenance and defense.

 10.2 Legal Actions. 
 10.2.1 Third Party Infringement. 
 (a) In General.

 (i) Notice. In the event either Party becomes aware of (A) any possible infringement of any Licensed Patent
Rights, Enanta Program Patent Rights or Abbott Program Patent Rights through the Development of a Candidate or the Commercialization of a Product, or (B) the submission by any Third Party of an abbreviated new drug application under the
Hatch-Waxman Act for a product that includes a Compound, Candidate or a Product (each, an “Infringement”), that Party shall promptly notify the other Party and provide it with all details of such Infringement of which it is
aware (each, an “Infringement Notice”). 
 (ii) Licensed Patent Rights. Both Abbott and Enanta
shall have the unilateral right to enforce any and all Licensed Patent Rights on any Product following the First Commercial Sale of such Product. All costs, including, without limitation, attorneys’ fees, relating to such legal proceedings or
other action shall be borne by the party enforcing such rights. In the event such an Infringement relates to any Licensed Patent Rights on any Compound, Candidate or Product prior to the First Commercial Sale of such Product, Enanta

  
 - 47 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
shall have the first right (not the obligation) to enforce such claim with respect to such Infringement. All costs, including, without limitation, attorneys’ fees, relating to such legal
proceedings or other action shall be borne by Enanta. If Enanta does not take or initiate commercially reasonable steps to initiate legal proceedings or take other actions regarding the Infringement within (A) twenty (20) days from any
Infringement Notice in the case of an Infringement resulting from the submission by any Third Party of an abbreviated new drug application under the Hatch-Waxman Act, and (B) one hundred twenty (120) days from any Infringement Notice that
relates to any other Licensed Patent Rights, then Abbott shall have the right and option to do so at its expense; provided, that Abbott shall not admit the invalidity or unenforceability of any such Licensed Patent Rights without Enanta’s prior
written consent. 
 (iii) Enanta Patent Rights. In the event such an Infringement relates to any Enanta Patent Rights,
Enanta shall have the first right and option to initiate legal proceedings or take other actions regarding such Infringement by reasonable steps. All costs, including, without limitation, attorneys’ fees, relating to such legal proceedings or
other action shall be borne by Enanta. If Enanta does not take or initiate commercially reasonable steps to initiate legal proceedings or take other actions regarding the Infringement (A) within ten (10) days from any Infringement Notice
if the Infringement relates to a Product being Commercialized by Abbott; (B) (twenty (20) days in the case of an Infringement resulting from the submission by any Third Party of an abbreviated new drug application under the Hatch-Waxman
Act); and (C) one hundred twenty (120) days for any other Infringement, then in each such case, Abbott shall have the right and option to do so at its expense. 
 (iv) Abbott Patent Rights. In the event such an Infringement relates to any Abbott Patent Rights, Abbott shall have the first right and option to initiate legal proceedings or take other actions
regarding such Infringement by reasonable steps. All costs, including, without limitation, attorneys’ fees, relating to such legal proceedings or other action shall be borne by Abbott. If Abbott does not take or initiate commercially reasonable
steps to initiate legal proceedings or take other actions regarding the Infringement within thirty (30) days from any Infringement Notice (or twenty (20) days in the case of an Infringement resulting from the submission by any Third Party
of an abbreviated new drug application under the Hatch-Waxman Act), then Enanta shall have the right and option to do so at its expense. 
 (v) No Settlement. Neither Party shall settle any Infringement claim or proceeding under Sections 10.2.1(a)(iii) or (iv) or 10.2.1(b) without the prior written consent of the other Party,
which consent shall not be unreasonably withheld, conditioned or delayed. 
 (vi) Representation. Each Party shall have
the right to be represented by counsel that it selects in any legal proceedings or other action instituted under Sections 10.2.1(a)(iii) or (iv) or 10.2.1(b) by the other Party. If a Party with the right to initiate legal proceedings under
Section 10.2.1 regarding an Infringement lacks standing to do so and the other Party has standing to initiate such legal proceedings, then the Party with standing shall initiate such legal proceedings at the request and expense of the other
Party. 

  
 - 48 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (b) Joint Patent Rights. In the event of an Infringement of a Joint Patent Right,
the Parties shall enter into discussions as to whether to initiate legal proceedings or take other actions regarding the Infringement. Unless otherwise agreed by the Parties: (i) each Party shall bear an equal share of the cost of any action,
suit or proceeding instituted under this Section 10.2.1(b); and (ii) all amounts recovered shall be allocated pursuant to Section 10.2.1(e). If the Parties are unable to determine whether and how to institute an action, suit or
proceeding for infringement of any such Joint Patent Right, either Party shall have the right to prosecute such Infringement, in which event that Party shall bear all of the expense and be entitled to retain all amounts that it recovers. 

(c) Right to Representation. Each Party shall have the right to participate, and be represented by counsel that it selects, in
any legal proceedings or other action instituted under this Section 10.2.1 by the other Party. If a Party with the right to initiate legal proceedings under Section 10.2.1 regarding an Infringement lacks standing to do so and the other
Party has standing to initiate such legal proceedings, then the Party with standing shall initiate such legal proceedings at the request and expense of the other Party. 
 (d) Cooperation. In any action, suit or proceeding instituted under this Section 10.2.1, the Parties shall cooperate with and assist each other in all reasonable respects. Upon the reasonable
request of the Party instituting such action, suit or proceeding, the other Party shall join therein and shall be represented using counsel of its own choice, at the requesting Party’s expense. 

(e) Allocation of Recoveries. Any amounts recovered by either Party pursuant to actions under Sections 10.2.1(a)(iii) or
(iv) or 10.2.1(b) with respect to any Infringement through the development or sale of a Compound or Product, whether by settlement or judgment, shall be allocated in the following order: (i) first, to reimburse Enanta and Abbott for their
reasonable out-of-pocket expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses); and (ii) then, to Enanta and Abbott in the same proportion as Abbott’s
historic profits on Net Sales of the Product or Products affected by the Infringement bears to Abbott’s historic royalties hereunder in respect of such Net Sales, in each case as determined in good faith. 

10.2.2 Defense of Claims. In the event that any action, suit or proceeding is brought against either Party or any Affiliate
or sublicensee of either Party alleging the infringement of the Technology or Patent Rights of a Third Party by reason of the conduct of the Research Program, the Development Program or the Commercialization of any Product: (a) Abbott shall
have the obligation to defend such action, suit or proceeding at its sole expense; (b) Enanta shall have the right to separate counsel at its own expense in any such action, suit or proceeding; and (c) the Parties shall cooperate with each
other in all reasonable respects in any such action, suit or proceeding. If such action, suit or proceeding relates to a Co-Developed Product in the Co-Development Territory, the cost and expense of the above shall be used to calculate Development
Costs for that Co-Developed Product. Each Party shall provide the other Party with prompt written notice of the commencement of any such suit, action or proceeding, or of any allegation of infringement of which such Party becomes aware, and shall
promptly furnish the other Party with a copy of each communication relating to the alleged infringement that is 

  
 - 49 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
received by such Party. Nothing in this Section 10.2.2 shall affect the right of Enanta to defend itself in any such action, suit or proceeding. Abbott shall not compromise, settle or
otherwise dispose of any such suit, action or proceeding that involves the use of Enanta Patent Rights, without Enanta’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. 

10.3 Trademark Prosecution. Abbott, at is sole expense, shall be responsible for the filing, prosecution, defense and
maintenance before all trademark offices of the Product Trademarks. 
  

	11.	TERM AND TERMINATION 

 11.1 Term. This Agreement shall commence on the Effective Date and shall continue in full force and effect until the end of the Research Program Term and, if Abbott is Developing a Candidate
or Commercializing a Product arising out of the Research Program, thereafter until (a) such time as Abbott is no longer Developing a Candidate for use in the Field and in the Territory or (b) if, as of the time Abbott is no longer
Developing any Candidates, Abbott is Commercializing a Product, until such time as all Royalty Terms for all Products and all Co-Development Terms for all Co-Developed Products have ended, unless earlier terminated in accordance with the provisions
of this Article 11 (the “Term”). 
 11.2 Termination. This Agreement may be terminated at
any time by either Party, or by the Party specified, as follows: 
 11.2.1 Unilateral Right to Terminate. Abbott
may terminate this Agreement at any time by giving written notice to Enanta not less than [*****] prior to any anniversary of the Approval Date. 
 11.2.2 Termination for Breach. Either Party may terminate this Agreement by providing written notice to the other Party, and such termination will be effective [*****] after the written
notice, if the other Party commits a material breach of this Agreement unless the other Party has cured the asserted material breach during such [*****] period. If the breach has been cured prior to expiration of the [*****] cure period, the notice
of termination will be void. In lieu of seeking termination of this Agreement, the Party asserting the material breach may seek compensatory damages and/or equitable relief as a remedy of an uncured material breach by the other Party.
Notwithstanding the foregoing, a material breach by a Party shall not give rise to the termination right under this Section 11.2.2 to the extent such material breach arises from a Force Majeure event described in Section 14.12; provided,
that the Party allegedly breaching the Agreement shall have the burden of demonstrating the occurrence of the Force Majeure event. 
 11.2.3 Termination for Insolvency. In the event either Party files for protection under the bankruptcy laws, makes an assignment for the benefit of creditors, appoints or suffers appointment
of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which is not discharged within sixty (60) days of the filing thereof, then the other Party may
terminate this Agreement effective immediately upon written notice to such Party. In connection therewith, all rights and licenses 

  
 - 50 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
granted under this Agreement are, and shall be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property” as
defined under Section 101(56) of the United States Bankruptcy Code. 
 11.3 Consequences of Termination of
Agreement. In the event this Agreement is terminated pursuant to Section 11.2, the following provisions shall apply, as applicable: 
 11.3.1 Termination by Abbott Pursuant to Section 11.2.1. If this Agreement is terminated by Abbott pursuant to Section 11.2.1, the following provisions shall apply: 

(a) If Abbott terminates the Agreement prior to the first anniversary of the first business day following the Approval Date, it shall
make a [*****] time payment to Enanta of [*****] to complete the Upfront Fee as provided in Section 6.1; 
 (b) the
licenses granted to Abbott pursuant to Sections 8.1.1 and 8.2.1 shall terminate upon the effective date of such termination; 

(c) Abbott shall be deemed to have granted to Enanta, on and after the date of termination, (i) a non-exclusive, perpetual,
fully-paid, worldwide, royalty-free license, with the rights to sublicense, under Abbott Program Technology and Abbott Patent Rights and (ii) an exclusive (even as to Abbott), perpetual, fully-paid, worldwide, royalty-free license, with the
rights to sublicense, under Abbott’s interest in Joint Technology and Joint Patent Rights, in either case, to Develop and have Developed Candidates resulting from Compounds and Abbott Compounds, other than Abbott Compounds listed on Schedule 1,
and Commercialize Products derived from such Candidates; 
 (d) all exclusivity obligations of Enanta under Section 8.5.1
shall terminate upon the effective date of such termination and Enanta shall thereafter have the right to Develop Candidates and Commercialize Products for any and all uses within the Field; 

(e) each Party shall promptly return all Confidential Information of the other Party that is not subject to a continuing license
hereunder; provided that each Party may retain one (1) copy of the Confidential Information of the other Party in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder;

 (f) upon request of Enanta, Abbott shall promptly, and in any event within sixty (60) days after Enanta’s request:
(i) transfer to Enanta all right, title and interest in and to all Product Trademarks and registrations thereof, if any; (ii) transfer to Enanta all of its right, title and interest in all Regulatory Filings, Drug Approval Applications and
Regulatory Approvals then in its name applicable to any Candidate or Product, and all material aspects of Confidential Information Controlled by it as of the date of termination relating to Regulatory Filings, Drug Approval Applications and
Regulatory Approvals; provided that Enanta shall as of the date of such transfer, assume all obligations and liabilities associated with such Regulatory Filings, Drug Approval Applications and Regulatory Approvals; (iii) notify the applicable
Regulatory Authorities and take any other action reasonably necessary to effect such transfer; 

  
 - 51 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
(iv) provide Enanta with copies of all correspondence between Abbott and such Regulatory Authorities relating to such Regulatory Filings, Drug Approval Applications and Regulatory Approvals;
(v) unless expressly prohibited by any Regulatory Authority, transfer control to Enanta of all clinical trials of any Candidate or Product being conducted as of the effective date of termination, and upon such transfer Enanta shall assume all
obligations and liabilities associated with continuing such clinical trials; (vi) assign (or cause its Affiliates to assign) to Enanta all agreements with any Third Party with respect to the conduct of clinical trials for any Candidate or
Product including, without limitation, agreements with contract research organizations, clinical sites and investigators, unless expressly prohibited by any such agreement (in which case Abbott shall cooperate with Enanta in all reasonable respects
to secure the consent of such Third Party to such assignment); (vii) provide Enanta with all supplies of any Candidate or Product in the possession of Abbott or any Affiliate or contractor of Abbott; and (viii) provide Enanta with copies
of all reports and data generated or obtained by Abbott or its Affiliates pursuant to this Agreement that relate to any Candidate or Product that has not previously been provided to Enanta; and 

(g) if Abbott has manufactured, is manufacturing or having manufactured any Candidate or Product or any intermediate thereof as of the
effective date of termination: (i) Abbott shall, if requested by Enanta, supply Enanta with its requirements for all such Candidate or Product and intermediate for up to [*****] following such termination [*****]; and (ii) within sixty
(60) days after Enanta’s request, Abbott shall provide to Enanta or its designee all information in its possession with respect to the manufacture of each such Candidate, Product or intermediate. 

11.3.2 Termination by Enanta Pursuant to Section 11.2.2. If this Agreement is terminated by Enanta pursuant to
Section 11.2.2, the following provisions shall apply: 
 (a) the licenses granted to Abbott pursuant to Sections 8.1.1 and
8.2.1 shall terminate upon the effective date of such termination; 
 (b) Abbott shall be deemed to have granted to Enanta, on
and after the date of termination, (i) a non-exclusive, perpetual, fully-paid, worldwide, royalty-free license, with the rights to sublicense, under Abbott Program Technology and Abbott Patent Rights with respect to Abbott Program Technology
and (ii) an exclusive (even as to Abbott), perpetual, fully-paid, worldwide, royalty-free license, with the rights to sublicense, under Abbott’s interest in Joint Technology and Joint Patent Rights, in either case, to Develop and have
Developed Candidates resulting from Compounds and Abbott Compounds, other than Abbott Compounds listed on Schedule 1, and Commercialize Products derived from such Candidates; 
 (c) all exclusivity obligations of Enanta under Section 8.5.1 shall terminate upon the effective date of such termination and Enanta shall thereafter have the right to Develop Candidates and
Commercialize Products for any and all uses within the Field; 
 (d) each Party shall promptly return all Confidential
Information of the other Party that are not subject to a continuing license hereunder; provided that each Party may retain one (1) copy of the Confidential Information of the other Party in its archives solely for the purpose of establishing
the contents thereof and ensuring compliance with its obligations hereunder; 

  
 - 52 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (e) upon request of Enanta, Abbott shall promptly, and in any event within sixty
(60) days after Enanta’s request: (i) transfer to Enanta all right, title and interest in and to all Product Trademarks and registrations thereof, if any; (ii) transfer to Enanta all of its right, title and interest in all
Regulatory Filings, Drug Approval Applications and Regulatory Approvals then in its name applicable to any Candidate or Product, and all material aspects of Confidential Information Controlled by it as of the date of termination relating to
Regulatory Filings, Drug Approval Applications and Regulatory Approvals; provided that Enanta shall as of the date of such transfer, assume all obligations and liabilities associated with such Regulatory Filings, Drug Approval Applications and
Regulatory Approvals; (iii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect such transfer; (iv) provide Enanta with copies all correspondence between Abbott and such Regulatory
Authorities relating to such Regulatory Filings, Drug Approval Applications and Regulatory Approvals; (v) unless expressly prohibited by any Regulatory Authority, transfer control to Enanta of all clinical trials of any Candidate or Product
being conducted as of the effective date of termination, and upon such transfer Enanta shall assume all obligations and liabilities associated with continuing such clinical trials; (vi) assign (or cause its Affiliates to assign) to Enanta all
agreements with any Third Party with respect to the conduct of clinical trials for any Candidate or Product including, without limitation, agreements with contract research organizations, clinical sites and investigators, unless expressly prohibited
by any such agreement (in which case Abbott shall cooperate with Enanta in all reasonable respects to secure the consent of such Third Party to such assignment); (vii) provide Enanta with all supplies of any Candidate or Product in the
possession of Abbott or any Affiliate or contractor of Abbott; and (viii) provide Enanta with copies of all reports and data generated or obtained by Abbott or its Affiliates pursuant to this Agreement that relate to any Compound or Product
that has not previously been provided to Enanta; and 
 (f) if Abbott has manufactured, is manufacturing or having manufactured
any Candidate or Product or any intermediate thereof as of the effective date of termination: (i) Abbott shall, if requested by Enanta, supply Enanta with its requirements for all such Candidate or Product and intermediate for up to [*****]
following such termination [*****], and (ii) within sixty (60) days after Enanta’s request, Abbott shall provide to Enanta or its designee all information in its possession with respect to the manufacture of each such Candidate,
Product or intermediate. 
 11.3.3 Termination by Abbott Pursuant to Section 11.2.2. If this Agreement is
terminated by Abbott pursuant to Section 11.2.2, the following provisions shall apply: 
 (a) Abbott shall continue to
have the licenses set forth in Sections 8.1.1 and 8.2.1 to Develop Candidates being Developed by Abbott as of the effective date of termination, if any, and to Commercialize Products being Commercialized by Abbott as of the effective date of
termination, if any, and to Commercialize Products that were Candidates at the time of termination, subject to a determination by the neutral in ADR of the level at which the milestone payments and Royalty Payments continue, it being understood by
the Parties that 

  
 - 53 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
the milestone payments and royalty rates set forth in this Agreement shall be modified with respect to a given Candidate or Product only to the extent the ADR determines that the material breach
that resulted in the termination by Abbott of this Agreement materially affected the Development of such Candidate and/or the Commercialization of such Product. 
 (b) all rights (including, without limitation, the Co-Development and Profit Share Option) and licenses granted to Enanta pursuant to Article 5 and Sections 8.1.2 and 8.2.2 shall terminate upon the
effective date of such termination; 
 (c) Enanta shall be deemed to have granted to Abbott, on and after the date of
termination, (i) a non-exclusive, perpetual, fully-paid, worldwide, royalty-free license, with the rights to sublicense, under Enanta Program Technology and Enanta Patent Rights and (ii) an exclusive (even as to Enanta), perpetual,
fully-paid, worldwide, royalty-free license, with the rights to sublicense, under Enanta’s interest in Joint Technology and Joint Patent Rights, in either case, to Develop and have Developed Candidates and Commercialize Products derived from
such Candidates; 
 (d) all exclusivity obligations of Abbott under Section 8.5.2 shall terminate upon the effective date
of such termination and Abbott shall thereafter have the right to Develop Candidates and Commercialize Products for any and all uses within the Field; and 
 (e) each Party shall promptly return all Confidential Information of the other Party that are not subject to a continuing license hereunder; provided that each Party may retain one (1) copy of the
Confidential Information of the other Party in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder. 
 11.3.4 Termination by Enanta Pursuant to Section 11.2.3. If Enanta terminates this Agreement pursuant to Section 11.2.3, to the extent not prohibited by Applicable Laws, the
provisions of Section 11.3.1 shall apply to such termination. 
 11.3.5 Termination by Abbott Pursuant to
Section 11.2.3. If Abbott terminates this Agreement pursuant to Section 11.2.3, to the extent not prohibited by Applicable Laws, the provisions of Section 11.3.3 shall apply to such termination. 

11.3.6 Breach of Compound or Product Diligence. If after Enanta followed the procedure set forth in Section 11.2.2 for
asserting a breach of contract and Abbott does not cure its breach for failure to use Commercially Reasonable Efforts to Develop a Candidate or Commercialize a Product in any Major Market Country, then Enanta shall have the right, in its sole
discretion upon ten (10) days written notice to Abbott, to designate such Candidate or Product as a Abandoned Compound. In such event: 
 (a) the licenses granted to Abbott under Section 8.2 of this Agreement to Commercialize such Product shall terminate upon the effective date of such reversion; 

(b) subject to the other terms of this Agreement, Abbott shall be deemed to have granted to Enanta and its Affiliates (i) an
exclusive, royalty-free, paid-up, 

  
 - 54 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
worldwide license, with the right to grant sublicenses, under Abbott Patent Rights and Abbott’s interest in Joint Patent Rights that would be infringed by the making, using in the Field,
importing or selling of such Abandoned Compound (or, for purposes of clarity, a Product derived therefrom) in the absence of a license to research, develop, make, have made, use, offer for sale, distribute for sale, sell, import and have imported
Abandoned Compounds in the Field and (ii) a non-exclusive, royalty-free, paid-up, worldwide license, with the right to grant sublicenses, under Abbott Technology and Abbott’s interest in Joint Technology to research, develop, have
developed, make, have made, use, distribute for sale, sell, offer for sale, import and have imported such Abandoned Compound in the Field, subject in each case to the restrictions on Enanta pursuant to Section 8.5.1; 

(c) upon request of Enanta, Abbott shall promptly, and in any event within sixty (60) days after Enanta’s request:
(i) grant to Enanta an exclusive, worldwide, royalty-free, paid-up license under all Product Trademarks applicable to such Product, if any; (ii) provide Enanta with access to, and grant Enanta the right and license to use and to reference,
all Regulatory Filings and Regulatory Approvals then in its name applicable to the Commercialization of such Product and all material aspects of Confidential Information Controlled by it as of the date such Compound or Product relating to such
Regulatory Filings and Regulatory Approvals is designated as a Abandoned Compound; (iii) provide Enanta with copies of all correspondence between Abbott and such Regulatory Authorities relating to such Regulatory Filings and Regulatory
Approvals; (iv) assign to Enanta all agreements between Abbott and any Third Party with respect to the conduct of clinical trials for such Product, including, without limitation, agreements or contracts with contract research organizations,
clinical sites and investigators, unless expressly prohibited by any such agreement; and (v) provide Enanta with copies of all reports and data obtained by Abbott or its Affiliates pursuant to this Agreement that relate to the Commercialization
of such Product; and 
 (d) if Abbott has manufactured, is manufacturing or is having manufactured such Product or any
intermediate of such Product as of the date such Candidate or Product is designated as a Abandoned Compound, upon request of Enanta, (i) Abbott shall supply Enanta with its requirements of such Product or intermediate for up to twenty-four
(24) months following such removal at a transfer price equal to Abbott’s Cost of Goods for the supply of such Product or intermediate plus fifteen percent (15%), and (ii) Abbott shall provide to Enanta or its designee all information
in its possession with respect to the manufacture of such Product. 
 11.4 Surviving Provisions. Termination or
expiration of this Agreement for any reason shall be without prejudice to: 
 (a) the rights and obligations of the Parties
provided in Sections 5.3.2, 6.3.2, 6.4, 6.5, 6.6, 6.7, 11.3, 11.4 and Articles 7, 12, 13 and 14 (including all other Sections or Articles referenced in any such Section or Article and including Article 1), all of which shall survive such
termination; 
 (b) any other rights or remedies provided at law or equity which either Party may otherwise have. 

  
 - 55 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

	12.	REPRESENTATIONS AND WARRANTIES 

 12.1 Mutual Representations and Warranties. Enanta and Abbott each represents and warrants to the other, as of the Effective Date, as follows: 

12.1.1 Organization. It is a corporation duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement. 
 12.1.2 Authorization. Upon receipt of the approval by the Abbott Board and Abbott’s Chief Executive Officer, the execution and delivery of this Agreement and the performance by Abbott
of the transactions contemplated hereby will have been duly authorized by all necessary corporate action. Upon receipt of the approval by the Enanta Board and Enanta’s Chief Executive Officer, the execution and delivery of this Agreement and
the performance by Enanta of the transactions contemplated hereby will have been duly authorized by all necessary corporate action. 
 12.1.3 No Violations. The transactions contemplated hereby and the performance by it of the transactions contemplated hereby will not violate (a) such Party’s certificate of
incorporation or bylaws, (b) any agreement, instrument or contractual obligation to which such Party is bound in any material respect, (c) any requirement of any Applicable Law, or (d) any order, writ, judgment, injunction, decree,
determination or award of any court or governmental agency presently in effect applicable to such Party. 
 12.1.4 Binding
Agreement. This Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance with its terms and conditions. 
 12.1.5 No Inconsistent Obligation. It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms of this
Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder. 
 12.2 Additional
Representations of Enanta. Enanta further represents and warrants to Abbott, as of the Effective Date, as follows: 

12.2.1 [*****]. 

12.2.2 [*****]. 

12.2.3 [*****]. 

12.2.4 [*****]. 

12.2.5 [*****]. 

  
 - 56 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

	13.	INDEMNIFICATION 

13.1 Indemnification of Abbott by Enanta. Enanta shall indemnify, defend and hold harmless Abbott, its Affiliates, their
respective directors, officers, employees and agents, and their respective successors, heirs and assigns (the “Abbott Indemnitees”), against all liabilities, damages, losses and expenses (including reasonable attorneys’
fees and expenses of litigation) (collectively, “Losses”) incurred by or imposed upon the Abbott Indemnitees, or any one of them, as a direct result of any claims, suits, actions, demands or judgments of Third Parties,
including, without limitation, personal injury and product liability matters and claims of suppliers and Enanta employees (collectively, “Claims”) arising out of (a) any action by Enanta in the conduct of the Research
Program other than any action that is a Disputed Matter and is approved by the JSC as an Abbott Decision pursuant to Section 2.1.6, (b) the Development or Commercialization of a Co-Developed Product, or (c) a breach of any
representation or warranty made by Enanta pursuant to Section 12.2; provided that, with respect to any Claim for which Enanta has an obligation to any Abbott Indenmitee pursuant to this Section 13.1 and Abbott has an obligation to any
Enanta Indemnitee pursuant to Section 13.2, each Party shall indemnify each of the other Party’s Indemnitees for its Losses to the extent of its responsibility for the facts underlying the Claim relative to the other Party. 

13.2 Indemnification of Enanta by Abbott. Abbott shall indemnify, defend and hold harmless Enanta, its Affiliates, their
respective directors, officers, employees and agents, and their respective successors, heirs and assigns (the “Enanta Indemnitees”), against any Losses incurred by or imposed upon the Enanta Indemnitees, or any one of them,
as a direct result of any Claims arising out of (a) any action by Abbott in the conduct of the Research Program, (b) the Development (including, without limitation, the conduct of clinical research) by Abbott of any Candidate, or
(c) the Commercialization (including, without limitation, the production, manufacture, promotion, import, sale or use by any Person) of any Product that is manufactured or sold by Abbott or by an Affiliate, Sublicensee, distributor or agent of
Abbott; provided that with respect to any Claim for which Enanta has an obligation to any Abbott Indemnitee pursuant to Section 13.1 and Abbott has an obligation to any Enanta Indemnitee pursuant to this Section 13.2, each Party shall
indemnify each of the other Party’s Indemnitees for its Losses to the extent of its responsibility for the facts underlying the Claim relative to the other Party. 
 13.3 Conditions to Indemnification. A Person seeking recovery under this Article 13 (the “Indemnified Party”) in respect of a Claim shall give prompt notice of
such Claim to the Party from which recovery is sought (the “Indemnifying Party”) and, provided that the Indemnifying Party is not contesting its obligation under this Article 13, shall permit the Indemnifying Party to control
any litigation relating to such Claim and the disposition of such claim; provided that the Indemnifying Party shall (a) act reasonably and in good faith with respect to all matters relating to the settlement or disposition of such Claim as the
settlement or disposition relates to Parties being indemnified under Article 13, (b) not settle or otherwise resolve such claim without the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld,
conditioned or delayed). The Indemnified Party shall cooperate with the Indemnifying Party in its defense of any such Claim in all reasonable respects and shall have the right to be present in person or through counsel at all legal proceedings with
respect to such Claim. 

  
 - 57 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 13.4 Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS
AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION,
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEIVIENT. 
 13.5 No Warranty of Success.
Nothing contained in this Agreement shall be construed as a warranty on the part of either Party that (a) the Research Program will yield any Compound or will otherwise be successful, or (b) the outcome of the Research Program or the
Development Program will be commercially exploitable in any respect. 
 13.6 Limited Liability. EXCEPT WITH
RESPECT TO INDEMNIFICATION OBLIGATIONS FOR THIRD PARTY CLAIMS SET FORTH IN SECTION 13.1 AND SECTION 13.2, AND EXCEPT WITH RESPECT TO A BREACH OF CONFIDENTIALITY OBLIGATIONS, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES
FOR (a) ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS OR LOST REVENUES, OR (b) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, WHETHER UNDER ANY CONTRACT,
WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY. 
 13.7 Insurance. Not later than
thirty (30) days before the date on which Abbott or any Affiliate or Sublicensee of Abbott shall, on a commercial basis, make, use, or sell any Products, and at all times thereafter until the expiration of all applicable statutes of limitation
pertaining to any such manufacture, marketing, possession, use, sale of other disposition of any Products, Abbott will, at its expense, and Enanta will, at its expense, with respect only to Co-Developed Products, obtain and maintain in full force
and effect, comprehensive general liability insurance, including product liability insurance and clinical trial insurance protecting the other Party, subject to Section 13.1 or 13.2, as the case may be, against all claims, obligations,
liabilities, and damages, based upon or arising out of actual or alleged bodily injury, personal injury, death, or any other damage to or loss of persons or property, cause by any such manufacture, marketing, possession, use, sale, or other
disposition. Notwithstanding the foregoing, Abbott may elect to self-insure with respect to any insurance coverage it is required to obtain hereunder. 
  

	14.	MISCELLANEOUS 

14.1 Arbitration. In the event of any dispute, difference or question arising between the Parties in connection with this
Agreement, the construction thereof, or the rights, duties or liabilities of either Party hereunder, other than any Disputed Matter that is submitted for resolution as provided in Section 2.1.6 (each, an “Arbitration
Matter”), the Parties shall initiate an arbitration proceeding to be conducted in accordance with the procedures set forth in Exhibit D attached hereto. 

  
 - 58 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 14.2 Change of Control. 

(a) Notice. If either Enanta or Abbott enters into an agreement that results or, if the transaction contemplated thereby is
completed, would result in a Change of Control (“Acquired Party”), the Acquired Party shall provide the other Party with prompt written notice describing such Change of Control in reasonable detail (the “Change of
Control Notice”). The Change of Control Notice shall be provided by the Acquired Party prior to execution of such agreement, if permitted under Applicable Laws and not prohibited by the terms of any agreement between the Acquired Party
and any Third Party (the “Acquiring Party”), and otherwise as soon as practicable thereafter and, in any event, not later than promptly following the consummation of the transaction contemplated by such agreement. 

(b) Effect of Change of Control. Notwithstanding any provision hereof, in the event of a Change of Control, the
exclusivity obligations of the Acquired Party described in Section 8.5 shall not apply to any compound or product owned or controlled by the Acquiring Party as of the date of consummation of the Change of Control. 

14.3 Notices. All notices and communications shall be in writing and delivered personally or by courier providing evidence
of delivery or mailed via certified mail, return receipt requested, addressed as follows, or to such other address as may be designated from time to time: 
  

			
	If to Abbott:	  	If to Enanta:
		  	
	 Abbott Laboratories
 100 Abbott
Park Road
 Building AP34, Dept. R50A

Abbott Park, IL 60064-3500
 Fax:
[*****]
 Attention: [*****]
	  	Enanta Pharmaceuticals, Inc.
 500 Arsenal Street

Watertown, MA 02472
 Tel: [*****]

Fax: [*****]
 Attention:
[*****]

		  	
	With a copy to:	  	With a copy to:
		  	
	 Abbott Laboratories
 Building
AP6D, D-364
 100 Abbott Park Road

Abbott Park, IL 60064-3500
 Fax:
[*****]
 Attention: [*****]
	  	[*****]

 Except as otherwise expressly provided in this Agreement or mutually agreed in writing, any notice,
communication or document (excluding payment) required to be given or made shall be deemed given or made and effective upon actual receipt, in each case addressed to a Parties at its address stated above or to such other address as such Party may
designate by written notice in accordance with this Section 14.3. 

  
 - 59 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 14.4 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York (USA), without regard to the application of principles of conflicts of law. 

14.5 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective
legal representatives, successors and permitted assigns. 
 14.6 Headings. Section and subsection headings are
inserted for convenience of reference only and do not form a part of this Agreement. 
 14.7 Counterparts. This
Agreement may be executed simultaneously in two (2) or more counterparts, each of which shall be deemed an original and both of which, together, shall constitute a single agreement. 

14.8 Amendment; Waiver. This Agreement may be amended, modified, superseded or canceled, and any of the terms of this
Agreement may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or failure of any Party at any time or times to require performance of any provisions shall
in no manner affect the rights at a later time to enforce the same. No waiver by any Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to
be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 
 14.9 No Third Party Beneficiaries. Except as set forth in Sections 13.1, and 13.2, no Third Party (including, without limitation, employees of either Party) shall have or acquire any rights
by reason of this Agreement. 
 14.10 Purposes and Scope. The Parties hereto understand and agree that this
Collaboration is limited to the activities, rights and obligations as set forth in this Agreement. Nothing in this Agreement shall be construed (a) to create or imply a general partnership between the Parties, (b) to make either Party the
agent of the other for any purpose, (c) to alter, amend, supersede or vitiate any other arrangements between the Parties with respect to any subject matters not covered hereunder, (d) to give either Party the right to bind the other,
(e) to create any duties or obligations between the Parties except as expressly set forth herein, or (f) to grant any direct or implied licenses or any other right other than as expressly set forth herein. 

14.11 Assignment and Successors. Neither this Agreement nor any obligation of a Party hereunder may be assigned by either
Party without the consent of the other which shall not be unreasonably withheld, except that each Party may assign this Agreement and the rights, obligations and interests of such Party, in whole or in part, to any of its Affiliates, or subject to
Section 14.2(b), to any purchaser of all of its assets and/or all of its assets to which this Agreement relates or to any successor corporation resulting from any merger or consolidation of such Party with or into such corporation. 

  
 - 60 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 14.12 Force Majeure. Neither Abbott nor Enanta shall be liable for failure of
or delay in performing obligations set forth in this Agreement, and neither Party shall be deemed in breach of its obligations, if such failure or delay is due to a Force Majeure. In event of such Force Majeure event, the Party affected thereby
shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 
 14.13
Interpretation. The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b) the rule of
construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall be construed fairly as to all
Parties and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement. 
 14.14 Integration; Severability. This Agreement and the Existing Agreements are the entire agreement with respect to the subject matter hereof and supersedes all other agreements and
understandings between the Parties with respect to such subject matter. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the
Parties that the remainder of the Agreement shall not be affected. 
 14.15 Further Assurances. Each of Enanta and
Abbott agrees to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including, without limitation, the filing of such additional assignments,
agreements, documents and instruments, as the other Party may at any time and from time to time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm
unto such other Party its rights and remedies under, this Agreement. 
 14.16 HSR Filing. Each Party shall, no
later than November 30, 2006 (or such later time as the Parties mutually agree in writing), file with the Federal Trade Commission any filing required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the
“HSR Act”), in connection with the transactions contemplated hereby. The Parties shall cooperate with each other to the extent necessary in the preparation of any such filing. Each party shall request early termination of
such filing by the Federal Trade Commission. Neither Party shall be required in connection with any filing under the HSR Act to commit or agree to any action, to obtain any consents, approvals, permits or authorizations to remove any impediments or
to resort to or respond to litigation or to agree to hold separate or divest any business or assets. 
 Abbott shall be responsible for paying
any fees required to be paid to governmental authorities in connection with its filings as a licensee, Enanta shall be responsible for paying any fees associated with its filings as a licensor and each Party shall bear its own expenses, including
but not limited to legal fees associated with preparing any such filing, subject to Section 14.17 below. 

  
 - 61 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 14.17 Board Approvals. The obligation of Enanta to effect the transactions
contemplated by this Agreement is subject to the receipt of approval by Enanta’s Board of Directors (the “Enanta Board”) and Enanta’s Chief Executive Officer. The obligation of Abbott to effect the transactions
contemplated by this Agreement is subject to the receipt of approval by Abbott’s Board of Directors (the “Abbott Board”) and Abbott’s Chief Executive Officer. In the event that such Abbott approvals are not obtained
on or before December 8, 2006, (a) Abbott shall reimburse Enanta for any fees or expenses incurred by Enanta in connection with the filing under the HSR Act described in Section 14.16, including but not limited to legal fees
associated with preparing such filing, and (b) this Agreement shall be terminated with no further force and effect. Each Party shall provide the other with evidence or certification of its Board of Directors or Chief Executive Officer approval,
as applicable, upon request. 
 [Remainder of page intentionally left blank.] 

  
 - 62 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 IN WITNESS WHEREOF, The Parties have caused this Agreement, to be executed by their duly
authorized representatives. 
  

			
	ENANTA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Jay R. Luly

	Name:	 	 Jay Luly, Ph.D

	Title:	 	 President and Chief Executive Officer

  

			
	ABBOTT LABORATORIES
		
	By:	 	 /s/ William G. Dempsey

	Name:	 	 William G. Dempsey

	Title:	 	 Executive Vice President, Pharmaceutical

		 	 Products Group

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 EXHIBIT A 

RESEARCH PLAN 
 The Research Program will involve the research and development of Enanta’s proprietary HCV protease inhibitor program identified in PCT nos. WO 2005010029 Al; WO 2004/093798 A2; WO 2004/072243 A2; WO
2004 113365 A2 and any HCV protease inhibitors identified by Enanta in the conduct of the Research Program and any other patent applications included in Schedule 4 as part of the Licensed Patent Rights. 

Enanta, with input from the JSC, will be primarily responsible for discovery activities including, but not limited to, medicinal chemistry, enzyme,
replicon and cytotoxicity assays, and initial metabolism and pharmacokinetic screens associated with the identification of [*****]during the Research Program Term. With approval of JSC, Abbott FTEs may be applied to Candidate identification research
to expand scope of chemistry or to otherwise improve the competitive position of the program. Abbott will have primary responsibility for Candidate selection activities including virology, pharmacokinetics, pharmaceutics, metabolism and safety
studies needed for the identification of [*****]. Abbott will have primary responsibility for process research, and the planning and execution of all preclinical IND-enabling studies on Candidate compounds. 

Abbott personnel will be responsible for preparation of data-summary documentation and presentations necessary to support internal assignment of Abbott
resources to support characterization of lead Compounds and IND-enabling pre-clinical research on Candidates. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 EXHIBIT B 

FORM OF STOCK PURCHASE AGREEMENT 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 CONFIDENTIAL 
 SERIES G CONVERTIBLE PREFERRED 
 STOCK PURCHASE AGREEMENT 

by and among 
 ENANTA PHARMACEUTICALS, INC. 
 and 

THE INVESTORS LISTED ON THE 
 SCHEDULE OF INVESTORS 
 attached hereto 

Dated [ — ], 20     

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 SERIES G CONVERTIBLE PREFERRED STOCK 

PURCHASE AGREEMENT 
 THIS SERIES E CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (“Agreement”) is made as of [ — ], 20    , by
and among Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), the investors named on the Schedule of Investors attached hereto (the “Initial Investors”) and the additional investors
added from time to time to the Schedule of Investors in accordance with Section 23 below (the “Additional Investors,” and together with the Initial Investors, the “Investors”). 

WHEREAS, the Investors wish to purchase from the Corporation, and the Corporation wishes to sell to the Investors, up to an aggregate of
[ — ] shares of the Corporation’s Series G Convertible Preferred Stock, par value $.01 per share (the “Series G Preferred Stock”). 

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, the parties hereby agree as
follows: 
 SECTION 1. Fourth Amended and Restated Certificate of Incorporation. On or prior to the date hereof, the
Corporation shall have filed with the Secretary of State of the State of Delaware its Fourth Amended and Restated Certificate of Incorporation (the “Restated Certificate”), a copy of which is attached hereto as Exhibit 1 (the
Restated Certificate as in effect on the date hereof being hereinafter sometimes also referred to as the “Certificate of Incorporation”), for the purpose of amending the authorized capital stock of the Corporation and setting forth
the designations and the powers, preferences and rights, and the qualifications, limitations and restrictions thereof, granted to or imposed upon the capital stock of the Corporation or the holders thereof, including the Series G Preferred Stock.

 SECTION 2. Purchase and Sale of the Series G Preferred Stock. 

2.1 Initial Series G Shares. Subject to the terms and conditions of this Agreement, at the Initial Closing (as defined in
Section 3.1), the Corporation agrees to issue and sell an aggregate of [ — ] shares of Series G Preferred Stock (the “Initial Series G Shares”) to the Initial
Investors, and each Initial Investor, acting severally and not jointly, agrees to purchase from the Corporation the number of Initial Series G Shares set forth opposite the name of such Initial Investor on the Schedule of Investors under the
column heading “Initial Series G Shares,” at a purchase price of $[ — ] per share. 
 2.2 Additional Series G Shares. 
 (a) Subject to the terms and
conditions of this Agreement, at each Scheduled Additional Closing (as defined in Section 3.2), the Corporation agrees to issue and sell an aggregate of [ — ] shares of Series G
Preferred Stock (the “Initial Investor Additional Series G Shares” and, together with the Initial Series G Shares, the “Initial Investor Series G Shares”) to the Initial Investors, and each Initial Investor, acting
severally and not jointly, agrees to purchase from the Corporation the number of Initial Investor Additional Series G Shares set forth opposite the name of such Initial Investor on the Schedule of Investors under the column headings
“Second Closing Series G Shares,” “Third Closing Series G Shares,” “Fourth Closing Series G Shares” and “Fifth Closing Series G Shares,” all at a purchase price of
$[ — ] per share. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (b) The Corporation may issue and sell an aggregate of up to [ — ] shares of Series G Preferred Stock (the “Additional Investor Series G Shares” and, together with the Initial Investor Additional Series G Shares, the “Additional Series G
Shares”) to one or more Additional Investors, each of which purchases Additional Investor Series G Shares at or before the date of the first Scheduled Additional Closing and agrees to purchase additional shares of the Additional Investor
Series G Shares in proportionate amounts on the same terms as the Initial Investors. Any Additional Investor shall be either (i) an existing stockholder of or an affiliate of an existing stockholder of the Corporation or (ii) a new
investor reasonably acceptable to the Corporation with the consent of the Corporation’s Series C-G Directors (as defined in the Restated Certificate). The Initial Investor Series G Shares and the Additional Investor Series G Shares are
collectively referred to as the “Series G Shares”. 
 (c) [The Corporation may, in its discretion, cancel any
Additional Closing upon written notice to the Initial Investors and any Additional Investors who had previously agreed to participate in such Additional Closing. In the event the Corporation cancels any Additional Closing, the number of Series G
Shares to have been purchased by each Investor at such Additional Closing shall thereafter be added to the number of Series G Shares to be purchased by each Investor at the (next Additional Closing scheduled to take place after such cancelled
Additional Closing.) 
 SECTION 3. Closing. 
 3.1 Initial Closing. The closing of the sale and purchase of the Initial Series G Shares (the “Initial Closing”) shall take place simultaneously with the execution of this
Agreement at the offices of Palmer & Dodge LLP, 111 Huntington Avenue, Boston, Massachusetts, U.S.A., or at such other location as may be agreed upon among the Initial Investors and the Corporation. At the Initial Closing, the Corporation
shall issue and deliver to each Initial Investor a certificate or certificates for shares of Series G Preferred Stock, registered in the name of such Initial Investor, in the amount representing the number of Initial Series G Shares being purchased
by such Initial Investor at the Initial Closing, against payment by such Initial Investor to the Corporation of the aggregate purchase price therefor in the form of (a) a wire transfer to a bank account designated by the Corporation or
(b) such other method of payment as the Corporation, in its sole discretion, may accept. 
 3.2 Additional
Closings. The closing of the sale and purchase of the Additional Series G Shares shall occur at (i) [ — ] additional closings (each, a “Scheduled Additional Closing”) to
take place at the offices of Palmer & Dodge LLP, 111 Huntington Avenue, Boston, Massachusetts, U.S.A., or at such other location as may be agreed upon among the Investors participating in such Scheduled Additional Closing, on each of [ — ] and (ii) one or more additional closings (each, an “Additional Investor Additional Closing” and together with the Scheduled Additional Closings, each an “Additional
Closing”) to take place no later than December 15, 2005 at the offices of Palmer & Dodge LLP, 111 Huntington Avenue, Boston, Massachusetts, U.S.A., or at such other location as may be agreed upon among the Corporation and the
Investors participating in such Additional Investor Additional Closing. At each 

  
 - 2 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
Additional Closing, the Corporation shall issue and deliver to each Investor participating in such Additional Closing a certificate or certificates for shares of Series G Preferred Stock,
registered in the name of such Investor, in the amount representing the number of Series G Shares being purchased by such Investor at such Additional Closing, against payment by such Investor to the Corporation of the aggregate purchase price
therefor in the form of (a) a wire transfer to a bank account designated by the Corporation or (b) such other method of payment as the Corporation, in its sole discretion, may accept. 

SECTION 4. Representations and Warranties of the Corporation. Except as set forth on Schedule 4, the Corporation hereby makes
the representations and warranties contained in this Section 4 to the Investors. The information contained on Schedule 4 shall be deemed to be representations and warranties of the Corporation and shall make explicit reference to the
particular representation or warranty (by reference to a subsection hereof) as to which exception is taken, provided that the information on Schedule 4 shall qualify as disclosure with respect to other representations or warranties for which
the appropriateness of such disclosure is reasonably apparent. 
 4.1 Organization. The Corporation is a
corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to own and lease its properties, to carry on its business as presently conducted and as
proposed to be conducted and to carry out the transactions contemplated by the Transaction Documents (as defined in Section 4.22 hereof). The Corporation is duly qualified as a foreign corporation and is in good standing in all such
jurisdictions in which the conduct of its business or its ownership or leasing of property requires such qualification. 

4.2 Capitalization. The entire authorized capital stock of the Corporation consists of: 

(a) [ — ] shares of Corporation’s Common Stock, par value $.01 per share
(“Common Stock”), of which (i) 3,794,270 shares have been issued and are outstanding, and are duly authorized, validly issued, fully paid and nonassessable; (ii) no shares are held as treasury shares; (iii) 822,830
shares have been reserved for issuance upon exercise of options granted or to be granted under the Corporation’s 1998 Equity Performance Plan (the “Equity Performance Plan”), of which
[ — ] shares have been issued as restricted stock or upon the exercise of options granted pursuant to the Equity Performance Plan and are included in the 3,794,270 shares of Common Stock
that are issued and outstanding; [ — ] shares are subject to currently outstanding options to purchase Common Stock; and [ — ]
shares are reserved for future issuance; (iv) [ — ] shares have been reserved for issuance under the Corporation’s 1995 Equity Incentive Plan (the “1995 Equity
Plan”), of which [ — ] shares have been issued as restricted stock or upon the exercise of options granted pursuant to the 1995 Equity Plan, all of which are included in the
3,794,270 shares of Common Stock that are issued and outstanding; [ — ] shares are subject to currently outstanding options to purchase Common Stock; and [ — ] shares are reserved for future issuance; (v) 379,450 shares have been reserved for issuance upon conversion of the Corporation’s Series A Convertible Preferred Stock, par value $.01 per
share (“Series A Preferred Stock”); (vi) 187,000 shares have been reserved for issuance upon conversion of the Corporation’s Series B Convertible Preferred Stock, par value $.01 per share (“Series B Preferred
Stock”); (vii) 2,563,603 shares have been reserved for issuance upon conversion of the 

  
 - 3 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
Corporation’s Series C Convertible Preferred Stock, par value $.01 per share (“Series C Preferred Stock”) (viii) 116,638 shares have been reserved for issuance upon
exercise of certain Common Stock Purchase Warrants dated December 1998 and May and August of 1999; (ix) 7,902,121 shares have been reserved for issuance upon conversion of the Corporation’s Series D Convertible Preferred Stock, par value
$.01 per share (“Series D Preferred Stock”), including [ — ] additional shares that have been reserved for issuance as a result of the reduction of the Series D Conversion
Price (as defined in the Restated Certificate) to $[ — ] as a result of the deemed issuance and sale by the Corporation of [ — ]
shares of Series G Preferred Stock; (x) 161,600 shares have been reserved for issuance upon exercise of certain Common Stock Purchase Warrants dated October 2000 and January and May of 2001; (xi) 21,238,570 shares have been reserved for
issuance upon conversion of the Corporation’s Series E Convertible Preferred Stock, par value $.01 per share (“Series E Preferred Stock”) including 2,473,308 shares that have been reserved for issuance upon conversion of the
shares of Series E Preferred Stock issuable upon exercise of the warrants to purchase shares of Series E Preferred Stock issued by the Corporation to the holders of Notes issued in March 2002, July, October and November 2003 and March 2004 and
to Silicon Valley Bank in December 2002; (xiii) 6,894,966 shares have been reserved for issuance upon conversion of the Corporation’s Series F Convertible Preferred Stock par value $.01 per share (“Series F Preferred
Stock”); and [ — ] shares have been reserved for issuance upon conversion of the Series G Preferred Stock; 
 (b) 379,450 shares of Series A Preferred Stock, all of which have been issued and are outstanding, and are duly authorized, validly issued, fully paid and nonassessable; 

(c) 187,000 shares of Series B Preferred Stock, all of which have been issued and are outstanding, and are duly authorized, validly
issued, fully paid and nonassessable; 
 (d) 2,563,603 shares of Series C Preferred Stock, all of which have been issued and are
outstanding, and are duly authorized, validly issued, fully paid and nonassessable; 
 (e) 5,988,334 shares of Series D
Preferred Stock, all of which have been issued and are outstanding, and are duly authorized, validly issued, fully paid and nonassessable; 
 (f) 16,158,953 shares of Series E Preferred Stock, of which (i) 14,261,598 shares have been issued and are outstanding, and are duly authorized, validly issued, fully paid and nonassessable and
(ii) 1,879,715 shares have been reserved for issuance upon exercise of the Series E Preferred Stock Warrants; 
 (g)
6,894,966 shares of Series F Preferred Stock, all of which have been issued and are outstanding, and are duly authorized, validly issued, fully paid and nonassessable; and 
 (h) [ — ] shares of Series G Preferred Stock, of which (i) [ — ] shares are
being issued at the Initial Closing and immediately thereafter will be issued and outstanding, and will be duly authorized, validly issued, fully paid and nonassessable and will be held of record by the Initial Investors and (ii) [ — ] shares have been reserved for issuance to the Initial Investors and one or more Additional Investors at the Additional Closings and immediately thereafter will be issued and outstanding, and will
be duly authorized, validly issued, fully paid and nonassessable and will be held of record by the Investors. 

  
 - 4 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Except as set forth in this Section 4.2 or in the Restated Certificate or the
Transaction Documents: (I) there are no outstanding shares of capital stock of the Corporation or warrants, options, agreements, convertible securities, rights or other commitments pursuant to which the Corporation is or may become obligated to
issue any shares of its capital stock or other securities of the Corporation; (II) there are no preemptive or similar rights to purchase or otherwise acquire shares of capital stock of the Corporation from the Corporation pursuant to any provision
of law, the Certificate of Incorporation or the by-laws, as amended to date, of the Corporation (the “By-laws”) or, any agreement to which the Corporation is a party, or otherwise; (III) there are no redemption or similar rights
whereby the Corporation is obligated, contractually or otherwise, to repurchase, redeem, or otherwise acquire any shares of capital stock of the Corporation; and (IV) there is no agreement, restriction or encumbrance with respect to the
registration, transfer, sale or voting of any shares of the Corporation’s capital stock (whether outstanding or issuable upon conversion or exercise of outstanding securities). 

The Corporation has not violated the Securities Act of 1933, as amended (the “Securities Act”) or any securities law of
any state or other jurisdiction in connection with the issuance of any securities prior to the date hereof. All of the outstanding shares of the Corporation’s capital stock and all other securities of the Corporation were offered, issued, and
sold, the Series G Shares (which have been sold at any Closing (as defined in Section 6)) will be offered, issued and sold, and the Reserved Shares (as defined below) will be issued in compliance with (i) all applicable preemptive or
similar rights of all persons and (ii) all applicable provisions of the Securities Act and the rules and regulations thereunder, and all applicable state securities laws and the rules and regulations thereunder. No person has any valid right to
rescind any purchase of any shares of capital stock or other securities of the Corporation. 
 4.3 Equity Investments;
Subsidiaries. The Corporation does not currently own, directly or indirectly, any capital stock or other proprietary interest in any corporation, association, trust, partnership, limited liability company, limited liability partnership,
joint venture or other entity. The Corporation does not have any subsidiaries or own any legal and/or beneficial interests in any other person. 
 4.4 Financial Statements. The audited balance sheet (the “Balance Sheet”) for the Corporation as of September 30, 2004 (the “Balance Sheet Date”) and
the related audited statements of income, stockholders’ equity and cash flows for the year then ended (collectively, the “Financial Statements”) (a) are in accordance with the books and records of the Corporation and
(b) present fairly the financial position and results of operations of the Corporation as of the date and for the periods indicated in accordance with generally accepted accounting principles (“GAAP”) applied on a consistent
basis. 
 4.5 Absence of Undisclosed Liabilities. The Corporation has no material liabilities or obligations of
any nature, whether accrued, absolute, contingent, or otherwise (including without limitation liabilities as guarantor or otherwise with respect to obligations of others) and whether due or to become due, except as incurred in the ordinary course of
business. 

  
 - 5 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 4.6 Absence of Changes. Since the Balance Sheet Date there has not been
(a) any material adverse change in the financial condition, results of operations, assets, liabilities, business or prospects of the Corporation, (b) any material asset or property of the Corporation made subject to a lien of any kind,
except liens for taxes not yet due and payable or non-consensual purchase money liens arising by operation of law and in the ordinary course of business, (c) any waiver of any valuable right of the Corporation, or the cancellation of any debt
or claim held by the Corporation, (d) any payment of dividends on, or other distribution with respect to, or any direct or indirect redemption or acquisition of, any shares of the capital stock of the Corporation, or any agreement or commitment
therefor, (e) any mortgage, pledge, sale, assignment or transfer of any tangible or intangible assets of the Corporation, except in the ordinary course of business, (f) any loan by the Corporation to, or any loan to the Corporation from,
any officer, director, employee or stockholder of the Corporation, or any agreement or commitment therefor, (g) any damage, destruction or loss (whether or not covered by insurance) materially and adversely affecting the assets, property or
business of the Corporation, or (h) any change in the accounting methods or practices followed by the Corporation. 

4.7 Encumbrances. The Corporation has good and marketable title to all of its property and assets, real, personal or mixed,
tangible or intangible, free and clear of all liens, security interests, charges and other encumbrances of any kind, except liens for taxes not yet due and payable. The Corporation enjoys peaceful and undisturbed possession under all leases under
which it is operating, and all said leases are valid and subsisting and in full force and effect. 
 4.8 Intellectual
Property Rights. 
 (a) The Corporation owns or has the legally enforceable right to use, and has the right to bring
actions for infringement of, all Intellectual Property Rights (as defined below) necessary or required for the conduct of its business as presently conducted or as proposed to be conducted. 

(b) The Corporation has no obligation to compensate any person for the use of any of its Intellectual Property Rights and the Corporation
has not granted any person any license or other rights to use any of such Intellectual Property Rights, whether requiring the payment of royalties or not. 
 (c) No product or process presently used, marketed or sold or proposed to be used, marketed or sold by the Corporation and no Intellectual Property Rights proposed to be licensed by the Corporation as
licensor violate or will violate any license or infringe or will infringe any Intellectual Property Rights of another, nor has the Corporation received any notice that any of its Intellectual Property Rights or the operation or proposed
operation of the Corporation’s business conflicts or will conflict with the rights of others; and to the Corporation’s knowledge, none of the Intellectual Property Rights have been or are being infringed or violated by others. 

(d) There are no claims pending or, to the Corporation’s knowledge, threatened to the effect that any of the Intellectual Property
Rights owned or licensed by the Corporation, or which the Corporation otherwise has rights to use, is invalid or unenforceable, or that would otherwise interfere in any material respect with the Corporation’s right to use any Intellectual
Property Rights being used in the Corporation’s business as currently conducted or as proposed to be conducted, nor does there exist any basis therefor. 

  
 - 6 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (e) All personnel of the Corporation, including employees, agents, consultants and
contractors, who have contributed to or participated in the conception or development of any of the Intellectual Property Rights owned by the Corporation have entered into an agreement that conveys to the Corporation full, effective and exclusive
ownership of all tangible and intangible property thereby arising. 
 (f) The Corporation has not entered into any agreement to
indemnify any other person against any charge of infringement of any Intellectual Property Rights. 
 As used herein, the term
“Intellectual Property Rights” means all patents, trademarks, service marks, trade names, copyrights, inventions, trade secrets, licenses, know-how, proprietary processes and formulae, applications for patents, trademarks, service marks
and copyrights, and other industrial and intellectual property rights. 
 4.9 Litigation. There is no action,
suit, claim, proceeding or investigation, at law, in equity or otherwise, or by or before any governmental instrumentality or other agency, now pending, or, to the Corporation’s knowledge, threatened against or affecting the Corporation, nor is
there any basis therefor known to the Corporation. 
 4.10 No Defaults. The Corporation is not in violation or
breach of, or in default under, any provision of (a) the Certificate of Incorporation or the By-Laws or (b) any material note, indenture, mortgage, lease, contract, purchase order or other instrument, document or agreement to which the
Corporation is a party or by which it or any of its property is bound or affected or any ruling, writ, injunction, order, judgment or decree of any court, administrative agency or other governmental body. To the Corporation’s knowledge, there
exists no condition, event or act which, after notice, lapse of time, or both, may constitute a violation or breach of, or a default under, any of the foregoing. 
 4.11 Employment of Officers, Employees and Consultants. To the Corporation’s knowledge, no third party may assert any valid claim against the Corporation, any Investor, or any
Designated Person (as defined below) with respect to (a) the continued employment by or association with the Corporation of any of the present officers or employees of, or consultants to, the Corporation (collectively, the “Designated
Persons”), or (b) the use or disclosure by the Corporation or any Designated Person of any information which the Corporation or any Designated Person would be prohibited from using or disclosing under any prior agreements or
arrangements or under any laws, including, without limitation, laws applicable to unfair competition, trade secrets or proprietary information. 
 The Corporation is in compliance in all material respects with all applicable federal and state laws respecting employment and employment practices, terms and conditions of employment, wages and hours,
and nondiscrimination in employment, and is not engaged in any unfair labor practice. None of the employees of the Corporation is covered by any collective bargaining agreement, and no collective bargaining agreement is currently being negotiated by
it. 

  
 - 7 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 4.12 Taxes. The Corporation has filed all federal, state, local and foreign
tax returns which are required to be filed by it and all such returns are true and correct. The Corporation has paid all taxes pursuant to such returns or pursuant to any assessments received by it or which it is obligated to withhold from amounts
owing to any employee, creditor or third party, except, in each case, for those which are not yet due and payable pursuant to such returns. There are no liens for taxes (other than current taxes not yet due and payable) on the assets of the
Corporation. The Corporation has established adequate reserves for all taxes accrued but not yet payable to the extent required by GAAP. All material tax elections of any type which the Corporation has made as of the date hereof are set forth in the
financial statements referred to in Section 4.4. No deficiency assessment with respect to or, proposed adjustment of the Corporation’s federal, state, county or local taxes, domestic and foreign, is pending or, to the knowledge of the
Corporation, threatened. Neither the Corporation nor any of its present or former stockholders has ever filed an election pursuant to Section 1362 of the Internal Revenue Code of 1986 (the “Code”), that the Corporation be taxed
as an S corporation. 
 4.13 [Reserved.] 
 4.14 Material Agreements. The Corporation has delivered or caused to be delivered to those Investors who have so requested in writing correct and complete copies of each Material
Agreement (as defined below), each as amended to date. Each such agreement, instrument, and commitment is a valid, binding and enforceable obligation of the Corporation, and to the Corporation’s knowledge, of the other party or parties thereto
(in each case, except as enforceability may be limited by bankruptcy, insolvency, or similar laws and except as the availability of equitable remedies is subject to the discretion of the court before they are sought), and is in full force and
effect. Neither the Corporation, nor to the best of its knowledge, any other party thereto, is, or is considered by any other party thereto to be, in breach of or not in compliance with any term of any such agreement, instrument, or commitment (nor,
to the Corporation’s knowledge, is there any basis for any of the foregoing), except for any breach or noncompliance that singly or in the aggregate would not have a material adverse effect on the financial condition, results of operations,
assets, liabilities, business or prospects of the Corporation. No claim, change order, request for equitable adjustment, or request for contract price or schedule adjustment, between the Corporation and any supplier or customer, relating to any
Material Agreement is pending or, to the Corporation’s knowledge, threatened, nor, to the Corporation’s knowledge, is there any basis for any of the foregoing. No Material Agreement includes or incorporates any provision, the effect of
which may be to enlarge or accelerate any of the obligations of the Corporation or to give additional rights to any other party thereto, or will terminate, lapse, or in any other way be affected, by reason of the transactions contemplated by this
Agreement. 
 As used in this Agreement, “Material Agreement” means any: 

(a) agreement for the purchase, sale, lease, or license by or from it of services, products, or assets, requiring total payments by or to
it in excess of $50,000 in any instance, or entered into other than in the ordinary course of business; 
 (b) agreement
requiring it to purchase all or substantially all of its requirements for a particular product or service from a particular supplier or suppliers, or requiring it to supply all of a particular customer’s or customers’ requirements for a
certain service or product; 

  
 - 8 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (c) agreement or other commitment pursuant to which it has agreed to indemnify or hold
harmless any other person, other than standard indemnification obligations with respect to the Corporation’s directors, employees and consultants; 
 (d) (i) employment agreement, (ii) consulting agreement, or (iii) agreement providing for severance payments or other additional rights or benefits (whether or not optional) in the event of the
sale or other change in control of it; 
 (e) agreement with any current or former “affiliate” (as defined in the
Securities Act), stockholder, officer, director, employee, or consultant of the Corporation, or with any person in which any such affiliate has an interest; 
 (f) joint venture or partnership agreement; 
 (g) agreement with any domestic or
foreign government or agency or executive office thereof or any subcontract between it and any third party relating to a contract between such third party and any domestic or foreign government or agency or executive office thereof; 

(h) agreement imposing non-competition or exclusive dealing obligations on it; 

(i) contract with any labor union; 
 (j) bonus, pension, profit-sharing, retirement, stock purchase, stock option, hospitalization, medical insurance or similar plan, contract or understanding in effect with respect to its employees or the
employees of others; 
 (k) agreement or indenture relating to the borrowing of money or to the mortgaging, pledging or
otherwise placing a lien on any assets of the Corporation; 
 (l) guaranty of any obligation for borrowed money or otherwise;

 (m) lease or agreement under which the Corporation is lessee of or holds or operates any property, real or personal, owned by
any other party; 
 (n) lease or agreement under which the Corporation is lessor of or permits any third party to hold or
operate any property, real or personal, owned or controlled by the Corporation; 
 (o) license or lease agreement with respect
to any Intellectual Property Rights; 
 (p) agreement or other commitment for capital expenditures in excess of $50,000;

  
 - 9 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (q) distributor, dealer or manufacturer’s representative contract or agreement which is
not terminable on less than ninety (90) days’ notice without cost or other liability to the Corporation; 
 (r) sales
agreement which entitles any customer to a rebate or right of set-off, to return any product to the Corporation after acceptance thereof or to delay the acceptance thereof, or which varies in any material respect from the Corporation’s standard
form contracts; 
 (s) agreement with any supplier containing any provision permitting any party other than the Corporation to
renegotiate the price or other terms, or containing any pay-back or other similar provision, upon the occurrence of a failure by the Corporation to meet its obligations under the agreement when due or the occurrence of any other event; 

(t) agreement for the future purchase of fixed assets or for the future purchase of materials, supplies or equipment in excess of its
normal operating requirements; 
 (u) agreement, or group of related agreements with the same party or any group of affiliated
parties, under which the Corporation has advanced or agreed to advance money, has agreed to lease any real property as lessee or lessor, or has agreed to lease any personal property as lessee or lessor if such lease for personal property was not
entered into in the ordinary course of business; 
 (v) contract, agreement or commitment under which the Corporation is
obligated to pay any broker’s fees, finder’s fees or any such similar fees, to any third party; 
 (w) except as set
forth above, any other agreement or group of related contracts with the same party continuing over a period of more than six months from the date or dates thereof (including renewals or extensions of options with another party), which agreement or
group of agreements is not terminable by the Corporation without penalty upon notice of thirty (30) days or less, but excluding any agreement or group of agreements with a customer of the Corporation for the sale, lease or rental of the
Corporation’s products or services if such agreement or group of agreements was entered into by the Corporation in the ordinary course of business; or 
 (x) any other contract, agreement, arrangement or understanding which is material to the business of the Corporation or which is material to a prudent investor’s understanding of the business of the
Corporation. 
 4.15 ERISA. The Corporation does not now sponsor, maintain, have any obligation to contribute to
or have any liability under, and never has sponsored, maintained, had any obligation to contribute to, or had any liability under, and is not now and has never otherwise been a party to, any Benefit Plan. For purposes of this Agreement,
“Benefit Plan” shall mean any plan, fund, program, policy, arrangement or contract, whether formal or informal, which is in the nature of (i) an employee pension benefit plan (as defined in Section (2) of the Employee Retirement
Income Security Act of 1974, as amended (“ERISA”)), (ii) an employee welfare benefit plan (as defined in section 3(1) of ERISA), (iii) a “multi-employer plan” (as defined in Section 3(37) of ERISA) or
(iv) any plan of deferred compensation, medical plan, life insurance plan, long-term disability plan, dental plan or other plan instituted with respect to any of the Corporation’s employees or former employees or beneficiaries thereof.

  
 - 10 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 4.16 U.S. Real Property Holding Corporation. The Corporation is not now, has
never been and has no current plans to become a “United States real property holding corporation,” as defined in Section 897(c)(2) of the Code and Section 1.897-2(b) of the Regulations promulgated by the Internal Revenue Service,
and the Corporation has never filed with the Internal Revenue Service a statement with its United States income tax returns under Section 1.897-2(h) of such Regulations stating that any shares of its capital stock constitute a U.S. real
property interest within the meaning of Section 897(c)(1) of the Code. 
 4.17 Environmental Protection. The
Corporation has not caused or allowed, or contracted with any party for, the generation, use, transportation, treatment, storage or disposal of any Hazardous Substances (as defined below) in connection with the operation of its business or
otherwise. The Corporation, the operation of its business, and any real property that the Corporation owns, leases or otherwise occupies or uses (the “Premises”) are in compliance with all applicable Environmental Laws (as defined
below) and orders or directives of any governmental authorities having jurisdiction under such Environmental Laws, including, without limitation, any Environmental Laws or orders or directives with respect to any cleanup or remediation of any
release or threat of release of Hazardous Substances. The Corporation has not received any citation, directive, letter or other communication, written or oral, or any notice of any proceeding, claim or lawsuit, from any person arising out of the
ownership or occupation of the Premises, or the conduct of its operations, and the Corporation is not aware of any basis therefor. The Corporation has obtained and is maintaining in full force and effect all necessary permits, licenses and approvals
required by all Environmental Laws applicable to the Premises and the business operations conducted thereon (including operations conducted by tenants on the Premises), and is in compliance with all such permits, licenses and approvals. The
Corporation has not caused or allowed a release, or a threat of release, of any Hazardous Substance onto, at or near the Premises, and, to the Corporation’s knowledge, neither the Premises nor any property at or near the Premises has ever been
subject to a release, or a threat of release, of any Hazardous Substance. For the purposes of this Agreement, the term “Environmental Laws” shall mean any federal, state or local law or ordinance or regulation pertaining to the protection
of human health or the environment, including, without limitation, the Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C. Sections 9601, et seq., the Emergency Planning and Community Right-to-Know Act, 42 U.S.C.
Sections 11001, et seq., and the Resource Conservation and Recovery Act, 42 U.S.C. Sections 6901, et seq. For purposes of this Agreement, the term “Hazardous Substances” shall include oil and petroleum products, asbestos,
polychlorinated biphenyls, urea formaldehyde and other materials classified as hazardous or toxic under any Environmental Laws. 

4.18 Foreign Corrupt Practices Act. The Corporation has not taken any action which would cause it to be in violation of the
Foreign Corrupt Practices Act of 1977, as amended, or any rules and regulations thereunder. To the Corporation’s knowledge, there is not now, and there has never been, any employment by the Corporation of, or beneficial ownership in the
Corporation by, any governmental or political official in any country in the world. 

  
 - 11 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 4.19 Federal Reserve Regulations. The Corporation is not engaged in the
business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulation U of the Board of Governors of the Federal Reserve System), and no part of the proceeds of the sale of Series G Shares will be used
to purchase or carry any margin stock or to extend credit to others for the purpose of purchasing or carrying any margin stock or in any other manner which would involve a violation of any of the regulations of the Board of Governors of the Federal
Reserve System. 
 4.20 Compliance. The Corporation has complied with, and is in compliance in all material
respects with, (i) all laws, statutes, governmental regulations, judicial or administrative tribunal orders, judgments, writs, injunctions, decrees, and similar commands applicable to it and its business, (ii) all unwaived terms and
provisions of all agreements, instruments, and commitments to which it is a party or to which it or any of its assets or properties is subject, except for any noncompliances that, both individually and in the aggregate, have not had and could not
reasonably be expected to have a material adverse effect on the financial condition, results of operations, assets, liabilities, business or prospects of the Corporation, and (iii) its charter documents and By-Laws, each as amended to date. The
Corporation has all federal, state, local and foreign governmental licenses, registrations and permits material to or necessary for the conduct of its business as currently conducted, such licenses, registrations and permits are in full force and
effect, and there have been no material violations of any such licenses, registrations or permits. No proceeding is pending or, to the Corporation’s knowledge, threatened, to revoke or limit any thereof. 

4.21 Insurance. No notice from any insurance carrier has been received by the Corporation claiming that the Corporation is
in default with respect to any provision contained in any insurance policy. 
 4.22 Authorization of Transaction
Documents. The execution, delivery and performance by the Corporation of (a) this Agreement, (b) the Third Amended and Restated Registration Rights Agreement of even date herewith by and among the Corporation, the Investors and the
other parties thereto in the form of Exhibit 4.22A (the “Registration Rights Agreement”), (c) the Third Amended and Restated Voting Agreement of even date herewith by and among the Corporation, the Investors and the
other parties thereto in the form of Exhibit 4.22B (the “Voting Agreement”), (d) the Third Amended and Restated Stock Restriction Agreement of even date herewith by and among the Corporation, the Investors and the other
parties thereto in the form of Exhibit 4.22C (the “Stock Restriction Agreement”) and (e) the Amended and Restated Investor Rights Agreement of even date herewith by and among the Corporation, the Investors and the other
parties thereto in the form of Exhibit 4.22D (the “Investor Rights Agreement”; together with this Agreement, the Registration Rights Agreement, the Voting Agreement and the Stock Restriction Agreement, the
“Transaction Documents”) have been duly authorized by all requisite corporate action. The Corporation has duly authorized, executed and delivered each Transaction Document, and each Transaction Document constitutes the valid and
binding obligation of the Corporation, enforceable in accordance with its terms. The execution, delivery and performance of the Transaction Documents, the issuance, sale and delivery of the Series G Shares, and the shares of Common Stock issuable
upon conversion of the Series G Shares (the “Reserved Shares”), and compliance with the provisions hereof and 

  
 - 12 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
thereof by the Corporation do not and will not, with or without the passage of time or the giving of notice or both, violate, conflict with or result in any breach of any of the terms, conditions
or provisions of, or constitute a default (or give rise to any right of termination, cancellation or acceleration) under, or result in the creation of any lien, security interest, charge or encumbrance upon any of the properties or assets of the
Corporation under, the Certificate of Incorporation or By-Laws, any Material Agreement, or any provision of law, statute, rule or regulation or any ruling, writ, injunction, order, judgment or decree of any court, administrative agency or other
governmental body. 
 4.23 Authorization of Series G Shares and Reserved Shares. The Restated Certificate has been
duly authorized by all requisite corporate action, and has been filed with the Secretary of State of the State of Delaware. The issuance, sale and delivery hereunder by the Corporation of the Series G Shares have been duly authorized by all
requisite corporate action of the Corporation, and when so issued, sold and delivered the Series G Shares will be validly issued and outstanding, fully paid and nonassessable, and not subject to preemptive or any other similar rights of the
stockholders of the Corporation or others. The issuance and delivery of the Reserved Shares have been duly authorized by all requisite corporate action of the Corporation, and the Reserved Shares have been duly reserved for issuance upon conversion
of any or all of the Series G Shares, and when so issued and delivered upon conversion of the Series G Shares, the Reserved Shares will be validly issued and outstanding, fully paid and nonassessable, and not subject to preemptive or any other
similar rights of the stockholders of the Corporation or others. 
 4.24 Related Transactions. No director,
officer or employee of the Corporation nor any “associate” (as defined in Rule 405 in the rules and regulations promulgated under the Securities Act) of any such person is indebted to the Corporation, nor is the Corporation indebted (or
committed to make loans or extend or guarantee credit) to any such person, nor is any such person a party to any transaction (other than as an employee or consultant) with the Corporation providing for the furnishing of services by, or rental of
real or personal property from, or otherwise requiring cash payments to, any such person. 
 4.25 Offerees. The
Corporation has not, either directly or through any agent, offered any Common Stock, Series G Preferred Stock, or other securities convertible into Common Stock, Series G Preferred Stock, or any security or securities similar to any thereof, for
sale to, or solicited any offers to buy any Common Stock, Series G Preferred Stock, or other securities convertible into Common Stock, Series G Preferred Stock, or any such similar security or securities from, or otherwise approached or negotiated
in respect thereof with, any person or entity other than the Investors. 
 4.26 Use of Proceeds. The net proceeds
received by the Corporation from the sale of the Series G Shares shall be used by the Corporation solely for the purpose of working capital and such other purposes as may be approved by the Board of Directors (including the approval of all of the
Series C-E Directors (as defined in the Investor Rights Agreement). 
 4.27 No Governmental Consent or Approval
Required. No authorization, consent, approval or other order of, declaration to, or filing with, any governmental agency or body is required to be made or obtained by the Corporation for or in connection with the valid and lawful
authorization, execution and delivery by the Corporation of the Transaction Documents, for or in 

  
 - 13 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
connection with the valid and lawful authorization, issuance, sale and delivery of the Series G Shares or for or in connection with the valid and lawful authorization, reservation, issuance, sale
and delivery of the Reserved Shares, except exemptive filings under applicable securities laws that have been made or that are not required to be made until after the Closing and that shall be made on a timely basis. 

4.28 Registration Rights. Except as contemplated by the Registration Rights Agreement, no person has any right to cause the
Corporation to effect the registration under the Securities Act of any shares of Common Stock or any other securities of the Corporation. 
 4.29 Employees. Each of the officers of the Corporation, each key employee and each other employee now employed by the Corporation who has access to confidential information of the
Corporation has executed an agreement regarding confidentiality, inventions and noncompetition, and such agreements are in full force and effect. No officer or key employee of the Corporation has advised the Corporation (orally or in writing) that
he intends to terminate employment with the Corporation. The Corporation has complied in all material respects with all applicable laws relating to the employment of labor, including provisions relating to wages, hours, equal opportunity, collective
bargaining and the payment of Social Security and other taxes, and with ERISA. 
 4.30 Exemptions from Securities
Laws. Subject to the accuracy of the representations and warranties of the Investors set forth in Section 5 hereof, the provisions of Section 5 of the Securities Act are inapplicable to the offering, issuance, sale
and delivery of the Series G Shares and the Reserved Shares, and no consent, approval, qualification or registration or filing under any state securities laws is required in connection therewith, except exemptive filings that have been made or that
are not required to be made until after the Initial Closing or any Additional Closing and that shall be made on a timely basis. 

4.31 [Small Business Concern. The Corporation, taken together with its “affiliates” (as that term
is defined in 13 C.F.R. § 121.103) is a “small business concern” within the meaning of 15 U.S.C. § 662(5), that is § 103(5) of the Small Business Investment Act of 1958, as amended (the “SBIC
Act”), and the regulations thereunder, including 13 C.F.R. § 107, and meets applicable size eligibility criteria set forth in 13 C.F.R. § 121.301(c)(1) or the industry standard covering the industry in which the
Corporation is primarily engaged as set forth in 13 C.F.R. § 13.301(c)(2). The Corporation does not presently engage in any activities for which a small business investment company is prohibited from providing funds by the SBIC Act and the
regulations thereunder, including 13 C.F.R. § 107.] 
 4.32 Books and Records. The books of
account, ledgers, order books, records and documents of the Corporation accurately and completely reflect all material information relating to the business of the Corporation, the location and collection of its assets, and the nature of all
transactions giving rise to the obligations or accounts receivable of the Corporation. 
 4.33 Disclosure. Neither
this Agreement nor any other document, certificate or written statement furnished to the Investors by or on behalf of the Corporation contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the
statements contained herein or therein not misleading. To the Corporation’s knowledge, there is 

  
 - 14 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
no fact or circumstance relating specifically to the business or condition of the Corporation that could reasonably be expected to result in a material adverse effect to the financial condition,
results of operations, assets, liabilities, business or prospects of the Corporation and that is not disclosed in Schedule 4. 

SECTION 5. Representations and Warranties of the Investors. Each of the Investors, severally and not jointly, represents and
warrants to the Corporation as follows: 
 5.1 Purchase for Investment. Such Investor is acquiring the Series G
Shares purchasable by it hereunder for its own account, for investment and not for, with a view to, or in connection with, any distribution or public offering thereof within the meaning of the Securities Act. 

5.2 Unregistered Securities; Legend. Such Investor understands that the Series G Shares and the Reserved Shares
(i) have not been, and will not be, registered under the Securities Act or any state securities law, by reason of their issuance in a transaction exempt from the registration requirements of the Securities Act and such laws, (ii) must be
held indefinitely unless they are subsequently registered under the Securities Act and such laws or subsequent disposition thereof is exempt from registration and (iii) will be subject to the restrictions on transfer set forth in
Section 8. Such Investor further understands that such exemption depends upon, among other things, the bona fide nature of such Investor’s investment intent expressed herein. 

5.3 Status of the Investors. Such Investor has not been formed for the specific purpose of acquiring the Series G Shares
pursuant to this Agreement. Such Investor understands the term “accredited investor” as used in Regulation D promulgated under the Securities Act and represents and warrants to the Corporation that such Investor is an “accredited
investor” for purposes of acquiring the Series G Shares purchasable by it hereunder. 
 5.4 Knowledge and Experience;
Economic Risk. Such Investor has sufficient knowledge and experience in business and financial matters and with respect to investment in securities of privately held companies so as to enable it to analyze and evaluate the merits and risks
of the investment contemplated hereby and is capable of protecting its interest in connection with this transaction. Such Investor is able to bear the economic risk of such investment, including a complete loss of the investment. 

5.5 Access to Information. Such Investor acknowledges that such Investor and its representatives have had the opportunity
to ask questions and receive answers from officers and representatives of the Corporation concerning the transactions contemplated by this Agreement, and to obtain any additional information which the Corporation possesses or can acquire in
connection with its purchase of the Series G Shares purchasable by it hereunder. 
 5.6 Rule 144. Such Investor
understands that the exemption from registration afforded by Rule 144 (the provisions of which are known to such Investor) promulgated by the Securities and Exchange Commission (the “Commission”) under the Securities Act depends
upon the satisfaction of various conditions, and that such exemption is not currently available. 

  
 - 15 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 SECTION 6. Conditions Precedent to Closings by the Investors. 

6.1 Conditions Precedent to Initial Closing by the Initial Investors. The obligation of each Initial Investor to purchase
and pay for the Initial Series G Shares being purchased by such Initial Investor at the Initial Closing is subject to satisfaction (or waiver by such Initial Investor) of the following conditions precedent at or before the Initial Closing:

 (a) Corporate Proceedings. All corporate and other proceedings to be taken and all waivers and consents to be obtained
in connection with the transactions contemplated by this Agreement shall have been taken or obtained and all documents incident to such transactions shall be reasonably satisfactory in form and substance to the Initial Investors and their counsel,
who shall have received all such originals or certified or other copies of such documents as they may reasonably request. 
 (b)
Representations and Warranties Correct. The representations and warranties made by the Corporation in Section 4 hereof shall be true and correct when made, and shall be true and correct at the time of the Initial Closing with the same
force and effect as if they had been made at and as of the time of the Initial Closing. 
 (c) Compliance with Covenants.
The Corporation shall have duly complied with and performed all covenants and agreements of the Corporation herein which are required to be complied with and performed at or before the Initial Closing. 

(d) Certificate of Compliance. The President and Chief Executive Officer of the Corporation shall have provided to the Initial
Investors a certificate, dated the date of the Initial Closing in form and substance reasonably satisfactory to the Initial Investors participating in such Closing, confirming compliance with the conditions set forth in Subsections 6.1(b) and
6.1(c). 
 (e) Opinion of Counsel. At the Initial Closing, each of the Initial Investors shall have received an opinion
of Palmer & Dodge LLP, counsel for the Corporation, addressed to the Initial Investors in the form attached hereto as Exhibit 6.1(e). 
 (f) Related Agreements and Documents. At or before the Initial Closing, the parties thereto shall have executed and delivered this Agreement, the Registration Rights Agreement, the Investor Rights
Agreement, the Voting Agreement and the Stock Restriction Agreement. In addition, the Initial Investors and their counsel shall have received copies of the following documents: (i) (A) the Certificate of Incorporation, certified as of a
recent date by the Secretary of State of the State of Delaware and (B) a certificate of said Secretary dated as of a recent date as to the due incorporation and good standing of the Corporation, the payment of all excise taxes by the
Corporation and listing all documents of the Corporation on file with said Secretary; (ii) a certificate of the Secretary or an Assistant Secretary of the Corporation dated the Initial Closing Date and certifying: (A) that attached thereto
is a true and complete copy of the By-Laws as in effect on the date of such certification; (B) that attached thereto is a true and complete copy of all resolutions adopted by the Board of Directors or the stockholders of the Corporation
authorizing the execution, delivery and performance of the Transaction Documents, the issuance, sale and delivery of the Series G Shares and the reservation, issuance and delivery 

  
 - 16 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
of the Reserved Shares, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated by the Transaction
Documents; (C) that the Restated Certificate has not been amended; and (D) to the incumbency and specimen signature of each officer of the Corporation executing any of the Transaction Documents, the stock certificates representing the
Series G Shares and any certificate or instrument furnished pursuant hereto, and a certification by another officer of the Corporation as to the incumbency and signature of the officer signing the certificate referred to in this clause (ii); and
(iii) such additional supporting documents and other information with respect to the operations and affairs of the Corporation as the Initial Investors or their counsel reasonably may request. 

(g) Securities Matters. All consents, approvals, qualifications, registrations, notices and filings required to be obtained or
effected as of the Initial Closing under any applicable securities laws of any state or other jurisdiction in connection with the issuance, sale and delivery of the Series G Shares and the Reserved Shares shall have been obtained or effected and
copies of the same delivered to each of the Initial Investors. 
 (h) Delivery of Certificates for Series G Shares. The
Corporation shall have delivered to each Initial Investor a certificate for the Series G Shares being purchased by such Initial Investor at the Initial Closing, registered in the name of such Initial Investor. 

(i) Purchase by Other Initial Investors. Each Initial Investor shall have purchased and paid for the Initial Series G Shares being
purchased by it at the Initial Closing and the aggregate investment of all Initial Investors shall be no less than $[7,000,000]. 
 6.2 Conditions Precedent to Scheduled Additional Closings by the Investors. The obligation of each Investor to purchase and pay for the Additional Series G Shares being purchased by such
Investor at a Scheduled Additional Closing (together with the Initial Closing and any other Additional Closing(s), each a “Closing”) is subject to satisfaction (or waiver by such Initial Investor) of the following conditions
precedent at or before such Scheduled Additional Closing: 
 (a) Completion of Initial Closing. The Initial Closing shall
have been consummated in accordance with the terms of this Agreement. 
 (b) Corporate Proceedings. None of the corporate
and other proceedings required to be taken nor the waivers and consents required to be obtained in connection with the Initial Closing shall have been rescinded or amended in a manner that prevents such Scheduled Additional Closing. 

(c) Delivery of Certificates for Series G Shares. The Corporation shall have delivered to each Investor a certificate for the
Additional Series G Shares being purchased by such Investor at the Scheduled Additional Closing, registered in the name of such Investor. 
 6.3 Conditions Precedent to First Additional Closing by the Additional Investors. The obligation of each Additional Investor to purchase and pay for the Additional Investor Series G Shares
being purchased by such Additional Investor at the first Additional 

  
 - 17-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
Closing in which such Additional Investor participates is subject to satisfaction (or waiver by such Additional Investor) of the following conditions precedent at or before such Additional
Closing: 
 (a) Corporate Proceedings. None of the corporate and other proceedings required to be taken nor the waivers
and consents required to be obtained in connection with the Initial Closing shall have been rescinded or amended in a manner that prevents such Additional Closing. 
 (b) Representations and Warranties Correct. The representations and warranties made by the Corporation in Section 4 hereof shall be true and correct at the time of such Additional Closing with
the same force and effect as if they had been made at and as of the time of such Additional Closing, except as set forth in any supplement or update to the Disclosure Schedules reasonably satisfactory to such Additional Investor. 

(c) Compliance with Covenants. The Corporation shall have duly complied with and performed all covenants and agreements of the
Corporation herein which are required to be complied with and performed at or before such Additional Closing. 
 (d)
Certificate of Compliance. The President and Chief Executive Officer of the Corporation shall have provided to such Additional Investor a certificate, dated the date of such Additional Closing in form and substance reasonably satisfactory to
such Additional Investor, confirming compliance with the conditions set forth in Subsections 6.3(b) and 6.3(c). 
 (e)
Delivery of Certificates for Series G Shares. The Corporation shall have delivered to each such Additional Investor a certificate for the Additional Investor Series G Shares being purchased by such Additional Investor at such Additional
Closing, registered in the name of such Additional Investor. 
 SECTION 7. Conditions Precedent to Closing by the
Corporation. The obligation of the Corporation to issue and sell the Series G Shares being sold to the Investors at any Closing is subject to satisfaction (or the waiver by the Corporation) of the following conditions precedent at or before
such Closing: 
 7.1 Representations and Warranties. The representations and warranties made by each Investor
purchasing shares at such Closing in Section 5 hereof shall be true and correct when made, and shall be true and correct in all material respects at the time of such Closing with the same force and effect as if they had been made at and as of
the time of such Closing. 
 7.2 Tender of Payment. Each Investor purchasing Series G Shares at the Closing shall
have tendered payment for such Series G Shares to the Corporation. 
 SECTION 8. Transfer of Shares; Restricted Shares.
“Restricted Shares” means (i) the Series G Shares, (ii) the shares of Common Stock issued or issuable upon conversion of the Series G Shares, (iii) any shares of capital stock of the Corporation acquired by the Investors
pursuant to the Investor Rights Agreement, and (iv) any other shares of capital stock of the Corporation issued in respect of such shares (as a result of stock splits, stock dividends, 

  
 - 18 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
reclassifications, recapitalizations, or similar events); provided, however, that shares of Common Stock which are Restricted Shares shall cease to be Restricted Shares (x) upon any
sale pursuant to a registration statement under the Securities Act, Section 4(1) of the Securities Act or Rule 144 under the Securities Act or (y) at such time as they become eligible for sale under Rule 144(k) under the Securities Act.

 8.1 Requirements for Transfer. 
 (a) Restricted Shares shall not be sold or transferred unless either (i) they first shall have been registered under the Securities Act or (ii) the Corporation first shall have been furnished
with an opinion of legal counsel, reasonably satisfactory to the Corporation, to the effect that such sale or transfer is exempt from the registration requirements of the Securities Act. 

(b) Notwithstanding the foregoing, no registration or opinion of counsel shall be required for (i) (A) a transfer by an
Investor which is a corporation to the parent or a wholly owned subsidiary of such corporation, (B) a transfer by an Investor which is a partnership to a partner of such partnership or a retired partner of such partnership who retires after the
date hereof, or to the estate of any such partner or retired partner, or to an affiliated limited partnership (or other entity) managed by the same management company or managing general partner of such Investor or by an entity which controls, is
controlled by, or is under common control with, such management company or managing general partner, (C) a transfer by an Investor which is a trust to any beneficiary of the trust, (D) a transfer by an Investor which is a limited liability
company to a member of such limited liability company or a retired member who resigns after the date hereof or to the estate of any such member or retired member, or to an affiliated limited liability company (or other entity) managed by the same
management company or managing member of such Investor or by an entity which controls, is controlled by, or is under common control with, such management company or managing member. 

8.2 Legend. Each certificate representing Restricted Shares shall bear a legend substantially in the following form:

 “The shares represented by this certificate have not been registered under the Securities Act of 1933, as amended (the
“Act”), and may not be offered, sold or otherwise transferred, pledged or hypothecated unless and until such shares are registered under such Act, or, if requested by the Company, an opinion of counsel satisfactory to the Company is
obtained to the effect that such registration is not required.” 
 The foregoing legend shall be removed from the
certificates representing any Restricted Shares, at the request of the holder thereof, at such time as they become eligible for resale pursuant to Rule 144(k) under the Securities Act. 
 SECTION 9. Fees; Brokers. 
 9.1 Fees. The
Corporation shall pay, and save the Investors harmless against all liability for the payment of: 
 (a) all costs and other
expenses incurred by the Corporation in connection with the preparation of the Transaction Documents and the Corporation’s performance of and compliance with all agreements and conditions contained herein and therein on its part to be performed
or complied with; and 

  
 - 19 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (b) all costs and other expenses incurred by the Corporation in connection with delivering
to the Investors the Series G Shares and the Reserved Shares. 
 The Corporation further agrees that it shall pay, and shall
save the Investors harmless from, any and all liability with respect to any stamp, issue or similar taxes which may be determined to be payable in connection with the execution, delivery and performance of this Agreement, the issuance of the Series
G Shares or the Reserved Shares or any modification, amendment or alteration of the terms or provisions of this Agreement. 

9.2 Brokers. The Corporation represents and warrants to the Investors that (a) neither the Corporation nor any of its
officers, directors, employees or stockholders, has employed any broker or finder in connection with the transactions contemplated by this Agreement, and (b) no person or entity will have, as a result of the transactions contemplated by this
Agreement, any right to, interest in, or claim against or upon the Corporation or any Investor for, any commission, fee or other compensation as a finder or broker because of any act or omission by the Corporation or any agent of the Corporation.
The Corporation agrees that it shall pay, and shall save the Investors harmless from, any and all liability with respect to any commission, fee or other compensation payable to any broker or finder in connection with the transactions contemplated by
this Agreement. 
 SECTION 10. Remedies. In case any one or more of the representations, warranties, covenants or
agreements set forth in this Agreement shall have been breached by the Corporation, the Investors may proceed to protect and enforce their rights either by suit in equity or by action at law, including, but not limited to, an action for damages as a
result of any such breach or an action for specific performance of any such covenant or agreement contained in this Agreement. No failure or delay on the part of any party to this Agreement in exercising any right, power or remedy hereunder shall
operate as a waiver thereof; nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The remedies herein provided are
cumulative and not exclusive of any remedies provided by law. 
 SECTION 11. Exchanges; Lost, Stolen or Mutilated Certificates.
Upon surrender by any Investor to the Corporation of any certificate representing Series G Shares or Reserved Shares, the Corporation at its expense shall issue in exchange therefor, and deliver to such Investor, new certificates representing such
Series G Shares or Reserved Shares, as the case may be, in such amounts or denominations as may be requested by such Investor. Upon receipt of evidence satisfactory to the Corporation of the loss, theft, destruction or mutilation of any certificate
representing any Series G Shares or Reserved Shares and in case of any such loss, theft or destruction, upon delivery of an indemnity agreement satisfactory to the Corporation, or in case of any such mutilation, upon surrender and cancellation of
such certificate, the Corporation at the Investor’s expense shall issue and deliver to such Investor a new certificate for such Series G Shares or Reserved Shares, of like tenor, in lieu of such lost, stolen or mutilated certificate.

  
 - 20 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 SECTION 12. Survival of Representations, Warranties and Agreements. The covenants,
representations and warranties of the parties contained herein shall survive the Closings hereunder. Each of the parties may rely on such covenants, representations and warranties irrespective of any investigation made, or notice or knowledge held
by, it or any other person. All statements contained in any certificate or other instrument delivered by any party pursuant to this Agreement or in connection with the transactions contemplated by this Agreement shall constitute representations and
warranties by such party under this Agreement, subject to the qualifications set forth herein and therein. 
 SECTION 13. Successors and
Assigns. This Agreement shall be binding upon, and inure to the benefit of, each of the parties hereto and, except as otherwise expressly provided herein, each other person who shall become a registered holder named in a certificate
evidencing Series G Shares or Reserved Shares transferred to such holder by any of the Investors or their permitted transferees, and (except as aforesaid) their respective legal representatives, successors and assigns. Notwithstanding the foregoing,
the Corporation shall not have the right to assign its rights hereunder with respect to the Investors’ commitment to make an investment at an Additional Closing without the prior written consent of the holders of at least two-thirds of the
voting power of the then outstanding Series G Shares and Reserved Shares, voting together on an as-if converted to Common Stock basis. 

SECTION 14. Entire Agreement; Effect on Prior Documents. This Agreement and the other documents referred to herein or delivered pursuant
hereto contain the entire agreement among the parties with respect to the financing transactions contemplated hereby and supersede all prior negotiations, commitments, agreements and understandings among them with respect thereto. Nothing in this
Agreement or the transactions hereby contemplated is intended to confer upon any other person any rights or remedies of any nature whatsoever. 

SECTION 15. Notices. All notices, requests, consents and other communications hereunder (“Notices”) to any party shall be
contained in a written instrument addressed to such party at the address set forth below or such other address as may hereafter be designated in writing by the addressee to the addressor listing all parties and shall be deemed given (a) when
delivered in person or duly sent by fax showing confirmation of receipt, (b) three days after being duly sent by first class mail postage prepaid (other than in the case of Notices to or from any non-U.S. resident), or (c) two days after
being duly sent by DHL, Federal Express or other recognized express international courier service: 
  

	 	(a)	if to the Corporation, to: 

Enanta Pharmaceuticals, Inc. 
 500 Arsenal Street 
 Watertown, MA 02472 

Attn: President 

Fax: [*****] 

  
 - 21 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 with a copy to: 
 Nathaniel S. Gardiner 
 Palmer & Dodge LLP 

111 Huntington Avenue 
 Boston, MA 02199-7613 
 Fax: 617-227-4420 

 

	 	(b)	if to the Investors, to their respective addresses as set forth on the signature pages of this Agreement. 

SECTION 16. Amendments; Waivers. This Agreement may be amended, and compliance with the provisions of this Agreement may be omitted or
waived, only by the written agreement of the Corporation and Investors or assignees of their rights hereunder holding two-thirds in voting power of the then outstanding Series G Shares and Reserved Shares taken as a whole. 

SECTION 17. Counterparts. This Agreement may be executed in any number of counterparts, each such counterpart shall be deemed to be an
original instrument, and all such counterparts together shall constitute but one agreement. Any such counterpart may contain one or more signature pages. 
 SECTION 18. Headings. The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be a part of this Agreement.

 SECTION 19. Nouns and Pronouns. Whenever the context may require, any pronouns used herein shall include the corresponding
masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa. 
 SECTION 20.
Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. 

SECTION 21. Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable
such provision in any other jurisdiction. 
 SECTION 22. Further Assurances. From and after the date of this Agreement, upon the
request of any Investor, the Corporation shall execute and deliver such instruments, documents and other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement
and the Series G Shares. 
 SECTION 23. Additional Investors. The Additional Investors shall become parties to this Agreement, and
shall be entitled to all of the benefits to and shall be subject to all of the obligations of “Investors” under this Agreement, all upon execution by such Additional Investor 

  
 - 22 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
of a counterpart signature page to this Agreement. The Corporation shall be authorized to add the name, amount of investment and number of Additional Investor Series G Shares purchased by each
Additional Investor at each Additional Closing to the Schedule of Investors. 
 SECTION 24. Adjustments for Stock Splits,
Etc. Wherever in this Agreement there is a reference to a specific number of shares of Common Stock or Series G Preferred Stock or any other class or series of capital stock, then, upon the occurrence of any subdivision,
combination or stock dividend of such class or series of stock, the specific number of shares so referenced in this Agreement shall automatically be proportionally adjusted to reflect the affect on the outstanding shares of such class or series of
stock by such subdivision, combination or stock dividend. 
 SECTION 25. Aggregation of Stock. All shares held or acquired by
affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

SECTION 26. Issuances of Series G Preferred Stock. Except as expressly provided in this Agreement, the Corporation shall not issue
or sell any shares of Series G Preferred Stock. 
 [Remainder of page intentionally left blank.] 

  
 - 23 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 IN WITNESS WHEREOF, the undersigned have executed this Series G Convertible Preferred Stock
Purchase Agreement as of the day and year first written above. 
  

			
	 ENANTA PHARMACEUTICALS, INC.

		
	 By:
	 	  

	 Name:
	 	Jay R. Luly
	 Title:
	 	President and Chief Executive Officer

  
 [Signature
Page to Series G Convertible Preferred Stock Purchase Agreement] 
 Confidential materials omitted and filed separately with
the Securities and Exchange Commission. 
 Asterisks denote such omission. 

 Enanta Pharmaceuticals, Inc. 

Investor Signature Page 
 By his, her or its execution and delivery of this signature page, the undersigned Investor hereby joins in and agrees to be bound by the terms and conditions of (i) the Series G Convertible Preferred
Stock Purchase Agreement (the “Purchase Agreement”) dated as of September     , 2005 (the “Effective Date”), by and among Enanta Pharmaceuticals, Inc. (the “Corporation”), and
the investors named on the Schedule of Investors thereto, as to the number of shares of Series G Convertible Preferred Stock set forth below, (ii) that certain Third Amended and Restated Voting Agreement dated as of the Effective Date
(the “Voting Agreement”), by and among the Corporation, the Founders (as defined therein) and the Investors (as defined therein) as a “Series G Investor” thereunder, and, if the undersigned is also a “Series C
Investor,” and/or a “Series D Investor” and/or a “Series E Investor” thereunder, as a “Series C Investor,” and/or as a “Series D Investor” and/or as a “Series E Investor,” as the case may be,
thereunder, (iii) that certain Third Amended and Restated Registration Rights Agreement dated as of the Effective Date (the “Registration Rights Agreement”), by and among the Corporation and the Investors (as defined therein)
as a “Series G Investor” thereunder, and, if the undersigned is also a “Series C Investor,” and/or a “Series D Investor,” and/or a “Series E Investor,” thereunder, as a “Series C Investor,”
and/or as a “Series D Investor” and/or as a “Series E Investor,” as the case may be, thereunder, (iv) that certain Third Amended and Restated Stock Restriction Agreement dated as of the Effective Date (the
“Stock Restriction Agreement”), by and among the Corporation, the Founders (as defined therein) and the Investors (as defined therein) as a “Series G Investor” thereunder, and, if the undersigned is also a
“Series C Investor,” and/or a “Series D Investor” and/or a “Series E Investor,” thereunder, as a “Series C Investor” and/or as a “Series D Investor,” and/or as a “Series E Investor”,
as the case may be, thereunder, and (v) that certain Amended and Restated Investor Rights Agreement dated as of the Effective Date (the “Investor Rights Agreement”), by and among the Corporation and the Investors (as defined
therein) as a “Series G Investor” thereunder, and, if the undersigned is also a “Series C Investor,” and/or a “Series D Investor” and/or a “Series E Investor,” thereunder, as a “Series C
Investor,” and/or as a “Series D Investor” and/or as a “Series E Investor,” as the case may be, thereunder, and authorizes this signature page to be attached as a counterpart to the Purchase Agreement, the Voting
Agreement, the Registration Rights Agreement, the Stock Restriction Agreement and the Investor Rights Agreement, or counterparts thereof. 
 EXECUTED as of this     day of             ,         . 

 

					
	By:	 	  

	Title:	 	

 
					
	
	  

	Print Name of Investor	 	
	Record Address:	 	  

					
	  

	  

					
	Telecopy No.:	 	  

					
	Number of Shares of	 	
	Series G Preferred Stock:	 	  

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Schedule of Investors 

 

																									
	 
Name of Investor
	  	Aggregate
Purchase 
Price	 	  	Initial
Series G 
Shares	 	 	Second Closing
Series G 
Shares	 	 	Third Closing
Series G 
Shares	 	 	Fourth Closing
Series G 
Shares	 	 	Fifth Closing
Series G 
Shares	 
	 Initial Investors
	  				  				 				 				 				 			
	 [name]
	  	$	            	  	  	 	[            	] 	 	 	[            	] 	 	 	[            	] 	 	 	[            	] 	 	 	[            	] 
	 [name]
	  	$            	 	  	  	 	[            	] 	 	 	[            	] 	 	 	[            	] 	 	 	[            	] 	 	 	[            	] 
	 [name]
	  	$            	 	  	  	 	[            	] 	 	 	[            	] 	 	 	[            	] 	 	 	[            	] 	 	 	[            	] 
	 [name]
	  	$            	 	  	  	 	[            	] 	 	 	[            	] 	 	 	[            	] 	 	 	[            	] 	 	 	[            	] 
	 Subtotal:
	  	$	            	  	  	 	[            	] 	 	 	[            	] 	 	 	[            	] 	 	 	[            	] 	 	 	[            	] 
							
	 Additional Investors
	  				  				 				 				 				 			
	 [name]
	  	$	            	  	  	 	—  	  	 				 				 				 			
	 [name]
	  	$	            	  	  	 	—  	  	 				 				 				 			
	 Subtotals:
	  	$	            	  	  	 	—  	  	 				 				 				 			
	 TOTALS:
	  	$	            	  	  	 	—  	  	 				 				 				 			

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Schedule 4 
 Disclosure Schedules 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Exhibit 1 
 Fourth Amended and Restated Certificate of Incorporation 
 of Enanta
Pharmaceuticals, Inc. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Exhibit 4.22A 
 Third Amended and Restated 
 Registration Rights Agreement 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Exhibit 4.22B 
 Third Amended and Restated  
 Voting Agreement 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Exhibit 4.22C 
 Third Amended and Restated  
 Stock Restriction Agreement 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Exhibit 4.22D 
 Amended and Restated Investor Rights Agreement 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Exhibit 6.1(e) 

Form of Legal Opinion  
 of Palmer & Dodge LLP 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 TABLE OF CONTENTS 

 

							
			
	 	  	 	  	Page	 
			
	SECTION 1.	  	FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION	  	 	1	  
			
	SECTION 2.	  	PURCHASE AND SALE OF THE SERIES G PREFERRED STOCK	  	 	1	  
			
	2.1  	  	Initial Series G Shares	  	 	1	  
			
	2.2  	  	Additional Series G Shares	  	 	1	  
			
	SECTION 3.	  	CLOSING	  	 	1	  
			
	3.1  	  	Initial Closing	  	 	1	  
			
	3.2  	  	Additional Closings	  	 	2	  
			
	SECTION 4.	  	REPRESENTATIONS AND WARRANTIES OF THE CORPORATION	  	 	2	  
			
	4.1  	  	Organization	  	 	2	  
			
	4.2  	  	Capitalization	  	 	3	  
			
	4.3  	  	Equity Investments; Subsidiaries	  	 	5	  
			
	4.4  	  	Financial Statements	  	 	5	  
			
	4.5  	  	Absence of Undisclosed Liabilities	  	 	5	  
			
	4.6  	  	Absence of Changes	  	 	6	  
			
	4.7  	  	Encumbrances	  	 	6	  
			
	4.8  	  	Intellectual Property Rights	  	 	6	  
			
	4.9  	  	Litigation	  	 	7	  
			
	4.10	  	No Defaults	  	 	7	  
			
	4.11	  	Employment of Officers, Employees and Consultants	  	 	7	  
			
	4.12	  	Taxes	  	 	8	  
			
	4.13	  	[Reserved.]	  	 	8	  
			
	4.14	  	Material Agreements	  	 	8	  
			
	4.15	  	ERISA	  	 	11	  
			
	4.16	  	U.S. Real Property Holding Corporation	  	 	11	  
			
	4.17	  	Environmental Protection	  	 	11	  
			
	4.18	  	Foreign Corrupt Practices Act	  	 	12	  
			
	4.19	  	Federal Reserve Regulations	  	 	12	  
			
	4.20	  	Compliance	  	 	12	  

  
 -i-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

							
			
	4.21	  	Insurance	  	 	13	  
			
	4.22	  	Authorization of Transaction Documents	  	 	13	  
			
	4.23	  	Authorization of Series G Shares and Reserved Shares	  	 	13	  
			
	4.24	  	Related Transactions	  	 	14	  
			
	4.25	  	Offerees	  	 	14	  
			
	4.26	  	Use of Proceeds	  	 	14	  
			
	4.27	  	No Governmental Consent or Approval Required	  	 	14	  
			
	4.28	  	Registration Rights	  	 	14	  
			
	4.29	  	Employees	  	 	14	  
			
	4.30	  	Exemptions from Securities Laws	  	 	15	  
			
	4.31	  	[Small Business Concern	  	 	15	  
			
	4.32	  	Books and Records	  	 	15	  
			
	4.33	  	Disclosure	  	 	15	  
			
	SECTION 5.	  	REPRESENTATIONS AND WARRANTIES OF THE INVESTORS	  	 	15	  
			
	5.1  	  	Purchase for Investment	  	 	15	  
			
	5.2  	  	Unregistered Securities; Legend	  	 	15	  
			
	5.3  	  	Status of the Investors	  	 	16	  
			
	5.4  	  	Knowledge and Experience; Economic Risk	  	 	16	  
			
	5.5  	  	Access to Information	  	 	16	  
			
	5.6  	  	Rule 144	  	 	16	  
			
	SECTION 6.	  	CONDITIONS PRECEDENT TO CLOSINGS BY THE INVESTORS	  	 	16	  
			
	6.1  	  	Conditions Precedent to Initial Closing by the Initial Investors	  	 	16	  
			
	6.2  	  	Conditions Precedent to Additional Closing by the Additional Investors	  	 	18	  
			
	SECTION 7.	  	CONDITIONS PRECEDENT TO CLOSING BY THE CORPORATION	  	 	19	  
			
	7.1  	  	Representations and Warranties	  	 	19	  
			
	7.2  	  	Tender of Payment	  	 	19	  
			
	SECTION 8.	  	TRANSFER OF SHARES. RESTRICTED SHARES	  	 	19	  
			
	8.1  	  	Requirements for Transfer	  	 	19	  
			
	8.2  	  	Legend	  	 	20	  
			
	SECTION 9.	  	FEES; BROKERS	  	 	20	  
			
	9.1  	  	Fees	  	 	20	  
			
	9.2  	  	Brokers	  	 	21	  

  
 -ii-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

					
			
	SECTION 10.	  	REMEDIES	  	21
			
	SECTION 11.	  	EXCHANGES; LOST, STOLEN OR MUTILATED CERTIFICATES	  	21
			
	SECTION 12.	  	SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS	  	21
			
	SECTION 13.	  	SUCCESSORS AND ASSIGNS	  	22
			
	SECTION 14.	  	ENTIRE AGREEMENT; EFFECT ON PRIOR DOCUMENTS	  	22
			
	SECTION 15.	  	NOTICES	  	22
			
	SECTION 16.	  	AMENDMENTS; WAIVERS	  	23
			
	SECTION 17.	  	COUNTERPARTS	  	23
			
	SECTION 18.	  	HEADINGS	  	23
			
	SECTION 19.	  	NOUNS AND PRONOUNS	  	23
			
	SECTION 20.	  	GOVERNING LAW	  	23
			
	SECTION 21.	  	SEVERABILITY	  	23
			
	SECTION 22.	  	FURTHER ASSURANCES	  	23
			
	SECTION 23.	  	ADDITIONAL INVESTORS	  	23
			
	SECTION 24.	  	ADJUSTMENTS FOR STOCK SPLITS, ETC	  	23
			
	SECTION 25.	  	AGGREGATION OF STOCK	  	24
			
	SECTION 26.	  	ISSUANCES OF SERIES G PREFERRED STOCK	  	24

  
 -iii-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 Schedules 
 Schedule of Investors 

					
	Schedule 4	  	-	  	Disclosure Schedules

 Exhibits 
  

					
	 Exhibit 1
	  	–	  	Fourth Amended and Restated Certificate of Incorporation of Enanta Pharmaceuticals, Inc.
	 Exhibit 4.22A
	  	–	  	Third Amended and Restated Registration Rights Agreement
	 Exhibit 4.22B
	  	–	  	Third Amended and Restated Voting Agreement
	 Exhibit 4.22C
	  	–	  	Third Amended and Restated Stock Restriction Agreement
	 Exhibit 4.22D
	  	–	  	Investor Rights Agreement
	 Exhibit 4.29A
	  	–	  	Employee Confidentiality, Inventions and Noncompetition Agreement
	 Exhibit 4.29B
	  	–	  	Consultant Confidentiality and Inventions Agreement
	 Exhibit 6.1(e)
	  	–	  	Form of Legal Opinion of Palmer & Dodge LLP

  
 -4-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 EXHIBIT C 

FORM OF PRESS RELEASE 
 ABBOTT AND ENANTA FORM WORLDWIDE ALLIANCE TO DEVELOP & 

COMMERCIALIZE HCV PROTEASE INHIBITORS 
 ABBOTT PARK, Ill., and WATERTOWN, Mass., Dec XX, 2006 – Abbott and Enanta Pharmaceuticals announced today that the companies have signed a worldwide agreement to develop and commercialize hepatitis C
virus (HCV) NS3 and NS3/4A protease inhibitors. Enanta has discovered several HCV protease inhibitors that have demonstrated attractive efficacy and pharmacokinetic profiles in pre-clinical studies. 

“Abbott’s innovative work in the protease inhibitor field against the Human Immunodeficiency Virus (HIV) has provided the
momentum and the foundation for our research interest in HCV infection,” said John Leonard, M.D., vice president, Global Pharmaceutical Research and Development, Abbott. “Enanta has done compelling work in its HCV protease inhibitor
program, and we look forward to working together on the advancement of this global program.” 
 “Abbott is a market
leader in the field of antiviral therapies, and we have a shared vision and commitment to the discovery and development of promising HCV therapies that address this high unmet medical need globally,” stated Jay R. Luly, President and CEO of
Enanta Pharmaceuticals. 
 Under the terms of the agreement, Abbott gains worldwide access to Enanta’s substantial
intellectual property position for a variety of different types of compounds, which includes several issued U.S. patents. Abbott also gains access to Enanta’s drug discovery capabilities in the HCV NS3 and NS3/4A protease inhibitor field.

 Additionally, Enanta will receive an upfront payment of $57 million, which includes a cash payment and an equity investment.
If all potential clinical and regulatory milestones are met, additional payments of up to $250 million will be made to Enanta, and further payments will be due if multiple products develop from the program. Enanta will receive double-digit royalties
and holds an option to fund 40 percent of development costs and U.S. commercialization efforts (sales and promotion costs) in exchange for a 40-percent profit share in the U.S. on medicines from this alliance that result in commercial approval.

 “Through this alliance, we will enhance our HCV protease inhibitor program and allow both companies to participate in
the long-term value creation of these compounds, by leveraging Enanta’s core expertise in chemistry and drug discovery, with Abbott’s proven track-record in the discovery, development, and commercialization of antiviral therapies,”
stated Yujiro S. Hata, Senior Vice President of Business Development at Enanta Pharmaceuticals. 

  
 -1-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 About Hepatitis C Virus 
 Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person’s risk
of developing chronic liver disease, cirrhosis, liver cancer and death. Liver disease associated with HCV infection is growing rapidly, and current therapies only provide sustained benefit in about half of patients with the genotypel form of the
virus. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated. 

About Enanta 
 Enanta
Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field. At the heart of Enanta is its commitment to
innovative chemistry that surpasses traditional medicinal chemistry approaches. The Company’s successful integration of chemistry with biology has created a new class of macrolide antibiotics that overcome bacterial resistance. Antibacterial
focus areas include community respiratory tract infections as well as hospital and community infections relating to MRSA. Additionally, Enanta has discovered antiviral agents targeted against the Hepatitis C virus (HCV). Enanta is a privately
held company with offices in Watertown, MA. More information about the company can be found at www.enanta.com. 
 About Abbott

 Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of
pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries. 
 Abbott’s news releases and other information are available on the company’s web site at www.abbott.com. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 EXHIBIT D 

ARBITRATION PROCEDURES 
 The Parties recognize that from time to time a dispute may arise relating to either Party’s rights or obligations under this Agreement. The Parties agree that any such dispute shall be resolved by
the Alternative Dispute Resolution (“ADR”) provisions set forth in this Exhibit, the result of which shall be binding upon the Parties. 
 To begin the ADR process, a Party first must send written notice of the dispute to the other Party for attempted resolution by good faith negotiations between their respective presidents (or their
designees) of the affected subsidiaries, divisions, or business units within twenty-eight (28) days after such notice is received (all references to “days” in this ADR provision are to calendar days). If the matter has not been
resolved within twenty-eight (28) days of the notice of dispute, or if the Parties fail to meet within such twenty-eight (28) days, either Party may initiate an ADR proceeding as provided herein. The Parties shall have the right to be
represented by counsel in such a proceeding. 
 1. To begin an ADR proceeding, a Party shall provide written notice to the other
Party of the issues to be resolved by ADR. Within fourteen (14) days after its receipt of such notice, the other Party may, by written notice to the Party initiating the ADR, add additional issues to be resolved within the same ADR. 

2. Within twenty-one (21) days following the initiation of the ADR proceeding, the parties shall select a mutually acceptable
neutral to preside in the resolution of any disputes in this ADR proceeding. If the parties are unable to agree on a mutually acceptable neutral within such period, either party may request the President of the CPR Institute for Dispute Resolution
(“CPR”), 366 Madison Avenue, 14th Floor, New York, New York 10017, to select a neutral pursuant to the following procedures: 
 (a) The CPR shall submit to the parties a list of not less than five (5) candidates within fourteen (14) days after receipt of the request, along with a Curriculum Vitae for each
candidate. No candidate shall be an employee, director, or shareholder of either party or any of their subsidiaries or affiliates. 
 (b) Such list shall include a statement of disclosure by each candidate of any circumstances likely to affect his or her impartiality. 

(c) Each Party shall number the candidates in order of preference (with the number one (1) signifying the greatest preference) and
shall deliver the list to the CPR within seven (7) days following receipt of the list of candidates. If a Party believes a conflict of interest exists regarding any of the candidates, that Party shall provide a written explanation of the
conflict to the CPR along with its list showing its order of preference for the candidates. Any Party failing to return a list of preferences on time shall be deemed to have no order of preference. 

  
 -1 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (d) If the Parties collectively have identified fewer than three (3) candidates deemed
to have conflicts, the CPR immediately shall designate as the neutral the candidate for whom the Parties collectively have indicated the greatest preference. If a tie should result between two candidates, the CPR may designate either candidate. If
the Parties collectively have identified three (3) or more candidates deemed to have conflicts, the CPR shall review the explanations regarding conflicts and, in its sole discretion, may either (i) immediately designate as the neutral the
candidate for whom the Parties collectively have indicated the greatest preference, or (ii) issue a new list of not less than five (5) candidates, in which case the procedures set forth in subparagraphs 2(a) - 2(d) shall be
repeated. 
 3. No earlier than twenty-eight (28) days or later than fifty-six (56) days after selection, the neutral
shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding shall take place at a location agreed upon by the parties. If the Parties cannot agree, the neutral shall designate a location other than the principal
place of business of either Party or any of their subsidiaries or affiliates. 
 4. At least seven (7) days prior to the
hearing, each Party shall submit the following to the other party and the neutral: 
 (a) a copy of all exhibits on which such
Party intends to rely in any oral or written presentation to the neutral; 
 (b) a list of any witnesses such Party intends to
call at the hearing, and a short summary of the anticipated testimony of each witness; 
 (c) a proposed ruling on each issue to
be resolved, together with a request for a specific damage award or other remedy for each issue. The proposed rulings and remedies shall not contain any recitation of the facts or any legal arguments and shall not exceed one (1) page per issue.
The parties agree that neither side shall seek as part of its remedy any punitive damages. 
 (d) a brief in support of such
party’s proposed rulings and remedies, provided that the brief shall not exceed twenty (20) pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. 

Except as expressly set forth in subparagraphs 4(a) - 4(d), no discovery shall be required or permitted by any means, including
depositions, interrogatories, requests for admissions, or production of documents. 
 5. The hearing shall be conducted on two
(2) consecutive days and shall be governed by the following rules: 
 (a) Each Party shall be entitled to five
(5) hours of hearing time to present its case. The neutral shall determine whether each Party has had the five (5) hours to which it is entitled. 
 (b) Each Party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal testimony, documents or other evidence, to
cross-

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
examine witnesses, and to make a closing argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-examination time shall be charged against the
Party conducting the cross-examination. 
 (c) The Party initiating the ADR shall begin the hearing and, if it chooses to make
an opening statement, shall address not only issues it raised but also any issues raised by the responding Party. The responding Party, if it chooses to make an opening statement, also shall address all issues raised in the ADR. Thereafter, the
presentation of regular and rebuttal testimony and documents, other evidence, and closing arguments shall proceed in the same sequence. 
 (d) Except when testifying, witnesses shall be excluded from the hearing until closing arguments. 
 (e) Settlement negotiations, including any statements made therein, shall not be admissible under any circumstances. Affidavits prepared for purposes of the ADR hearing also shall not be admissible. As to
all other matters, the neutral shall have sole discretion regarding the admissibility of any evidence. 
 6. Within seven
(7) days following completion of the hearing, each Party may submit to the other Party and the neutral a post-hearing brief in support of its proposed rulings and remedies, provided that such brief shall not contain or discuss any new evidence
and shall not exceed ten (10) pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. 
 7. The neutral shall rule on each disputed issue within fourteen (14) days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one of the
parties on each disputed issue but may adopt one Party’s proposed rulings and remedies on some issues and the other Party’s proposed rulings and remedies on other issues. The neutral shall not issue any written opinion or otherwise explain
the basis of the ruling. 
 8. The neutral shall be paid a reasonable fee plus expenses. These fees and expenses, along with the
reasonable legal fees and expenses of the prevailing Party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: 

(a) If the neutral rules in favor of one Party on all disputed issues in the ADR, the losing Party shall pay 100% of such fees and
expenses. 
 (b) If the neutral rules in favor of one Party on some issues and the other Party on other issues, the neutral
shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the Parties. The neutral shall allocate fees and expenses in a way that bears a reasonable relationship to the outcome of the ADR, with
the Party prevailing on more issues, or on issues of greater value or gravity, recovering a relatively larger share of its legal fees and expenses. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 9. The rulings of the neutral and the allocation of fees and expenses shall be binding,
non-reviewable, and non-appealable, and may be entered as a final judgment in any court having jurisdiction. 
 10. Except as
provided in paragraph 9 or as required by law, the existence of the dispute, any settlement negotiations, the ADR hearing, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed Confidential
Information. The neutral shall have the authority to impose sanctions for unauthorized disclosure of Confidential Information. 

11. All ADR hearings shall be conducted in the English language. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 SCHEDULE 1 

[*****] 

  
 -5-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 SCHEDULE 2 

ABBOTT PATENT RIGHTS 
 None. 

  
 -6-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 SCHEDULE 3 

[*****] 

  
 -7-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 SCHEDULE 4 

LICENSED PATENT RIGHTS 
  

													
	 Title
	  	 ENP-
 Numbers
	  	 Application
Number/ Patent
Number
	 	 Country
	 	 Filing
 Date
	 	 Patent Issue
Date
	 	 Status

	 Azapeptide
	  	ENP-057	  	7,125,845	 	US (Utility)	 	03-Jul-2003	 	24-Oct-2006	 	Granted
							
		  		  	05010029A1	 	PCT
Nationalization	 	19-May-2004	 	NA	 	Published
							
		  		  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
							
	 Quinoxaline
	  	ENP-060	  	10/826,743	 	US (Utility)	 	16-Apr-2004	 	NA	 	Allowed
							
		  		  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
							
		  		  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
							
		  		  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
							
		  		  	2004800129286	 	China	 	16-Apr-2004	 	NA	 	Published
							
		  		  	04750236.4	 	European Patent
Convention	 	16-Apr-2004	 	NA	 	Published
							
		  		  	06104304.7	 	Hong Kong	 	10-Apr-2004	 	NA	 	Published
							
		  		  	2006-513078	 	Japan	 	16-Apr-2004	 	NA	 	Pending
							
		  		  	1020057019856	 	Korea	 	16-Apr-2004	 	NA	 	Published
							
		  		  	US04/11841	 	PCT	 	16-Apr-2004	 	NA	 	Published
							
	 Tripeptide
	  	ENP-065	  	10/849,107	 	US (Utility)	 	15-May-2004	 	NA	 	Allowed
							
		  		  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
							
	 Heteroaryl
	  	ENP-066	  	10/774,047	 	US (Utility)	 	06-Feb-2004	 	NA	 	Published
							
		  		  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
							
		  		  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
							
		  		  	0480009268.6	 	China	 	06-Feb-2004	 	NA	 	Published
							
		  		  	047090204	 	European Patent
Convention	 	06-Feb-2004	 	NA	 	Published
							
		  		  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
							
	 [*****]
	  	[*****]	  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
							
		  		  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
							
		  		  	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]

  
 -1-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

													
	 Title
	  	 ENP-
 Numbers
	  	 Application
Number/Patent
Number
	  	 Country
	  	 Filing
 Date
	  	 Patent Issue
Date
	  	 Status

	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
		  		  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  	[*****]

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 SCHEDULE 5 

MATERIAL TERMS TO BE INCLUDED IN CO-PROMOTION AGREEMENT 

The Co-Promotion Agreement to be negotiated by the Parties upon exercise by Enanta of a Co-Promotion Option shall contain the following
material terms. Capitalized terms used in this Schedule 5 and not otherwise defined have the meanings given to them in the Agreement. 
 1. Co-Promotion Rights. 
 (a) Enanta and Abbott hereby acknowledge and agree
that the overall objective of co-promotion is to reach a broad customer audience, avoid confusion and redundancy of the marketing message for Co-Promoted Products and maximize the particular strengths that the Parties bring to the Co-Promotion of
Co-Promoted Products. In connection therewith, it is the expectation of the Parties that each Marketing and Sales Plan shall provide that Enanta will perform up to the Enanta Co-Development Percentage of the total Detailing effort made each Calendar
Year applicable to Co-Promoted Products in the Co-Promotion Territory (the “Co-Promotion Detailing Target”); provided, that, the allocation of the Detailing obligations between the Parties shall take into account the position of the
Detail, the number of calls and the quality/difficulty and relative importance of the target audience. All such Detailing calls shall be made in such markets as the JDCC reasonably considers to be appropriate for the successful Commercialization of
such Co-Promoted Product based on objective, quantifiable information and market research data with the objectives of allocating to each of Enanta and Abbott target audience and accounts from which each such Party will have the opportunity to attain
its Co-Promotion Detailing Target. Notwithstanding the commercially reasonable and diligent efforts of the Parties to effect an objective allocation of individual accounts and target audience between the Parties, the Parties recognize that it may be
necessary from time to time to reassign individual accounts and/or target audience between the Parties and the JDCC shall be entitled to review the allocation of accounts as it reasonably determines to be appropriate. 

(b) The object of Co-Promotion is to increase Co-Promotion efforts to the Co-Promotion Target Audience with a consistent marketing
message. It is recognized that the Parties bring particular strengths to the ongoing Commercialization of Co-Promoted Products in the Co-Promotion Territory. With respect to each Co-Promoted Product, the JDCC will assign to each Party a role in
Commercialization functions and activities as the JDCC considers to be reasonably appropriate for the successful Commercialization of such Co-Promoted Product. 
 (c) Abbott shall grant to Enanta a co-exclusive (together with Abbott and its Affiliates), royalty-free license, with the right to grant sublicenses solely to Affiliates, under the Abbott Technology and
Abbott Patent Rights, to Co-Promote Co-Promoted Products in the Co-Promotion Territory. 
 (d) Enanta and Abbott shall use an
integrated sales force to Detail each Co-Promoted Product. In connection therewith, neither Party will, without the other Party’s prior written consent, use a Representative to Detail a Co-Promoted Product if that Representative is

  
 -1-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
also Detailing a product that is approved for an indication that is directly competitive with the Co-Promoted Product. Enanta and Abbott hereby agree that each such Party shall be responsible for
ensuring that its Representatives Detail each Co-Promoted Product in a manner consistent with the Marketing and Sales Plan and/or the decisions of the JDCC. Notwithstanding the foregoing, in performing their respective Detailing obligations
hereunder, each of the Parties agrees to (a) use Representatives with an experience profile appropriate for the target audience and Detailing role as described in the Marketing and Sales Plan; (b) provide its own sales management
organization and infrastructure for its Representatives and (c) Detail the Co-Promoted Product in the first or second position. 
 2. Commercialization Efforts. Each Party shall use commercially reasonable efforts to execute its obligations under each Co-Promotion Marketing and Sales Plan, consistent with the applicable
Co-Promotion Commercialization Budget, and to cooperate diligently with each other in carrying out such Co-Promotion Marketing and Sales Plan. 
 3. Co-Promotion Marketing and Sales Plan and Budget. 
 (a) Preparation of
Plan and Budget. Abbott, in good faith consultation with Enanta, shall develop a Marketing and Sales Plan (“Co-Promoted Product Marketing and Sales Plan”) for each Co-Promoted Product for the Co-Promotion Territory, and each such
Co-Promotion Marketing and Sales Plan shall be reviewed and approved by the JDCC; provided that each such Co-Promotion Marketing and Sales Plan shall be consistent with Enanta’s rights under the Agreement. Each Co-Promotion Marketing and Sales
Plan shall include but not be limited to: (i) demographics and market dynamics, market strategies, estimated launch date(s) in the Co-Promotion Territory, a sales and expense forecast (including at least three (3) years of estimated sales
and expenses) for the Co-Promotion Territory, manufacturing plans and expected product profile; (ii) a market plan (including Advertising (to be defined in the Co-Promotion Agreement) and Detailing forecasts and pricing strategies pertaining to
discounts, samples and nominal price sales) for the Co-Promotion Territory; (iii) a commercialization budget (“Co-Promotion Commercialization Budget”) for each Co-Promoted Product for the Co-Promotion Territory, including the Third
Parties proposed to be utilized and, to the extent practicable, any proposed Third Party arrangements. Each Co-Promotion Commercialization Budget shall include a budget of the expenses expected to be incurred in connection with performing the
corresponding Co-Promotion Marketing and Sales Plan. Each Co-Promotion Marketing and Sales Plan and Co-Promotion Commercialization Budget shall be submitted to the JDCC for review and approval by a date to be established by the JDCC, taking into
account Abbott’s and Enanta’s annual budget planning calendars, but no later than December 31 of each year. It is contemplated that each Co-Promotion Marketing and Sales Plan and Co-Promotion Commercialization Budget will become more
comprehensive as the Co-Promotion of the applicable Co-Promoted Product evolves. 
 (b) Changes to Plans/Budgets. Any
significant change in a Co-Promotion Marketing and Sales Plan or Co-Promotion Commercialization Budget during the course of the year will be communicated promptly to the JDCC. In addition, Abbott shall provide an update on each Co-Promotion
Marketing and Sales Plan and Co-Promotion Commercialization Budget to the JDCC in a manner consistent (with respect to timing and content) with such updates as are reported internally by Abbott or its Affiliates on its or their other products at
such time, but no less frequently than semi-annually. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 (c) [*****]. 
 4. Control Over Advertising and Detailing. 
 (a) Neither Party shall engage
in any Advertising or use any label, package, literature or other written material (other than General Public Relations (to be defined in the Co-Promotion Agreement) in connection with a Co-Promoted Product in the Co-Promotion Territory, unless the
specific form and content thereof is approved by the JDCC. 
 (b) General Public Relations on the part of either Party need to
be approved by the JDCC, and all representations and statements pertaining to Co-Promoted Products that appear in General Public Relations of Enanta or Abbott and include subject matter not previously approved by the JDCC shall be subject to the
approval of the JDCC. 
 (c) All Advertising and Detailing undertaken by either Party hereto shall be undertaken in good faith
with a view towards maximizing the sales of the applicable Co-Promoted Product. 
 (d) Except with the prior written consent of
the other Party, neither Party shall use the name of the other Party or any Affiliate of the other Party in Advertising, Detailing or General Public Relations. 
 (e) Abbott shall have the sole responsibility for (i) deciding on pricing and for obtaining all pricing approvals as may be required for all Co-Promoted Products, (ii) conducting all billing and
collections for Co-Promoted Products; and (iii) overseeing and implementing all other reimbursement matters but shall, in all such cases, consult with, and reasonably consider the views of, the JDCC with respect to the foregoing. 

(f) Abbott shall have sole responsibility for arranging for the distribution and warehousing of Co-Promoted Products. 

(g) Neither Party shall engage in any Advertising or use any label, package, literature or other written material (other than General
Public Relations) in connection with a Co-Promoted Product unless the specific form and content thereof is approved by the JDCC. Without the prior written consent of the other party, no Party shall use the name of the other Party or any Affiliate of
the other Party in General Public Relations. 
 5. Sales Efforts in the Co-Promotion Territory. As part of each
Co-Promotion Marketing and Sales Plan for the Co-Promotion Territory, the JDCC shall determine the targeted level of sales of the applicable Co-Promoted Product for the Co-Promotion Target Audience for the Calendar Year covered by such Co-Promotion
Marketing and Sales Plan. Each Co-Promotion Marketing and Sales Plan shall provide each Party the opportunity to perform a percentage of the Detailing calls to the Co-Promotion Target Audience each calendar year as the JDCC reasonably considers to
be appropriate for the successful Commercialization of such Co-Promoted Product. The Parties shall allocate physicians in the Co-Promotion Target Audience in 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
an unbiased manner based on objective, quantifiable information and market research data with the objectives of allocating to each Party those physicians in the Co-Promotion Target Audience with
the appropriate Detailing frequency to optimize the penetration of such Co-Promoted Product and achieve such Co-Promotion’s sales target. Notwithstanding the commercially reasonable efforts of the Parties to effect an objective allocation
between them, the Parties recognize that it may be necessary from time to time to reassign individual medical professionals in the Co-Promotion Target Audience to optimize the targeted market opportunity, and, as a result, the JDCC shall be entitled
to review the allocation of medical professionals in the Co-Promotion Target Audience as it reasonably determines to be appropriate. 
 6. Training Program. The Parties shall (a) develop a training program for the promotion of all Products (including, without limitation, all Co-Promoted Products in the Co-Promotion Territory)
and (b) train all Representatives of both Parties to be used for the Co-Promotion of Co-Promoted Products in the Co-Promotion Territory as soon as practicable after the approval of the Marketing and Sales Plan by the JDCC. The Parties agree to
utilize such training programs on an ongoing basis to assure a consistent, focused promotional strategy and all such training shall be carried out at a time that is mutually acceptable to Enanta and Abbott. No Representative of either Party may
Detail a Co-Promotion Product unless such representative successfully completes the training program described in this Section 6. Except as provided herein, it is agreed that for the Product specific training, the internal costs and the
out-of-pocket costs of such training programs (including without limitation the out-of-pocket costs of the development, production, printing of such training materials) shall not be included as a Development Cost under this Agreement and shall be
treated as a Commercialization Expense. 
 7. Trademarks. Abbott shall select the Product Trademark under which each
Co-Promoted Product shall be marketed. The Parties shall market each Co-Promoted Product in the Co-Promotion Territory exclusively under such Product Trademark (all such trademarks being hereinafter referred to as the “Co-Promotion
Trademarks”), and Abbott shall grant Enanta a license to use such Co-Promotion Trademarks solely for such Co-Promotion. Abbott shall register the Co-Promotion Trademarks in the Co-Promotion Territory and shall take all such actions as are
required to continue and maintain in full force and effect in the Co-Promotion Territory the Co-Promotion Trademarks and the registrations thereof, and shall be solely responsible for all expenses incurred in connection therewith. As between the
Parties, Abbott shall be the exclusive owner of the Co-Promotion Trademarks in the Co-Promotion Territory. 
 8. Product
Recalls. In the event that any Regulatory Authority issues or requests a recall or takes similar action in connection with a Co-Promoted Product, or in the event a Party reasonably believes that an event, incident or circumstance has occurred
that may result in the need for a recall, market withdrawal or other corrective action regarding a Co-Promoted Product, such Party shall promptly advise the other Party thereof by telephone or facsimile. Following such notification, Abbott shall
decide and have control of whether to conduct a recall or market withdrawal (except in the event of a recall or market withdrawal mandated by a Regulatory Authority, in which case it shall be required) or to take other corrective action in any
country and the manner in which any such recall, market withdrawal or corrective action shall be conducted, subject to the oversight of the JDCC and provided that Abbott shall keep Enanta regularly informed regarding such recall, market withdrawal
or corrective action. In the event of a dispute about whether to recall a Co-Promoted Product or to conduct a market withdrawal or take other 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
corrective action, the final decision on such matter shall be made by Abbott. In the event that Enanta disagrees with any such decision for reasons related to safety of a Co-Promoted Product,
Enanta may elect to terminate its Co-Promotion of such Co-Promoted Product immediately by written notice to Abbott. Abbott shall bear all expenses of any such recall, market withdrawal or corrective action (including, without limitation, expenses
for notification, destruction and return of the affected Co-Promoted Product and any refund to customers of amounts paid for such Co-Promoted Product). 
 9. Co-Promotion Mechanism. 
 (a) Sales. All sales of Co-Promoted
Products in the Co-Promotion Territory shall be booked by Abbott. If, during the term of the Co-Promotion Agreement, Enanta receives orders from customers for a Co-Promoted Product, it shall refer such orders to Abbott. 

(b) Processing of Orders for Co-Promoted Products. 
 (i) All orders for Co-Promoted Products received and accepted by Abbott during the term of the Co-Promotion Agreement shall be executed by Abbott in a reasonably timely manner consistent with the general
practices applied by it in executing orders for other pharmaceutical products sold by it or its Affiliates. 
 (ii) Abbott
shall have the discretion to reject any order received by it for a Co-Promoted Product; provided, however, that Abbott shall not reject such orders on an arbitrary basis, but only with reasonable justification and consistent with the general
policies applied by it with respect to orders for other pharmaceutical products sold by it or its Affiliates. 
 (iii) Abbott
shall comply with all Applicable Laws in selling any Co-Promoted Product. 
 10. Termination of Co-Promotion
Participation. In addition to its termination right under Section 8, at the end of any Calendar Quarter, Enanta shall have the right, exercisable upon three (3) Calendar Quarters prior written notice (the “Co-Promotion Termination
Notice Period”) to Abbott, to terminate its Co-Promotion of any Co-Promoted Product. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 SCHEDULE 6 

CALCULATION OF OPERATING INCOME 
 “Advertising” means the advertising and promotion of the Co-Developed Products in the Co-Development Territory through any means, including, without limitation, (i) television and
radio advertisements; (ii) advertisements appearing in journals, newspapers, magazines or other media; (iii) seminars and conventions; (iv) packaging design; (v) professional education programs; (vi) samples (including
related costs for manufacturing, shipping, and use taxes), visual aids and other selling materials; (vii) hospital formulary committee presentations; and (viii) presentations to state and other governmental formulary committees; provided,
however, that Advertising shall exclude Detailing and General Public Relations. With regard to advertising and promotion that include products other than Co-Developed Products, the JDCC shall determine the percentage of such advertising and
promotion that will be deemed Advertising for the purposes of this Agreement. 
 “Annual Operating Income”
means the Operating Income derived in any Calendar Year. 
 “Commercialization Expense” means the sum of
(a) Promotion Expense; (b) Marketing Expense; (c) any reasonable internal and out-of-pocket costs, expenses and fees incurred in prosecuting, maintaining, enforcing and defending the Product Trademark, Licensed Patent Rights, and/or
Abbott Patent Rights covering a Co-Developed Product; (d) the cost of preparing and filing Drug Approval Applications with respect to Co-Developed Products; and (e) any other out-of-pocket cost or expense expressly stated to be a
Commercialization Expense in this Agreement or under the Marketing and Sales Plan. 
 [*****] 

“Detail” means, with respect to a Co-Developed Product, an interactive, live, face-to-face contact of a Representative
within the Co-Development Territory with a medical professional with prescribing authority or other individuals or entities that have a significant impact or influence on prescribing decisions, in an effort to increase physician prescribing
preferences of such Co-Developed Product for its approved uses within the Co-Development Territory, which shall involve (a) a primary product presentation (i.e. a Detail in which the Co-Developed Product is given an important emphasis) or
(b) a secondary product presentation (i.e. a non-primary product presentation; provided, however, the emphasis is not less than that placed upon other products presented), in each case as measured by the relevant Party’s internal recording
of such activity. When used as a verb, “Detailing” means performing Details. When used as an adjective, “Detailing” means of or related to performing Details. 

“Distribution Costs” means all freight and distribution costs incurred in connection with, and directly attributable to,
the distribution of a Co-Developed Product to the extent not otherwise included in Commercialization Expense. 

  
 -1-

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 “General Public Relations” means any public relations activity (including a
press release or image piece) which (i) promotes generally the business of a company or deals in a general manner with the activities of such company in a general pharmaceutical market; and (ii) mentions in an incidental manner the fact
that such company or its Affiliates markets or sells one or more of the Co-Developed Products or provides other incidental information concerning one or more of the Co-Developed Products. Announcements related to this Agreement or that concern
primarily the relationship of either Party to each other are not General Public Relations and must be agreed upon by both Parties in writing prior to release. 
 “Marketing Expense” means all reasonable out-of-pocket costs and all internal costs on an FTE basis equal to Abbott’s then applicable FTE Rate, annually for those individuals fully
dedicated to the Product incurred by the Parties that are directly attributable to the following functions for the sale, promotion and marketing of a Co-Developed Product in the Co-Development Territory: (a) market research on such Co-Developed
Product, (b) marketing communications, (c) corporate accounts, (d) managed care, (e) sales force training, (f) product hotlines, (g) reimbursement support, (h) contracting, (i) pricing, (j) conducting
compassionate use programs and for domestic Phase IV studies for Co-Developed Products (including without limitation fully absorbed manufacturing costs for any Co-Developed Product utilized in such compassionate use programs) and
(k) telemarketing services. Marketing Expense shall not include any General Public Relations or any other activities that promote the business of Abbott or Abbott as a whole without specifically referencing any Co-Developed Product. 

[*****] 

“Net Sales” has the meaning provided in Article 1. 

“Personnel Costs” means the reasonable costs of employment of personnel employed by or under contract to a Party
including, but not limited to, salaries, benefits (including the costs of cars or allowances therefore), travel, lodging, meals and office and computing supplies. 
 “Product Trademark” has the meaning provided in Article 1. 

“Promotion Expense” means all reasonable out-of-pocket costs and expenses incurred by Abbott and directly attributable
to the promotion of a Co-Developed Product in the Co-Development Territory to the extent that such costs are not included in Marketing Expense including, but not limited to (i) marketing, Advertising and promoting of Co-Developed Products
(including, without limitation, educational expenses, advocate development programs and symposia, sales meetings, direct to consumer/patient advertising, samples, agency fees for the development of promotional materials and printing of promotional
materials) and (ii) training and communication materials for the Co-Developed Products. 
 “Representative”
means an individual (a) employed and trained by Abbott or Enanta or (b) employed by a Third Party or self-employed and trained by or on behalf of Abbott or Enanta, in either case, to Detail a Product. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 “Third Party Royalties” means royalty payments made to any Third Party
pursuant to an agreement by and between a Party and such Third Party that are necessary to make, use, or sell such Co-Developed Product in the Co-Development Territory. 

 

	  	[*****]: 

  

	1.	[*****]. 

  

	2.	[*****]. 

  

	3.	[*****]. 

  

	4.	[*****]. 

  

	5.	[*****]. 

  

	6.	[*****]. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 [*****] 

  
 - 4 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 EXECUTION COPY 
 FIRST AMENDMENT TO COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT 
 This
First Amendment (this “First Amendment”), made this 27th day of January, 2009 to the Collaborative Development and License Agreement dated November 27, 2006 (the “Agreement”), is entered into by and between Abbott
Laboratories, having its principal office at 100 Abbott Park Road, Abbott Park, IL 60064-3500 (together with its affiliates, “Abbott”) and Enanta Pharmaceuticals, Inc., with principal offices at 500 Arsenal Street, Watertown, Massachusetts
02472 (“Enanta”). 
 NOW THEREFORE, in consideration of the mutual covenants contained herein, and for other good and
valuable consideration, the Parties hereto intending to be legally bound hereby agree as follows: 
 A. Any capitalized terms used and not
otherwise defined herein shall have the meanings set forth in the Agreement, 
 B. In Sections 1.18, 1.72, 2.1.4(h), 3.1, 3.5, 3,6, 4.1.1,
11.3.1(c), and 11.3.2(b) of the Agreement, any occurrence of the words (whether in the singular or the plural) “Compound or Abbott Compound” or “Compound and/or Abbott Compound” (and in the case of Sections 1.67, 1.74,
2.3.1, 4.5.1, 5.1, 5.2, 6.5.1(b), 10.2.1, and 11.3.6(c) the occurrence of the word “Compound”) shall be changed to the words “Compound, Abbott Compound, compound covered by Joint Patent Rights or compound covered by Joint
Technology.” In addition, each occurrence of the word “Compound” in Sections 8.2.2(b), 8.5.1(a), 8.5.2(a), 10.1.6, 11.3.2(e) and 12.2.3 shall be changed to “Compound or compound covered by Joint Patent Rights or compound covered
by Joint Technology.” 
 C. Section 1.29(a) of the Agreement is hereby deleted in its entirety, and the following Section 1.29(a)
is inserted in lieu of the deleted Section: 
 “(a) with respect to activities of either Party in the Research Program
and/or the conduct by Abbott of evaluation activities pursuant to Section 3.9, the efforts and resources typically used by companies that are similar in size to such Party in the performance of research programs with respect to, and/or the
evaluation of, comparable research compounds, and” 
 D. A new section 3.9 shall be added to the Agreement, as follows: 

3.9 Evaluation Period. Notwithstanding anything in this Agreement to the contrary, during the period
commencing upon the termination or expiration of the Research Program Term (including any extensions thereto) continuing for a period of six (6) months (as so extended, the “Evaluation Period”), Abbott shall have the right to analyze
any Compounds, Abbott Compounds, compounds covered by Joint Patent Rights or compound covered by Joint Technology that were synthesized prior to the termination or expiration of the Research Program

  
 - 1 -

 Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
Term (each, an “Evaluation Compound”) solely for the purpose of identifying one or more Compounds, Abbott Compounds, compounds covered by Joint Patent Rights or compounds covered by
Joint Technology suitable for further Development as Candidates. Either Party may nominate any Evaluation Compound as a Candidate by providing written notice to the JSC pursuant to Section 3.5 and the JSC may select any Evaluation Compound so
nominated as a Candidate pursuant to Section 3.6, subject to all applicable provisions of this Agreement (including, but not limited to, applicable provisions in Article 2 and Sections 3.3, 3.4, 3.5, 3.6 and 3.7 and this
Section 3.9), which provisions shall survive the termination or expiration of the Research Program Term. During the Evaluation Period, (a) chemistry scale-up of Evaluation Compounds is permitted (including, but not limited to, the use of
Enanta Technology and/or Program Technology), but no further medicinal chemistry will be conducted by Abbott under this Agreement; and (b) Section 8.1.1 and Section 8.3.1 shall apply to the evaluation activities conducted pursuant to
this Section 3.9. Abbott shall pay Enanta a non-refundable, non-creditable evaluation fee in the amount of [*****] by wire transfer of immediately available funds on the date of commencement of the Evaluation Period and fund [*****] Enanta FTEs
during the Evaluation Period at an annualized rate of [*****] per FTE. All amounts due hereunder for FTEs shall be payable on the first day of each calendar quarter occurring during the Evaluation Period. In addition to the foregoing: 

(a) As to each patent or patent application of a Joint Patent Right, Abbott and Enanta shall agree to apportion each such
patent or patent application into: (i) patent(s) and application(s) claiming only HCV NS3 or HCV NS3/4A protease inhibitor compounds, pharmaceutical compositions containing such compounds, methods for manufacturing such compounds and/or methods
of using such compounds in treating HCV infections; and/or (ii) patent(s) and application(s) claiming subject matter not set forth in the foregoing subsection 3.9(a)(i), including, without limitation, formulation technology, compounds other
than compounds set forth in subsection 3.9(a)(i), compositions containing compounds other than compounds set forth in subsection 3.9(a)(i), and/or methods of manufacturing compounds other than compounds set forth in subsection 3.9(a)(i). Upon the
expiration or termination of the Term (except if the Agreement is terminated pursuant to Section 11.3.3, 11.2.3, or is otherwise terminated for reasons of a Party’s bankruptcy or insolvency), Abbott shall be deemed to have assigned, and
hereby does assign, to Enanta all of Abbott’s right, title and interest solely to patents/patent applications set forth in subsection 3.9(a)(i) above, Patents and patent applications set forth in subsection 3.9(a)(ii) shall be jointly owned
upon the expiration or termination of the Term. Upon expiration or termination of the Term (except if the Agreement is terminated pursuant to Section 11.3.3, 11.2.3, or is otherwise terminated for reasons of a Party’s bankruptcy or
insolvency), Abbott shall grant Enanta an exclusive (even as to Abbott), perpetual, fully-paid, royalty-free, world-wide license, with the right to sublicense, under the patents and patent applications set forth in subsection 3.9(a)(ii) to Develop
and Commercialize HCV NS3 or HCV NS3/4A 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
protease inhibitor compounds claimed by such patents and patent applications as set forth in subsection 3.9(a)(i) in the Field. In the event that Abbott commercializes in the Field any HCV
protease inhibitors conceived after the Term as a result of utilizing the technology claimed in patents/patent applications set forth in subsection 3.9(a)(ii), Abbott shall pay Enanta a royalty on products containing such HCV protease inhibitors as
described in section 6.5.1; and in such event, Enanta shall grant Abbott an exclusive (even as to Enanta), perpetual, world-wide license, with the right to sublicense, under the patents/patent applications set forth in subsection 3.9(a)(ii) to make,
use, sell, offer to sell, or have made the aforesaid HCV protease inhibitors. In the event that Abbott and Enanta do not agree in apportioning claims in such patents and patent applications, then such dispute shall be resolved by joint patent
counsel selected by the JSC who (and whose firm) is not at the time of the dispute, and was not at any time during the five (5) years prior to the dispute, performing services for either of the Parties. The Parties shall share equally in the
expenses of such patent counsel. 
 (b) During the Evaluation Period, at Abbott’s request: (i) Enanta
shall render reasonable assistance (including, but not limited to, providing to Abbott available quantities of Compounds, compounds covered by Joint Patent Rights and compounds covered by Joint Technology) to Abbott to facilitate Abbott’s
activities undertaken pursuant to this Section 3.9; and (ii) the words “Evaluation Period” shall be inserted after the words “Research Term” in each of Sections 8.5.1(a) and 8.5.2(a). 

(c) During the Evaluation Period, Abbott shall use Commercially Reasonable Efforts to undertake its activities pursuant to
this Section 3.9 and shall comply with the reporting requirements of Section 3.5 of this Agreement. 

(d) After expiration of the Evaluation Period and continuing for the remainder of the Term, the Parties may nominate and
designate Evaluation Compounds as Candidates under the applicable provisions set forth in this Agreement, including, but not limited to Section 3.6. Upon the termination or expiration of the Term, the Parties’ respective rights to nominate
and designate Evaluation Compounds under Section 3.9 shall terminate. 
 E. A new section 3.10 shall be added to the Agreement, as follows:

 3.10 External Compounds. Either Party (a “Providing Party”) may, in its sole
discretion, provide the other Party (a “Receiving Party”) with access to any proprietary compound Controlled by such Providing Party that is not a Compound, Abbott Compound, compound covered by Joint Patent Rights or compound covered by
Joint Technology (each an “External Compound” and collectively, the “External Compounds”) solely to enable the Receiving Party to conduct research activities involving the combination of such External Compound with a Compound,
Abbott Compound, compound covered by Joint Patent Rights or compound covered by Joint Technology (“Combination Activities”). In 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
addition, a Providing Party may, in its sole discretion, conduct Combination Activities itself with an External Compound Controlled by such Providing Party. Prior to conducting any Combination
Activities hereunder the Parties shall obtain approval from the other Party. Notwithstanding anything in this Agreement to the contrary: (i) the Providing Party shall retain all right, title and interest in and to any such External Compound;
(ii) the Receiving Party shall receive no right, title or interest in or to, nor any express or implied license to use, such External Compound in any way, other than to perform Combination Activities expressly authorized by the Providing Party;
(iii) the Providing Party shall have no limitation on its ability, in its sole discretion, to withhold access under this Section 3.10 to any of its External Compounds, or to withdraw the Receiving Party’s access to any of its External
Compounds at any time for any or no reason immediately upon written notice; (iv) the Providing Party shall have sole and exclusive ownership of all right, title and interest in and to any Technology other than technology covered by Joint
Combination Patent Rights (as defined below), that is conceived or first reduced to practice by either Party in the conduct of Combination Activities that relates solely to the External Compound of the Providing Party or its use; (v) the
Providing Party and the Receiving Party shall jointly own any patent right that is conceived or first reduced to practice by either Party in the conduct of Combination Activities that relates solely to the use of an External Compound specifically in
combination with a Compound, Abbott Compound, compound covered by Joint Patent Rights or compound covered by Joint Technology (“Joint Combination Patent Right”); (vi) no Joint Technology, Joint Patent Rights or Abbott Improvements
shall result from any activities conducted by any Party with External Compounds; and (vii) the Providing Party, acting through patent counsel of its choice, shall be solely responsible for the preparation, filing, prosecution and maintenance of
Joint Combination Patent Rights; provided, that, for purposes of determining the remaining rights and obligations of the Parties with respect to the filing, prosecution and maintenance of any such patent rights by the Providing Party, such patent
rights shall be deemed to be Joint Patent Rights for purposes of this Agreement and shall be governed by Article 10 . Subject to Article 8 of this Agreement, the Providing Party shall have no limitation on its ability, in its sole discretion, to
conduct or direct any research, development, commercialization or any other activities with respect to any External Compound. In addition to the foregoing: 
 (a) all data and results (including raw data and reports) produced or generated by either Party in the conduct of Combination Activities will be shared with the other Party as soon as it is available and
may be used by both Parties subject to the limitations set forth in this Agreement. In addition, if the Receiving Party or the Providing Party will be conducting Combination Activities with respect to an External Compound, the Providing Party shall
provide the Receiving Party with detailed scientific data relating to such External Compound, including any preclinical and clinical data, but excluding compound structure with respect to the type of Combination Activities to be conducted at least
[*****] in advance of proposed start date of the Combination Activities; provided, that all such data 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
shall be treated as Confidential Information of the Providing Party. By way of example, it is the understanding of the Parties that the Providing Party will be obligated under this
Section 3.9(a) to provide virology data to the Receiving Party only to the extent that the Combination Activities to be conducted by the Receiving Party involve virology activities and to provide toxicology data to the Receiving Party only to
the extent that the Combination Activities to be conducted by the Receiving Party involve toxicology activities. 

(b) The Providing Party or Receiving Party, as the case may be, shall provide written notice to the other Party at least
[*****] in advance of the proposed start date of any proposed Combination Activities. 
 F. A new section 3.11 shall be added to the Agreement,
as follows: 
 3.11 Confidentiality of Information Concerning External Compounds. For purposes of
clarity, subject to Section 1.33, all information provided by a Providing Party to a Receiving Party regarding any External Compound pursuant to Section 3.10, and any information regarding any External Compound ascertained in connection
with activities authorized under Section 3.10, shall be Confidential Information of the Providing Party for purposes of this Agreement. Notwithstanding Article 7 of the Agreement, each of Abbott and Enanta agree that during the Term and for an
additional [*****] years thereafter, they shall not disclose (except only to employees to the extent necessary to enable such employees to perform the activities authorized under Section 3.10 above) or use (except as specifically allowed under
Section 3.10 above and Section 7.1.2), any Confidential Information provided by the Providing Party regarding any External Compound, or any Confidential Information regarding any External Compound ascertained in connection with activities
authorized under Section 3.10 without, in either case, the prior written authorization of the Providing Party. 
 G. Section 10.1.4 of
the Agreement is hereby deleted in its entirety, and the following Section 10.1.4 is inserted in lieu of the deleted Section: 
 10.1.4 Joint Patent Rights. The JSC shall determine the jurisdictions within the Territory in which patent applications will be filed with respect to Joint Patent Rights as well as the
patent counsel that shall represent both Enanta and Abbott for the preparation, filing, prosecution and maintenance of Joint Patent Rights. Each Party will independently select which countries it will financially support with respect to the
preparation, filing, prosecution and maintenance of Joint Patent Rights. The Parties shall share (at a rate of [*****] of the total costs with respect to each country) in the expenses incurred for the preparation, filing prosecution and maintenance
of Joint Patent Rights in each country independently selected by both Parties. The expenses incurred for the preparation, filing, prosecution and maintenance of Joint Patent Rights in any country that is selected by one Party but not by the other
Party shall be borne solely by the Party selecting that country. For purposes of clarity, (a) neither Party shall be obligated to share in the expenses incurred in the preparation, filing, prosecution and maintenance of

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 
any Patent Rights under this Agreement and (b) any decision by a Party not to share in the expenses incurred for the preparation, filing, prosecution and maintenance of Joint Patent Rights
in any country shall not affect the rights of such Party with respect to such Joint Patent Rights in such country. 
 H. Section 11.1 of
the Agreement is hereby deleted in its entirety, and the following Section 11.1 is inserted in lieu of the deleted Section: 
 11.1 Term. This Agreement shall commence on the Effective Date and shall continue in full force and effect until the end of the Evaluation Period and, if at the end of the Evaluation Period,
Abbott is Developing a Candidate or Commercializing a Product arising out of the Research Program, thereafter until (a) such time as Abbott is no longer Developing a Candidate for use in the Field and in the Territory or (b) if, as of the
time Abbott is no longer Developing any Candidates, Abbott is Commercializing any Product, until such time as all Royalty Terms for all Products and all Co-Development Terms for all Co-Developed Products have ended, unless earlier terminated in
accordance with the provisions of this Article 11 (the “Term”). 
 I. Abbott and Enanta agree that this First Amendment
shall be annexed to and made part of the Agreement. Any conflicts arising between this First Amendment and the Agreement shall be resolved in favor of the provisions of this First Amendment. Except as herein provided, all of the terms and conditions
in the Agreement remain unchanged and are hereby reaffirmed. 
 J. This First Amendment may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together will constitute one and the same instrument. 
 IN WITNESS WHEREOF,
Abbott and Enanta have each caused this First Amendment to be executed by a duly authorized representative as of the day and year first above written. 
  

									
	ABBOTT LABORATORIES	 		 	ENANTA PHARMACEUTICALS, INC.
					
	By:	 	 /s/ John M. Leonard
	 		 	By:	 	 /s/ Jay R. Luly

	Name:	 	 /s/ John M. Leonard
	 		 	Name:	 	 Jay R. Luly

	Title:	 	 Senior VP, Global Pharmaceutical
	 		 	Title:	 	 President and CEO

		 	 Research and Development
	 		 		 	

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 SECOND AMENDMENT TO COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT 

This Second Amendment (this “Second Amendment”), made this 9th day of December, 2009 (“Second Amendment Effective
Date”) to the Collaborative Development and License Agreement dated November 27, 2006 (as previously amended, the “Agreement”), is entered into by and between Abbott Laboratories, having its principal office at 100 Abbott Park
Road, Abbott Park, IL 60064-3500 (together with its affiliates, “Abbott”) and Enanta Pharmaceuticals, Inc., with principal offices at 500 Arsenal Street, Watertown, Massachusetts 02472 (“Enanta”). 

WHEREAS on November 27, 2006, the parties entered into a Collaborative Development and License Agreement; 

WHEREAS on January 27, 2009, the parties amended the November 27, 2006 Collaborative Development and License Agreement in a
First Amendment to Collaborative Development and License Agreement; 
 WHEREAS under the terms of the Agreement, the Research
Program Term is set to expire and Abbott and Enanta both desire to extend the Research Program Term; 
 NOW THEREFORE, in
consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto intending to be legally hound hereby agree as follows: 
 A. Any capitalized term used and not otherwise defined herein shall have the meaning set forth in the Agreement. 
 B. Section 1.99 of the Agreement is hereby deleted in its entirety and replaced by the following Section 1.99: 
 1.99 “Research Program Term” means the period beginning on the Approval Date and, subject to Section 3.8, ending on December 15, 2010. 

C. Notwithstanding anything in the Agreement to the contrary, Enanta shall commit to the Research Program at least [*****] FTEs during the period
beginning on the Second Amendment Effective Date and ending December 15, 2010. 
 D. The words “if extended as per
Section 3.8” shall be deleted from the second sentence of Section 6.3.1 in the Agreement. 
 E. [*****]. 

F. Abbott and Enanta agree that this Second Amendment shall be annexed to and made part of the Agreement. Any conflicts arising between this Second
Amendment and the Agreement shall be resolved in favor of the provisions of this Second Amendment. Except as herein provided, all of the terms and conditions in the Agreement remain unchanged. 

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission. 

 G. This Second Amendment may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together will constitute one and the same instrument. 
 IN WITNESS WHEREOF, Abbott and Enanta have
each caused this Second Amendment to be executed by a duly authorized representative as of the day and year first above written. 
  

									
	ABBOTT LABORATORIES	 		 	ENANTA PHARMACEUTICALS, INC.
					
	By:	 	 /s/ John M. Leonard
	 		 	By:	 	 /s/ Yujiro Hata

	Name:	 	 John M. Leonard, M.D.
	 		 	Name:	 	 Yujiro Hata

	Title:	 	 Senior Vice President, Pharmaceuticals
	 		 	Title:	 	 Chief Business Officer

		 	 Research and Development
	 		 		 	

  

Confidential materials omitted and filed separately with the Securities and Exchange Commission. 

Asterisks denote such omission.<![CDATA[Collaboration & License Agreement]]>

 Exhibit 10.2 
 Enanta has requested that portions of this document be accorded confidential treatment 
 pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as 
 amended. 
 COLLABORATION AND LICENSE AGREEMENT 

This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is made as of February 16, 2012 (“Effective
Date”), by and between Novartis Institutes for BioMedical Research, Inc., with its principal office at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“Novartis”) and Enanta Pharmaceuticals, Inc., with its
principal office at 500 Arsenal Street, Watertown, Massachusetts 02472 (“Enanta”). Novartis and Enanta are each referred to individually as a “Party” and together as the “Parties.” 

RECITALS 

WHEREAS, Novartis and its Affiliates are in the business of discovering, developing, manufacturing, marketing and selling pharmaceuticals
worldwide; 
 WHEREAS, Enanta owns or Controls the Enanta IP relating to the Enanta Compounds; 

WHEREAS, Enanta and Novartis are interested in generating Collaboration Compounds and new Enanta Compounds that target NS5A; and

 WHEREAS, Novartis wishes to obtain, and Enanta wishes to grant, exclusive rights to the Enanta Compounds and the
Collaboration Compounds in the Field and in the Territory on the terms and conditions set forth herein. 
 NOW, THEREFORE, in
consideration of the mutual covenants and agreements herein contained, the Parties agree as follows: 
  

	1.	DEFINITIONS AND INTERPRETATION 

  

	1.1	Definitions. Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized, shall have the meanings set forth below, or the
meaning as designated in the indicated places throughout this Agreement. 

 “Accounting Standards”
means, with respect to Enanta, US GAAP (United States Generally Accepted Accounting Principles) and, with respect to Novartis, the IFRS (International Financial Reporting Standards), in each case, as generally and consistently applied
throughout the Party’s organization. Each Party shall promptly notify the other in writing in the event that it changes the Accounting Standards pursuant to which its records are maintained, it being understood that each Party may only use
internationally recognized accounting principles (e.g. IFRS, US GAAP, etc). 
 “Acquired Product” shall
have the meaning set forth in Section 4.3. 
 “Acquired Program” shall have the meaning set forth in
Section 4.3. 
 “Acquirer” shall have the meaning set forth in the definition of Change of Control.

 Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

 “Affiliate” means, with respect to a Party, any entity or person that
controls, is controlled by, or is under common control with that Party. For the purpose of this definition, ‘control’ or ‘controlled’ means, direct or indirect, ownership of fifty percent (50%) or more of the shares of stock
entitled to vote for the election of directors in the case of a corporation or fifty percent (50%) or more of the equity interest in the case of any other type of legal entity; status as a general partner in any partnership; or any other
arrangement whereby the entity or person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity or the ability to cause the direction of the management or policies of a corporation
or other entity. The Parties acknowledge that in the case of entities organized under the laws of certain countries where the maximum percentage ownership permitted by law for a foreign investor is less than fifty percent (50%), such lower
percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity. 
 “Alliance Manager” shall have the meaning set forth in Section 5.1. 
 “Blended Rate” means (a) the total amount of royalties (stated in United States Dollars) that would be payable with respect to the relevant Product under Sections 11.3 and 11.4 in
all countries where royalties are due for Products as determined in accordance with the methodology provided in Section 11.5, without any applicable reduction in the royalty rate under Section 11.6 and/or 11.7, divided by (b) the
total Net Sales (stated in United States Dollars) of such Product in that same period in such countries, expressed as a percentage. 
 “Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.

 “Calendar Year” means a period of twelve (12) consecutive calendar months ending on December 31.

 “Change of Control” means, following the Effective Date, the occurrence that any Third Party, or group of
Third Parties acting in concert (collectively, an “Acquirer”): (a) becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the total voting power of the stock of Enanta or its Affiliates
then outstanding and normally entitled to vote in elections of its or their board of directors; (b) consolidates with or merges with or into Enanta or its Affiliates pursuant to a transaction in which more than fifty percent (50%) of the
total voting power of the voting securities outstanding of the surviving entity normally entitled to vote in elections of directors (or equivalent governing body) is not held by the Persons holding at least fifty percent (50%) of the
outstanding shares of the relevant entity preceding such consolidation or merger; (c) obtains, whether through conveyance, assignment, transfer or lease, all or substantially all of the assets of Enanta or its Affiliates; or (d) acquires
effective control of the management and policies of Enanta or its Affiliates. 
 “Claims” means all Third Party
demands, claims, actions, proceedings and liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, reasonable legal costs and other reasonable expenses of any nature whatsoever. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 2

 “Co-Detail Notice” has the meaning set forth in Section 10.2.

 “Co-Detail Option Exercise Notice” has the meaning set forth in Section 10.3. 

“Co-Detailing/Co-Detail” means co-Detailing activities for the Products to be conducted by Enanta through its own sales
force in the United States in the event that Enanta exercises its rights under Section 10.2. 
 “Co-Detailing
Agreement” has the meaning set forth in Section 10.3(c). 
 “Collaboration Compound” means any
NS5A Compound that is not an Enanta Compound and that is conceived of, reduced to practice or created (i) in the course of performance of the Research Program, or (ii) in the course of any exercise by Novartis or its Affiliates of the
license granted in Section 3.1(b) or otherwise through the material use of any scientific Confidential Information of Enanta, including any complexes, chelates, clathrates, esters, salts, stereoisomers, enantiomers, pro-drug forms, hydrates,
solvates, polymorphs, other non-covalent derivatives, metabolites, and crystalline forms of any such compounds. 

“Collaboration IP” means all Patent Rights, Know-How and other intellectual property that is owned or Controlled by
either Party or its Affiliates, and (i) generated in the course of performance of the Research Program, or (ii) generated by Novartis or its Affiliates outside of the Research Program in the course of any exercise by Novartis or its
Affiliates of the licenses granted hereunder and directly related to or claiming the structure of any Collaboration Compound, or directly related to the use, formulation or manufacture of any such Collaboration Compound, provided that in no event
shall Collaboration IP include any Enanta Patents or any Enanta Know-How. 
 “Combination Products” mean any
pharmaceutical product (in any formulation) containing one or more active pharmaceutical ingredients in addition to a Licensed Compound. 
 “Commercialize” means to market, promote, distribute, import, export, offer to sell and/or sell Product and/or conduct other Commercialization, and “Commercialization”
means commercialization activities relating to Product(s), including activities relating to marketing, promoting, distributing, importing, exporting, offering for sale and/or selling Product(s). 

“Commercially Reasonable Efforts” means the diligent expenditure of those efforts and resources that Novartis or its
Affiliates would reasonably use were it developing or commercializing its own pharmaceutical product that is of similar market and profit potential and of similar risk profile at a similar stage in its product life as the applicable Product, taking
into account, among other things, anticipated product labeling, anticipated financial return, relevant medical and clinical considerations, anticipated regulatory environment and competitive market conditions, all as measured by the facts and
circumstances at the time such efforts are due. For clarity, it is understood and 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 3

 
acknowledged that Commercially Reasonable Efforts in the Development or Commercialization of a Product may include sequential implementation of clinical trials and/or intervals between clinical
trials for data interpretation and clinical program planning and approval, to the extent such implementation is consistent with the scientific, technical and commercial factors relevant to Development or Commercialization of such Product in the
relevant country. 
 “Competing Product” means any product containing an NS5A Compound or related product, alone
or in combination with another active pharmaceutical ingredient, which is not a Licensed Compound or Product. 

“Confidential Information” means all Know-How and other proprietary information and data of a financial, commercial or
technical nature which the disclosing Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether disclosure is made orally, in writing or in electronic form, and including any other
information deemed Confidential information as expressly provided in this Agreement. 
 “Control” or
“Controlled” means, with respect to any Know How, Patent Rights, other intellectual property rights, or any proprietary or trade secret information, the legal authority or right (whether by ownership, license or otherwise) of a
Party to grant a license or a sublicense of or under such Know How, Patent Rights, or intellectual property rights to the other Party as contemplated hereunder, or to otherwise disclose such proprietary or trade secret information to the other Party
as contemplated hereunder, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party. 
 “Detail” means a face to face discussion between a sales representative and a Prescriber for the purposes of discussing and informing such Prescriber of the characteristics of the
Products. When used as a verb, the terms “Detail” or “Detailing” means to perform a Detail. 

“Develop” or “Development” means preclinical and clinical drug development activities relating to
Licensed Compounds or Products, including, without limitation, test method development and stability testing, assay and audit development, toxicology, formulation, quality assurance and quality control development, statistical analysis, clinical
trials and regulatory affairs, and the preparation, filing and prosecution of new drug applications and Regulatory Approvals and their equivalent worldwide. 
 “EMA” means the European Medicines Agency or any successor entity thereto. 
 “Enanta Background IF” means, subject to Section 20.1, all Patent Rights, Know-How and other intellectual property that are Controlled by Enanta or its Affiliates during the Term
that are not included within Enanta IP or Collaboration IP and that are necessary or useful for the conduct of the Research Program or the Development, manufacture, Commercialization, use, importation or sale of Licensed Compound(s) or Product(s) in
the Field and in the Territory, provided that Enanta Background IP shall not include 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 4

 
Patent Rights, Know-How or other intellectual property to the extent relating to any compound whose structure is proprietary to Enanta or its Affiliates and that is not an NS5A Compound, whether
used alone or in combination with any other molecule, including without limitation any NS5A Compound. 
 “Enanta
Compound” means (i) the small molecule known as EDP-239 and any other NS5A Compound claimed in the Enanta Patents, including any complexes, chelates, clathrates, esters, salts, stereoisomers, enantiomers, pro-drug forms, hydrates,
solvates, polymorphs, other non-covalent derivatives, metabolites, and crystalline forms of such compounds to the extent such structures are claimed in the Enanta Patents, and (ii) any other novel NS5A Compounds which are proprietary to and
Controlled by Enanta as of the Effective Date, but which are not claimed in the Enanta Patents as of such date. 

“Enanta IP” means the Enanta Patents and Enanta Know-How. 

“Enanta Know-How” means any Know-How owned or Controlled by Enanta or any of its Affiliates relating to the Licensed
Compounds that is reasonably necessary or useful for the research, Development, manufacture, Commercialization, use, importation or sale of Licensed Compound(s) in the Field and in the Territory and that is not generated solely or jointly by Enanta
or its Affiliates in the course of performance of the Research Program. However, Enanta Know-How shall not include Know-How owned or Controlled by Enanta or its Affiliates to the extent not relating to NS5A Compounds, including Know-How directed to
combination therapies, and which is or may be or become owned or Controlled by Enanta or its Affiliates, and which is or may become exclusively licensed to Third Parties in connection with collaborations regarding proprietary compounds directed to
HCV-relevant targets other than NS5A. 
 “Enanta Patents” means the patents and patent applications identified
in Exhibit A and all Patent Rights claiming priority thereto, and any other Patent Rights that are not Collaboration IP and are owned or Controlled by Enanta or any of its Affiliates to the extent they include claims to novel NS5A Compounds.
However, Enanta Patents shall not include claims in Patent Rights not listed in Exhibit A owned or Controlled by Enanta or its Affiliates which do not claim Enanta’s novel NS5A Compound structures, including claims directed to
combination therapies, and which are or may be or become owned or Controlled by Enanta or its Affiliates, and which are or may become exclusively licensed to Third Parties in connection with collaborations regarding Enanta’s proprietary
compounds directed to HCV-relevant targets other than NS5A. 
 “Encumbrance” means any claim, charge, equitable
interest, hypothecation, lien, mortgage, pledge, option, license, assignment to a Third Party, power of sale, retention of title by a Third Party, right of pre-emption, right of first refusal or security interest of any kind. 

“FDA” means the United States Food and Drug Administration or any successor entity thereto. 

“Field” means all uses. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 5

 “First Commercial Sale” means the first sale of a Product by or under the
authority of Novartis or an Affiliate, or a sublicensee of Novartis or of a Novartis Affiliate, to a Third Party in a country in the Territory following Regulatory Approval of such Product in that country or, if no such Regulatory Approval or
similar marketing approval is required, the date upon which such Product is first commercially launched in such country; provided that First Commercial Sale shall not include any distribution or other sale solely for so-called treatment IND sales,
named patient sales, compassionate or emergency use sales and pre-license sales. 
 “FPFV” means the
administration of the first dose of a Licensed Compound or Product to the first patient (or volunteer, as relevant) while participating in a clinical trial. 
 “FTE Rate” shall mean a rate of [*****] per annum based on the yearly time for a full-time equivalent scientific employee during the Research Term, consisting of a total of [*****] per
annum (“FTE”), to be pro-rated on a daily basis if necessary (per annum amount to be divided by [*****] to produce the rate per whole day consisting of eight hours); such rate to be restricted to scientific work and managerial
activities related directly to the Research Program. For the avoidance of doubt, such rate includes all benefits, travel, overhead and any other expenses. 
 “Generic Equivalent” means any product with the same active ingredient and administration route as the Product bioequivalent to and substitutable (i.e., “AA” or “AB”
therapeutic equivalence code or other therapeutic equivalence code hereafter created with similar meaning) for the Product and that is sold under an ANDA or NDA pursuant to the FDC Act, or pursuant to the applicable law of the relevant jurisdiction.

 “IND” means an Investigational New Drug application in the US filed with the FDA or the corresponding
application for the investigation of Products in any other country or group of countries, as defined in the applicable laws and regulations and filed with the Regulatory Authority of the relevant country or group of countries. 

“Insolvency Event” means, in relation to either Party, any one of the following: (a) that Party becomes insolvent
(as determined under the laws of that Party’s jurisdiction of organization); (b) that Party is the subject of voluntary or involuntary bankruptcy proceedings instituted on behalf of or against such Party (except for involuntary bankruptcy
proceedings which are dismissed within sixty (60) days); (c) an administrative receiver, receiver and manager, interim receiver, custodian, sequestrator or similar officer is appointed in respect of that Party; (d) a resolution shall
have been passed by that Party’s directors or stockholders to wind up that Party, other than a resolution for the solvent reconstruction or reorganization of that Party; (e) a resolution shall have been passed by that Party’s
directors or stockholders to make an application for an administration order or to appoint an administrator; or (f) that Party proposes or makes any general assignment, composition or arrangement with or for the benefit of all or some of that
Party’s creditors or makes or suspends or threatens to suspend making payments to all or some of that Party’s creditors or the Party submits to any type of voluntary arrangement. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 6

 “Invoice” shall mean an invoice substantially in the form of Exhibit
C. 
 “Joint Steering Committee” or “JSC” means the committee established as set forth in
Section 5.2. 
 “Know-How” means all technical information, know-how and data, including inventions
(whether patentable or not), discoveries, trade secrets, specifications, instructions, processes, formulae, materials, expertise and other technology applicable to compounds, formulations, compositions, products or to their manufacture, development,
registration, use or commercialization or methods of assaying or testing them or processes for their manufacture, formulations containing them, compositions incorporating or comprising them and including all biological, chemical, pharmacological,
biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise and information, regulatory filings and copies thereof, relevant
to the development, manufacture, use or commercialization of and/or which may be useful in studying, testing, development, production or formulation of products, or intermediates for the synthesis thereof. 

“Knowledge” means the actual knowledge of Enanta. 

“Licensed Compound” means any Enanta Compound or Collaboration Compound. 

“Loss of Market Exclusivity” means, with respect to any Product in any country, the following has occurred: (a) the
Net Sales of such Product in that country in any Calendar Year are less than [*****] in any Calendar Year of such Product in that country immediately preceding the launch of a Generic Equivalent; and (b) the decline in such sales is
attributable in material part to the marketing or sale in such country of a Generic Equivalent of such Product by a Third Party. 

“MAA” means an application for the authorization to market the Product in any country or group of countries outside the
United States, as defined in the applicable laws and regulations, and filed with the Regulatory Authority, of a given country or group of countries. 
 “Major EU Country” means any of France, Germany, Italy, Spain and the United Kingdom. 
 “Milestones” means the milestone events relating to the Products as set forth in Section 11.2. 
 “Milestone Payments” means the payments to be made by Novartis to Enanta upon the achievement of the corresponding Milestones as set forth in Section 11.2. 

“NDA” means a New Drug Application in the United States for authorization to market the Product, as defined in the
applicable laws and regulations of, and filed with, the FDA. 
 “Net Sales” means, with respect to any Product,
the gross amount invoiced by or on behalf of Novartis or any of its Affiliates or its or its Affiliates’ sublicensees (a “Seller”) 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 7

 
for such Product sold to Third Parties (other than to any such sublicensees for resale) in bona fide, arm’s length transactions, less deductions from gross sales booked on an accrual basis
as determined in accordance with Novartis’ Accounting Standards as consistently applied, less a deduction of [*****] for uncollectible amounts on previously sold items. The deductions from gross sales in accordance with Novartis Accounting
Standards may include, without limitation, the following: 
  

	 	(i)	normal trade and cash discounts actually given; 

  

	 	(ii)	amounts repaid or credited by reasons of defects, rejections, recalls or returns; 

 

	 	(iii)	rebates and chargebacks granted to customers and third parties (including, without limitation, Medicare, Medicaid, Managed Healthcare and similar types of rebates);

  

	 	(iv)	any amounts recorded in gross revenue associated with goods provided to customers for free; 

 

	 	(v)	amounts provided or credited to customers through coupons and other discount programs to the extent consistent with Seller’s normal practices;

  

	 	(vi)	delayed ship order credits, discounts or payments related to the impact of price increases between purchase and shipping dates; 

 

	 	(vii)	fee for service payments to customers for any non-separable services (including compensation for maintaining agreed inventory levels and providing information) to the
extent consistent with Seller’s normal practices; and 

  

	 	(viii)	other specifically identifiable deductions substantially similar to those itemized above in accordance with Novartis’ Accounting Standards.

 With respect to the calculation of Net Sales: 

 

	 	(1)	Net Sales shall only include the value charged or invoiced on the first arm’s length sale to a Third Party, and sales between or among Novartis and its Affiliates
and any sublicensees of either shall be disregarded for purposes of calculating Net Sales; 

  

	 	(2)	If a Product is delivered to the Third Party before being invoiced (or is not invoiced), Net Sales will be calculated at the time that the revenue recognition criteria
under Novartis Accounting Standards are met; 

  

	 	(3)	In the case of any sale of any Product that is not an arm’s-length transaction exclusively for cash, Net Sales shall be calculated as above on the fair market
value of the non-cash consideration received as reasonably determined by Novartis. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 8

	 	(4)	In the event that the Product is sold as a Combination Product, the Net Sales will be calculated by multiplying the Net Sales of the Combination Product by the
fraction, A/(A+B) where A is the weighted (by sales volume) average sale price in the relevant country of the Product containing the Licensed Compound as the sole active ingredient in finished form, and B is the weighted average sale price (by sales
volume) in that country of the product(s) containing the other active pharmaceutical ingredient(s) as the sole active ingredient(s) in finished form. Regarding prices comprised in the weighted average price when sold separately referred to above, if
these are available for different dosages from the dosages of Licensed Compound and other active pharmaceutical ingredient(s) that are included in the Combination Product, then Novartis shall be entitled to make a reasonable proportional adjustment
to such prices in calculating the royalty-bearing Net Sales of the Combination Product following consultation with Enanta. If the product(s) containing the Licensed Compound or the other active pharmaceutical ingredient(s) as the sole active
ingredient(s) are not sold as such and thus the weighted average sale price cannot be determined, the calculation of Net Sales for Combination Products will be agreed by the Parties at least thirty (30) days prior to the First Commercial Sale
of such Combination Product based on the relative value contributed by each active pharmaceutical ingredient (each Party’s agreement not to be unreasonably withheld or delayed). 

“Novartis Exclusivity Period” shall have the meaning set forth in Section 4.2. 

“NS5A Compound” shall mean a molecule: (a) to which [*****] that are [*****] to its inhibitory effects contain
[*****]; (b) whose activity against [*****] that is required for HCV replication is [*****]; and (c) that inhibits replication of [*****]. 
 “Patent Rights” means all patents and patent applications, including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, reissues, additions, renewals,
extensions, registrations, and supplemental protection certificates and the like of any of the foregoing. 

“Person” means any individual, partnership, limited liability company, firm, corporation, association, trust,
unincorporated organization or other entity. 
 “Phase I Clinical Trial” means a study in humans which provides
for the first introduction into humans of a product, conducted in normal volunteers or patients to get information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or
the foreign equivalent thereof). 
 “Phase II Clinical Trial” means a study in humans of the safety, dose
ranging and efficacy of a product, which is prospectively designed to generate sufficient data (if successful) to commence pivotal clinical trials, as further defined in 21 C.F.R. § 312.21(b) (or the foreign equivalent thereof). 

“Phase III Clinical Trial” means a controlled study in humans of the efficacy and safety of a product, which is
prospectively designed to demonstrate statistically whether such 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 9

 
product is effective and safe for use in a particular indication in a manner sufficient to file an application to obtain Regulatory Approval to market the product, as further defined in 21 C.F.R.
§ 312.21(c) (or the foreign equivalent thereof). 
 “Prescriber” means a healthcare professional authorized
to prescribe a Product or issue hospital orders for a Product, or those other allied professionals that are part of the treatment team and who are recognized for this purpose in the Commercialization plan, as applicable. 

“Prior CDA” means the Confidentiality Agreement between the Parties dated as of September 30, 2009 and amended on
November 17, 2011, and the Confidentiality Agreement between Parties dated September 9, 2011. 

“Product” means any pharmaceutical preparation (including drug substance and drug product) incorporating a Licensed
Compound as an active ingredient, alone or in combination with other active ingredients. 
 “Regulatory
Approval” means any and all approvals (including any applicable governmental price and reimbursement approvals), licenses, registrations, or authorizations of any Regulatory Authority that are necessary for the marketing and sale of a
Product in the relevant country or group of countries. 
 “Regulatory Authority” means any governmental agency
or authority responsible for granting Regulatory Approvals for Products, including the FDA, EMA and any corresponding national or regional regulatory authorities, as relevant. 
 “Regulatory Filings” means, with respect to the Licensed Compound(s) or Product(s), any submission to a Regulatory Authority of any appropriate regulatory application, and shall include,
without limitation, any submission to a regulatory advisory board, marketing authorization application, and any supplement or amendment thereto. For the avoidance of doubt, Regulatory Filings shall include any IND, NDA or the corresponding
application in any other country or group of countries. 
 “Research Plan” means the research plan attached as
Exhibit B to this Agreement and any amendments thereto. 
 “Research Program” means all research and drug
discovery activities conducted solely or jointly by the Parties during the Research Term pursuant to the Research Plan. 

“Research Term” means the period of funded research described in Section 2.3 (as may be extended in accordance
therewith and as shall terminate if the Term earlier terminates). 
 “Royalty Term” shall have the meaning set
forth in Section 11.3(b). 
 “Sales and Royalty Report” means a written report or reports showing, on a
Product-by-Product, and country-by-country basis, each of: (a) the Net Sales of each Product in each country in the Territory during the reporting period by Novartis and its Affiliates and

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 10

 
their respective sublicensees; (b) the royalties payable, in United States Dollars, which shall have accrued hereunder with respect to such Net Sales; (c) withholding taxes, if any,
required by applicable law to be deducted with respect to such royalties; and (d) the rate of exchange used by Novartis in determining the amount of United States Dollars payable hereunder, as determined in accordance with Section 12.2. If
no royalty or payment is due for any reporting period hereunder, Novartis shall so report. 
 “Senior Officers”
means, for Novartis, the Chief Executive Officer of Novartis or his/her designee, and for Enanta, the Chief Executive Officer of Enanta or his/her designee. 
 “Significant Pharmaceutical Company” means, with respect to a given Change of Control transaction, a company in the pharmaceutical industry that, [*****]. 

“Term” shall have the meaning set forth in Section 15.1. 

“Territory” means worldwide. 
 “Third Party” means any Person other than a Party or an Affiliate of a Party. 
 “United States” or “US” means the United States of America, its territories and possessions. 
 “USD” or “$” means United States Dollars, the lawful currency of the United States. 
 “Valid Claim” means: (a) a claim of an issued and unexpired patent under the Enanta IP or Collaboration IP, or a supplementary protection certificate thereof, which has not been held
permanently revoked, unenforceable or invalid by a decision of a court, patent office or other forum of competent jurisdiction, unappealable or unappealed within the time allowed for appeal and that is not admitted to be invalid or unenforceable
through reissue, disclaimer or otherwise (i.e., only to the extent the subject matter is disclaimed or is sought to be deleted or amended through reissue); or (b) a claim of a pending patent application under the Enanta IP or Collaboration IP
that has not been abandoned, finally rejected or expired without the possibility of appeal or refiling; provided that “Valid Claim” shall exclude any such claim in such a pending application that has not been granted within six
(6) years following the earliest priority filing date for such claim (unless and until such claim is granted). 
  

	1.2	Interpretation. In this Agreement, unless otherwise specified: 

  

	 	(a)	“includes” and ‘including’ shall mean respectively includes and including without limitation; 

 

	 	(b)	a Party includes its permitted assignees and/or the respective successors in title to substantially the whole of its undertaking; 

 

	 	(c)	a statute or statutory instrument or any of their provisions is to be construed as a reference to that statute or statutory instrument or such provision as the same may
have been or may from time to time hereafter be amended or re-enacted; 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 11

	 	(d)	words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders; 

 

	 	(e)	the Exhibits and other attachments form part of the operative provision of this Agreement and references to this Agreement shall, unless the context otherwise requires,
include references to the Exhibits and attachments; 

  

	 	(f)	the headings in this Agreement are for information only and shall not be considered in the interpretation of this Agreement; 

 

	 	(g)	general words shall not be given a restrictive interpretation by reason of their being preceded or followed by words indicating a particular class of acts, matters or
things; and 

  

	 	(h)	the Parties agree that the terms and conditions of this Agreement are the result of negotiations between the Parties and that this Agreement shall not be construed in
favor of or against any Party by reason of the extent to which any Party participated in the preparation of this Agreement. 

  

	2.	RESEARCH PROGRAM. 

  

	2.1	Goal. The objective of the Research Program shall be to discover, characterize, and optimize Enanta Compounds and/or Collaboration Compounds suitable for
Development and Commercialization by Novartis and its Affiliates as Product(s). 

  

	2.2	 Research Plan; Recordkeeping. During the Research Term, each Party and its Affiliates shall use commercially reasonable efforts to perform their
obligations under the Research Plan including by applying such tools, assays, reagents, capabilities and the like as are useful to the Research Program, based on the application of reasonable scientific judgment. An initial outline of the Research
Plan shall be attached to this Agreement as Exhibit B. The final Research Plan, shall be approved by the JSC within thirty (30) days after the Effective Date. Each Party and its Affiliates shall maintain complete and accurate
records of all work, results, data, and developments made pursuant to its efforts under the Research Plan. Such records shall fully and properly reflect all work done and results in sufficient detail and in good scientific manner appropriate for
patent and regulatory purposes. Each Party and its Affiliates shall grant to the other Party and its Affiliates reasonable access to all data (including, without limitation, all primary data and data contained in laboratory notebooks) that is
generated in the course of performance of the Research Program. Each Party shall maintain such laboratory notebooks and associated accessory records substantially in accordance with the requirements of Exhibit E. Novartis and its
Affiliates shall also have the right, at reasonable intervals and upon reasonable notice to Enanta, to have authenticated copies of such records made to use and transfer as permitted hereunder. Any data not otherwise contained in laboratory
notebooks and relevant to the Research Program or to Collaboration IP shall be provided to Novartis upon reasonable request in a format mutually agreed by the Parties. In the event of a termination of this Agreement by Enanta pursuant to
Section 15.2(a) or 15.4 or by Novartis pursuant to 15.3, Enanta shall have the right, at reasonable intervals and upon 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 12

	 	
reasonable notice to Novartis, to have authenticated copies made of Novartis’ laboratory notebooks and associated accessory records relevant to the Research Program or to Collaboration IP,
to use and transfer as permitted hereunder, and any data not otherwise contained in laboratory notebooks and relevant to the Research Program or to Collaboration IP shall be provided to Enanta upon reasonable request in a format mutually agreed by
the Parties. 

  

	2.3	 Term and Scope of Research Program. The Research Program shall commence on the Effective Date and shall continue until the first (1st) anniversary of the Effective Date (the “Research
Term”). No later than [*****] prior to expiration of the Research Term, the Parties may agree to extend the Research Term and shall discuss, in good faith, the scope of additional research funding to be provided to Enanta by Novartis and
the proposed Research Plan. In the event of a Change of Control, Novartis may terminate the Research Program by providing thirty (30) days’ prior written notice to Enanta. 

 

	3.	LICENSES 

  

	3.1	License Grant. 

  

	 	(a)	Subject to the terms and conditions of this Agreement, Enanta and its Affiliates hereby grant to Novartis and its Affiliates an exclusive (even as to Enanta and its
Affiliates), royalty-bearing, sublicensable (pursuant to Section 3.2) license, under the Enanta IP and the Collaboration IP to Develop, have developed, make, have made, use, distribute, have distributed, export, have exported, import, have
imported, promote, have promoted, market, have marketed, sell, have sold and offer to sell and otherwise Commercialize the Licensed Compound(s) and Product(s) in the Field and in the Territory. 

 

	 	(b)	Subject to the terms and conditions of this Agreement, Enanta and its Affiliates hereby grant to Novartis and its Affiliates an exclusive (even as to Enanta and its
Affiliates), royalty-bearing, sublicensable (pursuant to Section 3.2(c)) license, under the Enanta IP and the Collaboration IP to research Licensed Compound(s) and Product(s) for exploitation in the Field and in the Territory pursuant to the
license granted in (a) above. 

  

	 	(c)	The exclusive licenses granted above shall be subject to Enanta’s right to perform those aspects of the Research Program required to be performed by Enanta as
provided in this Agreement and described in the Research Plan, or as otherwise approved by the JSC. 

  

	3.2	Sublicensing and Subcontracting Rights. 

  

	 	(a)	Novartis and its Affiliates may sublicense the rights granted by Enanta under Section 3.1(a) of this Agreement at any time at its/their sole discretion and without
approval of Enanta, provided that Novartis shall remain responsible for the performance of this Agreement and shall cause such Third Party to comply with all applicable terms and conditions of this Agreement. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 13

	 	(b)	Notwithstanding any other provision of this Agreement, neither Novartis nor any of its Affiliates shall have the right to grant any sublicense which is a Naked Patent
License to any Third Party under any Patent Rights within the Enanta IP or any Patent Rights within the Collaboration IP that are owned solely by Enanta without the prior written consent of Enanta, which consent shall not be unreasonably withheld,
conditioned, or delayed. For purposes hereof, a “Naked Patent License” shall mean a sublicense under the relevant Patent Rights granted to a Third Party and permitting the Development or Commercialization of a Licensed Compound or
Product that was not under active Development or Commercialization by Novartis under the terms of this Agreement as of the time the relevant sublicense is granted. For clarity, this Section shall not prohibit any activities permitted by
Section 3.2(c) below. 

  

	 	(c)	In addition, Novartis may subcontract to Third Parties the performance of tasks and obligations reasonably related to Novartis’ research, Development and
Commercialization of Licensed Compounds and Products hereunder as Novartis deems reasonably appropriate, which subcontract may include a sublicense of rights necessary to performance of the subcontract as reasonably required, provided that Novartis
shall at all times remain primarily responsible and liable to Enanta for all such activities as if such activities had been undertaken by Novartis, for any failure of any subcontractor to comply with the terms of this Agreement, and Novartis shall
be fully liable to accordingly indemnify Enanta against any loss, damages, costs, claims or expenses which are awarded against, or incurred by Enanta as a result of any breach by any subcontractor of any of the provisions of the relevant
subcontract, as if the breach had been that of Novartis. 

  

	3.3	Enanta Background IP. Subject to Section 20.1, Enanta and its Affiliates hereby grant to Novartis and its Affiliates a non-exclusive license under the
Enanta Background IP (with the right to sublicense solely in connection with, and as reasonably relevant to, a sublicense granted pursuant to Section 3.2) to research, Develop, have developed, make, have made, use, distribute, have distributed,
export, have exported, import, have imported, promote, have promoted, market, have marketed, sell, have sold and offer to sell and otherwise Commercialize the Licensed Compound(s) and Product(s) in the Field in the Territory.

  

	3.4	No Other Rights. Novartis and its Affiliates expressly acknowledge and agree that they will not use Confidential Information of Enanta in the research,
development, or commercialization of any NS5A Compound that is not a Product, as defined in this Agreement, and shall have no rights to do so under any license or other right granted herein. Each Party expressly reserves and retains all intellectual
property rights not expressly granted herein, and no right or license under any Patent Rights, trademarks, Know-How or other proprietary rights of either Party is granted or shall be granted by implication. Except as otherwise expressly provided in
this Agreement, neither Party shall receive any rights under this Agreement to own, use or access the Patent Rights, Know-How or other intellectual property of the other Party. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 14

	4.	EXCLUSIVITY 

  

	4.1	Enanta Exclusivity to Novartis. During the Term of this Agreement, other than the performance of the Research Program during the Research Term, Enanta and its
Affiliates will not, alone or in collaboration with a Third Party, anywhere in the Territory, research, develop, manufacture or commercialize a Competing Product. Notwithstanding the foregoing, such prohibition shall not prevent Enanta and its
Affiliates from participating in (including without limitation receiving payments under) agreements with Third Parties with respect to products which include another active pharmaceutical ingredient used in combination with an NS5A Compound, so long
as Enanta has no active research or development role with respect to such NS5A Compound, and so long as Enanta provides no Enanta Know-How, and grants no rights under the Enanta IP or Collaboration IP, with respect to the research, development,
manufacture or commercialization of such NS5A Compounds under any such agreement. Notwithstanding anything in this Agreement to the contrary, in the event of a Change of Control of Enanta, the exclusivity obligations of Enanta set forth above shall
not restrict the research, development or commercialization of any compound, product or program owned or controlled by the relevant Acquirer, so long as all such activities are conducted independent of the Enanta scientific team (as it exists at the
date of consummation of the Change of Control) and without use of any proprietary Enanta Know-How, Enanta IP or Collaboration IP that is exclusively licensed to Novartis hereunder. 

 

	4.2	Novartis Exclusivity to Enanta. Except as set forth in Sections 4.3 and 4.4, Novartis and its Affiliates will not, directly or indirectly, [*****]
(a) [*****]; and (b) [*****] (subject to any extension as provided below, the “Novartis Exclusivity Period”). 

  

	4.3	Acquired Products and Acquired Programs. The provisions of Section 4.2 shall not apply to the continued actions relating to any Competing Product or any
NS5A Compound research or Development program, rights to which were acquired by Novartis or its Affiliates as the result of an acquisition by Novartis or its Affiliates of a Third Party, [*****] (such product, an “Acquired
Product”, and such program, an “Acquired Program”). In the event that Novartis or its Affiliates acquire an Acquired Product and/or Acquired Program, Novartis agrees that: 

 

	 	(a)	activities of Novartis and its Affiliates relating to any Acquired Product and Acquired Program will be staffed independently, except at senior executive levels, from
the activities conducted hereunder with respect to research, Development and Commercialization of Licensed Compounds and Products; 

  

	 	(b)	the licenses and rights granted by Enanta to Novartis and its Affiliates hereunder do not extend to such Acquired Product or Acquired Program; 

 

	 	(c)	the commitment of Novartis and its Affiliates to use Commercially Reasonable Efforts pursuant to Sections 7.2 and 9.1 hereof shall not be affected by any consideration
of the Acquired Product or Acquired Program, and Novartis and its Affiliates shall use all reasonable efforts to ensure that the Licensed Compound(s) and Product(s) Development timelines will be unaffected by the acquisition;

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 15

	 	(d)	any clinical trials with respect to any Acquired Product for which patient enrollment has commenced as of the consummation of the acquisition may be completed, but no
new clinical trials may be commenced with respect to any such Acquired Product until the Novartis Exclusivity Period has expired; 

  

	 	(e)	if the Acquired Program is in the preclinical or discovery stage, then no patient enrollment in a clinical trial of any Acquired Product will be commenced by Novartis
or any Affiliate until the Novartis Exclusivity Period has expired; 

  

	 	(f)	Novartis and its Affiliates may not use any Enanta Confidential Information or, during the Novartis Exclusivity Period, non-public clinical data resulting from the
Licensed Compound(s) or Product(s), for the benefit of such Acquired Product or Acquired Program; and 

  

	 	(g)	[*****]. 

  

	4.4	[*****]: 

  

	 	(a)	[*****]; 

  

	 	(b)	[*****]; 

  

	 	(c)	[*****]; and 

  

	 	(d)	[*****], 

 [*****]. 

 

	5.	GOVERNANCE 

  

	5.1	Alliance Managers. Within thirty (30) days following the Effective Date, each Party will appoint (and notify the other Party of the identity of) a senior
representative having a general understanding of pharmaceutical development and commercialization issues to act as its alliance manager under this Agreement (“Alliance Manager”). The Alliance Managers will serve as the contact point
between the Parties and will be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties, including periodic communications between the Parties in
connection with the Parties’ reporting requirements; providing single point communication for seeking consensus both internally within the respective Party’s organization and together regarding key global strategy and planning issues, as
appropriate, including facilitating review of external corporate communications; and raising cross-Party and/or cross-functional disputes in a timely manner. Each Party may replace its Alliance Manager on written notice to the other Party.

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 16

	5.2	Joint Steering Committee. 

  

	 	(a)	The Parties will establish a Joint Steering Committee, composed of three (3) senior personnel of Enanta and three (3) senior personnel of Novartis (one
(1) of which will be the Party’s Alliance Manager) and which personnel for each Party, collectively, shall have a general understanding of drug research, manufacturing, Development and Commercialization issues. 

 

	 	(b)	Within thirty (30) days following the Effective Date, each Party will designate its initial members to serve on the JSC and notify the other Party of the dates of
availability for the first meeting of the JSC. Each Party may replace its representatives on the JSC on prior written notice to the other Party. 

  

	 	(c)	The JSC will: (i) approve and revise the Research Plan; (ii) oversee the research activities pursuant to the Research Plan, including the research budget;
(iii) review and discuss research activities conducted by Novartis or its Affiliates with respect to Licensed Compound(s); (iv) review and discuss Development activities and plans with respect to Licensed Compound(s) and Product(s);
(v) review and discuss Novartis’ Commercialization plans and strategies with respect to the Product(s); and (vi) consider and act upon such other matters as specified in this Agreement. 

 

	 	(d)	The JSC also may, at any time it deems necessary or appropriate, establish additional joint committees and delegate such of its responsibilities as it determines
appropriate to such joint committees. 

  

	5.3	Meetings of the Joint Steering Committee. 

  

	 	(a)	The JSC shall meet [*****] and at such other times as the Parties may agree during [*****], after which the JSC shall meet [*****], after which it shall be dissolved.
The first meeting of the JSC shall be held as soon as reasonably practicable, but in no event later than sixty (60) days following the Effective Date. At the first meeting of the JSC, the members shall reasonably and in good faith determine how
it will function with respect to minutes, agendas, timelines and other administrative matters. Meetings shall be held at such place or places as are mutually agreed or by teleconference or videoconference. 

 

	 	(b)	Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend JSC meetings in a non-voting capacity, with
the consent of the other Party (which shall not be unreasonably withheld). 

  

	 	(c)	[*****] to act as chairperson of the JSC. The chairperson shall set agendas for JSC meetings provided that the agendas will include any matter requested by either
Party. 

  

	5.4	 Decision Making. Each Party shall in good faith consult with the other and take such other Party’s views into account in respect of any
matter before the JSC or any other committee established by the Parties hereunder, it being understood and agreed that 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 17

	 	
Novartis shall have sole control and decision-making with respect to the research, Development, manufacture and Commercialization of the Licensed Compound(s) and Product(s), subject to the terms
of this Agreement. If consensus cannot be reached with respect to any issue under the purview of the JSC, then the resolution and/or course of conduct shall be determined by Novartis, in its sole reasonable discretion. In exercising its final
decision-making authority with respect to JSC decisions, Novartis shall act in accordance with the objectives of the Research Program, and the terms of this Agreement, and shall exercise good faith, prudent scientific and business judgment in
accordance with the standards Novartis applies to other projects and products of similar scientific and commercial potential. Notwithstanding the foregoing, Enanta shall not be required to take any action by virtue of Novartis’ decision-making
authority under this Section 5.4 that Enanta reasonably believes would be inconsistent with the scope of the existing, mutually agreed Research Program, materially increase Enanta’s unreimbursed expenses, cause Enanta to violate the terms
of any other Agreement with a Third Party, or cause Enanta to violate any law or intellectual property right of any Third Party. 

  

	5.5	Costs of Governance. The Parties agree that the costs incurred by each Party in connection with its participation at any meetings under this Section 5 shall
be borne solely by such Party. 

  

	5.6	Change of Control. In the event of a Change of Control, Novartis may immediately dissolve the JSC by providing written notice to Enanta; provided that if the
Research Program is still ongoing, the JSC may not be dissolved until the end of the Research Program. 

  

	5.7	Post-JSC Reporting; Query Rights. 

  

	 	(a)	Upon dissolution of the JSC pursuant to Section 5.3(a), 5.6 or 16.1(c), Novartis shall commence providing progress reports to Enanta [*****] during the Term of
this Agreement, the first of which shall be due [*****] after the last JSC meeting. These reports shall include without limitation: (i) a summary of research activities conducted by Novartis or its Affiliates with respect to Licensed
Compound(s); (ii) a summary of Development activities and plans with respect to Licensed Compound(s) and Product(s); (iii) a summary of Novartis’ Commercialization activities and plans with respect to the Product(s), and (iv) a
summary of any key issues encountered during Development or Commercialization, including without limitation any issues regarding safety, toxicity, clinical trial delays or manufacturing concerns. 

 

	 	(b)	Enanta shall also have the right, from time to time, between reports provided under Section 5.7(a) and/or JSC meetings, as reasonably required to prepare for Board
meetings, investor meetings or the like, to inquire of Novartis, through Novartis’ Alliance Manager, whether there have been any significant developments with respect to the Development, manufacture or Commercialization of Products that have
not yet been reported to Enanta pursuant to Section 7.3(e) or otherwise, and Novartis shall promptly and in good faith provide any such information as reasonably requested by Enanta. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 18

	6.	DISCLOSURE OF ENANTA KNOW-HOW AND COOPERATION 

  

	6.1	Disclosure of Enanta Know-How. [*****] after the Effective Date, Enanta will transfer to Novartis copies of its Know-How, data, information and results related
to the Enanta Compounds that are necessary or useful for the Development, manufacture or Commercialization of the Enanta Compounds and Product(s). Following this initial transfer, at the reasonable request of Novartis, Enanta will provide reasonable
assistance to Novartis and its Affiliates in connection with Novartis’ exercise of the licenses and rights granted to Novartis under this Agreement, including by providing information to assist Novartis or its designated Affiliate in Developing
and manufacturing the Licensed Compound(s) and Product(s), and related activities. Without limiting the foregoing, requested information may include, without limitation, manufacturing batch records, Development reports, analytical results, filings
and correspondence with any Regulatory Authority (including notes or minutes of any meetings with any Regulatory Authority), raw material and excipient sourcing information, quality audit findings and any other relevant technical information
relating to the Licensed Compound(s) and/or the Product(s). 

  

	6.2	Compound Transfer. [*****] after the Effective Date, and from time to time during the Term of this Agreement, at the reasonable request of Novartis, Enanta or
its Affiliates, shall provide to Novartis or its designated Affiliate reasonable quantities of any Licensed Compounds in Enanta’s possession for use by Novartis and its Affiliates in connection with activities under this Agreement. For clarity,
except as provided in the Research Plan, Enanta shall not be required to synthesize any new quantities of Licensed Compounds for delivery pursuant to this Section 6.2, and shall be permitted to retain reasonable quantities of Licensed Compounds
for use pursuant to the Research Program or following any termination of Novartis’ rights hereunder. 

  

	6.3	Cooperation. Enanta shall provide cooperation under this Agreement, including without limitation pursuant to Sections 6.1 and 6.2, as reasonably requested by
Novartis. Any reasonable assistance requested during [*****] shall be provided by Enanta to Novartis and its Affiliates [*****]. Thereafter, any assistance requiring a material expenditure of effort on the part of Enanta and that is not included as
part of the Research Plan shall be provided [*****] commencing with the Effective Date [*****]. 

  

	6.4	Notwithstanding anything in this Agreement to the contrary, (i) in no event will Enanta personnel be required to travel pursuant Articles 6, 7 or 8 of this
Agreement without reimbursement of related expenses by Novartis, and (ii) in no event will Enanta be required to participate in, or conduct any activities related to, the research, development or commercialization of any Product which includes
[*****]. 

  

	7.	DEVELOPMENT 

  

	7.1	Development. From and after the Effective Date Novartis will be solely responsible for conducting the preclinical, clinical and other Development of the Licensed
Compound(s) and/or Product(s), all at Novartis’ sole expense. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 19

	7.2	Development Diligence. Novartis shall itself, or through its Affiliates or sublicensees, use Commercially Reasonable Efforts to Develop Licensed Compounds and
Products in the Field in the Territory. Subject to compliance with the foregoing, the Development of the Product(s) shall be in Novartis’ sole discretion. For the purposes of clarity, Commercially Reasonable Efforts in this context shall not be
deemed to require Novartis to Develop every Licensed Compound or Product in each indication in each country in the Territory. 

  

	7.3	Regulatory. 

  

	 	(a)	Novartis will: (i) determine the regulatory plans and strategies for the Licensed Compound(s) and/or Product(s); (ii) make all regulatory filings with respect
to the Product(s) either itself or through its Affiliates or sublicensees; and (iii) be responsible for obtaining and maintaining Regulatory Approvals throughout the Territory in the name of Novartis and/or its Affiliates and/or its
sublicensees. 

  

	 	(b)	Enanta shall fully cooperate with and provide assistance to Novartis and its Affiliates and sublicensees, at Novartis’ sole expense, in connection with filings to
any Regulatory Authority relating to the Licensed Compound(s) and/or Product(s), including by executing any required documents, providing reasonable access to personnel and providing Novartis and its designated Affiliates with copies of all
relevant, reasonably required documentation, provided that the first [*****]. Any additional regulatory assistance requiring a material expenditure of time or effort on the part of Enanta shall be provided at a reasonable expense rate mutually
agreed by the Parties. 

  

	 	(c)	To the extent required with respect to the Development or Commercialization of Licensed Compounds, Enanta shall grant or cause to be granted to Novartis and its
Affiliates or sublicensees cross-reference rights to any drug master files relevant to Licensed Compounds or Products, and other regulatory filings relevant to Licensed Compounds or Products, submitted by Enanta or its Affiliates with any Regulatory
Authority. 

  

	 	(d)	Subject to Section 14, Novartis and its Affiliates shall have the sole right to disclose the existence of any clinical trials conducted under this Agreement.

  

	 	(e)	Novartis shall keep Enanta’s Alliance Manager reasonably apprised of all material changes in the status of the Product Development programs, including without
limitation by providing at least fifteen (15) days’ prior written notice of the commencement of any new clinical trial of a Product, and by providing prompt notification with respect to any other significant developments with respect to
the Development, manufacture or Commercialization of Products including without limitation any issues regarding Product safety, toxicity, clinical trial delays or manufacturing concerns, or a material delay in any previously communicated Development
or Commercialization plan. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 20

	7.4	Compliance. Each Party agrees that in performing its obligations under this Agreement: (a) it shall comply with all applicable current international
regulatory standards, including cGMP, cGLP, cGCP and other rules, regulations and requirements; and (b) it will not employ or use any person that has been debarred under Section 306(a) or 306(b) of the U.S. Federal Food, Drug and Cosmetic
Act. 

  

	8.	MANUFACTURING 

  

	8.1	Manufacturing. Novartis and its Affiliates or its designated sublicensees shall be solely responsible, at Novartis’ expense, for the manufacture and supply
of the Licensed Compound(s) and Product(s) being Developed or Commercialized under this Agreement. 

  

	8.2	Manufacturing Know-How and Assistance. 

  

	 	(a)	During the Term of this Agreement, Enanta shall fully cooperate with and provide assistance to Novartis or its designee, through documentation, consultation, and
face-to-face meetings, to enable Novartis or its designee, in an efficient and timely manner, to proceed with manufacturing of the Licensed Compound(s) and to obtain all appropriate Regulatory Approvals for manufacturing. Cooperation for
manufacturing assistance shall not be subject to the cap of man hours in Section 6.3. 

  

	 	(b)	Following the Effective Date, the Parties will work together to transfer all ongoing obligations under any existing GMP manufacturing agreements relevant to Licensed
Compounds to Novartis. 

  

	9.	COMMERCIALIZATION 

  

	9.1	Commercialization. Subject to Article 10, Novartis and its Affiliates shall be solely responsible, at Novartis’ expense, for all aspects of
Commercialization of the Product(s) in the Territory, including planning and implementation, distribution, marketing, booking of sales, pricing and reimbursement. Novartis shall itself, or through its Affiliates or sublicensees, use Commercially
Reasonable Efforts to Commercialize Products in the Field in the Territory. Notwithstanding the foregoing, Novartis’ application of Commercially Reasonable Efforts shall not require Novartis or its Affiliates to Commercialize a Product in any
country or territory in which Novartis reasonably determines it is not commercially reasonable to do so for such Product(s), including without limitation for reasons of lack of rights to Product components other than Licensed Compounds in such
country or territory. 

  

	9.2	Pharmacovigilance. [*****], the Parties shall agree upon and implement a procedure for the mutual exchange of adverse event reports and safety information
associated with the Product. Details of the operating procedure respecting such adverse event reports and safety information exchange shall be the subject of a mutually-agreed written pharmacovigilance agreement between the Parties which shall be
entered into within [*****] period. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 21

	10.	CO-DETAILING 

  

	10.1	Enanta Co-Detail Right. Enanta shall have the right to Co-Detail Product(s) in the United States in accordance with agreed Commercialization plans and budgets
under certain preconditions as further specified below; provided that in the event of a Change of Control where the Acquirer is a Significant Pharmaceutical Company, Novartis may immediately terminate Enanta’s right to Co-Detail Products by
providing written notice to Enanta. 

  

	10.2	Co-Detail Option. At least [*****] before the planned submission of an NDA to the FDA for each Product being Developed hereunder to reach such stage, Novartis
will notify Enanta of Novartis’ preliminary estimate of the annual number of Details it anticipates for Products in the United States (the “Co-Detail Notice”) and will provide Enanta with a proposed Commercialization plan and
budget that includes, without limitation, an outline of the anticipated date of initiation of Detailing activities, the expected total number of sales representatives, as well as the anticipated date of First Commercial Sale for the relevant Product
in the United States. In the event that Enanta wishes to Co-Detail any such Product in the United States, it shall provide notice in writing to Novartis of such election no later than [*****] after its receipt of the Co-Detail Notice, which notice
shall contain the information as further provided in Sections 10.3(a) and (b) (the “Co-Detail Option Exercise Notice”). Prior to giving any such notice, Enanta may request reasonable discussions with Novartis regarding the
expected activities, which the Parties shall conduct in good faith. In the event that Enanta does not respond within the relevant [*****] period, Enanta shall be deemed to have declined to exercise its rights to Co-Detail the relevant Product. In
the event that Enanta does not elect to Co-Detail the first Product offered to it by Novartis, Enanta shall have the right to elect to Co-Detail the second Product offered to Enanta by Novartis on the same terms as provided above. In the event that
Enanta does not elect to Co-Detail the second Product offered to it by Novartis, then Enanta’s right to Co-Detail any Products hereunder shall terminate. 

 

	10.3	Co-Detail Mechanism. Any Co-Detail Option Exercise Notice provided by Enanta will: 

 

	 	(a)	specify Enanta’s desired level of participation in the Co-Detail of Products in the United States (the “Enanta Co-Detail Effort”);
provided, however, that the Enanta Co-Detail Effort shall not exceed [*****] of the total projected Detailing effort for Products in the United States as specified in the Co-Detail Notice. In the event that Novartis materially increases the
annual number of Details it anticipates for Products in the United States at any time after providing the Co-Detail Notice, then Enanta shall have the right to reduce the Enanta Co-Detail Effort commensurately, but such reduction shall apply to all
Products thereafter and may not later be increased by Enanta. In addition, in no event shall Novartis be required to decrease its sales force with respect to Products as a consequence of Enanta’s exercise of its Co-Detail right following
receipt of the second Co-Detail Notice as provided above; 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 22

	 	(b)	be accompanied by reasonably detailed plans demonstrating, to Novartis’ reasonable satisfaction, that Enanta will have in place, at least [*****] before the
earlier of the anticipated First Commercial Sale of such Product in the United States and/or contemplated start of Detailing activities for Products in the United States, as indicated in the Co-Detail Notice, the requisite sales force and sales
force infrastructure required to provide the Enanta Co-Detail Effort as follows: 

  

	 	(i)	Such sales force shall comprise Enanta-employed sales representatives who (A) have a level of experience and/or academic qualifications similar to standards
imposed by Novartis upon its own sales force for a comparable product, which Novartis shall provide to Enanta as part of the Co-Detail Notice; (B) devote not less [*****] and attention to Detailing of Products; and (C) are not engaged in
detailing any product for [*****] that is not a Product; and 

  

	 	(ii)	Such sales force infrastructure shall include (A) a sales force automation system through which sales representatives can record calls electronically, receive
email communications and reports, view sales reports and download specialist targets and lists; (B) a sample accountability system that complies with all applicable laws and regulations; (C) a sales training department; (D) a
department responsible for the design and administration of Enanta sales incentive plan; (E) a voice mail system; (F) a system for sales reporting and analysis; (G) a sales administration and operations department that handles, among
other things, fleet management; (H) a department that establishes and maintains territory alignments consistent with target customer lists provided by Novartis; (I) an electronic roster system that tracks sales force vacancy, turnover,
demographics and territory occupancy; (J) an electronic field expense reporting system; and (K) compliance reporting as required by all applicable laws and regulations. 

 

	 	(c)	Promptly following receipt of Enanta’s Co-Detail Option Exercise Notice, Novartis and Enanta will commence negotiations in good faith and enter into a more
detailed co-detailing agreement (the “Co-Detailing Agreement”) pursuant to which: (i) Enanta shall have the non-exclusive right to Co-Detail Products in the United States in accordance with the terms hereof; and (ii) the
Parties will set forth terms and conditions for the Co-Detail by Enanta of Products in the United States, containing reasonable and customary provisions for an agreement of such type. The Parties shall use commercially reasonable efforts to enter
into and execute the Co-Detailing Agreement no later than [*****] before the expected launch of the first Product for which Enanta has exercised its Co-Detail right. Either Party may assign such Co-Detailing Agreement or related duties to an
Affiliate following prior written notice to the other Party. In the event of a Change of Control involving a Significant Pharmaceutical Company, Novartis may immediately terminate the Co-Detailing Agreement by providing written notice to Enanta.

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 23

	 	(d)	Enanta’s Co-Detail activities hereunder and under the Co-Detailing Agreement shall be conducted in accordance with the Commercialization plan (including a
Commercialization budget) for the relevant Product, which shall be reasonably consistent with the Co-Detail Notice, unless otherwise mutually agreed. 

  

	 	(e)	For clarity, regardless of Enanta’s decision to Co-Detail, Novartis shall retain all decision-making authority related to Product branding, marketing plan,
advertising, materials, regulatory and legal affairs, and pricing and commercial terms and all other aspects of Commercializing the Products in the United States. 

 

	 	(f)	Enanta’s costs of performing Co-Detailing activities will be reimbursed by Novartis on an [*****] basis at an [*****] for such detailing activities (such [*****]
to be negotiated as part of the Co-Detailing Agreement). Enanta shall not be entitled to any other compensation for performing Co-Detailing activities unless agreed by the Parties in writing. 

 

	 	(g)	Once the Parties have entered into a Co-Detailing Agreement, Enanta shall be required to Co-Detail all Products in accordance with the terms of such Co-Detailing
Agreement. The Parties acknowledge and agree that such Co-Detailing Agreement shall be a separate agreement between the Parties and that a breach of any such agreement that is not a breach of the other sections of this Agreement shall not give rise
to a right to terminate this Agreement. For clarity, Enanta shall not be required to Co-Detail, or to continue to Co-Detail, any Product to the extent such activities would violate the terms of any agreement between Enanta and a Third Party.

  

	11.	FINANCIAL PROVISIONS 

  

	11.1	Upfront Payment; Reimbursement for Manufacture of EDP-239 Intermediates and QA Audit Expense. In consideration of the licenses and rights granted to Novartis and
its Affiliates hereunder, Novartis shall pay to Enanta a one-time upfront payment of $34 million within thirty (30) days after the Effective Date, subject to receipt by Novartis of an Invoice therefor, which Invoice shall be issued no earlier
than the Effective Date. In addition, Novartis shall pay to Enanta: (i) [*****]as a reimbursement for Enanta’s manufacturing expenses related to EDP-239 intermediates; and (ii) up to [*****] as a reimbursement for the expenses
[*****]. Novartis shall pay such amounts within [*****]subject to receipt by Novartis of an Invoice therefor, which Invoice shall be issued no earlier than the Effective Date. 

 

	11.2	Milestone Payments. In further consideration of the licenses and rights granted to Novartis hereunder, upon first achievement of each of the following Milestones
set forth below by any Product (or group of Products as provided below with respect to Sales Milestones), the corresponding one-time Milestone Payments shall be due and payable by Novartis to Enanta. Payment shall be made as provided in
Section 12.1. 

  

	 	(a)	Clinical Milestones 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 24

					
	 Milestone Event
	  	Milestone Payment	 
		
	 FPFV in the first Phase I Clinical Trial for a Product
	  	$	11 million	  
		
	 FPFV in the first Phase II Clinical Trial for a Combination Product involving patients infected with the Hepatitis C
virus
	  	$	15 million	  
		
	 FPFV in the first Phase III Clinical Trial for a Product
	  	 	[*****]	  

  

	 	(b)	Regulatory Approval Milestones 

  

					
	 Milestone Event
	  	Milestone Payment	 
		
	 First Regulatory Approval for a Product in the [*****]
	  	 	[*****]	  
		
	 First Regulatory Approval for a Product in the [*****]
	  	 	[*****]	  
		
	 First Regulatory Approval for a Product in the [*****]
	  	 	[*****]	  
		
	 First Regulatory Approval for a Product in the [*****]
	  	 	[*****]	  
		
	 First Regulatory Approval for a Product in [*****]
	  	 	[*****]	  
		
	 First Regulatory Approval for a Product in [*****]
	  	 	[*****]	  

  

	 	(c)	Sales Milestones (note: Product as used in this subsection (c) includes any and all Products which contain a particular Licensed Compound):

  

					
	 Milestone Event
	  	Milestone Payment	 
		
	 Annual Net Sales of a Product meets or exceeds [*****]
	  	 	[*****]	  
		
	 Annual Net Sales of a Product meets or exceeds [*****]
	  	 	[*****]	  
		
	 Annual Net Sales of a Product meets or exceeds [*****]
	  	 	[*****]	  
		
	 Annual Net Sales of a Product meets or exceeds [*****]
	  	 	[*****]	  

  

	 	(d)	 If a subsequent Clinical Milestone is achieved with respect to a Product before one or more prior Clinical Milestones (e.g., if the first FPFV in the
first Phase III Clinical Trial for the first Product occurs prior to FPFV in the first Phase II 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 25

	 	
Clinical Trial in HCV for the first Combination Product), then all prior “missed” Clinical Milestones shall be deemed achieved with respect to such Product upon achievement of the
subsequent Clinical Milestone and the corresponding missed Milestone Payment(s) shall become due and payable. 

  

	 	(e)	For the avoidance of doubt: (i) each Milestone Payment shall be payable only on the first occurrence of the relevant Milestone; and (ii) none of the Milestone
Payments shall be payable more than once. 

  

	11.3	Incremental Royalty Payments. 

  

	 	(a)	In further consideration of the licenses and rights to Novartis hereunder, during the applicable Royalty Term, Novartis will make royalty payments to Enanta on Net
Sales of the applicable Products in the Territory by Novartis, its Affiliates and sublicensees at the applicable rates set forth below, where Product as used in this subsection (a) only (and not any other subsection of this Section 11.3)
includes any and all Products which contain a particular Licensed Compound: 

  

					
	 Annual Net Sales of Product during the Royalty Term
	  	Royalty Rate	 
		
	 Up to and including [*****]
	  	 	[*****]	  
		
	 Increment from [*****]
	  	 	[*****]	  
		
	 Increment from [*****]
	  	 	[*****]	  
		
	 Increment over [*****]
	  	 	[*****]	  

  

	 	(b)	Royalties will be payable on a Product-by-Product and country-by-country basis from First Commercial Sale of such Product in such country until the later of:
(i) the expiration of the last to expire Valid Claim which, but for the licenses granted in this Agreement, would be infringed by the manufacture, use or sale of such Product in such country; and (ii) ten (10) years from the First
Commercial Sale of such Product in such country (“Royalty Term”). Following the Royalty Term on a Product-by-Product and country-by-country basis, the licenses granted to Novartis and its Affiliates under Section 3.1 with
respect to such Product(s) shall continue in effect, but shall become fully paid-up, non-exclusive, royalty-free, transferable, perpetual and irrevocable. For the avoidance of doubt, royalties shall be payable only once with respect to the same unit
of Product. 

  

	11.4	Know-How Royalty. For any period during the Royalty Term in which the sale of a Product in any country is not covered by a Valid Claim which, but for the
licenses granted in this Agreement, would be infringed by the manufacture, use or sale of such Product in such country, then the royalty rates applicable to Net Sales of such Product in such country during such period shall be reduced by [*****],
according to the methodology provided in Section 11.5 below. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 26

	11.5	Royalty Example. If, by way of example, Net Sales of a given Product in the Territory in a given Calendar Year are [*****], with Net Sales distributed across
countries as follows: (a) [*****] Net Sales in countries in which there is a Valid Claim; (b) [*****] Net Sales in countries where the manufacture, use or sale of the Product is not covered by a Valid Claim; and (c) [*****] Net Sales
in countries where the Royalty Term for such country has expired; then royalties due under Sections 11.3 and 11.4 for such Product in such Calendar Year shall be calculated as follows: Net Sales on which royalties are due shall be [*****] (=
(a) + (b)). The royalty rate applicable under Section 11.3 shall be calculated as [*****]. The royalties due for (a) above shall be calculated as [*****]. No royalties shall be due with regard to (c) above. Total royalties due
under Sections 11.3 and 11.4 shall be equal to [*****], subject to further reductions, if any, under Sections 11.6 and 11.7. 

  

	11.6	Loss of Market Exclusivity. In the event of a Loss of Market Exclusivity for any Product in any country, provided that Novartis has taken and is taking all
commercially reasonable actions available to it to enforce any Patent Rights it may own or control that could prevent relevant sales of a Generic Equivalent in such country, then the royalty rates applicable to Net Sales of such Product in such
country in accordance with Section 11.3 shall be reduced by [*****] as follows: for such purposes, the reduction will be calculated assuming that the royalty rate in such country is the Blended Rate for such Product (i.e., the reduced royalty
rate for such country shall be [*****] of the Blended Rate). Such reduction shall be first applied with respect to such country starting with sales in the Calendar Quarter following the Calendar Quarter in which Loss of Marketing Exclusivity occurs
for such Product in such country. 

  

	11.7	Third Party Obligations. 

  

	 	(a)	Notwithstanding the provisions of this Section 11.7, Enanta shall remain responsible for the payment of royalty, milestone and other payment obligations, if any,
due to Third Parties under any Enanta Patents or Enanta Know-How which have been licensed to Enanta and are sub-licensed to Novartis under this Agreement. All such payments shall be made promptly by Enanta in accordance with the terms of its license
agreement. 

  

	 	(b)	In the event that Novartis reasonably determines that rights to intellectual property owned or Controlled by a Third Party claiming the structure of any Licensed
Compound are required in order to avoid infringement of such Third Party’s rights, Novartis shall have the right to negotiate and acquire such rights through a license or otherwise. Novartis shall be entitled to deduct from the payments due to
Enanta under Sections 11.2 and 11.3 with respect to the relevant Licensed Compound or Product [*****] of the amounts paid (whether in the form of [*****]) by Novartis to such Third Party; provided, however, that in no event shall the amounts due to
Enanta from Novartis with respect to the relevant Product be reduced through this subsection 11.7(b) by more than [*****] of the amounts otherwise due for such Product in any Calendar Quarter. Any amount that Novartis is entitled to deduct that is
reduced by the above-recited limitation on the deduction shall be carried forward and Novartis may deduct such amount from subsequent payments due to Enanta with respect to the relevant Product until the full amount that Novartis was entitled to
deduct is deducted. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 27

	 	(c)	In the event that Novartis reasonably determines that it would be useful to acquire rights to intellectual property owned or Controlled by a Third Party, which
intellectual property rights do not pertain (i) to the structure of any Licensed Compound or (ii) to the structure of any other active ingredient in a Product or the formulation of only such other active ingredient, in order to Develop,
manufacture, Commercialize or sell a Product, Novartis shall have the right to negotiate and acquire such rights through a license or otherwise. Novartis shall be entitled to deduct from the payments due to Enanta under Section 11.3 with
respect to the relevant Licensed Compound or Product [*****] of the amounts paid (whether in the form of [*****]) by Novartis to such Third Party; provided, however, that in no event shall the [*****] due to Enanta from Novartis with respect to the
relevant Product be reduced through this subsection 11.7(c) by more than [*****] of the royalty amounts otherwise due for such Product in any Calendar Quarter; and provided further that, with respect to intellectual property relevant to more than
one active ingredient of a Combination Product, any such deductions shall be reasonably apportioned between or among the applicable components of the Combination Product. Any amount that Novartis is entitled to deduct that is reduced by the
above-recited limitation on the deduction shall be carried forward and Novartis may deduct such amount from subsequent [*****] due to Enanta with respect to the relevant Product until the full amount that Novartis was entitled to deduct is deducted.

  

	11.8	Royalty Floor. Except in connection with a termination by Novartis pursuant to Section 15.2(b), in no event shall the total royalty payable to Enanta for
any Product in any country in any Calendar Quarter after giving effect to all applicable reductions set forth herein, be reduced to less than [*****] of the rate specified in Section 11.3(a) for sales of a given Product in any given country.

  

	11.9	Research Funding. Enanta shall support the Research Program with [*****] Enanta FTEs during each year of the Research Term, as further specified in the agreed
Research Plan. Novartis shall pay Enanta quarterly in arrears for such FTEs at the FTE Rate within [*****] after receipt of an Invoice therefor. Any pre-approved out-of pocket expenses shall be invoiced for reimbursement along with any such FTEs.

  

	11.10	No Projections. Enanta and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of
anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise been discussed by the Parties are merely intended to define the Milestone Payments and royalty
obligations to Enanta in the event such Milestones or Net Sales levels are achieved. NEITHER ENANTA NOR NOVARTIS MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY COMMERCIALIZE ANY PRODUCT OR, IF
COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 28

	12.	REPORTS AND PAYMENT TERMS 

  

	12.1	Payment Terms. 

  

	 	(a)	Novartis shall provide Enanta with written notice of the achievement of each Milestone within [*****] after such Milestone has been achieved. After receipt of such
notice (if applicable), Enanta shall submit an Invoice to Novartis with respect to the corresponding Milestone Payment. Novartis shall pay such Milestone Payment within [*****] after receipt of such Invoice. 

 

	 	(b)	Within [*****] after each Calendar Quarter during the Term of this Agreement following the First Commercial Sale of a Product, Novartis will provide to Enanta a Sales
and Royalty Report. Enanta shall submit an Invoice with respect to the royalty amount shown therein. Novartis shall pay such royalty amount within [*****] after receipt of the Invoice. 

 

	 	(c)	All payments from Novartis to Enanta shall be made by wire transfer in United States Dollars to the credit of such bank account as may be designated by Enanta in this
Agreement or in writing to Novartis. Any payment which falls due on a date which is not a Business Day in Cambridge, Massachusetts or Basel, Switzerland may be made on the next succeeding Business Day in Cambridge, Massachusetts or Basel,
Switzerland. 

  

	12.2	Currency. All payments under this Agreement shall be payable in United States Dollars. When conversion of payments from any foreign currency is required to be
undertaken by Novartis, the United States Dollar equivalent shall be calculated using Novartis’ then-current standard exchange rate methodology applied in its external reporting for the conversion of foreign currency sales into United States
Dollars. Upon request by Enanta, Novartis shall provide Enanta with information on Novartis’ then-current currency exchange policy. 

  

	12.3	Taxes. Enanta will pay any and all taxes levied on account of any payments made to it under this Agreement. If any taxes are required to be withheld by Novartis,
Novartis will: (a) deduct such taxes from the payment made to Enanta; (b) timely pay the taxes to the proper taxing authority; (c) send proof of payment to Enanta; and (d) reasonably assist Enanta in its efforts to obtain a
credit for such tax payment. Each Party agrees to reasonably assist the other Party in lawfully claiming exemptions from and/or minimizing such deductions or withholdings under double taxation laws or similar circumstances. 

 

	12.4	Interest Due. Without limiting any other rights or remedies available to Enanta, Novartis shall pay Enanta interest on any late payments made under this
Agreement, whether late due to late payment of an Invoice or due to late notification to Enanta of the corresponding event or report giving rise to the Invoice pursuant to Section 12.1, at a rate per annum equal to [*****].

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 29

	12.5	Records and Audit Rights. 

  

	 	(a)	Each Party shall keep complete, true and accurate books and records in accordance with its Accounting Standards in relation to this Agreement, including, with respect
to Novartis and its Affiliates, in relation to Net Sales and royalties, and with respect to Enanta, in relation to FTE efforts expended under the Research Program. Novartis and its Affiliates shall require any sublicensees to keep (all in accordance
with generally accepted accounting principles, consistently applied), complete and accurate records in sufficient detail to properly reflect relevant Net Sales and to enable the royalties payable hereunder to be determined. Each Party or other
selling entity will keep such books and records for at least three (3) years following the Calendar Year to which they pertain. 

  

	 	(b)	Enanta may upon written request, cause an internationally-recognized independent accounting firm (the “Auditor”) which is reasonably acceptable to
Novartis to inspect the relevant records of Novartis and its Affiliates to verify the royalties payable by Novartis and the related reports, statements, records and books of accounts, as applicable. Novartis may upon written request, cause an
Auditor that is reasonably acceptable to Enanta to inspect the relevant records of Enanta and its Affiliates as reasonably required to verify the amounts payable by Novartis hereunder or Enanta’s required FTE support or reimbursable expenses,
as applicable. Before beginning its audit, the Auditor shall execute an undertaking acceptable to Party being audited by which the Auditor agrees to keep confidential all information reviewed during the audit. The Auditor shall have the right to
disclose to the auditing Party only its conclusions regarding any payments owed under this Agreement. 

  

	 	(c)	Each Party and its Affiliates shall make their records available for inspection by the Auditor during regular business hours at such place or places where such records
are customarily kept, upon receipt of reasonable advance notice from the other Party. The records shall be reviewed solely to verify the accuracy of payments hereunder and compliance with this Agreement. Such inspection right shall not be exercised
more than once in any calendar year and not more frequently than once with respect to records covering any specific period of time. In addition, the auditing Party agrees to hold in strict confidence all information received and all information
learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or to the extent required to comply with any law, regulation or judicial order. 

 

	 	(d)	The Auditor shall provide its audit report and basis for any determination to the audited Party at the time such report is provided to the auditing Party before it is
considered final. 

  

	 	(e)	In the event that the final result of any such inspection reveals an undisputed underpayment or overpayment, the underpaid or overpaid amount shall be settled promptly.

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 30

	 	(f)	The auditing Party shall pay for such audits, as well as its expenses associated with enforcing its rights with respect to any payments hereunder. In addition, if an
underpayment (with respect to royalties) or overpayment (with respect to research-related payments to Enanta) of more than ten percent (10%) of the total payments due hereunder for the applicable calendar year is discovered, the fees and
expenses charged by the Auditor shall be paid by the audited Party. 

  

	 	(g)	To the extent applicable, Novartis and its Affiliates shall include in each sublicense granted by it to any sublicensee a provision requiring the sublicensee to
maintain records of sales made pursuant to such license and to grant access to such records by Novartis’ designated independent accountant to the same extent and under the same obligations as required of Novartis under this Agreement. Enanta
shall have the right to request audits of sublicensees by Novartis for reasonable cause. Novartis shall advise Enanta in advance of each audit of any sublicensee with respect to Product sales. Novartis will provide Enanta with a summary of the
results received from the audit and, if Enanta so requests, a copy of the audit report with respect to Product sales. Novartis shall pay for any such audits of sublicensees, provided that Enanta will pay for any such audits of sublicensees that are
expressly requested by Enanta in writing. Notwithstanding the foregoing, if an underpayment of more than [*****] is discovered, the fees and expenses charged by the Auditor shall be paid by Novartis, unless otherwise borne by the sublicensee.

  

	13.	INTELLECTUAL PROPERTY RIGHTS 

  

	13.1	Ownership of Inventions. 

  

	 	(a)	All Know-How arising from the Parties’ activities under this Agreement, and any patent applications and patents covering inventions therein, made solely by
employees or consultants of a Party shall be solely owned by such Party. All Know-How arising from the Parties’ activities under this Agreement, and any patent applications and patents covering inventions therein, made jointly by employees or
consultants of both Parties shall be owned jointly by the Parties. Determination of inventorship shall be made in accordance with United States patent laws. 

 

	 	(b)	Enanta’s rights in any such Know-How and Patent Rights which are Enanta Patents, Enanta Know-How or Collaboration IP, as appropriate, will be exclusively licensed
to Novartis as provided in Section 3.1. Subject to the foregoing, each Party may use, or license to any Third Party, any jointly owned Know-How and Patent Rights for any purpose consistent with the provisions of this Agreement without
accounting to or obtaining the approval of the other Party. However, neither Party shall assign to any Third Party its interest in any jointly owned Patent Rights without the other Party’s prior written consent (not to be unreasonably
withheld), except to the extent permitted in Section 20.1. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 31

	13.2	Patent Prosecution. 

  

	 	(a)	Novartis shall, in consultation with Enanta, be responsible for filing, prosecuting and maintaining the Enanta IP (in the name of Enanta) and Collaboration IP (in the
name(s) of the owner(s) thereof as determined in accordance with Section 13.1(a)) at Novartis’ own cost and expense. Novartis shall use Commercially Reasonable Efforts to obtain appropriate patent protection with respect to claimed
inventions that are supported by the relevant specification, whether or not relevant to Products being actually Developed or Commercialized by Novartis hereunder. Enanta shall fully cooperate with Novartis in connection with the filing, prosecution
and maintenance of the Enanta IP and the Collaboration IP to the extent reasonably requested by Novartis, including by providing access to relevant persons and executing all documentation reasonably requested by Novartis. Novartis shall consult with
Enanta and keep Enanta reasonably informed of the status of such Enanta IP and Collaboration IP, and provide copies of all relevant documents in a timely manner for Enanta’s review and comment, including any material reduction in scope, and
will reasonably consider any Enanta comments in good faith, it being understood and agreed, however, that Novartis shall have the authority to make, in good faith, all final decisions relating thereto. 

 

	 	(b)	Novartis will notify Enanta of any decision not to file applications for, or to cease prosecution and/or maintenance of, or not to continue to pay the expenses of
prosecution and/or maintenance of, any Enanta IP and Collaboration IP, including without limitation any decision to abandon any pending or issued claim in the Enanta IP or Collaboration IP. Novartis will provide such notice at least thirty (30)
days prior to any relevant filing or payment due date, or any other due date that requires action, in connection with such Patent Right and/or claim. In such event, Novartis shall permit Enanta, at its sole discretion and expense, to file or to
continue prosecution or maintenance of such Enanta IP or Collaboration IP, Novartis shall fully cooperate with Enanta in connection with the filing, prosecution and maintenance of the Enanta IP and the Collaboration IP to the extent reasonably
requested by Enanta, including by providing access to relevant persons and executing all documentation reasonably requested by Enanta. 

  

	13.3	Patent Infringement. 

  

	 	(a)	Each Party will promptly notify the other of any infringement by a Third Party of any of the Enanta IP or Collaboration IP of which it becomes aware, including any
“patent certification” filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions and of any declaratory judgment, opposition, or similar action alleging the
invalidity, unenforceability or non-infringement (collectively “Third Party Infringement”). 

  

	 	(b)	 To the extent reasonably related to any exclusive license granted to Novartis under this Agreement, Novartis will have the first right to bring and
control any legal action in connection with the Third Party Infringement at its own expense as it reasonably determines appropriate, and Enanta shall have the right, at its own expense, to be represented in any such action by counsel of its own
choice. If 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 32

	 	
Novartis fails to bring an action or proceeding with respect to, or to otherwise terminate, any such infringement of any Enanta IP or Collaboration IP: (i) within one hundred twenty
(120) days following the notice of alleged infringement; or (ii) prior to twenty (20) days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, Enanta
shall have the right, but not the obligation, upon written approval of Novartis (such approval not to be unreasonably withheld or delayed), to bring and control any such action at its own expense and by counsel of its own choice, and Novartis shall
have the right, at its own expense, to be represented in any such action by counsel of its own choice; provided, however, that if Novartis notifies Enanta in writing prior to ten (10) days before such time limit for the filing of any such
action that Novartis intends to file such action before the time limit, then Novartis shall be obligated to file such action before the time limit, and Enanta will not have the right to bring and control such action. 

 

	 	(c)	At the request and expense of the Party prosecuting the relevant action pursuant to Section 13.3(b), the other Party shall provide reasonable assistance in
connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required. 

  

	 	(d)	In connection with any proceeding pursuant to Section 13.3(b), Novartis shall not enter into any settlement admitting the invalidity of, or otherwise impairing
Enanta’s rights in, the Enanta IP or the Collaboration IP without the prior written consent of Enanta, which will not be unreasonably withheld or delayed. 

 

	 	(e)	Any recoveries resulting from such an action relating to a claim of Third Party Infringement subject to Section 13.3(b) shall be first applied against payment of
each Party’s costs and expenses in connection therewith. In the event that Novartis brought such action, any remainder will be retained by (or if received by Enanta, paid to) Novartis; provided, however, that any portion of such remainder that
is attributable to lost profits with respect to the Product shall be subject to a royalty payment to Enanta of [*****]. In the event that Enanta brought any such action, any remainder shall be divided equally between Enanta and Novartis.

  

	13.4	Trademarks. Novartis shall have the right to brand the Products using Novartis related trademarks and any other trademarks and trade names it determines
appropriate for the Product, which may vary by country or within a country (“Product Marks”). Novartis shall own all rights in the Product Marks and register and maintain the Product Marks in the countries and regions it determines
reasonably necessary. 

  

	13.5	Patent Marking. To the extent commercially feasible and consistent with prevailing business and legal practices, Novartis shall mark, and shall cause its
Affiliates and sublicensees to mark, all Products that are manufactured or sold under this Agreement with the number of each issued patent owned or controlled by Enanta that applies to such Products. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 33

	13.6	Data Exclusivity and Orange Book Listings. With respect to data exclusivity periods (such as those periods listed in the FDA’s Orange Book (including
without limitation any available pediatric extensions) or periods under national implementations of Article 11.1(a)(iii) of Directive 2001/EC/83, or similar periods as may be applicable to a biologic or drug, and all international equivalents),
Novartis shall use commercially reasonable efforts consistent with its obligations under applicable law (including any applicable consent order) to seek, maintain and enforce all such data exclusivity periods available for the Products exclusively
licensed by Novartis hereunder. With respect to filings in the FDA Orange Book or other similar filings or listings as may be applicable to a biologic or drug (and foreign equivalents) for issued patents for a Product, upon request by Novartis,
Enanta shall provide reasonable cooperation to Novartis in filing and maintaining any such listing and filings. 

  

	13.7	Patent Extensions. 

  

	 	(a)	If requested by Novartis, Enanta shall cooperate in obtaining patent term restoration (under but not limited to Drug Price Competition and Patent Term Restoration Act),
supplemental protection certificates or their equivalents, and patent term extensions with respect to the Enanta Patents in any country and/or region where applicable. Enanta shall provide all reasonable assistance requested by Novartis, including
permitting Novartis to proceed with applications for such in the name of Enanta, if deemed appropriate by Novartis, and executing documents and providing any relevant information to Novartis. 

 

	 	(b)	If elections with respect to obtaining any such patent term extensions are to be made, Novartis shall have the right to make the election to seek patent term extension,
restoration or supplemental protection, provided that such election shall be made in accordance with industry norms. 

  

	14.	CONFIDENTIALITY 

  

	14.1	Duty of Confidence. 

Subject to the other provisions of this Section 14, all Confidential Information disclosed by a Party or its Affiliates under this
Agreement will be maintained in confidence and otherwise safeguarded by the recipient Party. The recipient Party may only use Confidential Information of the other Party for the purposes of this Agreement and pursuant to the rights granted to the
recipient Party under this Agreement. Subject to the other provisions of this Section 14, each Party shall hold as confidential such Confidential Information of the other Party or its Affiliates in the same manner and with the same protection
as such recipient Party maintains its own confidential information. Subject to the other provisions of this Section 14, a recipient Party may only disclose Confidential Information of the other Party to employees, agents, contractors,
consultants and advisers of the Party and its Affiliates and sublicensees and to Third Parties to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this Agreement; and provided that such Persons are
bound to maintain the confidentiality of the Confidential Information in a manner consistent with the confidentiality provisions of this Agreement. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 34

	14.2	Exceptions. The obligations under this Section 14 shall not apply to any information to the extent the recipient Party can demonstrate by competent evidence
that such information: 

  

	 	(a)	is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the public domain through no breach of this Agreement or either
Prior CDA by the recipient Party or its Affiliates; 

  

	 	(b)	was known to, or was otherwise in the possession of, the recipient Party or its Affiliates prior to the time of disclosure by the disclosing Party or any of its
Affiliates; 

  

	 	(c)	is disclosed to the recipient Party or an Affiliate on a non-confidential basis by a Third Party lawfully in possession thereof who is entitled to disclose it without
breaching any confidentiality obligation to the disclosing Party or any of its Affiliates; or 

  

	 	(d)	is independently developed by or on behalf of the recipient Party or its Affiliates, as evidenced by its written records, without reference to the Confidential
Information disclosed by the disclosing Party or its Affiliates under this Agreement. 

  

	14.3	Authorized Disclosures. In addition to disclosures allowed under Section 14.2, to the extent (and only to the extent) that it is reasonably necessary or
appropriate to fulfill its obligations or exercise its rights under this Agreement, the recipient Party may disclose Confidential Information belonging to the disclosing Party in the following instances: 

 

	 	(a)	filing or prosecuting Patent Rights as permitted by this Agreement; 

  

	 	(b)	in connection with Regulatory Filings for Products made pursuant to this Agreement; 

 

	 	(c)	prosecuting or defending litigation as permitted by this Agreement; 

  

	 	(d)	subject to Sections 14.4 and 14.5, complying with applicable governmental laws and regulations (including, without limitation, the rules and regulations of the
Securities and Exchange Commission or any national securities exchange) and with judicial process, if in the reasonable opinion of the recipient Party’s counsel, such disclosure is necessary for such compliance; and 

 

	 	(e)	 disclosure, in connection with the performance of this Agreement and solely on a need-to-know basis, to: Affiliates; potential sublicensees; or
employees, independent contractors (including without limitation consultants and clinical investigators) or agents, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use no less restrictive than the
obligations set forth in this Section 14; provided, however, that the recipient Party 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 35

	 	
shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Section 14 to treat such Confidential Information as required under this
Section 14. 

  

	 	(f)	If and whenever any Confidential Information is disclosed in accordance with this Section 14.3, such disclosure shall not cause any such information to cease to be
Confidential Information except to the extent that such permitted disclosure results in a public disclosure of such information (otherwise than by breach of this Agreement). Where reasonably possible and subject to Sections 14.4 and 14.5, the
recipient Party shall notify the disclosing Party of the recipient Party’s intent to make such disclosure pursuant to paragraphs (a) through (d) of this Section 14.3 sufficiently prior to making such disclosure so as to allow the
Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information. 

  

	14.4	Required Disclosure. A recipient Party may disclose Confidential Information pursuant to interrogatories, requests for information or documents, subpoena, civil
investigative demand issued by a court or governmental agency or as otherwise required by law; provided however, that the recipient Party shall notify the disclosing Party promptly upon receipt thereof, giving (where practicable) the disclosing
Party sufficient advance notice to permit it to oppose, limit or seek confidential treatment for such disclosure, and to file for patent protection if relevant; and provided, further, that the recipient Party shall furnish only that portion of the
Confidential Information which it is advised by counsel is legally required whether or not a protective order or other similar order is obtained by the disclosing Party. 

 

	14.5	Securities Filings. In the event either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other
jurisdiction a registration statement or any other disclosure document which describes or refers to this Agreement under the Securities Act of 1933, as amended, the Securities Exchange Act, of 1934, as amended, or any other applicable securities
law, the Party shall notify the other Party of such intention and shall provide such other Party with a copy of relevant portions of the proposed filing not less than five (5) business days prior to such filing (and any revisions to such
portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto relating to the Agreement, and shall use reasonable efforts to obtain confidential treatment of any information concerning the Agreement
that such other Party requests be kept confidential, and shall only disclose Confidential Information which it is advised by counsel is legally required to be disclosed. No such notice shall be required under this Section 14.5 if the substance
of the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by the either Party hereunder or otherwise approved by the other Party. 

 

	14.6	 Terms of Agreement. The existence and the terms and conditions of this Agreement that the Parties have not specifically agreed to disclose
pursuant to Section 14.5 or Section 19 shall be considered Confidential Information of both Parties. Either Party may disclose such terms on a need-to-know basis to a bona fide investor (provided that

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 36

	 	
such investor is not, and is not affiliated with, a pharmaceutical company), investment banker, and their attorneys and agents, provided that each such Person to whom such information is to be
disclosed is informed of the confidential nature of such information and has entered into a written agreement with the Party, or is otherwise bound by professional rules, requiring such Person to keep such information confidential. Promptly after
the Effective Date, the Parties shall agree upon a redacted form of this Agreement, the relevant provisions of which may be disclosed on a need-to-know basis to potential licensees, acquirers or merger partners and their attorneys and agents,
provided that each such Person to whom such information is to be disclosed is informed of the confidential nature of such information and has entered into a written agreement with the Party, or is otherwise bound by professional rules, requiring
such Person to keep such information confidential. 

  

	14.7	Ongoing Obligation for Confidentiality. Upon early termination of this Agreement for any reason, each Party and its Affiliates shall immediately return to the
other Party or destroy any Confidential Information disclosed by the other Party, except for one copy which may be retained in its confidential files for archive purposes. 

 

	15.	TERM AND TERMINATION 

  

	15.1	Term. The term of this Agreement will commence upon the Effective Date and continue until the expiration of all royalty payment obligations of Novartis
hereunder, unless earlier terminated as permitted by this Agreement (the “Term”). 

  

	15.2	Termination for Cause. 

  

	 	(a)	Termination by Enanta for Cause. If Novartis is in material breach of any material obligation hereunder (other than with respect to a breach of Novartis’
obligations under Sections 7.2 or 9.1 with respect to any given Product, which is governed by Section 15.4), Enanta may give written notice to Novartis specifying the claimed particulars of such breach, and in the event such material breach is
not cured within the relevant time period specified below after such notice, Enanta shall have the right thereafter to terminate this Agreement immediately by giving written notice to Novartis to such effect. Novartis shall have [*****] to either
cure such breach (except to the extent such breach involves the failure to make a payment when due, which breach must be cured within [*****] following such notice) or, if cure cannot be reasonably effected within such [*****] period, to deliver to
Enanta a plan for curing such breach which is reasonably sufficient to effect a cure within a reasonable period not to exceed [*****]. Following delivery of such plan, Novartis shall use commercially reasonable efforts to carry out the plan and cure
the breach. Any termination by Enanta under this Section and the effects of termination provided herein shall be without prejudice to any damages or other legal or equitable remedies to which it may be entitled from Novartis.

  

	 	(b)	 Partial Termination by Novartis for Cause. If Enanta is in material breach of any material obligation hereunder, Novartis may give written
notice to Enanta 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 37

	 	
specifying the claimed particulars of such breach and its desire to partially terminate certain aspects of this Agreement as provided in Section 16.1. In the event that Enanta does not
dispute the existence or materiality of an alleged breach specified in such notice and such material breach is not cured following such notice as provided below, Novartis shall have the right thereafter to terminate certain aspects of this Agreement
immediately as provided in Section 16.1 by giving written notice to Enanta to such effect. Enanta shall have [*****] to either cure any such breach or, if cure cannot be reasonably effected within such [*****] period, to deliver to Novartis a
plan for curing such breach which is reasonably sufficient to effect a cure within a reasonable period not to exceed [*****]. Following delivery of such plan, Enanta shall use commercially reasonable efforts to carry out the plan and cure the
breach. If Enanta disputes in good faith the existence or materiality of an alleged breach and provides notice to Novartis of such dispute within the first [*****] of the [*****] notice period specified above, Novartis shall not have the right to
implement the payment reduction set forth in Section 16.1(b) unless and until the existence of such material breach or failure by Enanta has been confirmed in accordance with Section 20.5, and Enanta has failed to cure such breach within
[*****] following such confirmation. It is understood and acknowledged that during the pendency of any such dispute as to the existence or materiality of an alleged breach, all of the terms and conditions of this Agreement shall remain in effect and
the Parties shall continue to perform all of their respective obligations hereunder; provided that Novartis shall place into a mutually agreed escrow account [*****] which become due during the pendency of such proceedings. In the event that the
existence of such material breach or failure by Enanta is confirmed in accordance with Section 20.5, and Enanta fails to cure such breach as provided above following such confirmation, then Novartis shall be entitled to receive [*****]. In the
event that the existence of such material breach or failure by Enanta is not confirmed in accordance with Section 20.5, or if Enanta cures such breach as provided above, then Enanta shall be entitled to receive the amounts in escrow. Any
termination by Novartis under this Section and the effects of termination provided herein shall be without prejudice to any damages or other legal or equitable remedies to which it may be entitled from Enanta. 

 

	 	(c)	 Full Termination by Novartis for Cause. If Enanta is in material breach of any material obligation hereunder, Novartis may give written notice
to Enanta specifying the claimed particulars of such breach and its desire to fully terminate this Agreement with the consequences as set forth in Section 16.2. In the event such material breach is not cured within the relevant time period
specified below after such notice, Novartis shall have the right thereafter to terminate this Agreement immediately with the consequences as set forth in Section 16.2 by giving written notice to Enanta to such effect. Enanta shall have [*****]
to either cure such breach or, if cure cannot be reasonably effected within such [*****] period, to deliver to Novartis a plan for curing such breach which is reasonably sufficient to effect a cure within a reasonable period not to exceed [*****].
Following delivery of such plan, Enanta shall use commercially reasonable efforts to carry out the plan and cure the breach. Any termination by Novartis under this 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 38

	 	
Section and the effects of termination provided herein shall be without prejudice to any damages or other legal or equitable remedies to which it may be entitled from Enanta.

  

	 	(d)	Either Enanta or Novartis may terminate this Agreement without notice if an Insolvency Event occurs in relation to the other Party. In any event when a Party first
becomes aware of the likely occurrence of any Insolvency Event in regard to that Party, it shall promptly so notify the other Party in sufficient time to give the other Party sufficient notice to protect its interests under this Agreement.

  

	 	(e)	Novartis may terminate this Agreement in the event Enanta rejects this Agreement under Section 365 of the United States Bankruptcy Code, 11 U.S.C. §§ 101
et seq. (the “Code”). 

  

	15.3	Termination by Novartis Without Cause. Novartis may terminate this Agreement without cause at any time after the Effective Date in its entirety or on a Licensed
Compound-by-Licensed Compound basis at any time on one hundred twenty (120) days’ prior written notice to Enanta. 

  

	15.4	Termination by Enanta For Failure of Novartis to Use Commercially Reasonable Efforts. 

 

	 	(a)	Subject to Section 15.4(b), Enanta shall have the right to terminate the rights licensed to Novartis under the Agreement with respect to a given Product if
Novartis is in breach of its obligations as set forth in Sections 7.2 or 9.1 with respect to such Product, provided however, that Novartis’ rights shall not terminate unless (i) Novartis is given [*****] prior written notice by Enanta of
Enanta’s intent to terminate, stating the reasons and justification for such termination, and (ii) Novartis, or its Affiliate or sublicensee, has not taken good faith commercially reasonable steps during the [*****] period following such
notice to diligently pursue the Development and/or Commercialization of the relevant Product. 

  

	 	(b)	If Novartis disputes in good faith the existence or materiality of an alleged breach specified in a notice provided by Enanta pursuant to Section 15.4(a), and
Novartis provides notice to Enanta of such dispute within the first [*****] of the [*****] notice period specified in Section 15.4(a), Enanta shall not have the right to terminate rights under this Agreement unless and until the existence of
such material breach or failure by Novartis has been determined in accordance with Section 20.5 and Novartis fails to cure such breach within [*****] following such determination. It is understood and acknowledged that during the pendency of
any such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 39

	15.5	Rights in Bankruptcy. 

  

	 	(a)	The Parties agree that this Agreement constitutes an executory contract under Section 365 of the Code for the license of “intellectual property” as
defined under Section 101 of the Code and constitutes a license of “intellectual property” for purposes of any similar laws in any other country in the Territory. The Parties further agree that Novartis, as licensee of such rights
under this Agreement, will retain and may fully exercise all of its protections, rights and elections under the Code, including, but not limited to, Section 365(n) of the Code, and any similar laws in any other country in the Territory. The
Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Enanta under the Code and any similar laws in any other country in the Territory, Novartis will be entitled to a complete duplicate of (or complete
access to, as appropriate) any such intellectual property and all embodiments of such intellectual property to the extent included in the license grants hereunder and reasonably related to the practice of such license, and the same, if not already
in its possession, will be promptly delivered to it: (i) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless Enanta elects to continue to perform all of its obligations under this Agreement; or
(ii) if not delivered under (i) above, following the rejection of this Agreement by or on behalf of Enanta upon written request therefor by Novartis. 

 

	 	(b)	All rights, powers and remedies of Novartis provided for in this Section 15.5 are in addition to and not in substitution for any and all other rights, powers and
remedies now or hereafter existing at law or in equity (including, without limitation, under the Code and any similar laws in any other country in the Territory). In the event of an Insolvency Event in relation to Enanta, Novartis, in addition to
the rights, power and remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such remedies as may now or hereafter exist at law or in equity (including, without limitation, under
the Code). 

  

	16.	EFFECT OF TERMINATION 

  

	16.1	Partial Termination by Novartis for Cause. Upon partial termination of this Agreement by Novartis pursuant to Section 15.2(b): 

 

	 	(a)	any licenses granted by Novartis to Enanta hereunder will terminate and revert to Novartis; 

 

	 	(b)	the licenses and other rights granted by Enanta to Novartis and its Affiliates under Article 3 will remain in effect in accordance with their respective terms;
provided, however, that (i) the amount of any Milestone Payments and royalties applicable to Net Sales of Product which become due after the effective date of partial termination shall be reduced by [*****]; and (ii) Novartis shall have
the right to offset any damages Novartis has suffered as a result of Enanta’s breach, in such amounts as are finally determined to be due to Novartis pursuant to Section 20.5 or otherwise agreed by Enanta in writing, against any such
Milestone Payments and/or royalties which become due after the effective date of partial termination; and 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 40

	 	(c)	the Agreement will otherwise remain in full force and effect except that (i) Novartis will have the right to dissolve the JSC upon written notice to Enanta,
(ii) Novartis’ obligations pursuant to Section 4.2 will terminate, and (iii) Enanta’s rights to Co-Detail Products pursuant to Article 10 will terminate and Novartis will have the right to immediately terminate any
Co-Detailing Agreement by providing written notice to Enanta. 

  

	16.2	Full Termination by Novartis for Cause. Upon termination of this Agreement by Novartis pursuant to Section 15.2(c), (d) or (e):

  

	 	(a)	any licenses and other rights granted by either Party to the other Party hereunder will terminate and revert to the granting Party; 

 

	 	(b)	Novartis will cooperate with Enanta promptly and as reasonably requested by Enanta to transition the responsibility for the filing, prosecution, and maintenance of the
Enanta IP back to Enanta. The provisions of Section 13.2 shall continue to apply with respect to Collaboration IP unless otherwise agreed in writing by the Parties; 

 

	 	(c)	Novartis hereby grants Enanta a right of first negotiation, exercisable by written notice to Novartis at any time within [*****] after such termination, to obtain a
worldwide, exclusive, royalty-bearing license, with the right to sublicense, under Collaboration IP owned in whole or in part by Novartis or its Affiliates, and under any other Patent Rights and Know-How Controlled by Novartis or its Affiliates that
are not included in the Collaboration IP and that are reasonably necessary to continue to Develop or Commercialize Products then being Developed or Commercialized under this Agreement, to research, develop, make, have made, use, sell, have sold,
offer for sale and import Licensed Compound(s) and Product(s), on commercially reasonable terms to be negotiated in good faith by the Parties for up to an additional [*****] following exercise of such right of first negotiation;

  

	 	(d)	any license granted to Enanta as described in the preceding subsection (c) will include, to the extent requested by Enanta, the right to use clinical and
regulatory data and information generated by Novartis for regulatory purposes relating to the Licensed Compounds and/or Products and will provide for Novartis to transfer and assign to Enanta all of its right, title and interest in and to all
regulatory submissions and Regulatory Approvals and all drug master files and drug dossiers with respect to the Products (other than those related to manufacturing facilities); and 

 

	 	(e)	except as set forth in this Section 16, the rights and obligations of the Parties hereunder shall terminate as of the date of such termination.

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 41

	16.3	Termination by Enanta for Cause or by Novartis Without Cause. Upon termination of this Agreement by Enanta pursuant to Section 15.2(a) or (d) or
Section 15.4 or by Novartis pursuant to Section 15.3: 

  

	 	(a)	any licenses and other rights granted by either Party to the other under this Agreement will terminate and revert to the granting Party; 

 

	 	(b)	Novartis will cooperate with Enanta promptly and as reasonably requested by Enanta to transition the responsibility for the filing, prosecution, and maintenance of the
Enanta IP back to Enanta. The provisions of Section 13.2 shall continue to apply with respect to Collaboration IP unless otherwise agreed in writing by the Parties; 

 

	 	(c)	Novartis will transfer and assign to Enanta all of its right, title and interest in and to all regulatory submissions with respect to the Products that were filed by
Enanta prior to the Effective Date and transferred to Novartis hereunder; 

  

	 	(d)	 in the event that this Agreement is terminated on or before the 2nd anniversary of the end of the Research Term, then Novartis will grant Enanta and its Affiliates a worldwide,
exclusive, fully paid, perpetual license, with the right to sublicense, under all Collaboration IP owned in whole or in part by Novartis or its Affiliates, to research, develop, make, have made, use, sell, have sold, offer for sale and import
Licensed Compound(s) and Product(s); 

  

	 	(e)	 in the event that this Agreement is terminated after the 2nd anniversary of the end of the Research Term, then the Parties shall negotiate in good faith the terms under which
Enanta shall obtain a worldwide, exclusive, license, with the right to sublicense, under Collaboration IP owned in whole or in part by Novartis or its Affiliates, to develop, make, have made, use, sell, have sold, offer for sale and import Licensed
Compounds and Products; 

  

	 	(f)	in addition to the foregoing, upon request of Enanta following any such termination, the Parties shall negotiate in good faith the terms under which Enanta shall obtain
a worldwide, exclusive, royalty-bearing license, with the right to sublicense, under any other Patent Rights and Know-How Controlled by Novartis or its Affiliates that are not included in the Collaboration IP and that are reasonably necessary to
continue to Develop or Commercialize Products then being Developed or Commercialized under this Agreement, to develop, make, have made, use, sell, have sold, offer for sale and import any such Product then being Developed or Commercialized under
this Agreement; 

  

	 	(g)	 in the event that the Parties cannot agree upon the terms for any license to be negotiated as provided above within [*****] after such termination,
then, if requested by Enanta during such [*****], the Parties shall refer the matter to arbitration before a mutually acceptable single independent arbitrator, who shall be experienced in the pharmaceutical business, provided that if the Parties
cannot agree upon such single arbitrator within [*****], such arbitrator will be promptly 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 42

	 	
chosen by the Parties in accordance with the then-prevailing rules of arbitration of the International Chamber of Commerce. For such arbitration, each Party shall submit final proposed terms to
the arbitrator within [*****] of his/her appointment, together with a brief or other written memorandum supporting the merits of their final proposal, provided that each Party will submit its final proposed terms to the other Party at least [*****]
prior to submission to the independent arbitrator. The arbitrator shall promptly convene a hearing, at which time each Party shall have an agreed upon time to argue and present witnesses in support of its final proposal. The independent arbitrator
will select between the two sets of terms (i.e., the independent arbitrator will select one of the sets of terms submitted by the Parties, and will not propose a third set of terms, and shall have no discretion or authority with respect to modifying
the proposed terms of either of the Parties), and shall render his/her opinion in writing within [*****] after the hearing described above. The decision of the arbitrator shall be final and binding on the Parties. The Parties shall equally bear all
expenses and costs of the arbitration, including the costs associated with the arbitrators’ services, but not the costs incurred by either Party in connection with the preparation for and the presentation of its case. 

 

	 	(h)	any license granted to Enanta as described in the preceding subsection (e) or (f) will include, to the extent requested by Enanta, the right to use clinical
and regulatory data and information generated by Novartis for regulatory purposes relating to the Licensed Compounds and/or Products and will provide for Novartis to transfer and assign to Enanta all of its right, title and interest in and to all
regulatory submissions and Regulatory Approvals and all drug master files and drug dossiers with respect to the Products (other than those related to manufacturing facilities) and for Novartis to reasonably cooperate with Enanta, at Enanta’s
request and expense, with respect to the transfer of relevant Development and Commercialization activities to Enanta, and to provide Enanta with reasonable access to relevant manufacturing and formulation Know-How; and 

 

	 	(i)	except as set forth in this Section 16, the rights and obligations of the Parties hereunder shall terminate as of the date of such termination.

  

	16.4	Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Without
limiting the foregoing, the provisions of Articles 1, 12, 16, 18 and 20, and Sections 3.4, 11.10, 13.1, 15.5, 17.4, 19.2, and any other obligations and rights which are expressly intended to survive, shall survive expiration or termination of this
Agreement. The provisions of Section 14 (Confidentiality) shall survive the termination or expiration of this Agreement for a period of [*****]. 

  

	16.5	Termination Not Sole Remedy. Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything
contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 43

	17.	REPRESENTATIONS, WARRANTIES AND COVENANTS 

  

	17.1	Representations, Warranties and Covenants by Each Party. Each Party represents and warrants to the other as of the Effective Date that: 

 

	 	(a)	it is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation; 

 

	 	(b)	it has full corporate power and authority to execute, deliver, and perform this Agreement, and has taken all corporate action required by law and its organizational
documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement; 

  

	 	(c)	this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms; 

 

	 	(d)	other than compliance with the HSR Act, all consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by
such Party in connection with this Agreement have been obtained; 

  

	 	(e)	the execution and delivery of this Agreement and all other instruments and documents required to be executed pursuant to this Agreement do not and shall not
(i) conflict with or result in a breach of any provision of its organizational documents, (ii) result in a breach of any agreement to which it is a party; or (iii) violate any law; and 

 

	 	(f)	all of its employees, officers, and consultants who have been involved with the Enanta IP or who will be involved in the Research Program have executed agreements or
have existing obligations under applicable laws requiring assignment to such Party of all inventions made during the course of and as the result of their association with such Party free from Encumbrances and obligating the individual to maintain as
confidential such Party’s Confidential Information as well as confidential information of other parties (including the other Party and its Affiliates) which such individual may receive, to the extent required to support such Party’s
obligations under this Agreement; 

  

	 	(g)	with respect to Novartis, it shall self-insure and, with respect to Enanta, it shall maintain insurance with respect to its activities and obligations under this
Agreement in such amounts as are commercially reasonable in the industry for companies conducting similar business and shall require any of its Affiliates undertaking activities under this Agreement to do the same; 

 

	 	(h)	it will perform all activities under this Agreement in compliance with all applicable laws and regulations, including but not limited to those relating to the conduct
of human clinical studies, animal testing, biotechnological research and the handling and containment of biohazardous materials, and laws and regulations relating to health, safety and the environment, fair labor practices and unlawful
discrimination; 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 44

	 	(i)	(i) neither such Party nor, to the actual knowledge of such Party, any employee, agent or subcontractor of such Party involved or to be involved in the Development of
the Licensed Compound(s) and/or the Product(s) has been debarred under Subsection (a) or (b) of Section 306 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 335a); (ii) no Person who is known by such Party to have been
debarred under Subsection (a) or (b) of Section 306 of said Act will be employed by such Party in the performance of any activities hereunder; and (iii) to the actual knowledge of such Party, no Person on any of the FDA clinical
investigator enforcement lists (including, but not limited to, the (1) Disqualified/Totally Restricted List, (2) Restricted List and (3) Adequate Assurances List) will participate in the performance of any activities hereunder.

  

	17.2	Representations and Warranties by Enanta. Enanta represents and warrants to Novartis as of the Effective Date that: 

 

	 	(a)	Exhibit A sets forth a complete and accurate list of all Enanta Patents in existence as of the Effective Date, indicating the owner, Enanta, and/or co-owner(s)
thereof if such Enanta IP is not solely owned by Enanta; 

  

	 	(b)	Exhibit A includes a complete list of all the patents and patent applications that Enanta has filed on novel NS5A compound structures; 

 

	 	(c)	[*****]; 

  

	 	(d)	[*****]; 

  

	 	(e)	[*****]; 

  

	 	(f)	[*****]; 

  

	 	(g)	[*****]; 

  

	 	(h)	[*****]; 

  

	 	(i)	[*****]; 

  

	 	(j)	[*****]; 

  

	 	(k)	[*****]; 

  

	 	(l)	[*****]; and 

  

	 	(m)	[*****]. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 45

	17.3	Covenants of Enanta. Enanta covenants and agrees that: 

  

	 	(a)	it will not grant any interest in the Enanta IP which is inconsistent with the terms and conditions of this Agreement, nor shall Enanta assign its right, title or
interest in or to the Enanta IP to any Third Party except as permitted in Section 20.1; and 

  

	 	(b)	if, at any time after execution of this Agreement, it becomes aware that it or any employee, agent or subcontractor of Enanta who participated, or is participating, in
the performance of any activities hereunder is on, or is being added to the FDA Debarment List or any of the three (3) FDA Clinical Investigator Restriction Lists referenced in Section 17.1(i), it will provide written notice of this to
Novartis within two (2) business days of its becoming aware of this fact; 

  

	 	(c)	subject to Section 14.3, it will use all reasonable precautions to preserve the confidentiality of the Enanta Know-How to the extent that such Enanta Know-How is
subject to an exclusive license to Novartis and its Affiliates. 

  

	17.4	No Other Warranties. EXCEPT AS EXPRESSLY STATED IN THIS SECTION 17, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF
OF NOVARTIS OR ENANTA; AND (B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR
NON-INFRINGEMENT. 

  

	18.	INDEMNIFICATION; LIABILITY 

  

	18.1	Indemnification by Enanta. Enanta shall indemnify and hold Novartis, its Affiliates, and their respective officers, directors and employees (“Novartis
Indemnitees”) harmless from and against any Claims against them to the extent arising or resulting from: 

  

	 	(a)	Enanta’s, or any of its Affiliates’, sublicensees’ or contractors’ actions in connection with the Research Program; 

 

	 	(b)	the negligence or willful misconduct of Enanta or any of its Affiliates; or 

 

	 	(c)	the breach of any of the obligations, covenants, warranties or representations made by Enanta to Novartis and its Affiliates under this Agreement;

 provided, however, that Enanta shall not be obliged to so indemnify, defend and hold harmless the Novartis
Indemnitees for any Claims to the extent Novartis has an obligation to indemnify Enanta Indemnitees pursuant to Section 18.2 or to the extent that such Claims arise from the breach, negligence or willful misconduct of Novartis or the Novartis
Indemnitee. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 46

	18.2	Indemnification by Novartis. Novartis shall indemnify and hold Enanta, its Affiliates, and their respective officers, directors and employees (“Enanta
Indemnitees”) harmless from and against any Claims against them to the extent arising or resulting from: 

  

	 	(a)	Novartis’, or any of its Affiliates’, sublicensees’ or contractors’ actions in connection with the Development, manufacture or Commercialization of
the Licensed Compound(s) or Product(s) or performance of the Research Program; 

  

	 	(b)	the negligence or willful misconduct of Novartis or any of its Affiliates; or 

 

	 	(c)	the breach of any of the obligations, covenants, warranties or representations made by Novartis to Enanta under this Agreement; 

provided, however, that Novartis and its Affiliates shall not be obliged to so indemnify, defend and hold harmless the Enanta Indemnitees
for any Claims to the extent Enanta has an obligation to indemnify Novartis Indemnitees pursuant to Section 18.1 or to the extent that such Claims arise from the breach, negligence or willful misconduct of Enanta or the Enanta Indemnitee.

  

	18.3	Indemnification Procedure. 

  

	 	(a)	For the avoidance of doubt, all indemnification claims in respect of a Novartis Indemnitee or Enanta Indemnitee shall be made solely by Novartis or Enanta,
respectively. 

  

	 	(b)	A Party seeking indemnification hereunder (“Indemnified Party”) shall notify the other Party (“Indemnifying Party”) in writing
reasonably promptly after the assertion against the Indemnified Party of any Claim or fact in respect of which the Indemnified Party intends to base a Claim for indemnification hereunder (“Indemnification Claim Notice”), but
the failure or delay to so notify the Indemnifying Party shall not relieve the Indemnifying Party of any obligation or liability that it may have to the Indemnified Party, except to the extent that the Indemnifying Party demonstrates that its
ability to defend or resolve such Claim is adversely affected thereby. The Indemnification Claim Notice shall contain a description of the Claim and the nature and amount of the Claim (to the extent that the nature and amount of such Claim is known
at such time). Upon the request of the Indemnifying Party, the Indemnified Party shall furnish promptly to the Indemnifying Party copies of all correspondence, communications and official documents (including court documents) received or sent in
respect of such Claim. 

  

	 	(c)	 Subject to the provisions of subsections (d) and (e) below, the Indemnifying Party shall have the right, upon written notice given to the
Indemnified Party within thirty (30) days after receipt of the Indemnification Claim Notice, to assume the defense and handling of such Claim, at the Indemnifying Party’s sole expense, in which case the provisions of subsection
(d) below shall govern. The assumption of the defense of a Claim by the Indemnifying Party shall not be construed as acknowledgement that the Indemnifying Party is liable to indemnify any indemnitee in respect of the Claim, nor shall it
constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party’s claim for indemnification. In the event that it is ultimately decided that the Indemnifying Party is not obligated to indemnify or hold
an Indemnitee harmless 

  

					
	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	 	
 47
	  

	 	
from and against the Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including attorneys’ fees and costs of suit) and any losses
incurred by the Indemnifying Party in its defense of the Claim. If the Indemnifying Party does not give written notice to the Indemnified Party, within thirty (30) days after receipt of the Indemnification Claim Notice, of the Indemnifying
Party’s election to assume the defense and handling of such Claim, the provisions of sub-Section (e) below shall govern. 

  

	 	(d)	Upon assumption of the defense of a Claim by the Indemnifying Party: (i) the Indemnifying Party shall have the right to and shall assume sole control and
responsibility for dealing with the Claim; (ii) the Indemnifying Party may, at its own cost, appoint as counsel in connection with conducting the defense and handling of such Claim any law firm or counsel reasonably selected by the Indemnifying
Party; (iii) the Indemnifying Party shall keep the Indemnified Party informed of the status of such Claim; and (iv) the Indemnifying Party shall have the right to settle the Claim on any terms the Indemnifying Party chooses; provided,
however, that it shall not, without the prior written consent of the Indemnified Party, agree to a settlement of any Claim which could lead to liability or create any financial or other obligation on the part of the Indemnified Party for which the
Indemnified Party is not entitled to indemnification hereunder or which admits any wrongdoing or responsibility for the claim on behalf of the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and shall be entitled
to participate in, but not control, the defense of such Claim with its own counsel and at its own expense. In particular, the Indemnified Party shall furnish such records, information and testimony, provide witnesses and attend such conferences,
discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours by the Indemnifying Party to, and reasonable retention by the Indemnified
Party of, records and information that are reasonably relevant to such Claim, and making the Indemnified Party, the Indemnitees and its and their employees and agents available on a mutually convenient basis to provide additional information and
explanation of any records or information provided. 

  

	 	(e)	If the Indemnifying Party does not give written notice to the Indemnified Party as set forth in subsection (c) or fails to conduct the defense and handling of any
Claim in good faith after having assumed such, the Indemnified Party may, at the Indemnifying Party’s expense, select counsel reasonably acceptable to the Indemnifying Party in connection with conducting the defense and handling of such Claim
and defend or handle such Claim in such manner as it may deem appropriate. In such event, the Indemnified Party shall keep the Indemnifying Party timely apprised of the status of such Claim and shall not settle such Claim without the prior written
consent of the Indemnifying Party, which consent shall not be unreasonably withheld. If the Indemnified Party defends or handles such Claim, the Indemnifying Party shall cooperate with the Indemnified Party, at the Indemnified Party’s request
but at no expense to the Indemnified Party, and shall be entitled to participate in the defense and handling of such Claim with its own counsel and at its own expense. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 48

	18.4	Mitigation of Loss. Each Indemnified Party will take and will procure that its Affiliates take all such reasonable steps and action as are necessary or as the
Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Section 18. Nothing in this Agreement shall or shall be deemed to relieve any Party of any common law or other duty to
mitigate any losses incurred by it. 

  

	18.5	Special, Indirect and Other Losses. NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE BREACH OF STATUTORY DUTY OR OTHERWISE
FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY
PROVIDES INDEMNIFICATION UNDER THIS SECTION 18. 

  

	18.6	No Exclusion. Neither Party excludes any liability for death or personal injury caused by its negligence or that of its employees, agents or sub-contractors.

  

	19.	PUBLICATIONS AND PUBLICITY 

  

	19.1	Publications. 

  

	 	(a)	Except to the extent made in accordance with the provisions of Section 14 or Section 19.2, any proposed public disclosure (whether written, electronic, oral
or otherwise) by Enanta relating to the Licensed Compound(s) or Product(s) shall require the prior written consent of Novartis. 

  

	 	(b)	For the avoidance of doubt, Novartis or any of its Affiliates may, without any required consents from Enanta, but, to the extent practicable, with at least [*****]
prior written notice to Enanta, publish or have published information about clinical trials related to the Licensed Compound(s) or Product(s), including the results of such clinical trials. This paragraph shall not affect the rights or obligations
of the Parties pursuant to Section 14. 

  

	19.2	Publicity. 

  

	 	(a)	Neither Party shall use the name, symbol, trademark, trade name or logo of the other Party or its Affiliates in any press release, publication or other form of public
disclosure without the prior written consent of the other Party in each instance (such consent not to be unreasonably withheld or delayed), except for those disclosures made in accordance with Section 14 or for which consent has already been
obtained. 

  

	 	(b)	 Except as provided in Section 14, each Party agrees not to issue any press release or other public statement, whether oral or written, disclosing
the existence of this 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 49

	 	
Agreement, the terms hereof or any information relating to this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed;
provided, however, that Novartis may issue press releases and other public statements as it deems reasonably appropriate in connection with the Development and Commercialization of Products under this Agreement without such consent but, to the
extent practicable, with at least [*****] prior written notice to Enanta. 

  

	19.3	The Parties acknowledge and agree that a good faith breach by Novartis of any requirement to give prior notice pursuant to this Section 19 shall not be
grounds for any termination of this Agreement by Enanta. 

  

	20.	GENERAL PROVISIONS 

  

	20.1	Assignment. This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party; provided, however,
that either Party may assign this Agreement, without the consent of the other Party to any of its Affiliates or to a successor to all or substantially all of its business or assets to which this Agreement relates. Any purported assignment in
contravention of this Section 20.1 shall, at the option of the non-assigning Party, be null and void and of no effect. In the event that this Agreement is assigned by a Party in connection with the sale or transfer of all or substantially all
of the business and assets of such Party to which the subject matter of this Agreement pertains, notwithstanding any provisions of this Agreement to the contrary, such assignment shall not provide the non-assigning Party with rights or access to
intellectual property or technology of the acquirer of the assigning Party. No assignment shall release either Party from responsibility for the performance of any accrued obligation of such Party hereunder. This Agreement shall be binding upon and
enforceable against the successor to or any permitted assignees from either of the Parties hereto. 

  

	20.2	Extension to Affiliates. Novartis shall have the right to extend the rights, immunities and obligations granted in this Agreement to one or more of its
Affiliates. All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to Novartis. Novartis shall remain primarily liable
for any acts or omissions of its Affiliates. 

  

	20.3	Severability. Should one or more of the provisions of this Agreement become void or unenforceable as a matter of law, then this Agreement shall be construed as
if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will use their commercially reasonable efforts to substitute for the invalid or unenforceable provision a valid and
enforceable provision which conforms as nearly as possible with the original intent of the Parties. 

  

	20.4	Governing Law and Jurisdiction. This Agreement shall be governed by and construed under the laws of the Commonwealth of Massachusetts, without reference to
conflicts of laws principles. The Parties hereby irrevocably submit to the exclusive jurisdiction of and venue in the state and federal courts located in Boston, Massachusetts, without restricting any right of appeal. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 50

	20.5	Dispute Resolution. 

  

	 	(a)	Except as otherwise set forth in this Agreement, in the event of an unresolved matter, dispute or issue under this Agreement (“Dispute”), the Parties
will refer the Dispute to the Alliance Managers for discussion and resolution. If the Alliance Managers are unable to resolve such Dispute within thirty (30) days of the Dispute being referred to them by either Party in writing, either Party
may require that the Parties forward the matter to the Senior Officers (or designees with similar authority to resolve such dispute), who shall attempt in good faith to resolve such Dispute. If the Senior Officers cannot resolve such Dispute within
thirty (30) days of the matter being referred to them in writing, then the Dispute will be resolved as provided in Section 20.5(b), (c) or (d) below, as applicable. 

 

	 	(b)	For any Dispute not settled in accordance with Section 20.5(a), a Party wishing to commence arbitration shall first serve notice on the other Party that a Dispute
has arisen and demand that mediation commence. The mediation shall last no longer than sixty (60) days and shall be conducted pursuant to the ICC ADR Rules of the International Chamber of Commerce (“ICC”) then in effect. Each Party
shall pay its own expenses incurred in connection with such mediation, and the fees and expenses of the mediator shall be divided evenly between the Parties. Notwithstanding anything else contained herein, any Party to such mediation shall have the
right to commence arbitration in accordance with Section 20.5(c) below at any time after the expiration of sixty (60) days after service of such demand for mediation under this subsection. 

 

	 	(c)	Any unresolved Disputes between the Parties relating to, arising out of or in any way connected with this Agreement or any term or condition hereof, or the performance
by either Party of its obligations hereunder, whether before or after termination of this Agreement, shall be resolved by final and binding arbitration. Whenever a Party shall decide to institute arbitration proceedings, it shall give written notice
to that effect to the other Party. Arbitration shall be held in Boston, Massachusetts, according to the Rules of Arbitration of the ICC in effect at the time of the arbitration, except as they may be modified herein or by mutual agreement of the
Parties. No arbitrator (nor any panel of arbitrators) shall have the power to award punitive damages under this Agreement and such award is expressly prohibited. Decisions of the arbitrator(s) shall be final and binding on the Parties. Judgment on
the award so rendered may be entered in any court of competent jurisdiction. The costs of the arbitration shall be borne as determined by the arbitrator(s). 

 

	 	(d)	 Notwithstanding anything to the contrary, either Party may at any time seek to obtain preliminary injunctive relief or other applicable provisional
relief from a court of competent jurisdiction with respect to an issue arising under this Agreement if the rights of such Party would be prejudiced absent such relief. A 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 51

	 	
request by a Party to a court of competent jurisdiction for interim measures necessary to preserve the Party’s rights, including attachments or injunctions, shall not be deemed incompatible
with, or a waiver of, the agreement to mediate or arbitrate contained in this Section 20.5. Notwithstanding anything to the contrary in this Section 20.5, any disputes regarding the scope, validity, enforceability or inventorship of any
patents or patent applications shall be submitted for final resolution by a court of competent jurisdiction. 

  

	20.6	Force Majeure. Neither Party shall be responsible to the other for any failure or delay in performing any of its obligations under this Agreement or for other
nonperformance hereunder if such delay or nonperformance is caused by strike, stoppage of labor, lockout or other labor trouble, fire, flood, accident, war, act of terrorism, act of God or of the government of any country or of any local government,
or by cause unavoidable or beyond the control of any Party hereto. In such event, the Party affected will use commercially reasonable efforts to resume performance of its obligations. 

 

	20.7	Waivers and Amendments. The failure of any Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not
constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver shall be effective unless it has been given in writing and signed by the Party giving such waiver. No
provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party. 

  

	20.8	Relationship of the Parties. Nothing contained in this Agreement shall be deemed to constitute a partnership, joint venture, or legal entity of any type between
Enanta and Novartis, or to constitute one as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby, as a partnership for any tax purposes. Each Party shall act solely as an
independent contractor, and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit the other. 

  

	20.9	Notices. All notices, consents, waivers, and other communications under this Agreement must be in writing and will be deemed to have been duly given when:
(a) delivered by hand (with written confirmation of receipt); (b) sent by fax (with written confirmation of receipt), provided that a copy is immediately sent by an internationally recognized overnight delivery service (receipt requested);
or (c) when received by the addressee, if sent by an internationally recognized overnight delivery service (receipt requested), in each case to the appropriate addresses and fax numbers set forth below (or to such other addresses and fax
numbers as a Party may designate by notice): 

 If to Enanta: 

Enanta Pharmaceuticals, Inc. 
 500 Arsenal Street 
 Watertown, Massachusetts 02472 

Attention: Chief Executive Officer 
 Facsimile No.: 617-607-0530 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 52

 If to Novartis: 

Novartis Institutes for BioMedical Research, Inc. 
 250 Massachusetts Avenue 
 Cambridge, Massachusetts 02139 

Attention: General Counsel 
 Facsimile No.: (617) 871-3354 
  

	20.10	Further Assurances. Novartis and Enanta hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge and deliver any and
all such other documents and take any such other action as may be reasonably necessary to carry out the intent and purposes of this Agreement. 

  

	20.11	Compliance with Law. Each Party shall perform its obligations under this Agreement in accordance with all applicable laws. No Party shall, or shall be required
to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may violate, any applicable law. 

 

	20.12	Corporate Citizenship. Novartis gives preference to parties who share Novartis’ societal and environmental values as set forth in the “Novartis Third
Party Code of Conduct” which is attached as Exhibit D. 

  

	20.13	No Third Party Beneficiary Rights. The provisions of this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they
shall not be construed as conferring any rights to any Third Party (including any third party beneficiary rights). 

  

	20.14	English Language. This Agreement is written and executed in the English language. Any translation into any other language shall not be an official version of
this Agreement and in the event of any conflict in interpretation between the English version and such translation, the English version shall prevail. 

  

	20.15	Expenses. Except as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other experts and
all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this Agreement. 

  

	20.16	Entire Agreement. This Agreement, together with its Exhibits, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof
and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the
substantive provisions of this Agreement shall prevail. 

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 53

	20.17	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. 

  

	20.18	Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy
referred to in this Agreement or otherwise available under law. 

 IN WITNESS WHEREOF, the Parties intending to be
bound have caused this Agreement to be executed by their duly authorized representatives. 
  

									
	 NOVARTIS INSTITUTES FOR
 BIOMEDICAL RESEARCH, INC.
	 		 	ENANTA PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Christian Klee
	 		 	By:	 	 /s/ Jay R. Luly

					
	Name:	 	 Christian Klee
	 		 	Name:	 	 Jay R. Luly

					
	Title:	 	 VP and CFO
	 		 	Title:	 	 President and CEO

  

					
		 	 Confidential materials omitted and filed separately with the Securities and Exchange

Commission. Asterisks denote such omission.
	 	
 54

 Enanta has requested that portions of this document be accorded confidential treatment

 pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as 

amended. 

EXHIBIT A 

ENANTA PATENTS 
  

													
	 Country Name
	  	Sub	  	Status	  	Appl’n #	  	Filing Date	  	Patent #	  	Issue Date
	
	 4014.1182 (ENP-182) “Linked Dibenzimidazole Antivirals”

							
	 [*****]
	  		  	[*****]	  	[*****]	  	[*****]	  		  	
	 Patent Cooperation Treaty
	  		  	Natl Proc	  	US10/023645	  	09-Feb-2010	  		  	
	 United States of America
	  		  	Expired	  	61/151,079	  	09-Feb-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1183 (ENP-183) “Novel Dibenzimidazole Derivatives”

							
	 United States of America
	  		  	PRO	  	61/153,224	  	17-Feb-2009	  		  	
	 United States of America
	  	1	  	PRO	  	61/156,239	  	27-Feb-2009	  		  	
	 United States of America
	  	2	  	ORD	  	12/702,692	  	09-Feb-2012	  		  	
	
	 4014.1184 (ENP-184) “Linked Dibenzimidazole Derivatives”

							
	 United States of America
	  		  	Expired	  	61/153,231	  	17-Feb-2009	  		  	
	 United States of America
	  	1	  	Expired	  	61/156,110	  	27-Feb-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1185 (ENP-185) “Linked Dilmidazole Antivirals”

							
	 Patent Cooperation Treaty
	  		  	Natl Proc	  	US10/024447	  	17-Feb-2010	  		  	
	 United States of America
	  		  	Expired	  	61/153,234	  	17-Feb-2009	  		  	
	 United States of America
	  	1	  	Expired	  	61/156,160	  	27-Feb-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1186 (ENP-186) “Novel Dilmidazole Antivirals”

							
	 United States of America
	  		  	PRO	  	61/153,240	  	17-Feb-2009	  		  	
	 United States of America
	  	1	  	PRO	  	61/156,284	  	27-Feb-2009	  		  	
	 United States of America
	  	2	  	ORD	  	12/707,200	  	17-Feb-2010	  		  	
	
	 4014.1187 (ENP-187) “Novel Benzimidazole Derivatives”

							
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	

  

Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

													
	 Country Name
	  	Sub	  	Status	  	Appl’n #	  	Filing Date	  	Patent #	  	Issue Date
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 Patent Cooperation Treaty
	  		  	Natl Proc	  	US10/025741	  	01-March-2010	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 United States of America
	  		  	Expired	  	61/156,131	  	27-Feb-2009	  		  	
	 United States of America
	  	1	  	Allowed	  	12/714,583	  	01-March-2010	  	8101643	  	24-Jan-2012
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 United States of America
	  	3	  	Unfiled	  		  		  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1188 (ENP-188) “Hepatitis C Virus Inhibitors”

							
	 United States of America
	  		  	Expired	  	61/158,071	  	06-Mar-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1189 (ENP-189) “Hepatitis C Virus Inhibitors”

							
	 United States of America
	  		  	Expired	  	61/156,268	  	27-Feb-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1190 (ENP-190) “Hepatitis C Virus Inhibitors”

							
	 Patent Cooperation Treaty
	  		  	Natl Proc	  	US10/038699	  	15-Jun-2010	  		  	
	 United States of America
	  		  	Expired	  	61/187,374	  	16-Jun-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	

 Confidential materials omitted and filed separately
with the Securities and Exchange 
 Commission. Asterisks denote such omission. 

  
 2 

													
	 Country Name
	  	Sub	  	Status	  	Appl’n #	  	Filing Date	  	Patent #	  	Issue Date
	
	 4014.1191 (ENP-191) “Hepatitis C Virus Inhibitors”

							
	 United States of America
	  		  	Expired	  	61/222,586	  	02-Jul-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
				
	 4014.1192 (ENP-192) “Hepatitis C Virus Inhibitors”
	  		  		  	
							
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 United States of America
	  		  	Expired	  	61/241,489	  	10-Sept-2010	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1198 (ENP-198) “Hepatitis C Virus Inhibitors”

							
	 United States of America
	  		  	Expired	  	61,241,578	  	11-Sep-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1199 (ENP-199) “Hepatitis C Virus Inhibitors”

							
	 United States of America
	  		  	Expired	  	61/241,595	  	11-Sep-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1200 (ENP-200) “Hepatitis C Virus Inhibitors”

							
	 United States of America
	  		  	PRO	  	61/241,617	  	11-Sep-2009	  		  	
	 United States of America
	  	1	  	ORD	  	12/879,028	  	10-Sep-2010	  		  	
	
	 4014.1201 (ENP-201) “Hepatitis C Virus Inhibitors”

							
	 United States of America
	  		  	Expired	  	61/241,577	  	11-Sep-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
				
	 4014.1202 (ENP-202) “Hepatitis C Virus Inhibitors”
	  		  		  	
							
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 United States of America
	  		  	Expired	  	61/241,598	  	11-Sep-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1204 (ENP-204) “Hepatitis C Virus Inhibitors”

							
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 United States of America
	  		  	Expired	  	61/286,178	  	14-Dec-2009	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1205 (ENP-205) “Hepatitis C Virus Inhibitors”

							
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	

 Confidential materials omitted and filed separately
with the Securities and Exchange 
 Commission. Asterisks denote such omission. 

  
 3 

													
	 Country Name
	  	Sub	  	Status	  	Appl’n #	  	Filing Date	  	Patent #	  	Issue Date
	 United States of America
	  		  	Expired	  	61/297,918	  	25-Jan-2010	  		  	
	 United States of America
	  	1	  	Expired	  	61/314,304	  	16-Mar-2010	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1209 (ENP-209) “Combination Pharmaceutical Agents as Inhibitors of HCV
Replication”

							
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 United States of America
	  		  	Expired	  	61/310,579	  	04-Mar-2010	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1210 (ENP-210) “Hepatitis C Virus Inhibitors”

							
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 United States of America
	  		  	Expired	  	61/322,438	  	09-Apr-2010	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1211 (ENP-211) “Hepatitis C Virus Inhibitors”

							
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 United States of America
	  		  	Expired	  	61/372,999	  	12-Aug-2010	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	
	 4014.1216 (ENP-216) “Hepatitis C Virus Inhibitors”

							
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 United States of America
	  		  	Expired	  	61/351,327	  	04-Jun-2010	  		  	
	 United States of America
	  	1	  	Expired	  	61/415,447	  	19-Nov-2010	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  		  		  		  		  		  	
							
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  		  		  		  		  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	
	 [*****]
	  		  		  		  		  		  	
	 [*****]
	  	[*****]	  	[*****]	  	[*****]	  	[*****]	  		  	

 Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

  
 4 

 Enanta has requested that portions of this document be accorded confidential treatment

 pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as 

amended. 

EXHIBIT B 

RESEARCH PLAN 
 [*****]

 Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

 EXHIBIT C 
 SAMPLE INVOICE 
  

					
	Company Name	 		  	INVOICE
			
	Street Address	 		  	DATE: Month Day, Year
	City, State ZIP Code	 		  	INVOICE #: XX
	Phone 1xxxxxx	 		  	NOVARTIS PO#: XXXXXXXX
	Fax 1xxxxx	 		  	

 Bill To: 

Novartis Institutes for Biomedical Research 

Attn: Novartis Contact Name 
 P.O. Box 5990

 Portland, OR 97228-5990 

Upfront/Milestone/Royalty or any other payment debit in reference to Research Collaboration and License Agreement between Enanta Pharmaceuticals, Inc.
and Novartis Institutes for BioMedical Research, Inc. effective as of (date). 
  

							
	 PO Line
Number
	  	 DESCRIPTION
	  	AMOUNT	 
			
	1	  	 Upfront payment with reference made to the relevant section of the contract
	  	$	XX.XX	  
		  		  	  
	  
	 
		
	 TOTAL
	  	$	XX.XX	  
		  		  	  
	  
	 

  

			
	Remit to:	  	
	Bank Wire Information:
	Bank Name:	  	XX
	Account No.:	  	XX
	ABA#:	  	XX (only applicable in the US)
	IBAN:	  	XX (only applicable in Europe)
	SWIFT CODE:	  	XX (applicable US and Europe)

 Note for e-mail submissions of invoices: 
 The address is: [*****] 
 Attached invoice files must contain a Novartis issued
purchase order number (PO) on them and cannot be zipped. Invoices without a PO number on them or zipped attachments will not be accepted for processing. 
 Note to Enanta: When payments shift to post-PoC, Novartis to provide Enanta with new contact information for the invoices. 
 Confidential materials omitted and filed separately with the Securities and Exchange 
 Commission. Asterisks denote such omission. 

 EXHIBIT D 
 NOVARTIS THIRD PARTY CODE OF CONDUCT 
 [to be inserted] 

Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

					
		  	Novartis Third Party Code of Conduct	  	
	
	

			
		  	Novartis wants to be known for being a responsible corporate citizen. We do everything that we can to operate in a manner that is sustainable – economically, socially and
environmentally – in the best interests of the long-term success of our enterprise and its stakeholders.	  	
			
		  	In support of this goal, Novartis firmly supports the principles of the United Nations Global Compact and the Pharmaceutical Industry Principles for Responsible Supply Chain
Management, and we are committed to reflecting these in our business principles and practices.	  	
			
		  	www.novartis.com/supplier	  	

  

					
		  	

	  	Version 2.0, April 2007

 Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

 Supply Chain Principles  |  2 

 

 Pharmaceutical Industry Principles for Responsible Supply Chain Management 

This document outlines the Pharmaceutical Industry Principles for Responsible Supply Chain Management (the “Principles”) for ethics, labor,
health and safety, environment and related management systems. The Principles may be voluntarily supported by any business in the pharmaceutical industry. 
 Companies supporting the Principles: 
  

	•	 	 Will integrate and apply these Principles in a manner consistent with their own supplier programs. 

 

	•	 	 Believe that society and business are best served by responsible business behaviors and practices. Fundamental to this belief is the understanding that
a business must, at a minimum, operate in full compliance with all applicable laws, rules and regulations. 

  

	•	 	 Are aware of differences in culture and the challenges associated with interpreting and applying these Principles globally. While companies supporting
the Principles believe that what is expected is universal, it is understood that the methods for meeting these expectations may be different and must be consistent with the laws, values and cultural expectations of the different societies in the
world. 

  

	•	 	 Believe the Principles are best implemented through a continual improvement approach that advances supplier performance over time.

 Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

  
 2 

 Supply Chain Principles  |  3 

 

 Ethics 
 Suppliers shall conduct their business in an ethical manner and act with integrity. The ethics elements include: 
 1. Business Integrity and Fair Competition 
 All corruption, extortion and embezzlement are
prohibited. Suppliers shall not pay or accept bribes or participate in other illegal inducements in business or government relationships. Suppliers shall conduct their business consistent with fair and vigorous competition and in compliance with all
applicable anti-trust laws. Suppliers shall employ fair business practices, including accurate and truthful advertising. 
 2. Identification
of Concerns 
 All workers should be encouraged to report concerns or illegal activities in the workplace, without threat of reprisal,
intimidation or harassment. Suppliers shall investigate and take corrective action if needed. 
 3. Animal Welfare 

Animals shall be treated humanely, with pain and stress minimized. Animal testing should be performed after consideration to replace animals, reduce the
numbers of animals used or refine procedures to minimize distress. Alternatives should be used wherever scientifically valid and acceptable to regulators. 
 4. Privacy 
 Suppliers shall safeguard and make only proper use of confidential information
to ensure that company, worker and patient privacy rights are protected. 
 Confidential materials omitted and filed
separately with the Securities and Exchange 
 Commission. Asterisks denote such omission. 

  
 3 

 Supply Chain Principles  |  4 

 

 Labor 
 Suppliers shall be committed to uphold the human rights of workers and to treat them with dignity and respect. The labor elements include: 
 1. Freely Chosen Employment 
 Suppliers shall not use forced, bonded, indentured or
involuntary prison labor. 
 2. Child Labor and Young Workers 
 Suppliers shall not use child labor. The employment of young workers below the age of 18 shall only occur in non-hazardous work and when young workers are above a country’s legal age for employment
or the age established for completing compulsory education. 
 3. Non-Discrimination 

Suppliers shall provide a workplace free of harassment and discrimination. Discrimination for reasons such as race, color, age, gender, sexual
orientation, ethnicity, disability, religion, political affiliation, union membership or marital status is not condoned. 
 4. Fair Treatment

 Suppliers shall provide a workplace free of harsh and inhumane treatment, including any sexual harassment, sexual abuse, corporal
punishment, mental or physical coercion or verbal abuse of workers and no threat of any such treatment. 
 5. Wages, Benefits and Working
Hours 
 Suppliers shall pay workers according to applicable wage laws, including minimum wages, overtime hours and mandated benefits.

 Suppliers shall communicate with the worker the basis on which they are being compensated in a timely manner. Suppliers are also expected to
communicate with the worker whether overtime is required and the wages to be paid for such overtime. 
 6. Freedom of Association

 Open communication and direct engagement with workers to resolve workplace and compensation issues is encouraged. 

Suppliers shall respect the rights of workers, as set forth in local laws, to associate freely, join or not join labor unions, seek representation and
join workers’ councils. Workers shall be able to communicate openly with management regarding working conditions without threat of reprisal, intimidation or harassment. 
 Confidential materials omitted and filed separately with the Securities and Exchange 
 Commission. Asterisks denote such omission. 

  
 4 

 Supply Chain Principles  |  5 

 

 Health and Safety 
 Suppliers shall provide a safe and healthy working environment, including for any company-provided living quarters. The health and safety elements include: 

1. Worker Protection 
 Suppliers shall
protect workers from over exposure to chemical, biological and physical hazards, physically demanding tasks in the workplace and in any company-provided living quarters. 
 2. Process Safety 
 Suppliers shall have programs in place to prevent or mitigate
catastrophic releases of chemicals. 
 3. Emergency Preparedness and Response 
 Suppliers shall identify and assess emergency situations in the workplace and any company-provided living quarters, and minimize their impact by implementing emergency plans and response procedures.

 4. Hazard Information 

Safety information relating to hazardous materials – including pharmaceutical compounds and pharmaceutical intermediate materials – shall be
available to educate, train and protect workers from hazards. 
 Confidential materials omitted and filed separately with the
Securities and Exchange 
 Commission. Asterisks denote such omission. 

  
 5 

 Supply Chain Principles  |  6 

 

 Environment 
 Suppliers shall operate in an environmentally responsible and efficient manner, and they shall minimize adverse impacts on the environment. Suppliers are encouraged to conserve natural resources, to avoid
the use of hazardous materials where possible and to engage in activities that reuse and recycle. 
 The environmental elements include:

 1. Environmental Authorizations 
 Suppliers shall comply with all applicable environmental regulations. All required environmental permits, licenses, information registrations and restrictions shall be obtained and their operational and
reporting requirements followed. 
 2. Waste and Emissions 
 Suppliers shall have systems in place to ensure the safe handling, movement, storage, recycling, reuse or management of waste, air emissions and wastewater discharges. Any waste, wastewater or emissions
with the potential to adversely impact human or environmental health shall be appropriately managed, controlled and treated prior to release into the environment. 
 3. Spills and Releases 
 Suppliers shall have systems in place to prevent and mitigate
accidental spills and releases to the environment. 
 Confidential materials omitted and filed separately with the Securities
and Exchange 
 Commission. Asterisks denote such omission. 

  
 6 

 Supply Chain Principles  |  7 

 

 Management Systems 
 Suppliers shall use management systems to facilitate continual improvement and compliance with the expectations of these principles. The management systems elements include: 

1. Commitment and Accountability 

Suppliers shall demonstrate commitment to the concepts described in this document by allocating appropriate resources. 

2. Legal and Customer Requirements 

Suppliers shall identify and comply with applicable laws, regulations, standards and relevant customer requirements. 

3. Risk Management 
 Suppliers shall have
mechanisms to determine and manage risks in all areas addressed by this document. 
 4. Documentation 

Suppliers shall maintain documentation necessary to demonstrate conformance with these expectations and compliance with applicable regulations.

 5. Training and Competency 

Suppliers shall have a training program that achieves an appropriate level of knowledge, skills and abilities in management and workers to address these
expectations. 
 6. Continual Improvement 
 Suppliers are expected to continually improve by setting performance objectives, executing implementation plans and taking necessary corrective actions for deficiencies identified by internal or external
assessments, inspections and management reviews. 
 Confidential materials omitted and filed separately with the Securities
and Exchange 
 Commission. Asterisks denote such omission. 

  
 7 

 

 
  
 Corporate Citizenship Guideline # 5

 Third Party Management 
  

 
 Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

  

					
	Corporate Citizenship Guideline 5	  	
	Initial Version:	  	approved by ECN August 21, 2003	  	Page 1 of 6
	Version 2.2:	  	approved by 3PO’s and Head Corporate Services July 10, 2007	  	

 8 

 

 
  
  

			
		  	Purpose and References
	  
 1. Purpose of this

guideline
	  	  
 This Guideline was issued by the Novartis Group Executive Committee
(ECN) on August 21, 2003. In line with the CC Policy and Guideline #1, paragraph 10, it sets forth the Corporate Citizenship criteria which Novartis takes into account in selecting its suppliers and service providers (Third Parties).

 
 Novartis supports the “Pharmaceutical Supply Chain initiative” (PSCI) (see
also www.pharmaceuticalsupplychain.org). This guideline explains how Novartis integrates these principles in its supplier program.

	  
 2. Reference to Novartis Third Party Code of
Conduct
	  	  
 To communicate the expectations from the Third Parties, Novartis
has established a “Third Party Code of Conduct”, which specifies these expectations and is in line with the “Pharmaceutical Industry Principles for Responsible Supply Chain Management”.

	  
 3. Reference to Guidance Note 5.1
	  	  
 This Guideline is accompanied by the Guidance Note 5.1
“Practical Implementation Recommendations for Corporate Citizenship in Third Party Relations” which provides details for: selecting evaluation criteria; creating a dialogue on Corporate Citizenship principles through the use of standard
questionnaires; performing assurance visits; and providing special support in certain situations that Novartis deems warranted.
  

Responsibilities

	  
 4. Divisions, Business Units, Novartis
International
	  	  
 The Division Heads, Heads of Consumer Health Business Units, and
the Head of Corporate Services are responsible for proper implementation of this Guideline within their units. They shall nominate a Third Party Officer (3PO) within their units. By preference, the 3PO shall be the head of a purchasing department or
the head of a supply chain function.

	  
 5. Third Party Officer’s Responsibility
	  	  
 The 3PO shall ensure that for all purchasing operations within
his/her unit, a “Third Party Management Process” is in place which covers purchasing operations in all affiliates and sites. The 3PO is the driving force within the unit to implement this Guideline (= CC5), including recruitment and
training of local 3PM’s and ensuring high quality of data and risk assessment associated to the CC5 process.

	  
 6. Third Party Management
	  	  
 In each local operational unit a responsible “Third Party
Manager” (3PM) assures that responsibilities and processes are established, maintained and implemented. It should address: (1) the process by which Third Parties are identified, selected and contracted, and (2) the manner in which support by
relevant functions (e.g. HR, HSE, Legal, Compliance Officers) is provided.

	  
 7. Ownership and Operating Responsibility
	  	  
 This Guideline and its associated Guidance Note # 5.1 are owned and
maintained by Group Purchasing.
  
 The Chief Procurement Officer shall,
together with the 3PO’s ensure consistent application within Novartis as well as periodical reviews, as required. This is achieved by regular 3PO meetings, chaired by the Chief Procurement Officer. The 3PO’s also approve SOP’s for
consistent management of CC5.
  
 Proper management of CC5 is supported by a
central database (GLOSUD), which is maintained by Group Purchasing, the data being entered by all Divisions, Business Units or Novartis International.
  

Principles & Expectations

	  
 8. Our principles and expectations
	  	  
 Novartis gives preference to Third Parties that share the societal
and environmental values required by the Global Compact. As a consequence, Third Parties are expected to comply with minimum standard requirements concerning ethics, labor, health, safety and environmental protection and management systems,
specified in the Novartis Third Party Code of Conduct and set forth in paragraphs 9 – 13 of this Guideline.

 Confidential materials omitted and filed separately with the Securities and Exchange 
 Commission. Asterisks denote such omission. 

  

					
	Corporate Citizenship Guideline 5	  	
	Initial Version:	  	approved by ECN August 21, 2003	  	Page 2 of 6
	Version 2.2:	  	approved by 3PO’s and Head Corporate Services July 10, 2007	  	

 9 

 

 
  

			
		  	 Compliance with the Third Party Code of Conduct shall be assessed before contracting with any Third Party and shall constitute an
element of equal importance among other evaluation criteria such as price or quality.
  
 While we recognize that there are different legal and cultural environments in which our Business Partners operate throughout the world, it is Novartis’ intention to work collaboratively with Third
Parties to achieve these goals on a long term and sustainable basis.

	  
 9. Ethics
	  	  
 Suppliers shall conduct their business in an ethical manner and act
with integrity. The ethics elements include:
  
 1. Business Integrity and
Fair Competition
  
 All corruption, extortion and embezzlement are
prohibited. Suppliers shall not pay or accept bribes or participate in other illegal inducements in business or government relationships. Suppliers shall conduct their business consistent with fair and vigorous competition and in compliance with all
applicable anti-trust laws. Suppliers shall employ fair business practices including accurate and truthful advertising.
  
 2. Identification of Concerns
  
 All workers should be encouraged to report concerns or illegal activities in the workplace without threat of reprisal, intimidation or harassment. Suppliers shall investigate and take corrective action if
needed.
  
 3. Animal Welfare

 
 Animals shall be treated humanely with pain and stress minimized. Animal testing
should be performed after consideration to replace animals, to reduce the numbers of animals used, or to refine procedures to minimize distress. Alternatives should be used wherever these are scientifically valid and acceptable to
regulators.
  
 4. Privacy

 
 Suppliers shall safeguard and make only proper use of confidential information to
ensure that company, worker, and patient privacy rights are protected.

	  
 10. Labor
	  	  
 Suppliers shall be committed to uphold the human rights of workers
and to treat them with dignity and respect. The Labor elements include:
  

1. Freely Chosen Employment
  

Suppliers shall not use forced, bonded or indentured labor or involuntary prison labor.

 
 2. Child Labor and Young Workers

 
 Suppliers shall not use child labor. The employment of young workers below the age of
18 shall only occur in non hazardous work and when young workers are above a country’s legal age for employment or the age established for completing compulsory education.

 
 3. Non-Discrimination

 
 Suppliers shall provide a workplace free of harassment and discrimination.
Discrimination for reasons such as race, color, age, gender, sexual orientation, ethnicity, disability, religion, political affiliation, union membership or marital status is not condoned.

 
 4. Fair Treatment

 
 Suppliers shall provide a workplace free of harsh and inhumane treatment, including
any sexual harassment, sexual abuse, corporal punishment, mental or physical coercion or verbal abuse of workers and no threat of any such treatment.

Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

  

					
	Corporate Citizenship Guideline 5	  	
	Initial Version:	  	approved by ECN August 21, 2003	  	Page 3 of 6
	Version 2.2:	  	approved by 3PO’s and Head Corporate Services July 10, 2007	  	

 10 

 

 
  

			
		  	 5. Wages, Benefits and Working Hours
  

Suppliers shall pay workers according to applicable wage laws, including minimum wages, overtime hours and mandated benefits.

 
 Suppliers shall communicate with the worker the basis on which they are being
compensated in a timely manner. Suppliers are also expected to communicate with the worker whether overtime is required and the wages to be paid for such overtime.
  

6. Freedom of Association
  

Open communication and direct engagement with workers to resolve workplace and compensation issues is encouraged.

 
 Suppliers shall respect the rights of workers, as set forth in local laws, to
associate freely, join or not join labor unions, seek representation and join workers’ councils. Workers shall be able to communicate openly with management regarding working conditions without threat of reprisal, intimidation or
harassment.

	  
 11. Health and Safety
	  	  
 Suppliers shall provide a safe and healthy working environment,
including for any company provided living quarters. The Health and Safety elements Include: 
  
 1. Worker Protection
  

Suppliers shall protect workers from over exposure to chemical, biological, physical hazards and physically demanding tasks in the work place and in any
company provided living quarters. 
  
 2. Process
Safety
  
 Suppliers shall have programs in place to prevent or mitigate
catastrophic releases of chemicals. 
  
 3. Emergency Preparedness
and Response
  
 Suppliers shall identify and assess emergency situations
in the workplace and any company provided living quarters, and to minimize their impact by implementing emergency plans and response procedures.
  

4. Hazard Information
  
 Safety information relating to hazardous materials - including pharmaceutical compounds and pharmaceutical intermediate materials - shall be available to educate, train, and protect workers from
hazards.

	  
 12. Environment
	  	  
 Suppliers shall operate in an environmentally responsible and
efficient manner and they shall minimize adverse impacts on the environment. Suppliers are encouraged to conserve natural resources, to avoid the use of hazardous materials where possible and to engage in activities that reuse and recycle. The
environmental elements include:
  
 1. Environmental
Authorizations
  
 Suppliers shall comply with all applicable
environmental regulations. All required environmental permits, licenses, information registrations and restrictions shall be obtained and their operational and reporting requirements followed.

 
 2. Waste and Emissions

 
 Suppliers shall have systems in place to ensure the safe handling, movement, storage,
recycling, reuse, or management of waste, air emissions and wastewater discharges. Any waste, wastewater or emissions with the potential to adversely impact human or environmental health shall be appropriately managed, controlled and treated prior
to release into the environment.
  
 3. Spills and Releases

 
 Suppliers shall have systems in place to prevent and mitigate accidental spills and
releases to the environment.

 Confidential materials omitted and
filed separately with the Securities and Exchange 
 Commission. Asterisks denote such omission. 

  

					
	Corporate Citizenship Guideline 5	  	
	Initial Version:	  	approved by ECN August 21, 2003	  	Page 4 of 6
	Version 2.2:	  	approved by 3PO’s and Head Corporate Services July 10, 2007	  	

 11 

 

 
  

			
	13. Management Systems	  	 Suppliers shall use management systems to facilitate continual improvement and compliance with the expectations of these principles. The
management system elements include:
  
 1. Commitment and
Accountability
  
 Suppliers shall demonstrate commitment to the concepts
described in this document by allocating appropriate resources.
  
 2.
Legal and Customer Requirements
  
 Suppliers shall identify and comply
with applicable laws, regulations, standards and relevant customer requirements.
  
 3. Risk Management
  

Suppliers shall have mechanisms to determine and manage risks in all areas addressed by this document.

 
 4. Documentation

 
 Suppliers shall maintain documentation necessary to demonstrate conformance with
these expectations and compliance with applicable regulations.
  
 5.
Training and Competency
  
 Suppliers shall have a training program that
achieves an appropriate level of knowledge, skills and abilities in management and workers to address these expectations.
  
 6. Continual Improvement
  

Suppliers are expected to continually improve by setting performance objectives, executing implementation plans and taking necessary corrective actions
for deficiencies identified by internal or external assessments, inspections, and management reviews.
  
 Novartis Management Process

	  
 14. Information
	  	  
 Third Parties shall be made aware of the Third Party Code of
Conduct and the compliance requirements to qualify for a business relationship with Novartis.

	  
 15. Clause in contract
	  	  
 Relevant contracts shall include explicit reference to the Third
Party Code of Conduct and the compliance requirement to qualify for a business relationship with Novartis.

	  
 16. Classification of third parties
	  	  
 All Third Parties will be classified in one of five categories
according to the industry they are in, the country in which they operate, their annual revenues with Novartis and the judgment of the buyer/3PM regarding the level of risks associated with their operations.

	  
 17. Class 0
	  	  
 The following Third Parties are out of scope and classified as
Class 0: Medical doctors, Key opinion leaders, government agencies and inter company transfers.

	  
 18. Class 1
	  	  
 Third Parties classified as non-critical (Class 1), shall be made
aware of the Third Party Code of Conduct and the fact that Novartis gives preference to Third Parties that comply with these Principles or substantially similar standards.

	  
 19. Class 2
	  	  
 Third Parties classified as critical (Class 2) shall be asked
explicitly for information about their level of compliance with the Third Party Code of Conduct and to provide basic corporate citizenship related information about their business (“self-assessment”). To this end Novartis provides a form
to be used as is, or to be completed with questions of specific interest to the Business unit.

	  
 20. Class 3 or 4
	  	  
 For Third Parties classified as very critical (Class 3 or 4),
Novartis shall seek additional assurance of their commitment to and implementation of the Third Party Code of Conduct. This assurance may include a request by Novartis to conduct assurance visits to the Third Party site in order to learn about the
level of

 Confidential materials omitted and filed separately
with the Securities and Exchange 
 Commission. Asterisks denote such omission. 

  

					
	Corporate Citizenship Guideline 5	  	
	Initial Version:	  	approved by ECN August 21, 2003	  	Page 5 of 6
	Version 2.2:	  	approved by 3PO’s and Head Corporate Services July 10, 2007	  	

 12 

 

 
  

			
		  	compliance with the Third Party Code of Conduct. For Third Parties using Novartis materials, processes, techniques, or know-how, e.g. toll or contract manufacturers, an assurance
visit is mandatory for approval. As a basis for preparation and conducting the assurance visit, Novartis provides a questionnaire to be used as is, or to be completed with questions of specific interest to the unit. Follow-up visits should be
conducted on a regular basis. Novartis shall maintain the data received during this process for ongoing compliance evaluations.
	  
 21. Improvement programs and special support (Class
4)
	  	  
 In cases where the results of the assurance visits and inquiries
are unsatisfactory, Novartis may assist the Third Party in developing an improvement program designed to raise the level of compliance with the Third Party Code of Conduct. If concerns persist regarding the commitment or capability of the Third
Party to improve of its own accord, a decision must be made at Corporate Steering Committee level as to whether special support should be provided (= Class 4) or the contract terminated. If an agreed improvement program is not completed within three
years, or if the respective audit results are not satisfactory, then the contract shall be terminated.

	  
 22. Assessment process for known Third Parties
	  	  
 In cases where, in view of a previous or an ongoing business
relationship, sufficient information about a specific Third Party is already available, the assessment process can be simplified and reduced to the level necessary to ascertain the Third Party’s compliance with the Third Party Code of Conduct.
Such deviations from the standard assessment process must be justified and documented and must be approved by the 3PO.
  
 Reporting Criteria & Measurements

	  
 23. Reporting to Senior Management
	  	  
 The Chief Procurement Officer is responsible for coordination of
internal reporting on CC5 implementation, including the establishment of appropriate KPI’s for managing continuous improvement.
  

The 3PO’s are responsible for reporting the KPI achievements to the Executive Committee of their unit and to the Chief Procurement
Officer.

	  
 24. Status of compliance and impact
	  	  
 A qualitative and quantitative assessment of the status of
compliance and impact within the units is part of the KPI’s.

	  
 26. Reporting
	  	  
 The Chief Procurement Officer is responsible for establishing the
format for reporting, the frequency, and the recipients of the reporting.
 Escalation procedure

	  
 26. Termination of Third Party relationship
	  	  
 Indications for termination of a contractual relationship (see
above 21) are escalated by the 3PM through the 3PO to the Division Head(s) or Head(s) of Consumer Health Business Unit(s). If the decision to terminate the relationship is not unanimous, the Chief Procurement Officer will bring the controversy to
the attention of the CC Steering Committee. The Chairman of the CC Steering Committee will raise the controversy at the ECN.

	  
 27. Non compliance
	  	  
 Material non compliance of a business unit to the CC5 process as
described in the relevant guidelines and SOP’s, as well as continual failure to meet the KPI’s is escalated by the Chief Procurement Officer to the CC Steering Committee. The Chairman of the CC Steering Committee will raise material non
compliance at the ECN.

  

			
	Version 2.2, July 4, 2007:	  	 Proposed Changes to Article 7 (Ownership and Operating Responsibility)
 Proposed Changes to Articles 23-27 (Reporting, Escalation)
  
 Circular approval by the 3PO’s July 4, 2007
 Final Approval with modification of
Articles 26/27 by Head Corporate Services July 10, 2007

 Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

  

					
	Corporate Citizenship Guideline 5	  	
	Initial Version:	  	approved by ECN August 21, 2003	  	Page 6 of 6
	Version 2.2:	  	approved by 3PO’s and Head Corporate Services July 10, 2007	  	

 13 

 EXHIBIT E 
 Global Laboratory Notebook Guidelines 
 Laboratory notebooks shall be
issued and used in substantial compliance with the following: 
 This laboratory notebook is to be used to make a systematic, permanent record
of all experimental work, and to record ideas or concepts which might be used to support patents, product registrations, and other activities. No other form of notebook may be used to record experimental observations. Loose-leaf binders may only he
used to store accessory data which cannot be pasted into the notebook. Provide sufficient experimental detail to allow an independent scientist with basic skills in the appropriate discipline to reproduce the work. 

The book is issued to you and it is your personal responsibility to ensure its confidentiality and physical security at all times until it is handed over
to the Research Archive for permanent storage. This will usually mean that the book is to remain on [Party]’s premises and that any relocation must be properly authorized. This Laboratory Notebook must be submitted to the local Research Archive
for microfilming/scanning and safe storage ASAP after completion, at the latest, 3 months after the last entry. ALL lab notebooks irrespective of whether completed or only partially filled must be closed out and returned to the Research Archive one
year after issue, or immediately if you relocate to a different site, or leave [Party]. 

 

 General 
 On receipt of a new notebook immediately ensure that the identification panel is correctly filled in, and then register your signature, initials, and employee number in the “Table of Contributors and
Signatures”. 
 Keep records clear, objective, accurate, and ensure they are dated unambiguously. Signatures must NEVER be back-dated or
otherwise falsified. 
 Write preferably using a ball point pen in permanent black, waterproof ink. Do not use pencil, or ink which may run if
wet. 
 Whenever practicable, record directly into the lab notebook. 
 Handwriting must be legible to be of evidential value. 
 Use pages in a chronological, sequential
order. Do not leave empty spaces or empty pages. Cross through empty space on partly used pages with a diagonal line or X. 
 NEVER remove pages
from the book and do not obscure the printed page numbers. Keep all entries within the printed margins. 
 When making corrections cross out
with a single line. The original entry must remain readable. 
 ALL corrections and additions must be initiated and dated. Explain
corrections if they change the interpretation of the experiment. Corrections may normally only be made by the original author. 
 Books which
are discontinued but not filled must he properly terminated by writing “Book Discontinued - No Entries Beyond This Page” on the first empty page. This final page must be signed by the author and witnessed. 

NEVER make negative or derogatory statements about yourself, your

 
Witnesses must record their signature, initials and employee number in the “Table of Contributors and Signatures” the first time they witness each book. 

Only permanent NIBR employees can be witnesses. 

Indexing 
 Lab notebooks must
contain a “Table of Contents” which must contain sufficient information to facilitate easy review of the book contents by an independent reader. 
 Define all abbreviations used in the “Table of Abbreviations”. 
 Reference all accessory
records not pasted into the notebook on page XX. 
 Use a uniform format for lab notebook references - this should comprise the book number
(mandatory) + page number (mandatory) + line number (optional) e.g. E-0000-56(-35). 
 Structure 

Structure lab notebook entries to assist interpretation by independent readers. Use headings where appropriate. The description of experiments must
include (but not necessarily be limited to) at least the following items - 
  

	•	 	 Date and Title (when the page was started) 

  

	•	 	 Materials - Record the source and batch numbers of key materials. 

 

	•	 	 Method - Provide sufficient experimental detail to allow an independent worker with basic skills in the same scientific discipline to reproduce
the work. Record all deviations from standard protocols however small. 

  

	•	 	 Result - Record ALL experiments and findings, even those which work, or Novartis products in the notebook.

 

  

Confidential materials omitted and filed separately with the Securities and Exchange 

Commission. Asterisks denote such omission. 

 
 Accessory Data 
 Paste accessory data into the book with a permanent adhesive. Sign or initial over the edges of sheets pasted into the book. Do not overlay or fold material pasted into the book. 

Accessory data which is too bulky to paste into the book must be stored in files or binders which are properly labeled and bi-directionally cross
referenced. Files or binders must be specifically identified and then labels should contain a cross reference to the laboratory notebook number Key items of accessory data must be signed and dated. Electronic accessory data helpful for the
interpretation of the experiment should be digitally signed and stored. 
 Authorship and Signatures 

Entries should wherever possible be made only by the person to whom the book is issued. In exceptional cases where multiple authorship is unavoidable, it
must be clear who recorded which entries and when. Multiple authorship should be defined in the “Table of Contributors and Signatures”. 
 Sign and date each page as soon as it is completed (including any blank pages that are crossed out). 
 Completed pages (including crossed out blank pages) must be witnessed and dated within 2 weeks of the author’s signature. 
 A witness should be capable of appreciating the work recorded, and for patent protection, the witness should not have the potential to become a co-inventor of the work being witnessed,

 
may be considered to have “not worked” or be “negative”, however describe these as not having returned the expected results, or if a reaction, as not having produced the
desired product. 
  

	•	 	 Interpretation - must be objective and supported by the experimental data Avoid the use of subjective comments and opinions such as
“obvious”, “routine”, “clearly”. 

 Ideas 

Record novel concepts and ideas. Be as specific as possible e.g. suggest compounds to be made, their possible utility, and proposed synthetic routes or
test methods. Ideas for novel concepts must be signed, and promptly witnessed to be of value. 
 Confidentiality and Physical Security

 The notebook remains the property of [Party] at all times and will contain confidential, proprietary, and trade secret information
that must not be disclosed to unauthorized persons. 
 Notebooks must be kept locked in fire-resistant storage when not in use. 

Notebooks must not be removed from [Party] premises unless appropriate authorization has been obtained. 

Copies of laboratory notebook pages should be made only if absolutely necessary. Copies must be treated as confidential material like the book itself
Paper copies must be destroyed according to [Party] standard practices (i.e. shredding, diamond cutting, etc.) as soon as they have served their purpose.

 

  
 Confidential
materials omitted and filed separately with the Securities and Exchange 
 Commission. Asterisks denote such omission.

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]